



US 20240200102A1

(19) **United States**

(12) **Patent Application Publication**  
**Kim**

(10) **Pub. No.: US 2024/0200102 A1**

(43) **Pub. Date: Jun. 20, 2024**

(54) **FUSION PROTEINS COMPRISING AN  
INTEIN POLYPEPTIDE AND METHODS OF  
USE THEREOF**

*C12N 9/12* (2006.01)

*C12N 9/22* (2006.01)

*C12N 15/113* (2006.01)

(52) **U.S. Cl.**

CPC ..... *C12N 15/90* (2013.01); *C07K 14/195*

(2013.01); *C12N 9/1276* (2013.01); *C12N*

*9/22* (2013.01); *C12N 15/113* (2013.01); *C07K*

*2319/92* (2013.01); *C12N 2310/20* (2017.05);

*C12N 2800/80* (2013.01)

(71) Applicant: **Pairwise Plants Services, Inc.**,  
Durham, NC (US)

(72) Inventor: **Yongjoo Kim**, Chapel Hill, NC (US)

(21) Appl. No.: **18/541,481**

(22) Filed: **Dec. 15, 2023**

(57)

**ABSTRACT**

**Related U.S. Application Data**

(60) Provisional application No. 63/387,767, filed on Dec.  
16, 2022.

Described herein are fusion proteins that include an intein polypeptide along with methods of using of such proteins. Fusion proteins described herein may include a Cas12a polypeptide and an intein polypeptide or a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and an intein polypeptide. Also described herein are compositions and systems for modifying or editing a target nucleic acid.

**Publication Classification**

**Specification includes a Sequence Listing.**

(51) **Int. Cl.**

*C12N 15/90* (2006.01)

*C07K 14/195* (2006.01)




**FIG. 1**


CMV	N-term mCherry	NpuN
CMV	NpuC	C-term mCherry

**FIG. 2**

**Average P4 mCherry Fluorescence (Median EDA)**




**FIG. 3**




**FIG. 4**

**Comparison of mCherry Fluorescence of mCherry v. mCherry Control Inteins**




**FIG. 5**



- Description:**
- LbCpf1 x pUC19
  - ▨ RT(5M) - LbCpf1-Brex27 x pUC19
  - ▧ RT(5M)-Cas12a175-NpuN x NpuC-176Cas12a-Brex27
  - ▩ RT(5M)-Cas12a310-NpuN x NpuC-311Cas12a-Brex27
  - RT(5M)-Cas12a406-NpuN x NpuC-407Cas12a-Brex27
  - RT(5M)-Cas12a441-NpuN x NpuC-442Cas12a-Brex27
  - ▬ RT(5M)-Cas12a550-NpuN x NpuC-551Cas12a-Brex27
  - RT(5M)-NpuN x NpuC-Cas12a-Brex27
  - ▨ RT(5M) x Cas12a-Brex27


**FIG. 6**



**Description:**

- LbCpf1 x pUC19
- RT(5M) - LbCpf1-Brex27 x pUC19
- RT(5M)-Cas12a175-NpuN x NpuC-176Cas12a-Brex27
- RT(5M)-Cas12a310-NpuN x NpuC-311Cas12a-Brex27
- RT(5M)-Cas12a406-NpuN x NpuC-407Cas12a-Brex27
- RT(5M)-Cas12a441-NpuN x NpuC-442Cas12a-Brex27
- RT(5M)-Cas12a550-NpuN x NpuC-551Cas12a-Brex27
- RT(5M)-NpuN x NpuC-Cas12a-Brex27
- RT(5M) x Cas12a-Brex27

**FIG. 7**



**Description:**

- LbCpf1 x pUC19
- RT(5M) - LbCpf1-Brex27 x pUC19
- RT(5M)-Cas12a175-NpuN x NpuC-176Cas12a-Brex27
- RT(5M)-Cas12a310-NpuN x NpuC-311Cas12a-Brex27
- RT(5M)-Cas12a406-NpuN x NpuC-407Cas12a-Brex27
- RT(5M)-Cas12a441-NpuN x NpuC-442Cas12a-Brex27
- RT(5M)-Cas12a550-NpuN x NpuC-551Cas12a-Brex27
- RT(5M)-NpuN x NpuC-Cas12a-Brex27
- RT(5M) x Cas12a-Brex27

**FUSION PROTEINS COMPRISING AN  
INTEIN POLYPEPTIDE AND METHODS OF  
USE THEREOF**

STATEMENT REGARDING ELECTRONIC  
FILING OF A SEQUENCE LISTING

**[0001]** A Sequence Listing in XML format, entitled 1499-116\_ST26.xml, 502,046 bytes in size, generated on Dec. 14, 2023, and filed herewith, is hereby incorporated by reference in its entirety for its disclosures.

FIELD

**[0002]** This invention relates to fusion proteins (e.g., engineered proteins) that include a Cas12a polypeptide and an intein polypeptide and to methods of use of such proteins. The invention also relates to fusion proteins (e.g., engineered proteins) that include a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and an intein polypeptide and to methods of use of such proteins. The invention further relates to compositions and systems for modifying or editing a target nucleic acid.

BACKGROUND OF THE INVENTION

**[0003]** Large genome editing agents (e.g., those over 2000 amino acids in length) are usually delivered into tissues using means other than Adeno-associated virus (AAV) vectors. For example, large genome editing agents may be delivered using lipid nanoparticle mediated RNP delivery, which has no size limit, or using mRNA or DNA. However, these approaches prohibit use in applications where the use of AAV is necessary, for example, applications for delivery to the brain of a subject.

**[0004]** Accordingly, new methods for preparing and/or delivering genome editing agents are needed.

SUMMARY OF THE INVENTION

**[0005]** A first aspect of the present invention is directed to a fusion protein comprising an intein polypeptide. In some embodiments, the fusion protein comprises a Cas12a polypeptide fused to an intein polypeptide. In some embodiments, the fusion protein comprises a polypeptide of interest fused to an intein polypeptide. In some embodiments, the fusion protein comprises a reverse transcriptase polypeptide fused to an intein polypeptide. A nucleic acid molecule encoding a fusion protein as described herein is also provided.

**[0006]** Another aspect of the present invention is directed to a complex comprising: a Cas12a protein that is prepared from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a first Cas12a polypeptide fused to a first intein polypeptide and the second fusion protein comprises a second Cas12a polypeptide fused to a second intein polypeptide; a guide nucleic acid (e.g., a guide RNA); and optionally a deaminase.

**[0007]** An additional aspect of the present invention is directed to a complex comprising: an engineered protein (e.g., a base editor or a templated editor such as a REDRAW editor) that is prepared from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the

second fusion protein comprises a Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA).

**[0008]** A further aspect of the present invention is directed to a method of modifying a target nucleic acid, the method comprising: contacting the target nucleic acid with: a Cas12a protein that is prepared from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a first Cas12a polypeptide fused to a first intein polypeptide and the second fusion protein comprises a second Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA), optionally wherein the Cas12a protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**[0009]** Another aspect of the present invention is directed to a method of modifying a target nucleic acid, the method comprising: contacting the target nucleic acid with: an engineered protein (e.g., a base editor or a templated editor such as a REDRAW editor) that is prepared from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the second fusion protein comprises a Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA), optionally wherein the engineered protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**[0010]** An additional aspect of the present invention is directed to a composition comprising: a first fusion protein that comprises a first Cas12a polypeptide fused to a first intein polypeptide; and a second fusion protein that comprises a second Cas12a polypeptide fused to a second intein polypeptide.

**[0011]** A further aspect of the present invention is directed to a composition comprising: a first fusion protein that comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second fusion protein that comprises a Cas12a polypeptide fused to a second intein polypeptide.

**[0012]** Another aspect of the present invention is directed to a composition comprising: a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide.

**[0013]** An additional aspect of the present invention is directed to a composition comprising: a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide.

**[0014]** A further aspect of the present invention is directed to a kit comprising: a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide.

**[0015]** Another aspect of the present invention is directed to a kit comprising: a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide.

**[0016]** An additional aspect of the present invention is directed to a method of modifying a target nucleic acid, the method comprising: introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide; contacting the target nucleic acid in the cell with a protein comprising at least a portion of the first Cas12a polypeptide and at least a portion of the second Cas12a polypeptide and a guide nucleic acid (e.g., a guide RNA), optionally wherein the protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**[0017]** Another aspect of the present invention is directed to a method of modifying a target nucleic acid, the method comprising: introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide; contacting the target nucleic acid in the cell with a protein comprising at least a portion of the polypeptide of interest and at least a portion of the Cas12a polypeptide and a guide nucleic acid (e.g., a guide RNA), optionally wherein the protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**[0018]** The invention further provides expression cassettes and/or vectors comprising a nucleic acid construct of the present invention, and cells comprising a polypeptide, fusion protein and/or nucleic acid construct of the present invention. Additionally, the invention provides kits comprising a nucleic acid construct of the present invention and expression cassettes, vectors and/or cells comprising the same.

**[0019]** It is noted that aspects of the invention described with respect to one embodiment, may be incorporated in a different embodiment although not specifically described relative thereto. That is, all embodiments and/or features of any embodiment can be combined in any way and/or combination. Applicant reserves the right to change any originally filed claim and/or file any new claim accordingly, including the right to be able to amend any originally filed claim to depend from and/or incorporate any feature of any other claim or claims although not originally claimed in that manner. These and other objects and/or aspects of the present invention are explained in detail in the specification set forth below. Further features, advantages and details of the present invention will be appreciated by those of ordinary skill in the art from a reading of the figures and the

detailed description of the preferred embodiments that follow, such description being merely illustrative of the present invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0020]** FIG. 1 is a schematic illustration of two exemplary split proteins for mCherry.

**[0021]** FIG. 2 is a graph showing the average mCherry fluorescence for different proteins, which can measure the intein splicing activity for a mCherry reconstitution assay. (1): is the expression of wildtype full length mCherry. (2): is only expressing N-terminal mCherry fused to N-terminal Npu split intein. (3): is only expressing C-terminal mCherry fused to C-terminal Npu split intein with the GEP mutation that enhances intein activity and robustness. (4) is only expressing C-terminal mCherry fused to wildtype (WT) C-terminal Npu split intein. (5) is expressing both N- and C-terminal mCherry parts, using the wildtype variant of the Npu intein. (6) is expressing both N- and C-terminal mCherry parts, using the GEP variant of the Npu intein.

**[0022]** FIG. 3 is a schematic illustration of two split proteins for Redraw Editor 2 (RE2) comprising Cas12a showing exemplary split sites according to some embodiments of the present invention.

**[0023]** FIG. 4 is a graph showing the effect of a two amino acid insertion (e.g., a CF or CA residues) on mCherry fluorescence.

**[0024]** FIG. 5 is a graph showing the percentage of indels generated using non-split and split Redraw editors using crRNAs according to some embodiments of the present invention.

**[0025]** FIG. 6 is a graph showing the percentage of indels generated using non-split and split Redraw editors using stagRNAs according to some embodiments of the present invention.

**[0026]** FIG. 7 is a graph showing the percentage of precise edits generated using non-split and split Redraw editors using stagRNAs according to some embodiments of the present invention.

#### DETAILED DESCRIPTION

**[0027]** The present invention now will be described hereinafter with reference to the accompanying drawings and examples, in which embodiments of the invention are shown. This description is not intended to be a detailed catalog of all the different ways in which the invention may be implemented, or all the features that may be added to the instant invention. For example, features illustrated with respect to one embodiment may be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from that embodiment. Thus, the invention contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following descriptions are intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations and variations thereof.



**[0028]** Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.

**[0029]** All publications, patent applications, patents and other references cited herein are incorporated by reference in their entireties for the teachings relevant to the sentence and/or paragraph in which the reference is presented.

**[0030]** Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the present invention also contemplates that in some embodiments of the invention, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a composition comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.

**[0031]** As used in the description of the invention and the appended claims, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

**[0032]** Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).

**[0033]** The term “about,” as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of  $\pm 10\%$ ,  $\pm 5\%$ ,  $\pm 1\%$ ,  $\pm 0.5\%$ , or even  $\pm 0.1\%$  of the specified value as well as the specified value. For example, “about X” where X is the measurable value, is meant to include X as well as variations of  $\pm 10\%$ ,  $\pm 5\%$ ,  $\pm 1\%$ ,  $\pm 0.5\%$ , or even  $\pm 0.1\%$  of X. A range provided herein for a measurable value may include any other range and/or individual value therein.

**[0034]** As used herein, phrases such as “between X and Y” and “between about X and Y” should be interpreted to include X and Y. As used herein, phrases such as “between about X and Y” mean “between about X and about Y” and phrases such as “from about X to Y” mean “from about X to about Y.”

**[0035]** Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if the range 10 to 15 is disclosed, then 11, 12, 13, and 14 are also disclosed.

**[0036]** The term “comprise,” “comprises” and “comprising” as used herein, specify the presence of the stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof.

**[0037]** As used herein, the transitional phrase “consisting essentially of” means that the scope of a claim is to be interpreted to encompass the specified materials or steps recited in the claim and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.

Thus, the term “consisting essentially of” when used in a claim of this invention is not intended to be interpreted to be equivalent to “comprising.”

**[0038]** As used herein, the terms “increase,” “increasing,” “enhance,” “enhancing,” “improve” and “improving” (and grammatical variations thereof) describe an elevation of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 150%, 200%, 300%, 400%, 500% or more such as compared to another measurable property or quantity (e.g., a control value).

**[0039]** As used herein, the terms “reduce,” “reduced,” “reducing,” “reduction,” “diminish,” and “decrease” (and grammatical variations thereof), describe, for example, a decrease of at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% such as compared to another measurable property or quantity (e.g., a control value). In some embodiments, the reduction can result in no or essentially no (i.e., an insignificant amount, e.g., less than about 10% or even 5%) detectable activity or amount.

**[0040]** A “heterologous nucleotide sequence” or a “recombinant nucleotide sequence” is a nucleotide sequence not naturally associated with a host cell into which it is introduced, including non-naturally occurring multiple copies of a naturally occurring nucleotide sequence.

**[0041]** A “native” or “wild-type” nucleic acid, nucleotide sequence, polypeptide or amino acid sequence refers to a naturally occurring or endogenous nucleic acid, nucleotide sequence, polypeptide or amino acid sequence. Thus, for example, a “native nucleic acid” is a nucleic acid that is naturally occurring in or endogenous to a reference organism. A “homologous” nucleic acid sequence is a nucleotide sequence naturally associated with a host cell into which it is introduced.

**[0042]** As used herein, the terms “nucleic acid,” “nucleic acid molecule,” “nucleotide sequence” and “polynucleotide” refer to RNA or DNA that is linear or branched, single or double stranded, or a hybrid thereof. The term also encompasses RNA/DNA hybrids. When dsRNA is produced synthetically, less common bases, such as inosine, 5-methylcytosine, 6-methyladenine, hypoxanthine and others can also be used for antisense, dsRNA, and ribozyme pairing. For example, polynucleotides that contain C-5 propyne analogues of uridine and cytidine have been shown to bind RNA with high affinity and to be potent antisense inhibitors of gene expression. Other modifications, such as modification to the phosphodiester backbone, or the 2'-hydroxy in the ribose sugar group of the RNA can also be made.

**[0043]** As used herein, the term “nucleotide sequence” refers to a heteropolymer of nucleotides or the sequence of these nucleotides from the 5' to 3' end of a nucleic acid molecule and includes DNA or RNA molecules, including cDNA, a DNA fragment or portion, genomic DNA, synthetic (e.g., chemically synthesized) DNA, plasmid DNA, mRNA, and anti-sense RNA, any of which can be single stranded or double stranded. The terms “nucleotide sequence” “nucleic acid,” “nucleic acid molecule,” “nucleic acid construct,” “recombinant nucleic acid,” “oligonucleotide” and “polynucleotide” are also used interchangeably herein to refer to a heteropolymer of nucleotides. Nucleic acid molecules and/or nucleotide sequences provided herein are presented herein in the 5' to 3' direction, from left to right

and are represented using the standard code for representing the nucleotide characters as set forth in the U.S. sequence rules, 37 CFR §§ 1.821-1.825 and the World Intellectual Property Organization (WIPO) Standard ST.25. A “5' region” as used herein can mean the region of a polynucleotide that is nearest the 5' end of the polynucleotide. Thus, for example, an element in the 5' region of a polynucleotide can be located anywhere from the first nucleotide located at the 5' end of the polynucleotide to the nucleotide located halfway through the polynucleotide. A “3' region” as used herein can mean the region of a polynucleotide that is nearest the 3' end of the polynucleotide. Thus, for example, an element in the 3' region of a polynucleotide can be located anywhere from the first nucleotide located at the 3' end of the polynucleotide to the nucleotide located halfway through the polynucleotide.

**[0044]** As used herein, the term “gene” refers to a nucleic acid molecule capable of being used to produce mRNA, antisense RNA, miRNA, anti-microRNA antisense oligodeoxyribonucleotide (AMO) and the like. Genes may or may not be capable of being used to produce a functional protein or gene product. Genes can include both coding and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences and/or 5' and 3' untranslated regions).

**[0045]** A polynucleotide, gene, or polypeptide may be “isolated” by which is meant a nucleic acid or polypeptide that is substantially or essentially free from components normally found in association with the nucleic acid or polypeptide, respectively, in its natural state. In some embodiments, such components include other cellular material, culture medium from recombinant production, and/or various chemicals used in chemically synthesizing the nucleic acid or polypeptide.

**[0046]** The term “mutation” refers to point mutations (e.g., missense, or nonsense, or insertions or deletions of single base pairs that result in frame shifts), insertions, deletions, and/or truncations. When the mutation is a substitution of a residue within an amino acid sequence with another residue, or a deletion or insertion of one or more residues within a sequence, the mutations are typically described by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue.

**[0047]** The terms “complementary” or “complementarity,” as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence “A-G-T” (5' to 3') binds to the complementary sequence “T-C-A” (3' to 5'). Complementarity between two single-stranded molecules may be “partial,” in which only some of the nucleotides bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands.

**[0048]** “Complement” as used herein can mean 100% complementarity with the comparator nucleotide sequence or it can mean less than 100% complementarity (e.g., “substantially complementary,” such as about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and the like, complementarity).

**[0049]** A “portion” or “fragment” of a nucleotide sequence or polypeptide (including a domain) will be understood to mean a nucleotide sequence or polypeptide of reduced length (e.g., reduced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more residue(s) (e.g., nucleotide(s) or peptide(s)) relative to a reference nucleotide sequence or polypeptide, respectively, and comprising, consisting essentially of and/or consisting of a nucleotide sequence or polypeptide of contiguous residues, respectively, identical or almost identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical) to the reference nucleotide sequence or polypeptide. In some embodiments, a portion of a reference nucleotide sequence or polypeptide is about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or more of the full-length reference nucleotide sequence or polypeptide. Such a nucleic acid fragment or portion according to the invention may be, where appropriate, included in a larger polynucleotide of which it is a constituent. As an example, a repeat sequence of guide nucleic acid of this invention may comprise a portion of a wild-type CRISPR-Cas repeat sequence (e.g., a wild-type Type V CRISPR Cas repeat, e.g., a repeat from the CRISPR Cas system that includes, but is not limited to, Cas12a (Cpf1), Cas12b, Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c1, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b, and/or Cas14c, and the like). Similarly a portion of a polypeptide may be included in a larger polypeptide of which it is a constituent.

**[0050]** Different nucleic acids or proteins having homology are referred to herein as “homologues.” The term homologue includes homologous sequences from the same and other species and orthologous sequences from the same and other species. “Homology” refers to the level of similarity between two or more nucleic acid and/or amino acid sequences in terms of percent of positional identity (i.e., sequence similarity or identity). Homology also refers to the concept of similar functional properties among different nucleic acids or proteins. Thus, the compositions and methods of the invention further comprise homologues to the nucleotide sequences and polypeptides of this invention. “Orthologous” and “orthologs” as used herein, refers to homologous nucleotide sequences and/or amino acid sequences in different species that arose from a common ancestral gene during speciation. A homologue or ortholog of a nucleotide sequence of this invention has a substantial sequence identity (e.g., at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100%) to said nucleotide sequence of the invention.

**[0051]** As used herein “sequence identity” refers to the extent to which two optimally aligned polynucleotide or polypeptide sequences are invariant throughout a window of alignment of components, e.g., nucleotides or amino acids. “Identity” can be readily calculated by known methods including, but not limited to, those described in: *Computational Molecular Biology* (Lesk, A. M., ed.) Oxford University Press, New York (1988); *Biocomputing: Informatics and Genome Projects* (Smith, D. W., ed.) Academic Press, New York (1993); *Computer Analysis of Sequence Data*,

*Part I* (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, New Jersey (1994); *Sequence Analysis in Molecular Biology* (von Heinje, G., ed.) Academic Press (1987); and *Sequence Analysis Primer* (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).

**[0052]** As used herein, the term “percent sequence identity” or “percent identity” refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference (“query”) polynucleotide molecule (or its complementary strand) as compared to a test (“subject”) polynucleotide molecule (or its complementary strand) when the two sequences are optimally aligned. In some embodiments, “percent identity” can refer to the percentage of identical amino acids in an amino acid sequence as compared to a reference polypeptide.

**[0053]** As used herein, the phrase “substantially identical,” or “substantial identity” in the context of two nucleic acid molecules, nucleotide sequences or protein sequences, refers to two or more sequences or subsequences that have at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% nucleotide or amino acid residue identity, when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection. In some embodiments of the invention, the substantial identity exists over a region of consecutive nucleotides of a nucleotide sequence of the invention that is about 10 nucleotides to about 20 nucleotides, about 10 nucleotides to about 25 nucleotides, about 10 nucleotides to about 30 nucleotides, about 15 nucleotides to about 25 nucleotides, about 30 nucleotides to about 40 nucleotides, about 50 nucleotides to about 60 nucleotides, about 70 nucleotides to about 80 nucleotides, about 90 nucleotides to about 100 nucleotides, or more nucleotides in length, and any range therein, up to the full length of the sequence. In some embodiments, the nucleotide sequences can be substantially identical over at least about 20 nucleotides (e.g., about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 nucleotides). In some embodiments, a substantially identical nucleotide or protein sequence performs substantially the same function as the nucleotide (or encoded protein sequence) to which it is substantially identical.

**[0054]** For sequence comparison, typically one sequence acts as a reference sequence to which one or more test sequence(s) are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

**[0055]** Optimal alignment of sequences for aligning a comparison window are well known to those skilled in the art and may be conducted by tools such as the local homology algorithm of Smith and Waterman, the homology alignment algorithm of Needleman and Wunsch, the search for similarity method of Pearson and Lipman, and optionally by computerized implementations of these algorithms such as GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG® Wisconsin Package® (Accelrys Inc., San Diego, CA) as well as web-based alignment programs such

as Clustal Omega, EMBOSS Needle, EMBOSS Stretcher, EMBOSS Water, LALIGN, GGSEARCH2SEQ, EMBOSS Cons, Kalign, MAFFT, MUSCLE, and T-Coffee. In some embodiments, an “optimal alignment” of two sequences (e.g., two polypeptide sequences) is the highest scoring alignment, optionally from an alignment conducted by a tool such as the local homology algorithm of Smith and Waterman, the homology alignment algorithm of Needleman and Wunsch, the search for similarity method of Pearson and Lipman, GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG® Wisconsin Package® (Accelrys Inc., San Diego, CA), Clustal Omega, EMBOSS Needle, EMBOSS Stretcher, EMBOSS Water, LALIGN, GGSEARCH2SEQ, EMBOSS Cons, Kalign, MAFFT, MUSCLE, and/or T-Coffee. In some embodiments, an “optimal alignment” of two sequences (e.g., two polypeptide sequences) is the alignment that provides the highest percent sequence identity, optionally allowing for one or more gap(s) to be introduced into one or both sequences. An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical components which are shared by the two aligned sequences divided by the total number of components in the reference sequence segment, e.g., the entire reference sequence or a smaller defined part of the reference sequence. Percent sequence identity is represented as the identity fraction multiplied by 100. The comparison of one or more sequence(s) may be to a full-length sequence or a portion thereof, or to a longer sequence. For purposes of this invention “percent identity” and/or optimal alignment may be determined using Basic Local Alignment Search Tool (BLAST) provided by the National Center for Biotechnology Information such as BLASTX, for translated nucleotide sequences, BLASTN for polynucleotide sequences, and BLASTP for polypeptide sequences.

**[0056]** Two nucleotide sequences may also be considered substantially complementary when the two sequences hybridize to each other under stringent conditions. In some representative embodiments, two nucleotide sequences considered to be substantially complementary hybridize to each other under highly stringent conditions.

**[0057]** “Stringent hybridization conditions” and “stringent hybridization wash conditions” in the context of nucleic acid hybridization experiments such as Southern and Northern hybridizations are sequence dependent, and are different under different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in Tijssen *Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes* part I chapter 2 “Overview of principles of hybridization and the strategy of nucleic acid probe assays” Elsevier, New York (1993). Generally, highly stringent hybridization and wash conditions are selected to be about 5° C. lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH.

**[0058]** The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the  $T_m$  for a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleotide sequences which have more than 100 complementary residues on a filter in a Southern or northern blot is 50% formamide with 1 mg of heparin at 42° C., with the hybridization being carried out overnight. An example of highly stringent wash

conditions is 0.1 5M NaCl at 72° C. for about 15 minutes. An example of stringent wash conditions is a 0.2×SSC wash at 65° C. for 15 minutes (see, Sambrook, *infra*, for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example of a medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is 1×SSC at 45° C. for 15 minutes. An example of a low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4-6×SSC at 40° C. for 15 minutes. For short probes (e.g., about 10 to 50 nucleotides), stringent conditions typically involve salt concentrations of less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3, and the temperature is typically at least about 30° C. Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. In general, a signal to noise ratio of 2× (or higher) than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization. Nucleotide sequences that do not hybridize to each other under stringent conditions are still substantially identical if the proteins that they encode are substantially identical. This can occur, for example, when a copy of a nucleotide sequence is created using the maximum codon degeneracy permitted by the genetic code.

**[0059]** A polynucleotide and/or recombinant nucleic acid construct of this invention can be codon optimized for expression. In some embodiments, a polynucleotide, nucleic acid construct, expression cassette, and/or vector of the present invention (e.g., that comprises/encodes a fusion protein, a nucleic acid binding polypeptide (e.g., a DNA binding polypeptide such as a sequence-specific DNA binding domain from a polynucleotide-guided endonuclease, a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN), an Argonaute protein, and/or a CRISPR-Cas effector protein), a guide nucleic acid, a cytosine deaminase and/or adenine deaminase) may be codon optimized for expression in an organism (e.g., an animal such as a human, a plant, a fungus, an archaeon, or a bacterium). In some embodiments, the codon optimized nucleic acid constructs, polynucleotides, expression cassettes, and/or vectors of the invention have about 70% to about 99.9% (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% or 100%) identity or more to the reference nucleic acid constructs, polynucleotides, expression cassettes, and/or vectors but which have not been codon optimized.

**[0060]** In any of the embodiments described herein, a polynucleotide or nucleic acid construct of the invention may be operatively associated with a variety of promoters and/or other regulatory elements for expression in an organism or cell thereof (e.g., a mammal and/or a mammalian cell, a plant and/or a cell of a plant, etc.). Thus, in some embodiments, a polynucleotide or nucleic acid construct of this invention may further comprise one or more promoters, introns, enhancers, and/or terminators operably linked to one or more nucleotide sequences. In some embodiments, a promoter may be operably associated with an intron (e.g., Ubi1 promoter and intron). In some embodiments, a promoter associated with an intron maybe referred to as a “promoter region” (e.g., Ubi1 promoter and intron).

**[0061]** By “operably linked” or “operably associated” as used herein in reference to polynucleotides, it is meant that

the indicated elements are functionally related to each other, and are also generally physically related. Thus, the term “operably linked” or “operably associated” as used herein, refers to nucleotide sequences on a single nucleic acid molecule that are functionally associated. Thus, a first nucleotide sequence that is operably linked to a second nucleotide sequence means a situation when the first nucleotide sequence is placed in a functional relationship with the second nucleotide sequence. For instance, a promoter is operably associated with a nucleotide sequence if the promoter effects the transcription or expression of said nucleotide sequence. Those skilled in the art will appreciate that the control sequences (e.g., promoter) need not be contiguous with the nucleotide sequence to which it is operably associated, as long as the control sequences function to direct the expression thereof. Thus, for example, intervening untranslated, yet transcribed, nucleic acid sequences can be present between a promoter and the nucleotide sequence, and the promoter can still be considered “operably linked” to the nucleotide sequence.

**[0062]** As used herein, the term “linked,” or “fused” in reference to polypeptides, refers to the covalent attachment of one polypeptide to another. A polypeptide may be linked or fused to another polypeptide (e.g., at the N-terminus or the C-terminus) directly (e.g., via a peptide bond) or through a linker (e.g., a peptide linker). Two polypeptides being directly fused (e.g., a direct linkage) refers to the covalent attachment of one amino acid residue of a first polypeptide of the two polypeptides to an amino acid residue of a second polypeptide of the two polypeptides without an intervening element between the two amino acid residues. For example, first and second polypeptides may be directly linked via a peptide bond between the first and second polypeptides without an intervening element (e.g., a linker) between the first and second polypeptides. Two polypeptides being indirectly fused (e.g., an indirect linkage) refers to an intervening element (e.g., a linker such as a peptide linker) that is present between the two polypeptides and is covalently attached to each, optionally the intervening element may attach one end of a first polypeptide of the two polypeptides to an end of the second polypeptide of the two polypeptides.

**[0063]** A “fusion protein” as used herein refers to two or more polypeptides that are covalently attached (e.g., directly or indirectly) so that they are transcribed and translated as a single unit and thereby produce a single polypeptide comprising the two or more polypeptides. In some embodiments, the two or more polypeptides may naturally be encoded by separate genes, but, in the form of a fusion protein, are encoded by a single gene.

**[0064]** The term “linker” is art-recognized and refers to a chemical group or a molecule linking two molecules or moieties, e.g., linking two polypeptides or domains of a fusion protein, such as, for example, a Cas12a polypeptide and an intein polypeptide. A linker may be comprised of a single linking molecule (e.g., a single amino acid) or may comprise more than one linking molecule. In some embodiments, the linker can be an organic molecule, group, polymer, or chemical moiety such as a bivalent organic moiety. In some embodiments, the linker may be an amino acid or it may be a peptide. In some embodiments, the linker is a peptide (e.g., a peptide linker).

**[0065]** In some embodiments, a peptide linker useful with this invention may be about 2 to about 100 or more amino acids in length, for example, about 2, 3, 4, 5, 6, 7, 8, 9, 10,

11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids in length (e.g., about 2 to about 40, about 2 to about 50, about 2 to about 60, about 4 to about 40, about 4 to about 50, about 4 to about 60, about 5 to about 40, about 5 to about 50, about 5 to about 60, about 9 to about 40, about 9 to about 50, about 9 to about 60, about 10 to about 40, about 10 to about 50, about 10 to about 60, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 amino acids to about 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more amino acids in length (e.g., about 105, 110, 115, 120, 130, 140 150 or more amino acids in length)). In some embodiments, a peptide linker may comprise glycine (G) and serine (S) such as a GS linker. In some embodiments, a peptide linker may comprise a cysteine (C) and alanine (A) such as a CA linker. In some embodiments, a peptide linker may comprise a cysteine (C) and phenylalanine (F) such as a CF linker. In some embodiments, the peptide linker is a GS linker, a CA linker, or a CF linker having 2, 3, or 4 amino acid residues, optionally 2 or 4 amino acid residues. In some embodiments, the peptide linker has one of the amino acid sequences of SEQ ID NOs:1-35. In some embodiments, the peptide linker may comprise an amino acid sequence of CA, CF, (GGS)<sub>n</sub>, GS, SG, GSSG (SEQ ID NO:31), GSSGSS (SEQ ID NO:32), GSSGSSGS (SEQ ID NO:33), (GSS)<sub>n</sub> (SEQ ID NO:34), (GSS)<sub>n</sub>GS (SEQ ID NO:35), S(GGS)<sub>n</sub> (SEQ ID NO:25), SGGS (SEQ ID NO:26), (GSS)<sub>n</sub>G (SEQ ID NO:191), or (GGGGS)<sub>n</sub> (SEQ ID NO:27), wherein n is an integer of 1-20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, the peptide linker may comprise the amino acid sequence: SGGSGGSGGS (SEQ ID NO:28). In some embodiments, the peptide linker may comprise the amino acid sequence: SGSETPGTSESATPES (SEQ ID NO:29), also referred to as the XTEN linker. In some embodiments, the peptide linker may comprise the amino acid sequence: SGGSSGGSSG-SETPGTSESATPESGGSSGGS (SEQ ID NO:30), also referred to as the GS-XTEN-GS linker. In some embodiments, a peptide linker has an amino acid sequence of SEQ ID NOs:189 or SEQ ID NOs:190.

**[0066]** As used herein, the term “linked,” or “fused” in reference to polynucleotides, refers to the covalent attachment of one polynucleotide to another polynucleotide. In some embodiments, two or more polynucleotide molecules may be linked by a linker that can be an organic molecule, group, polymer, or chemical moiety such as a bivalent organic moiety. A polynucleotide may be linked or fused to another polynucleotide (at the 5' end or the 3' end) via a direct covalent linkage or through one or more linking nucleotides. In some embodiments, a polynucleotide motif of a certain structure may be inserted within another polynucleotide sequence (e.g., extension of the hairpin structure in guide RNA). In some embodiments, the linking nucleotides may be naturally occurring nucleotides. In some embodiments, the linking nucleotides may be non-naturally occurring nucleotides. Two polynucleotides being directly

fused (e.g., a direct linkage) refers to the covalent attachment of one nucleotide of a first polynucleotide of the two polynucleotides to a nucleotide of a second polynucleotide of the two polynucleotides without an intervening element between the two polynucleotides. For example, first and second polynucleotides may be directly linked via a phosphodiester bond between the first and second polynucleotides without an intervening element (e.g., a linker) between the first and second polynucleotides. Two polynucleotides being indirectly fused (e.g., an indirect linkage) refers to an intervening element (e.g., a linker such as a polynucleotide linker) that is present between the two polynucleotides and is covalently attached to each, optionally the intervening element attaches one end of a first polynucleotide of the two polynucleotides to an end of the second polynucleotide of the two polynucleotides.

**[0067]** A “promoter” is a nucleotide sequence that controls or regulates the transcription of a nucleotide sequence (e.g., a coding sequence) that is operably associated with the promoter. The coding sequence controlled or regulated by a promoter may encode a polypeptide and/or a functional RNA. Typically, a “promoter” refers to a nucleotide sequence that contains a binding site for RNA polymerase II and directs the initiation of transcription. In general, promoters are found 5', or upstream, relative to the start of the coding region of the corresponding coding sequence. A promoter may comprise other elements that act as regulators of gene expression; e.g., a promoter region. These include a TATA box consensus sequence, and often a CAAT box consensus sequence (Breathnach and Chambon, (1981) *Annu. Rev. Biochem.* 50:349). In plants, the CAAT box may be substituted by the AGGA box (Messing et al., (1983) in *Genetic Engineering of Plants*, T. Kosuge, C. Meredith and A. Hollaender (eds.), Plenum Press, pp. 211-227). In some embodiments, a promoter region may comprise at least one intron (e.g., SEQ ID NO:36 or SEQ ID NO:37).

**[0068]** Promoters useful with this invention can include, for example, constitutive, inducible, temporally regulated, developmentally regulated, chemically regulated, tissue-preferred and/or tissue-specific promoters for use in the preparation of recombinant nucleic acid molecules, e.g., “synthetic nucleic acid constructs” or “protein-RNA complex.” These various types of promoters are known in the art.

**[0069]** The choice of promoter may vary depending on the temporal and spatial requirements for expression, and also may vary based on the host cell to be transformed. Promoters for many different organisms are well known in the art. Based on the extensive knowledge present in the art, the appropriate promoter can be selected for the particular host organism of interest. Thus, for example, much is known about promoters upstream of highly constitutively expressed genes in model organisms and such knowledge can be readily accessed and implemented in other systems as appropriate.

**[0070]** In some embodiments, a promoter functional in a plant may be used with the constructs of this invention. Non-limiting examples of a promoter useful for driving expression in a plant include the promoter of the RubisCo small subunit gene 1 (PrbcS1), the promoter of the actin gene (Pactin), the promoter of the nitrate reductase gene (Pnr) and the promoter of duplicated carbonic anhydrase gene 1 (Pdca1) (See, Walker et al. *Plant Cell Rep.* 23:727-735 (2005); Li et al. *Gene* 403:132-142 (2007); Li et al. *Mol Biol. Rep.* 37:1143-1154 (2010)). PrbcS1 and Pactin are

constitutive promoters and Pnr and Pdca1 are inducible promoters. Pnr is induced by nitrate and repressed by ammonium (Li et al. *Gene* 403:132-142 (2007)) and Pdca1 is induced by salt (Li et al. *Mol Biol. Rep.* 37:1143-1154 (2010)). In some embodiments, a promoter useful with this invention is RNA polymerase II (Pol II) promoter. In some embodiments, a U6 promoter or a 7SL promoter from *Zea mays* may be useful with constructs of this invention. In some embodiments, the U6c promoter and/or 7SL promoter from *Zea mays* may be useful for driving expression of a guide nucleic acid. In some embodiments, a U6c promoter, U6i promoter and/or 7SL promoter from *Glycine max* may be useful with constructs of this invention. In some embodiments, the U6c promoter, U6i promoter and/or 7SL promoter from *Glycine max* may be useful for driving expression of a guide nucleic acid.

**[0071]** Examples of constitutive promoters useful for plants include, but are not limited to, cestrum virus promoter (cmp) (U.S. Pat. No. 7,166,770), the rice actin 1 promoter (Wang et al. (1992) *Mol. Cell. Biol.* 12:3399-3406; as well as U.S. Pat. No. 5,641,876), CaMV 35S promoter (Odell et al. (1985) *Nature* 313:810-812), CaMV 19S promoter (Lawton et al. (1987) *Plant Mol. Biol.* 9:315-324), nos promoter (Ebert et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:5745-5749), Adh promoter (Walker et al. (1987) *Proc. Natl. Acad. Sci. USA* 84:6624-6629), sucrose synthase promoter (Yang & Russell (1990) *Proc. Natl. Acad. Sci. USA* 87:4144-4148), and the ubiquitin promoter. The constitutive promoter derived from ubiquitin accumulates in many cell types. Ubiquitin promoters have been cloned from several plant species for use in transgenic plants, for example, sunflower (Binet et al., 1991. *Plant Science* 79: 87-94), maize (Christensen et al., 1989. *Plant Molec. Biol.* 12: 619-632), and *arabidopsis* (Norris et al. 1993. *Plant Molec. Biol.* 21:895-906). The maize ubiquitin promoter (UbiP) has been developed in transgenic monocot systems and its sequence and vectors constructed for monocot transformation are disclosed in the European patent publication EP0342926. The ubiquitin promoter is suitable for the expression of the nucleotide sequences of the invention in transgenic plants, especially monocotyledons. Further, the promoter expression cassettes described by McElroy et al. (*Mol. Gen. Genet.* 231: 150-160 (1991)) can be easily modified for the expression of the nucleotide sequences of the invention and are particularly suitable for use in monocotyledonous hosts.

**[0072]** In some embodiments, tissue specific/tissue preferred promoters can be used for expression of a heterologous polynucleotide in a plant cell. Tissue specific or preferred expression patterns include, but are not limited to, green tissue specific or preferred, root specific or preferred, stem specific or preferred, flower specific or preferred or pollen specific or preferred. Promoters suitable for expression in green tissue include many that regulate genes involved in photosynthesis and many of these have been cloned from both monocotyledons and dicotyledons. In one embodiment, a promoter useful with the invention is the maize PEPC promoter from the phosphoenol carboxylase gene (Hudspeth & Grula, *Plant Molec. Biol.* 12:579-589 (1989)). Non-limiting examples of tissue-specific promoters include those associated with genes encoding the seed storage proteins (such as 0-conglycinin, cruciferin, napin and phaseolin), zein or oil body proteins (such as oleosin), or proteins involved in fatty acid biosynthesis (including acyl carrier protein, stearoyl-ACP desaturase and fatty acid

desaturases (fad 2-1)), and other nucleic acids expressed during embryo development (such as Bce4, see, e.g., Kridl et al. (1991) *Seed Sci. Res.* 1:209-219; as well as EP Patent No. 255378). Tissue-specific or tissue-preferential promoters useful for the expression of the nucleotide sequences of the invention in plants, particularly maize, include but are not limited to those that direct expression in root, pith, leaf or pollen. Such promoters are disclosed, for example, in WO 93/07278, incorporated by reference herein for its disclosure of promoters. Other non-limiting examples of tissue specific or tissue preferred promoters useful with the invention the cotton rubisco promoter disclosed in U.S. Pat. No. 6,040,504; the rice sucrose synthase promoter disclosed in U.S. Pat. No. 5,604,121; the root specific promoter described by de Framond (FEBS 290:103-106 (1991); European patent EP 0452269 to Ciba-Geigy); the stem specific promoter described in U.S. Pat. No. 5,625,136 (to Ciba-Geigy) and which drives expression of the maize trpA gene; the cestrum yellow leaf curling virus promoter disclosed in WO 01/73087; and pollen specific or preferred promoters including, but not limited to, ProOsLPS10 and ProOsLPS11 from rice (Nguyen et al. *Plant Biotechnol. Reports* 9(5):297-306 (2015)), ZmSTK2\_USP from maize (Wang et al. *Genome* 60(6):485-495 (2017)), LAT52 and LAT59 from tomato (Twell et al. *Development* 109(3):705-713 (1990)), Zm13 (U.S. Pat. No. 10,421,972), PLA<sub>2</sub>-6 promoter from *arabidopsis* (U.S. Pat. No. 7,141,424), and/or the ZmC5 promoter from maize (International PCT Publication No. WO 1999/042587).

**[0073]** Additional examples of plant tissue-specific/tissue preferred promoters include, but are not limited to, the root hair-specific cis-elements (RHEs) (KIM ET AL. *The Plant Cell* 18:2958-2970 (2006)), the root-specific promoters RCc3 (Jeong et al. *Plant Physiol.* 153:185-197 (2010)) and RB7 (U.S. Pat. No. 5,459,252), the lectin promoter (Lindstrom et al. (1990) *Der. Genet.* 11:160-167; and Vodkin (1983) *Prog. Clin. Biol. Res.* 138:87-98), corn alcohol dehydrogenase 1 promoter (Dennis et al. (1984) *Nucleic Acids Res.* 12:3983-4000), S-adenosyl-L-methionine synthetase (SAMS) (Vander Mijnsbrugge et al. (1996) *Plant and Cell Physiology*, 37(8):1108-1115), corn light harvesting complex promoter (Bansal et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:3654-3658), corn heat shock protein promoter (O'Dell et al. (1985) *EMBO J.* 5:451-458; and Rochester et al. (1986) *EMBO J.* 5:451-458), pea small subunit RuBP carboxylase promoter (Cashmore, "Nuclear genes encoding the small subunit of ribulose-1,5-bisphosphate carboxylase" pp. 29-39 In: *Genetic Engineering of Plants* (Hollaender ed., Plenum Press 1983; and Poulsen et al. (1986) *Mol. Gen. Genet.* 205:193-200), Ti plasmid mannopine synthase promoter (Langridge et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:3219-3223), Ti plasmid nopaline synthase promoter (Langridge et al. (1989), supra), *petunia* chalcone isomerase promoter (van Tunen et al. (1988) *EMBO J.* 7:1257-1263), bean glycine rich protein 1 promoter (Keller et al. (1989) *Genes Dev.* 3:1639-1646), truncated CaMV 35S promoter (O'Dell et al. (1985) *Nature* 313:810-812), potato patatin promoter (Wenzler et al. (1989) *Plant Mol. Biol.* 13:347-354), root cell promoter (Yamamoto et al. (1990) *Nucleic Acids Res.* 18:7449), maize zein promoter (Kriz et al. (1987) *Mol. Gen. Genet.* 207:90-98; Langridge et al. (1983) *Cell* 34:1015-1022; Reina et al. (1990) *Nucleic Acids Res.* 18:6425; Reina et al. (1990) *Nucleic Acids Res.* 18:7449; and Wandelt et al. (1989) *Nucleic Acids Res.* 17:2354), globulin-1 promoter

(Belanger et al. (1991) *Genetics* 129:863-872),  $\alpha$ -tubulin promoter (Sullivan et al. (1989) *Mol. Gen. Genet.* 215:431-440), PEPCase promoter (Hudspeth & Grula (1989) *Plant Mol. Biol.* 12:579-589), R gene complex-associated promoters (Chandler et al. (1989) *Plant Cell* 1:1175-1183), and chalcone synthase promoters (Franken et al. (1991) *EMBO J.* 10:2605-2612).

**[0074]** Useful for seed-specific expression is the pea vicilin promoter (Czako et al. (1992) *Mol. Gen. Genet.* 235:33-40); as well as the seed-specific promoters disclosed in U.S. Pat. No. 5,625,136. Useful promoters for expression in mature leaves are those that are switched at the onset of senescence, such as the SAG promoter from *Arabidopsis* (Gan et al. (1995) *Science* 270:1986-1988).

**[0075]** In addition, promoters functional in chloroplasts can be used. Non-limiting examples of such promoters include the bacteriophage T3 gene 9 5' UTR and other promoters disclosed in U.S. Pat. No. 7,579,516. Other promoters useful with the invention include but are not limited to the S-E9 small subunit RuBP carboxylase promoter and the Kunitz trypsin inhibitor gene promoter (Kti3).

**[0076]** Additional regulatory elements useful with this invention include, but are not limited to, introns, enhancers, termination sequences and/or 5' and 3' untranslated regions.

**[0077]** An intron useful with this invention can be an intron identified in and isolated from a plant and then inserted into an expression cassette to be used in transformation of a plant. As would be understood by those of skill in the art, introns can comprise the sequences required for self-excision and are incorporated into nucleic acid constructs/expression cassettes in frame. An intron can be used either as a spacer to separate multiple protein-coding sequences in one nucleic acid construct, or an intron can be used inside one protein-coding sequence to, for example, stabilize the mRNA. If they are used within a protein-coding sequence, they are inserted "in-frame" with the excision sites included. Introns may also be associated with promoters to improve or modify expression. As an example, a promoter/intron combination useful with this invention includes but is not limited to that of the maize Ubi1 promoter and intron.

**[0078]** Non-limiting examples of introns useful with the present invention include introns from the ADHI gene (e.g., Adh1-S introns 1, 2 and 6), the ubiquitin gene (Ubi1), the RuBisCO small subunit (rbcS) gene, the RuBisCO large subunit (rbcL) gene, the actin gene (e.g., actin-1 intron), the pyruvate dehydrogenase kinase gene (pdk), the nitrate reductase gene (nr), the duplicated carbonic anhydrase gene 1 (Tdca1), the psbA gene, the atpA gene, or any combination thereof.

**[0079]** An "editing system" as used herein refers to any site-specific (e.g., sequence-specific) nucleic acid editing system now known or later developed, which system can introduce a modification (e.g., a mutation) in a nucleic acid in target specific manner. For example, an editing system (e.g., a site- and/or sequence-specific editing system) can include, but is not limited to, a CRISPR-Cas editing system, a meganuclease editing system, a zinc finger nuclease (ZFN) editing system, a transcription activator-like effector nuclease (TALEN) editing system, a base editing system and/or a prime editing system, each of which may comprise one or more polypeptide(s) and/or one or more polynucleotide(s) that when present and/or expressed together (e.g., as a system) in a composition and/or cell can modify (e.g.,

mutate) a target nucleic acid in a sequence specific manner. In some embodiments, an editing system (e.g., a site- and/or sequence-specific editing system) can comprise one or more polynucleotide(s) and/or one or more polypeptide(s), including but not limited to a nucleic acid binding polypeptide (e.g., a DNA binding domain), a nuclease, another polypeptide, and/or a polynucleotide. In some embodiments, a CRISPR-Cas editing system is provided, wherein a fusion protein of the present invention is used to provide a Cas12a protein of the CRISPR-Cas editing system. An editing system of the present invention may modify a target nucleic acid that is present in a cell or outside a cell (e.g., a method of the present invention may be carried out in vitro, ex vivo, and/or in vivo).

**[0080]** In some embodiments, an editing system comprises one or more sequence-specific nucleic acid binding polypeptide(s) (e.g., a DNA binding domain) that can be from, for example, a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease (e.g., CRISPR-Cas effector protein), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN) and/or an Argonaute protein. In some embodiments, an editing system comprises one or more cleavage polypeptide(s) (e.g., nucleases) including, but not limited to, an endonuclease (e.g., Fok1), a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease (e.g., CRISPR-Cas effector protein), a zinc finger nuclease, and/or a transcription activator-like effector nuclease (TALEN).

**[0081]** A "nucleic acid binding polypeptide" as used herein refers to a polypeptide or domain that binds and/or is capable of binding a nucleic acid (e.g., a target nucleic acid). A DNA binding domain or DNA binding polypeptide is an exemplary nucleic acid binding polypeptide and may be a site- and/or sequence-specific nucleic acid binding domain. In some embodiments, a nucleic acid binding polypeptide may be a sequence-specific nucleic acid binding polypeptide such as, but not limited to, a sequence-specific binding domain from, for example, a polynucleotide-guided endonuclease, a CRISPR-Cas effector protein (e.g., a CRISPR-Cas endonuclease), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN) and/or an Argonaute protein. In some embodiments, a nucleic acid binding polypeptide comprises a cleavage domain (e.g., a nuclease domain) such as, but not limited to, an endonuclease (e.g., Fok1), a polynucleotide-guided endonuclease, a CRISPR-Cas endonuclease, a zinc finger nuclease, and/or a transcription activator-like effector nuclease (TALEN). In some embodiments, the nucleic acid binding polypeptide associates with and/or is capable of associating with (e.g., forms a complex with) one or more nucleic acid molecule(s) (e.g., forms a complex with a guide nucleic acid as described herein), which may direct and/or guide the nucleic acid binding polypeptide to a specific target nucleotide sequence (e.g., a gene locus of a genome) that is complementary to the one or more nucleic acid molecule(s) (or a portion or region thereof), thereby causing the nucleic acid binding polypeptide to bind to the nucleotide sequence at the specific target site. In some embodiments, the nucleic acid binding polypeptide is a CRISPR-Cas effector protein as described herein.

**[0082]** In some embodiments, an editing system comprises or is a ribonucleoprotein such as an assembled ribonucleoprotein complex (e.g., a ribonucleoprotein that comprises a CRISPR-Cas effector protein, a guide nucleic acid, and

optionally a deaminase). In some embodiments, a ribonucleoprotein of an editing system may be assembled together (e.g., a pre-assembled ribonucleoprotein including a CRISPR-Cas effector protein, a guide nucleic acid, and optionally a deaminase) such as when contacted to a target nucleic acid or when introduced into a cell (e.g., a mammalian cell or a plant cell) (e.g., at the time of contacting the components of the ribonucleoprotein to a target nucleic acid and/or at the time of introducing the components of the ribonucleoprotein into a cell). In some embodiments, a ribonucleoprotein of an editing system may assemble into a complex (e.g., a non-covalently bound complex) while a portion of the ribonucleoprotein is contacting a target nucleic acid and/or may assemble after and/or during introduction into a plant cell. In some embodiments, an editing system may be assembled (e.g., into a non-covalently bound complex) when introduced into a plant cell. In some embodiments, a ribonucleoprotein may comprise a fusion protein of the present invention, a guide nucleic acid, and optionally a deaminase. In some embodiments, a ribonucleoprotein of an editing system may be contacted to a target nucleic acid and/or may be introduced into a plant cell. In some embodiments, an editing system may be assembled (e.g., into a non-covalently bound complex) when introduced into a plant cell. In some embodiments, a ribonucleoprotein may comprise a protein of the present invention (e.g., a protein prepared using a composition and/or method of the present invention), a guide nucleic acid, and optionally a deaminase and/or reverse transcriptase. In some embodiments, a protein of the present invention comprises a CRISPR-Cas effector protein and the protein is used in place of (e.g., substituted for) a CRISPR-Cas effector protein (e.g., in a composition, complex, kit, method, and/or system such as an editing system described herein) and/or functions as a CRISPR-Cas effector protein, templated editor, and/or base editor, optionally in a composition, complex, ribonucleoprotein, kit, method, system, and/or editing system of the present invention.

**[0083]** The terms “transgene” or “transgenic” as used herein refer to at least one nucleic acid sequence that is taken from the genome of one organism or produced synthetically, and which is then introduced into a host cell (e.g., a plant cell) or organism or tissue of interest and which is subsequently integrated into the host’s genome by means of “stable” transformation or transfection approaches. In contrast, the term “transient” transformation or transfection or introduction refers to a way of introducing molecular tools including at least one nucleic acid (DNA, RNA, single-stranded or double-stranded or a mixture thereof) and/or at least one amino acid sequence, optionally comprising suitable chemical or biological agents, to achieve a transfer into at least one compartment of interest of a cell, including, but not restricted to, the cytoplasm, an organelle, including the nucleus, a mitochondrion, a vacuole, a chloroplast, or into a membrane, resulting in transcription and/or translation and/or association and/or activity of the at least one molecule introduced without achieving a stable integration or incorporation into the genome and thus without inheritance of the respective at least one molecule introduced into the genome of a cell. The term “transgene-free” refers to a condition in which a transgene is not present or found in the genome of a host cell or tissue or organism of interest.

**[0084]** In some embodiments, a polynucleotide and/or a nucleic acid construct of the invention can be an “expression

cassette” or can be comprised within an expression cassette. As used herein, “expression cassette” means a recombinant nucleic acid molecule comprising, for example, a nucleic acid construct of the invention (e.g., a polynucleotide encoding a fusion protein of the present invention, a polynucleotide encoding a cytosine deaminase, a polynucleotide encoding an adenine deaminase, a polynucleotide encoding a deaminase fusion protein, a polynucleotide encoding a peptide tag, a polynucleotide encoding an affinity polypeptide, a polynucleotide encoding a glycosylase, and/or a polynucleotide comprising a guide nucleic acid), wherein the nucleic acid construct is operably associated with at least a control sequence (e.g., a promoter). Thus, some embodiments of the invention provide expression cassettes designed to express, for example, a nucleic acid construct of the invention. When an expression cassette comprises more than one polynucleotide, the polynucleotides may be operably linked to a single promoter that drives expression of all of the polynucleotides or the polynucleotides may be operably linked to one or more separate promoters (e.g., three polynucleotides may be driven by one, two or three promoters in any combination). Thus, for example, a polynucleotide encoding a fusion protein, a polynucleotide encoding a deaminase (e.g., an adenine deaminase), and a polynucleotide comprising a guide nucleic acid comprised in an expression cassette may each be operably associated with a single promoter or one or more of the polynucleotide(s) may be operably associated with separate promoters (e.g., two or three promoters) in any combination, which may be the same or different from each other.

**[0085]** In some embodiments, an expression cassette comprising the polynucleotides/nucleic acid constructs of the invention may be optimized for expression in an organism (e.g., an animal, a plant, a bacterium and the like).

**[0086]** An expression cassette comprising a nucleic acid construct of the invention may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components (e.g., a promoter from the host organism operably linked to a polynucleotide of interest to be expressed in the host organism, wherein the polynucleotide of interest is from a different organism than the host or is not normally found in association with that promoter). An expression cassette may also be one that is naturally occurring but has been obtained in a recombinant form useful for heterologous expression.

**[0087]** An expression cassette can optionally include a transcriptional and/or translational termination region (i.e., termination region) and/or an enhancer region that is functional in the selected host cell. A variety of transcriptional terminators and enhancers are known in the art and are available for use in expression cassettes. Transcriptional terminators are responsible for the termination of transcription and correct mRNA polyadenylation. A termination region and/or the enhancer region may be native to the transcriptional initiation region, may be native to a gene encoding a CRISPR-Cas effector protein or a gene encoding a deaminase, may be native to a host cell, or may be native to another source (e.g., foreign or heterologous to the promoter, to a gene encoding the CRISPR-Cas effector protein or a gene encoding the deaminase, to a host cell, or any combination thereof).

**[0088]** An expression cassette of the invention also can include a polynucleotide encoding a selectable marker, which can be used to select a transformed host cell. As used



herein, “selectable marker” means a polynucleotide sequence that when expressed imparts a distinct phenotype to the host cell expressing the marker and thus allows such transformed cells to be distinguished from those that do not have the marker. Such a polynucleotide sequence may encode either a selectable or screenable marker, depending on whether the marker confers a trait that can be selected for by chemical means, such as by using a selective agent (e.g., an antibiotic and the like), or on whether the marker is simply a trait that one can identify through observation or testing, such as by screening (e.g., fluorescence). Many examples of suitable selectable markers are known in the art and can be used in the expression cassettes described herein.

**[0089]** The expression cassettes, the nucleic acid molecules/constructs and polynucleotide sequences described herein can be used in connection with vectors. The term “vector” refers to a composition for transferring, delivering or introducing a nucleic acid (or nucleic acids) into a cell. A vector may comprise a nucleic acid construct comprising one or more nucleotide sequence(s) to be transferred, delivered or introduced into a cell. Vectors for use in transformation of host organisms are well known in the art. Non-limiting examples of general classes of vectors include viral vectors (e.g., Adeno-associated virus (AAV) vectors), plasmid vectors, phage vectors, phagemid vectors, cosmid vectors, fosmid vectors, bacteriophages, artificial chromosomes, minicircles, or *Agrobacterium* binary vectors in double or single stranded linear or circular form which may or may not be self transmissible or mobilizable. In some embodiments, a viral vector can include, but is not limited, to a retroviral, lentiviral, adenoviral, adeno-associated, or herpes simplex viral vector. A vector as defined herein can transform a prokaryotic or eukaryotic host either by integration into the cellular genome or exist extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication). Additionally, included are shuttle vectors by which is meant a DNA vehicle capable, naturally or by design, of replication in two different host organisms, which may be selected from actinomycetes and related species, bacteria and eukaryotic (e.g., higher plant, mammalian, yeast or fungal cells). In some embodiments, the nucleic acid in the vector is under the control of, and operably linked to, an appropriate promoter or other regulatory elements for transcription in a host cell. The vector may be a bi-functional expression vector which functions in multiple hosts. In the case of genomic DNA, this may contain its own promoter and/or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter and/or other regulatory elements for expression in the host cell. Accordingly, a nucleic acid construct of this invention and/or expression cassettes comprising the same may be comprised in vectors as described herein and as known in the art.

**[0090]** As used herein, “contact,” “contacting,” “contacted,” and grammatical variations thereof, refer to placing the components of a desired reaction together under conditions suitable for carrying out the desired reaction (e.g., transformation, transcriptional control, genome editing, nicking, and/or cleavage). Thus, for example, a target nucleic acid may be contacted with a nucleic acid construct of the invention encoding, for example, a nucleic acid binding polypeptide (e.g., a DNA binding polypeptide such as a sequence-specific DNA binding protein (e.g., a polynucleotide-guided endonuclease, a CRISPR-Cas effector

protein (e.g., a CRISPR-Cas endonuclease), a zinc finger nuclease, a transcription activator-like effector nuclease (TALEN) and/or an Argonaute protein)), a guide nucleic acid, and optionally a cytosine deaminase and/or adenine deaminase under conditions whereby the nucleic acid binding polypeptide (e.g., a CRISPR-Cas effector protein) is expressed, and the nucleic acid binding polypeptide forms a complex with the guide nucleic acid, the complex hybridizes to the target nucleic acid, and optionally the cytosine deaminase and/or adenine deaminase is/are recruited to the nucleic acid binding polypeptide (and thus, to the target nucleic acid) or the cytosine deaminase and/or adenine deaminase are fused to the nucleic acid binding polypeptide, thereby modifying the target nucleic acid. In some embodiments, the cytosine deaminase and/or adenine deaminase and the nucleic acid binding polypeptide localize at the target nucleic acid, optionally through covalent and/or non-covalent interactions.

**[0091]** In some embodiments, a target nucleic acid may be contacted with a nucleic acid construct of the invention encoding a fusion protein of the present invention, a guide nucleic acid, and optionally a cytosine deaminase and/or adenine deaminase under conditions whereby the fusion protein is produced, or a target nucleic acid may be contacted with a fusion protein of the present invention, a guide nucleic acid, and optionally a cytosine deaminase and/or adenine deaminase. The fusion protein can form a complex with the guide nucleic acid, and the complex can hybridize to the target nucleic acid, and optionally the cytosine deaminase and/or adenine deaminase is/are recruited to the fusion protein (and thus, to the target nucleic acid) or the cytosine deaminase and/or adenine deaminase are fused to the fusion protein, thereby modifying the target nucleic acid. The cytosine deaminase and/or adenine deaminase and the fusion protein may localize at the target nucleic acid, optionally through covalent and/or non-covalent interactions.

**[0092]** As used herein, “modifying” or “modification” in reference to a target nucleic acid includes editing (e.g., mutating), covalent modification, exchanging/substituting nucleic acids/nucleotide bases, deleting, cleaving, and/or nicking of a target nucleic acid to thereby provide a modified nucleic acid and/or altering transcriptional control of a target nucleic acid to thereby provide a modified nucleic acid. In some embodiments, a modification may include an insertion and/or deletion of any size and/or a single base change (SNP) of any type. In some embodiments, a modification comprises a SNP. In some embodiments, a modification comprises exchanging and/or substituting one or more (e.g., 1, 2, 3, 4, 5, or more) nucleotides. In some embodiments, an insertion or deletion may be about 1 base to about 30,000 bases or more in length (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950,

960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 20,500, 21,000, 21,500, 22,000, 22,500, 23,000, 23,500, 24,000, 24,500, 25,000, 25,500, 26,000, 26,500, 27,000, 27,500, 28,000, 28,500, 29,000, 29,500, 30,000 bases in length or more, or any value or range therein). Thus, in some embodiments, an insertion or deletion may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 to about 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 bases in length, or any range or value therein; about 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 bases to about 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 bases or more in length, or any value or range therein; about 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 bases to about 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10,000 bases or more in length, or any value or range therein; or about 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, or 5000 bases or more in length, or any value or range therein. In some embodiments, an insertion or deletion may be about 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, or 10,000 bases to about 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, 20,000, 20,500, 21,000, 21,500, 22,000, 22,500, 23,000, 23,500, 24,000, 24,500, 25,000, 25,500, 26,000, 26,500,

27,000, 27,500, 28,000, 28,500, 29,000, 29,500, or 30,000 bases or more in length, or any value or range therein.

**[0093]** “Recruit,” “recruiting” or “recruitment” as used herein refer to attracting one or more polypeptide(s) or polynucleotide(s) to another polypeptide or polynucleotide (e.g., to a particular location in a genome) using protein-protein interactions, nucleic acid protein interactions (e.g., RNA-protein interactions), and/or chemical interactions. Protein-protein interactions can include, but are not limited to, peptide tags (epitopes, multimerized epitopes) and corresponding affinity polypeptides, RNA recruiting motifs and corresponding affinity polypeptides, and/or chemical interactions. Example chemical interactions that may be useful with polypeptides and polynucleotides for the purpose of recruitment can include, but are not limited to, rapamycin-inducible dimerization of FRB-FKBP; Biotin-streptavidin interaction; SNAP tag (Hussain et al. *Curr Pharm Des.* 19(30):5437-42 (2013)); Halo tag (Los et al. *ACS Chem Biol.* 3(6):373-82 (2008)); CLIP tag (Gautier et al. *Chemistry & Biology* 15:128-136 (2008)); DmrA-DmrC heterodimer induced by a compound (Tak et al. *Nat Methods* 14(12):1163-1166 (2017)); Bifunctional ligand approaches (fuse two protein-binding chemicals together) (VoB et al. *Curr Opin Chemical Biology* 28:194-201 (2015)) (e.g. dihydrofolate reductase (DHFR) (Kopyteck et al. *Cell Cehm Biol* 7(5):313-321 (2000)).

**[0094]** “Introducing,” “introduce,” “introduced” (and grammatical variations thereof) in the context of a polynucleotide of interest or editing system means presenting a nucleotide sequence of interest (e.g., polynucleotide, a nucleic acid construct, and/or a guide nucleic acid) and/or editing system (e.g., a polynucleotide, polypeptide, and/or ribonucleoprotein) to a host organism or cell of said organism (e.g., host cell; e.g., a plant cell) in such a manner that the nucleotide sequence and/or editing system gains access to the interior of a cell. Thus, for example, a nucleic acid construct of the invention encoding a fusion protein of the present invention, a guide nucleic acid, and/or a cytosine deaminase and/or adenine deaminase may be introduced into a cell of an organism, thereby transforming the cell with the fusion protein, guide nucleic acid, and/or cytosine deaminase and/or adenine deaminase. In some embodiments, a fusion protein of the present invention and/or a guide nucleic acid may be introduced into a cell of an organism, optionally wherein the fusion protein and guide nucleic acid may be comprised in a complex (e.g., a ribonucleoprotein). In some embodiments, the organism is a eukaryote (e.g., a mammal such as a human).

**[0095]** The term “transformation” as used herein refers to the introduction of a nucleic acid, polypeptide, and/or ribonucleoprotein (e.g., heterologous nucleic acid, polypeptide, and/or ribonucleoprotein) into a cell. Transformation of a cell may be stable or transient. Thus, in some embodiments, a host cell or host organism may be stably transformed with a polynucleotide/nucleic acid molecule of the invention. In some embodiments, a host cell or host organism may be transiently transformed with a nucleic acid construct, a polypeptide, and/or a ribonucleoprotein of the invention.

**[0096]** “Transient transformation” in the context of a polynucleotide, polypeptide, and/or ribonucleoprotein means that a polynucleotide, polypeptide, and/or ribonucleoprotein is introduced into the cell and does not integrate into the genome of the cell.

**[0097]** By “stably introducing” or “stably introduced” in the context of a polynucleotide introduced into a cell is intended that the introduced polynucleotide is stably incorporated into the genome of the cell, and thus the cell is stably transformed with the polynucleotide.

**[0098]** “Stable transformation” or “stably transformed” as used herein means that a nucleic acid molecule is introduced into a cell and integrates into the genome of the cell. As such, the integrated nucleic acid molecule is capable of being inherited by the progeny thereof, more particularly, by the progeny of multiple successive generations. “Genome” as used herein includes the nuclear and the plastid genome, and therefore includes integration of the nucleic acid into, for example, the chloroplast or mitochondrial genome. Stable transformation as used herein can also refer to a transgene that is maintained extrachromosomally, for example, as a minichromosome or a plasmid.

**[0099]** Transient transformation may be detected by, for example, an enzyme-linked immunosorbent assay (ELISA) or Western blot, which can detect the presence of a peptide or polypeptide encoded by one or more transgene introduced into an organism. Stable transformation of a cell can be detected by, for example, a Southern blot hybridization assay of genomic DNA of the cell with nucleic acid sequences which specifically hybridize with a nucleotide sequence of a transgene introduced into an organism (e.g., a mammal, plant, etc.). Stable transformation of a cell can be detected by, for example, a Northern blot hybridization assay of RNA of the cell with nucleic acid sequences which specifically hybridize with a nucleotide sequence of a transgene introduced into a host organism. Stable transformation of a cell can also be detected by, e.g., a polymerase chain reaction (PCR) or other amplification reactions as are well known in the art, employing specific primer sequences that hybridize with target sequence(s) of a transgene, resulting in amplification of the transgene sequence, which can be detected according to standard methods. Transformation can also be detected by direct sequencing and/or hybridization protocols well known in the art.

**[0100]** Accordingly, in some embodiments, nucleotide sequences, polynucleotides, nucleic acid constructs, and/or expression cassettes of the invention may be expressed transiently and/or they can be stably incorporated into the genome of the host organism. Thus, in some embodiments, a nucleic acid construct of the invention may be transiently introduced into a cell with a guide nucleic acid and as such, no DNA maintained in the cell.

**[0101]** A nucleic acid construct, polypeptide, and/or ribonucleoprotein of the invention can be introduced into a cell by any method known to those of skill in the art. In some embodiments, transformation methods include, but are not limited to, transformation via bacterial-mediated nucleic acid delivery (e.g., via *Agrobacteria*), viral-mediated nucleic acid delivery, silicon carbide and/or nucleic acid whisker-mediated nucleic acid delivery, liposome mediated nucleic acid delivery, microinjection, microparticle bombardment, calcium-phosphate-mediated transformation, cyclodextrin-mediated transformation, electroporation, nanoparticle-mediated transformation, sonication, infiltration, PEG-mediated nucleic acid uptake, as well as any other electrical, chemical, physical (mechanical) and/or biological mechanism that results in the introduction of nucleic acid into the cell (e.g., a plant cell or an animal cell), including any combination thereof. In some embodiments of the invention,

transformation of a cell comprises nuclear transformation. In some embodiments, transformation of a cell comprises plastid transformation (e.g., chloroplast transformation). In some embodiments, a recombinant nucleic acid construct of the invention can be introduced into a cell via conventional breeding techniques.

**[0102]** Procedures for transforming both eukaryotic and prokaryotic organisms are well known and routine in the art and are described throughout the literature (See, for example, Jiang et al. 2013. *Nat. Biotechnol.* 31:233-239; Ran et al. *Nature Protocols* 8:2281-2308 (2013)). General guides to various plant transformation methods known in the art include Miki et al. (“Procedures for Introducing Foreign DNA into Plants” in *Methods in Plant Molecular Biology and Biotechnology*, Glick, B. R. and Thompson, J. E., Eds. (CRC Press, Inc., Boca Raton, 1993), pages 67-88) and Rakowoczy-Trojanowska (*Cell. Mol. Biol. Lett.* 7:849-858 (2002)).

**[0103]** A nucleotide sequence, polypeptide, and/or ribonucleoprotein therefore can be introduced into a host organism or its cell in any number of ways that are well known in the art. The methods of the invention do not depend on a particular method for introducing one or more nucleotide sequence(s), polypeptide(s), and/or ribonucleoprotein(s) into the organism, only that they gain access to the interior of at least one cell of the organism. Where more than one nucleotide sequence, polypeptide, and/or ribonucleoprotein is to be introduced, they can be assembled as part of a single nucleic acid construct, or as separate nucleic acid constructs, and can be located on the same or different nucleic acid constructs. Accordingly, a nucleotide sequence, polypeptide, and/or ribonucleoprotein can be introduced into the cell of interest in a single transformation event, and/or in separate transformation events, or, alternatively, where relevant, a nucleotide sequence can be incorporated into a plant, for example, as part of a breeding protocol. In some embodiments, the cell is a eukaryotic cell (e.g., a plant cell or a mammalian such as a human cell).

**[0104]** In some embodiments, a nucleic acid construct of the invention (e.g., a polynucleotide encoding a fusion protein of the present invention, a polynucleotide encoding a deaminase, and/or a guide nucleic acid and/or expression cassettes and/or vectors comprising the same) may be operably linked to at least one regulatory sequence, optionally, wherein the at least one regulatory sequence may be codon optimized for expression in a plant. In some embodiments, the at least one regulatory sequence may be, for example, a promoter, an operon, a terminator, or an enhancer. In some embodiments, the at least one regulatory sequence may be a promoter. In some embodiments, the regulatory sequence may be an intron. In some embodiments, the at least one regulatory sequence may be, for example, a promoter operably associated with an intron or a promoter region comprising an intron. In some embodiments, the at least one regulatory sequence may be, for example a ubiquitin promoter and its associated intron (e.g., *Medicago truncatula* and/or *Zea mays* and their associated introns). In some embodiments, the at least one regulatory sequence may be a terminator nucleotide sequence and/or an enhancer nucleotide sequence.

**[0105]** In some embodiments, a nucleic acid construct of the invention may be operably associated with a promoter region, wherein the promoter region comprises an intron, optionally wherein the promoter region may be a ubiquitin

promoter and intron (e.g., a *Medicago* or a maize ubiquitin promoter and intron, e.g., SEQ ID NO:36 or SEQ ID NO:37). In some embodiments, the nucleic acid construct of the invention that is operably associated with a promoter region comprising an intron may be codon optimized for expression in a plant.

**[0106]** In some embodiments, a nucleic acid construct of the invention may encode one or more (e.g., 1, 2, 3, 4, or more) polypeptide(s) of interest. The one or more polypeptides of interest may be codon optimized for expression in a eukaryote (e.g., a human or a plant). In some embodiments, a fusion protein may comprise one or more (e.g., 1, 2, 3, 4, or more) polypeptide(s) of interest.

**[0107]** A polypeptide of interest useful with this invention can include, but is not limited to, a polypeptide or protein domain having deaminase activity, nickase activity, recombinase activity, transposase activity, methylase activity, glycosylase (DNA glycosylase) activity, glycosylase inhibitor activity (e.g., uracil-DNA glycosylase inhibitor (UGI)), a reverse transcriptase, a peptide tag (e.g., a GCN4 peptide tag), demethylase activity, transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nuclease activity, single-strand RNA cleavage activity, double-strand RNA cleavage activity, restriction endonuclease activity (e.g., FokI), nucleic acid binding activity, methyltransferase activity, DNA repair activity, DNA damage activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, polymerase activity (e.g., DNA polymerase activity), ligase activity, helicase activity, a nuclear localization sequence or activity, T-DNA processing and/or transfer (e.g., VirD2), an affinity polypeptide, a peptide tag, and/or photolyase activity. In some embodiments, the polypeptide of interest is a FokI nuclease, or a uracil-DNA glycosylase inhibitor. When encoded in a nucleic acid (polynucleotide, expression cassette, and/or vector) the encoded polypeptide or protein domain may be codon optimized for expression in an organism. In some embodiments, a polypeptide of interest may be linked to a fusion protein of the present invention or to a CRISPR-Cas effector protein domain to provide a CRISPR-Cas fusion protein. In some embodiments, a CRISPR-Cas fusion protein that comprises a CRISPR-Cas effector protein domain linked to a recruiting motif (e.g., a peptide tag) may also be linked to a polypeptide of interest (e.g., a CRISPR-Cas effector protein domain may be, for example, linked to both a recruiting motif (e.g., a peptide tag or an affinity polypeptide) and, for example, a polypeptide of interest.

**[0108]** In some embodiments, an editing system of the present invention comprises a CRISPR-Cas effector protein. As used herein, a “CRISPR-Cas effector protein” is a protein or polypeptide that cleaves, cuts, or nicks a nucleic acid; binds a nucleic acid (e.g., a target nucleic acid and/or a guide nucleic acid); and/or that identifies, recognizes, or binds a guide nucleic acid as defined herein. In some embodiments, a CRISPR-Cas effector protein may be an enzyme (e.g., a nuclease, endonuclease, nickase, etc.) and/or may function as an enzyme. In some embodiments, a CRISPR-Cas effector protein refers to a CRISPR-Cas nuclease. In some embodiments, a CRISPR-Cas effector protein comprises nuclease activity and/or nickase activity, comprises a nuclease domain whose nuclease activity and/or nickase activity has been reduced or eliminated, comprises single stranded

DNA cleavage activity (ss DNase activity) or which has ss DNase activity that has been reduced or eliminated, and/or comprises self-processing RNase activity or which has self-processing RNase activity that has been reduced or eliminated. A CRISPR-Cas effector protein may bind to a target nucleic acid. A CRISPR-Cas effector protein may be a Type I, II, III, IV, V, or VI CRISPR-Cas effector protein. In some embodiments, a CRISPR-Cas effector protein may be from a Type I CRISPR-Cas system, a Type II CRISPR-Cas system, a Type III CRISPR-Cas system, a Type IV CRISPR-Cas system, Type V CRISPR-Cas system, or a Type VI CRISPR-Cas system. In some embodiments, a CRISPR-Cas effector protein of the invention may be from a Type II CRISPR-Cas system or a Type V CRISPR-Cas system. In some embodiments, a CRISPR-Cas effector protein may be a Type II CRISPR-Cas effector protein, for example, a Cas9 effector protein. In some embodiments, a CRISPR-Cas effector protein may be Type V CRISPR-Cas effector protein, for example, a Cas12 effector protein. In some embodiments, a CRISPR-Cas effector protein may be Cas12a and optionally may have an amino acid sequence of any one of SEQ ID NOs:38-60 or 192-195 and/or a nucleotide sequence of any one of SEQ ID NOs:61-63. In some embodiments, a CRISPR-Cas effector protein may be an active Cas12a and optionally may have an amino acid sequence of SEQ ID NO:46 or 55. In some embodiments, a CRISPR-Cas effector protein may be an inactive (i.e., dead) Cas12a and optionally may have an amino acid sequence of SEQ ID NO:38.

**[0109]** Exemplary CRISPR-Cas effector proteins include, but are not limited to, a Cas9, C2c1, C2c3, Cas12a (also referred to as Cpf1), Cas12b, Cas12c, Cas12d, Cas12e, Cas13a, Cas13b, Cas13c, Cas13d, Cas1, Cas1B, Cas2, Cas3, Cas3', Cas3'', Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4 (dinG), and/or Csf5 nuclease, optionally wherein the CRISPR-Cas effector protein may be a Cas9, Cas12a (Cpf1), Cas12b, Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12g, Cas12h, Cas12i, C2c4, C2c5, C2c8, C2c9, C2c10, Cas14a, Cas14b, and/or Cas14c effector protein.

**[0110]** In some embodiments, a CRISPR-Cas effector protein useful with the invention may comprise a mutation in its nuclease active site and/or nuclease domain (e.g., a RuvC, HNH, e.g., a RuvC site of a Cas12a nuclease domain; e.g., a RuvC site and/or HNH site of a Cas9 nuclease domain). A CRISPR-Cas effector protein having a mutation in its nuclease active site and/or nuclease domain, and therefore, no longer comprising nuclease activity, is commonly referred to as “inactive” or “dead,” e.g., dCas12a. In some embodiments, a CRISPR-Cas effector protein having a mutation in its nuclease active site and/or nuclease domain may have impaired activity or reduced activity (e.g., nickase activity) as compared to the same CRISPR-Cas effector protein without the mutation.

**[0111]** A Type V CRISPR-Cas effector protein useful with embodiments of the invention may be a Cas12a. The CRISPR-Cas effector protein may be a Type V Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas nuclease. Cas12a differs in several respects from the more well-known Type II CRISPR Cas9 nuclease.

For example, Cas9 recognizes a G-rich protospacer-adjacent motif (PAM) that is 3' to its guide RNA (gRNA, sgRNA, crRNA, crDNA, CRISPR array) binding site (protospacer, target nucleic acid, target DNA) (3'-NGG), while Cas12a recognizes a T-rich PAM that is located 5' to the target nucleic acid (5'-TTN, 5'-TTTN). In fact, the orientations in which Cas9 and Cas12a bind their guide RNAs are very nearly reversed in relation to their N and C termini. Furthermore, Cas12a enzymes use a single guide RNA (gRNA, CRISPR array, crRNA) rather than the dual guide RNA (sgRNA (e.g., crRNA and tracrRNA)) found in natural Cas9 systems, and Cas12a processes its own gRNAs. Additionally, Cas12a nuclease activity produces staggered DNA double stranded breaks instead of blunt ends produced by Cas9 nuclease activity, and Cas12a relies on a single RuvC domain to cleave both DNA strands, whereas Cas9 utilizes an HNH domain and a RuvC domain for cleavage.

**[0112]** A CRISPR Cas12a effector protein useful with this invention may be any known or later identified Cas12a (previously known as Cpf1) (see, e.g., U.S. Pat. No. 9,790,490, which is incorporated by reference for its disclosures of Cpf1 (Cas12a) sequences). The term "Cas12a" refers to an RNA-guided protein that can have nuclease activity, the protein comprising a guide nucleic acid binding domain and an active, inactive, or partially active DNA cleavage domain, thereby the RNA-guided nuclease activity of the Cas12a may be active, inactive or partially active, respectively. In some embodiments, a Cas12a useful with the invention may comprise a mutation in the nuclease active site (e.g., RuvC site of the Cas12a domain). A Cas12a having a mutation in its nuclease domain and/or nuclease active site, and therefore, no longer comprising nuclease activity, is commonly referred to as deadCas12a (e.g., dCas12a). In some embodiments, a Cas12a having a mutation in its nuclease domain and/or nuclease active site may have impaired activity, e.g., may have reduced nickase activity.

**[0113]** In some embodiments, a CRISPR-Cas effector protein (e.g., Cas12a) may be optimized for expression in an organism, for example, in an animal (e.g., a mammal such as a human), a plant, a fungus, an archaeon, or a bacterium. In some embodiments, a CRISPR-Cas effector protein (e.g., Cas12a) may be optimized for expression in a plant.

**[0114]** Any deaminase domain/polypeptide useful for base editing may be used with this invention. A "cytosine deaminase" and "cytidine deaminase" as used herein refer to a polypeptide or domain thereof that catalyzes or is capable of catalyzing cytosine deamination in that the polypeptide or domain catalyzes or is capable of catalyzing the removal of an amine group from a cytosine base. Thus, a cytosine deaminase may result in conversion of cytosine to a thymidine (through a uracil intermediate), causing a C to T conversion, or a G to A conversion in the complementary strand in the genome. Thus, in some embodiments, the cytosine deaminase encoded by the polynucleotide of the invention generates a C→T conversion in the sense (e.g., "+"; template) strand of the target nucleic acid or a G→A conversion in antisense (e.g., "-", complementary) strand of the target nucleic acid. In some embodiments, a cytosine deaminase encoded by a polynucleotide of the invention generates a C to T, G, or A conversion in the complementary strand in the genome.

**[0115]** A cytosine deaminase useful with this invention may be any known or later identified cytosine deaminase from any organism (see, e.g., U.S. Pat. No. 10,167,457 and

Thuronyi et al. *Nat. Biotechnol.* 37:1070-1079 (2019), each of which is incorporated by reference herein for its disclosure of cytosine deaminases). Cytosine deaminases can catalyze the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively. Thus, in some embodiments, a deaminase or deaminase domain useful with this invention may be a cytidine deaminase domain, catalyzing the hydrolytic deamination of cytosine to uracil. In some embodiments, a cytosine deaminase may be a variant of a naturally-occurring cytosine deaminase, including, but not limited to, a primate (e.g., a human, monkey, chimpanzee, gorilla), a dog, a cow, a rat or a mouse. Thus, in some embodiments, an cytosine deaminase useful with the invention may be about 70% to about 100% identical to a wild-type cytosine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and any range or value therein, to a naturally occurring cytosine deaminase).

**[0116]** In some embodiments, a cytosine deaminase useful with the invention may be an apolipoprotein B mRNA-editing complex (APOBEC) family deaminase. In some embodiments, the cytosine deaminase may be an APOBEC1 deaminase, an APOBEC2 deaminase, an APOBEC3A deaminase, an APOBEC3B deaminase, an APOBEC3C deaminase, an APOBEC3D deaminase, an APOBEC3F deaminase, an APOBEC3G deaminase, an APOBEC3H deaminase, an APOBEC4 deaminase, a human activation induced deaminase (hAID), an rAPOBEC1, FERNY, and/or a CDA1, optionally a pmCDA1, an atCDA1 (e.g., At2g19570), and evolved versions of the same. Evolved deaminases are disclosed in, for example, U.S. Pat. No. 10,113,163, Gaudelli et al. *Nature* 551(7681):464-471 (2017)) and Thuronyi et al. (*Nature Biotechnology* 37: 1070-1079 (2019)), each of which are incorporated by reference herein for their disclosure of deaminases and evolved deaminases. In some embodiments, the cytosine deaminase may be an APOBEC1 deaminase having the amino acid sequence of SEQ ID NO:64. In some embodiments, the cytosine deaminase may be an APOBEC3A deaminase having the amino acid sequence of SEQ ID NO:65. In some embodiments, the cytosine deaminase may be an CDA1 deaminase, optionally a CDA1 having the amino acid sequence of SEQ ID NO:66. In some embodiments, the cytosine deaminase may be a FERNY deaminase, optionally a FERNY having the amino acid sequence of SEQ ID NO:67. In some embodiments, the cytosine deaminase may be a rAPOBEC1 deaminase, optionally a rAPOBEC1 deaminase having the amino acid sequence of SEQ ID NO:68. In some embodiments, the cytosine deaminase may be a hAID deaminase, optionally a hAID having the amino acid sequence of SEQ ID NO:69 or SEQ ID NO:70. In some embodiments, a cytosine deaminase useful with the invention may be about 70% to about 100% identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% identical) to the amino acid sequence of a naturally occurring cytosine deaminase (e.g., "evolved deaminases") (see, e.g., SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73). In some embodiments, a cytosine deaminase useful with the invention may be about 70% to about 99.5% identical (e.g., about 70%, 71%, 72%, 73%,

74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical) to the amino acid sequence of any one of SEQ ID NOs:64-73 (e.g., at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of any one of SEQ ID NOs:64-73). In some embodiments, a polynucleotide encoding a cytosine deaminase may be codon optimized for expression in a plant and the codon optimized polypeptide may be about 70% to 99.5% identical to the reference polynucleotide.

**[0117]** An “adenine deaminase” and “adenosine deaminase” as used herein refer to a polypeptide or domain thereof that catalyzes or is capable of catalyzing the hydrolytic deamination (e.g., removal of an amine group from adenine) of adenine or adenosine. In some embodiments, an adenine deaminase may catalyze the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, the adenosine deaminase may catalyze the hydrolytic deamination of adenine or adenosine in DNA. In some embodiments, an adenine deaminase encoded by a nucleic acid construct of the invention may generate an A→G conversion in the sense (e.g., “+”; template) strand of the target nucleic acid or a T→C conversion in the antisense (e.g., “-”, complementary) strand of the target nucleic acid. An adenine deaminase useful with this invention may be any known or later identified adenine deaminase from any organism (see, e.g., U.S. Pat. No. 10,113,163, which is incorporated by reference herein for its disclosure of adenine deaminases).

**[0118]** In some embodiments, an adenosine deaminase may be a variant of a naturally-occurring adenine deaminase. Thus, in some embodiments, an adenosine deaminase may be about 70% to 100% identical to a wild-type adenine deaminase (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical, and any range or value therein, to a naturally occurring adenine deaminase). In some embodiments, the deaminase or deaminase does not occur in nature and may be referred to as an engineered, mutated or evolved adenosine deaminase. Thus, for example, an engineered, mutated or evolved adenine deaminase polypeptide or an adenine deaminase domain may be about 70% to 99.9% identical to a naturally occurring adenine deaminase polypeptide/domain (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical, and any range or value therein, to a naturally occurring adenine deaminase polypeptide or adenine deaminase domain). In some embodiments, the adenosine deaminase may be from a bacterium, (e.g., *Escherichia coli*, *Staphylococcus aureus*, *Haemophilus influenzae*, *Caulobacter crescentus*, and the like). In some embodiments, a polynucleotide encoding an adenine deaminase polypeptide/domain may be codon optimized for expression in a plant.

**[0119]** In some embodiments, an adenine deaminase domain may be a wild-type tRNA-specific adenosine deaminase domain, e.g., a tRNA-specific adenosine deaminase (TadA) and/or a mutated/evolved adenosine deaminase

domain, e.g., mutated/evolved tRNA-specific adenosine deaminase domain (TadA\*). In some embodiments, a TadA domain may be from *E. coli*. In some embodiments, the TadA may be modified, e.g., truncated, missing one or more N-terminal and/or C-terminal amino acids relative to a full-length TadA (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal and/or C terminal amino acid residues may be missing relative to a full length TadA). In some embodiments, a TadA polypeptide or TadA domain does not comprise an N-terminal methionine. In some embodiments, a wild-type *E. coli* TadA comprises the amino acid sequence of SEQ ID NO:74. In some embodiments, a mutated/evolved *E. coli* TadA\* comprises the amino acid sequence of any one of SEQ ID NOs:75-78. In some embodiments, a polynucleotide encoding a TadA/TadA\* may be codon optimized for expression in a plant. In some embodiments, an adenine deaminase may comprise all or a portion of an amino acid sequence of any one of SEQ ID NOs:79-84. In some embodiments, an adenine deaminase may comprise all or a portion of an amino acid sequence of any one of SEQ ID NOs:74-84.

**[0120]** In some embodiments, a nucleic acid construct of this invention may further encode a glycosylase inhibitor (e.g., a uracil glycosylase inhibitor (UGI) such as uracil-DNA glycosylase inhibitor). In some embodiments, the invention provides fusion proteins comprising a UGI and/or one or more polynucleotides encoding the same, optionally wherein the one or more polynucleotides may be codon optimized for expression in a plant.

**[0121]** A “uracil glycosylase inhibitor” useful with the invention may be any protein or polypeptide that is capable of inhibiting a uracil-DNA glycosylase base-excision repair enzyme. In some embodiments, a UGI domain comprises a wild-type UGI or a fragment thereof. In some embodiments, a UGI domain useful with the invention may be about 70% to about 100% identical (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100% identical and any range or value therein) to the amino acid sequence of a naturally occurring UGI domain. In some embodiments, a UGI domain may comprise the amino acid sequence of SEQ ID NO:85 or a polypeptide having about 70% to about 99.5% identity to the amino acid sequence of SEQ ID NO:85 (e.g., at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to the amino acid sequence of SEQ ID NO:85). For example, in some embodiments, a UGI domain may comprise a fragment of the amino acid sequence of SEQ ID NO:85 that is 100% identical to a portion of consecutive nucleotides (e.g., 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides; e.g., about 10, 15, 20, 25, 30, 35, 40, 45, to about 50, 55, 60, 65, 70, 75, 80 consecutive nucleotides) of the amino acid sequence of SEQ ID NO:85. In some embodiments, a UGI domain may be a variant of a known UGI (e.g., SEQ ID NO:85) having about 70% to about 99.5% identity (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% identity, and any range or value therein) to the known UGI. In some embodiments, a polynucleotide encoding a UGI may be codon optimized for expression in a plant (e.g.,

a plant) and the codon optimized polypeptide may be about 70% to about 99.5% identical to the reference polynucleotide.

**[0122]** A fusion protein of the present invention may be used in combination with a guide nucleic acid (e.g., guide RNA (gRNA), CRISPR array, CRISPR RNA, crRNA) that is designed to function with the fusion protein to modify a target nucleic acid. A guide nucleic acid useful with this invention may comprise at least one spacer sequence and at least one repeat sequence. The guide nucleic acid is capable of forming a complex with the fusion protein (e.g., with a nuclease domain of the fusion protein) and the spacer sequence is capable of hybridizing to a target nucleic acid, thereby guiding the complex to the target nucleic acid, wherein the target nucleic acid may be modified (e.g., cleaved or edited) and/or modulated (e.g., modulating transcription) by a deaminase (e.g., a cytosine deaminase and/or adenine deaminase) or reverse transcriptase, optionally present in and/or recruited to the complex.

**[0123]** A “guide nucleic acid,” “guide RNA,” “gRNA,” “CRISPR RNA/DNA” “crRNA” or “crDNA” as used herein means a nucleic acid that comprises at least one spacer sequence, which is complementary to (and hybridizes to) a target nucleic acid (e.g., a target DNA and/or protospacer), and at least one repeat sequence (e.g., a repeat of a Type V Cas12a CRISPR-Cas system, or a fragment or portion thereof, wherein the repeat sequence may be linked to the 5' end and/or the 3' end of the spacer sequence. In some embodiments, the guide nucleic acid comprises DNA. In some embodiments, the guide nucleic acid comprises RNA (e.g., is a guide RNA). The design of a gRNA of this invention may be based on a Type I, Type II, Type III, Type IV, Type V, or Type VI CRISPR-Cas system. In some embodiments, a Cas12a gRNA may comprise, from 5' to 3', a repeat sequence (full length or portion thereof (“handle”); e.g., pseudoknot-like structure) and a spacer sequence.

**[0124]** In some embodiments, a guide nucleic acid may comprise more than one repeat sequence-spacer sequence (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more repeat-spacer sequences) (e.g., repeat-spacer-repeat, e.g., repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer-repeat-spacer, and the like). The guide nucleic acids of this invention are synthetic, human-made and not found in nature. A gRNA can be quite long and may be used as an aptamer (like in the MS2 recruitment strategy) or other RNA structures hanging off the spacer.

**[0125]** A “repeat sequence” as used herein, refers to, for example, any repeat sequence of a wild-type CRISPR Cas locus (e.g., a Cas9 locus, a Cas12a locus, a C2c1 locus, etc.) or a repeat sequence of a synthetic repeat sequence (e.g., a synthetic crRNA) that is functional with the CRISPR-Cas effector protein encoded by the nucleic acid constructs of the invention. A repeat sequence useful with this invention can be any known or later identified repeat sequence of a CRISPR-Cas locus (e.g., Type I, Type II, Type III, Type IV, Type V or Type VI) or it can be a synthetic repeat designed to function in a Type I, II, III, IV, V or VI CRISPR-Cas system. A repeat sequence may comprise a hairpin structure and/or a stem loop structure. In some embodiments, a repeat sequence may form a pseudoknot-like structure at its 5' end (i.e., “handle”). Thus, in some embodiments, a repeat sequence can be identical to or substantially identical to a repeat sequence from wild-type Type I CRISPR-Cas loci, Type II, CRISPR-Cas loci, Type III, CRISPR-Cas loci, Type

IV CRISPR-Cas loci, Type V CRISPR-Cas loci and/or Type VI CRISPR-Cas loci. A repeat sequence from a wild-type CRISPR-Cas locus may be determined through established algorithms, such as using the CRISPRfinder offered through CRISPRdb (see, Grissa et al. *Nucleic Acids Res.* 35(Web Server issue):W52-7). In some embodiments, a repeat sequence or portion thereof is linked at its 3' end to the 5' end of a spacer sequence, thereby forming a repeat-spacer sequence (e.g., guide nucleic acid, guide RNA/DNA, crRNA, crDNA).

**[0126]** In some embodiments, a repeat sequence comprises, consists essentially of, or consists of at least 10 nucleotides depending on the particular repeat and whether the guide nucleic acid comprising the repeat is processed or unprocessed (e.g., about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 to 100 or more nucleotides, or any range or value therein; e.g., about). In some embodiments, a repeat sequence comprises, consists essentially of, or consists of about 10 to about 20, about 10 to about 30, about 10 to about 45, about 10 to about 50, about 15 to about 30, about 15 to about 40, about 15 to about 45, about 15 to about 50, about 20 to about 30, about 20 to about 40, about 20 to about 50, about 30 to about 40, about 40 to about 80, about 50 to about 100 or more nucleotides.

**[0127]** A repeat sequence linked to the 5' end of a spacer sequence can comprise a portion of a repeat sequence (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or more contiguous nucleotides of a wild-type repeat sequence). In some embodiments, a portion of a repeat sequence linked to the 5' end of a spacer sequence can be about five to about ten consecutive nucleotides in length (e.g., about 5, 6, 7, 8, 9, 10 nucleotides) and have at least 90% sequence identity (e.g., at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) to the same region (e.g., 5' end) of a wild-type CRISPR Cas repeat nucleotide sequence. In some embodiments, a portion of a repeat sequence may comprise a pseudoknot-like structure at its 5' end (e.g., “handle”).

**[0128]** A “spacer sequence” as used herein is a nucleotide sequence that is complementary to a target nucleic acid (e.g., target DNA) (e.g., protospacer). The spacer sequence can be fully complementary or substantially complementary (e.g., at least about 70% complementary (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more)) to a target nucleic acid. Thus, in some embodiments, the spacer sequence can have one, two, three, four, or five mismatches as compared to the target nucleic acid, which mismatches can be contiguous or noncontiguous. In some embodiments, the spacer sequence can have 70% complementarity to a target nucleic acid. In other embodiments, the spacer nucleotide sequence can have 80% complementarity to a target nucleic acid. In still other embodiments, the spacer nucleotide sequence can have 85%, 90%, 95%, 96%, 97%, 98%, 99% or 99.5% complementarity, and the like, to the target nucleic acid (protospacer). In some embodiments, the spacer sequence is 100% complementary to the target nucleic acid. A spacer sequence may have a length from about 15 nucleotides to about 30 nucleotides (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides, or any range or value therein). Thus, in some embodiments, a spacer

sequence may have complete complementarity or substantial complementarity over a region of a target nucleic acid (e.g., protospacer) that is at least about 15 nucleotides to about 30 nucleotides in length. In some embodiments, the spacer is about 20 nucleotides in length. In some embodiments, the spacer is about 21, 22, or 23 nucleotides in length.

**[0129]** In some embodiments, the 5' region of a spacer sequence of a guide nucleic acid may be fully complementary to a target nucleic acid, while the 3' region of the spacer may be substantially complementary to the target nucleic acid (such as for a spacer in a Type V CRISPR-Cas system), or the 3' region of a spacer sequence of a guide nucleic acid may be fully complementary to a target nucleic acid, while the 5' region of the spacer may be substantially complementary to the target nucleic acid (such as for a spacer in a Type II CRISPR-Cas system), and therefore, the overall complementarity of the spacer sequence to the target nucleic acid may be less than 100%. Thus, for example, in a guide nucleic acid for a Type V CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides in the 5' region (i.e., seed region) of, for example, a 20 nucleotide spacer sequence may be 100% complementary to the target nucleic acid, while the remaining nucleotides in the 3' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleic acid. In some embodiments, the first 1 to 8 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8, nucleotides, and any range therein) of the 5' end of the spacer sequence may be 100% complementary to the target nucleic acid, while the remaining nucleotides in the 3' region of the spacer sequence are substantially complementary (e.g., at least about 50% complementary (e.g., 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more)) to the target nucleic acid.

**[0130]** As a further example, in a guide nucleic acid for a Type II CRISPR-Cas system, the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides in the 3' region (i.e., seed region) of, for example, a 20 nucleotide spacer sequence may be 100% complementary to the target nucleic acid, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 70% complementary) to the target nucleic acid. In some embodiments, the first 1 to 10 nucleotides (e.g., the first 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides, and any range therein) of the 3' end of the spacer sequence may be 100% complementary to the target nucleic acid, while the remaining nucleotides in the 5' region of the spacer sequence are substantially complementary (e.g., at least about 50% complementary (e.g., at least about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more or any range or value therein)) to the target nucleic acid.

**[0131]** In some embodiments, a seed region of a spacer may be about 8 to about 10 nucleotides in length, about 5 to about 6 nucleotides in length, or about 6 nucleotides in length.

**[0132]** In some embodiments, an editing system of the present invention comprises an extended guide nucleic acid, a fusion protein of the present invention, and optionally a reverse transcriptase. In some embodiments, a fusion protein of the present invention comprises all or a portion of a

reverse transcriptase. In some embodiments, a fusion protein of the present invention, an extended guide nucleic acid, and optionally a reverse transcriptase may form a complex or may be comprised in a complex that is capable of interacting with a target nucleic acid.

**[0133]** In some embodiments, a guide nucleic acid further comprises a reverse transcriptase template and may be referred to as an extended guide nucleic acid. An "extended guide nucleic acid" as used herein is a guide nucleic acid as described herein that further comprises a reverse transcriptase template (RTT) and/or a primer binding site (PBS). In some embodiments, an extended guide nucleic acid is an engineered prime editing guide RNA (pegRNA). An extended guide nucleic acid may be a targeted allele guide RNA (tagRNA) or a stabilized targeted allele guide RNA (stagRNA). A "tagRNA" as used herein refers to an extended guide nucleic acid that comprises a PBS and a RTT and has target strand complementarity. A "stagRNA" as used herein refers to a tagRNA that comprises a stabilization motif. A stabilization motif may be present at the 3' and/or 5' end of a tagRNA. In some embodiments, a stabilization motif is present at the 3' end of a tagRNA. Exemplary stabilization motifs include, but are not limited to, recruiting motifs, RNA hairpins, pseudoknot sequences, and/or PP7 motifs (e.g., a PP7 RNA hairpin sequence). In some embodiments, a stagRNA is a tagRNA that comprises a PP7 RNA hairpin sequence. In some embodiments, a CRISPR-Cas effector protein (e.g., a Type II or Type V CRISPR-Cas effector protein), a reverse transcriptase, and an extended guide nucleic acid can form a complex or are comprised in a complex.

**[0134]** In some embodiments, an extended guide nucleic acid comprises an extended portion that includes a primer binding site and a reverse transcriptase template, wherein the reverse transcriptase template comprises the modification (e.g., edit) to be incorporated into a target nucleic acid. In some embodiments, an extended guide nucleic acid comprises, at its 3' end, a primer binding site and a modification (e.g., an edit) to be incorporated into the target nucleic acid (e.g., a reverse transcriptase template). In some embodiments, an extended guide nucleic acid comprises: (1) a sequence that interacts (e.g., recruits and/or binds) with a CRISPR-Cas effector protein (e.g., a CRISPR-Cas nuclease), (2) a spacer having substantial complementarity to a first site on a target nucleic acid (e.g., a CRISPR RNA (crRNA) (a first crRNA) and/or tracrRNA+crRNA (sgRNA)), and (3) a nucleic acid encoded repair template (e.g., an RNA encoded repair template) comprising a primer binding site and an RNA template (e.g., that encodes the modification to be incorporated into the target nucleic acid). In some embodiments, an extended guide nucleic acid (e.g., an extended guide RNA) may comprise, 5'-3', a spacer sequence, a repeat sequence, and an extended portion, the extended portion comprising, 5' to 3', a reverse transcriptase template and a primer binding site. In some embodiments, an extended guide nucleic acid may comprise, 5'-3', a spacer sequence, a repeat sequence and an extended portion, the extended portion comprising, 5' to 3', a primer binding site and a reverse transcriptase template. In some embodiments, an extended guide nucleic acid may comprise, 5'-3', an extended portion, a spacer sequence, and a repeat sequence, wherein the extended portion comprises, 5' to 3', a reverse transcriptase template and a primer binding site. In some embodiments, an extended guide nucleic acid may comprise,



5'-3', an extended portion, a spacer sequence, and a repeat sequence, wherein the extended portion comprises, 5' to 3', a primer binding site and a reverse transcriptase template.

**[0135]** According to some embodiments, an extended guide nucleic acid (e.g., a pegRNA) may have a structure and/or be designed as described in Anzalone et al., *Nature*, 2019 December; 576(7785): 149-157. In some embodiments, an extended guide nucleic acid comprises a primer binding site (PBS) optionally having a sequence of 1, 2, 3, 4, or 5 to 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides and a reverse transcriptase template (RT template) sequence optionally having a sequence of 65 nucleotides or more. In some embodiments, a PBS of an extended guide nucleic acid has a sequence of less than 15 nucleotides and has a sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 nucleotides (e.g., a sequence of 5 or 6 nucleotides in length). The RT template sequence may be after the PBS sequence in the 5' to 3' direction. In some embodiments, the RT template sequence of the extended guide nucleic acid has a length of greater than 65 nucleotides and may comprise about 50 or more nucleotides of heterology relative to the target site (e.g., target nucleic acid), followed by about 15 or more nucleotides of homology relative to the target site. In some embodiments, the RT template sequence of the extended guide nucleic acid is after the PBS sequence and the RT template sequence has a length of greater than 65 nucleotides with the sequence including more than 50 nucleotides of heterology relative to the target site, followed by more than 15 nucleotides of homology relative to the target site. Accordingly, in some embodiments, when the extended guide nucleic acid is reverse transcribed, the resulting newly transcribed sequence may hybridize and/or is configured to hybridize with the unnicked strand of the target site, which may thereby create a heteroduplex DNA with a large insertion into the newly synthesized strand. Upon repair of this mismatched DNA, the resultant repaired DNA may contain a large insertion (e.g., greater than 50 nucleotides) of DNA sequence. In some embodiments, the method may provide a large deletion (e.g., greater than 50 nucleotides) of DNA sequence. In some embodiments, the PBS and the 15 or more nucleotides of homology to the target site may comprise homology arms, which may serve to insert the heterology into the target site optionally using homology directed repair. The inserted DNA may correspond to any functional sequence of DNA such as, but not limited to: a functional transgene; a fragment of DNA that is inserted into a gene in a way that, when the gene is transcribed, would produce a hairpin RNA that is sufficient to silence homologous genes through RNAi; and/or one or more functional site-specific recombination sites, e.g. lox, frt, which could then be used in subsequent Cre or FLP mediated site-specific recombination processes. In some embodiments, an extended guide nucleic acid may be too large to produce using a PolIII promoter *in vivo*. In some embodiments, an extended guide nucleic acid may be operatively associated with and/or produced using a PolIII promoter. In some embodiments, a DNA binding polypeptide (e.g., a DNA binding domain) and/or DNA endonuclease may have a structure and/or be designed as described in Anzalone et al., *Nature*, 2019 December; 576(7785): 149-157. In some embodiments, a DNA binding domain and/or DNA endonuclease is a CRISPR Cas polypeptide such as a Cas9 nickase, a nicking variant of another CRISPR Cas polypeptide, or Cas12a.

**[0136]** In some embodiments, two extended guide nucleic acids (e.g., pegRNAs) may be used (e.g., an editing system may comprise two extended guide nucleic acids). One or both of the two extended guide nucleic acids may have a structure and/or be designed as described in Anzalone et al., *Nature*, 2019 December; 576(7785): 149-157. The two extended guide nucleic acids may comprise a primer binding site (PBS) optionally having a sequence of 1, 2, 3, 4, or 5 to 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides and a reverse transcriptase template (RT template) sequence optionally having a sequence of 50 nucleotides or more. The RT template sequences of the two extended guide nucleic acids may be complementary to each other and as such the polynucleotides that are respectively reverse transcribed from each the RT templates will be complementary to each other and will be able to hybridize with each other. This may allow for the intermediates that are produced by this system and/or method to join together two sections of DNA that are otherwise separated by more than 50 nucleotides, e.g. within a chromosome, or that are positioned on two separate pieces of DNA, e.g. on two different chromosomes. After repair of the intermediates, the resultant products may produce, depending on the design of the RT template, large deletions, large inversions, or inter-chromosomal recombinations. Since all of these products are produced by homology directed repair, the products may be predictably precise and/or reproducible. In some embodiments, a DNA binding polypeptide (e.g., a DNA binding domain) and/or DNA endonuclease may have a structure and/or be designed as described in Anzalone et al., *Nature*, 2019 December; 576(7785): 149-157. In some embodiment, a DNA binding polypeptide and/or DNA endonuclease is a CRISPR Cas polypeptide such as a Cas9 nickase, a similar nicking variant of another CRISPR Cas polypeptide, or Cas12a. In some embodiments, a DNA binding polypeptide and/or DNA endonuclease is a Cas9 nuclease, a similar nuclease from another CRISPR Cas polypeptide, or Cas12a. Using a nuclease (rather than a nickase) may facilitate the intra- or interchromosomal recombination processes through single-strand annealing of the more than 50 nucleotide 3' overhangs that would be produced at each of the two target sites corresponding to the two pegRNA target nucleic acids. In some embodiments, an editing system comprises one extended guide nucleic acid and a guide nucleic acid that is devoid of a reverse transcriptase template and/or primer binding site.

**[0137]** An extended guide nucleic acid may comprise a CRISPR nucleic acid (e.g., CRISPR RNA, CRISPR DNA, crRNA, crDNA) and/or a CRISPR nucleic acid and a tracr nucleic acid; and (b) an extended portion comprising a primer binding site and a reverse transcriptase template (RT template), wherein the RT template encodes a modification to be incorporated into the target nucleic acid. The CRISPR nucleic acid may be a Type II or Type V CRISPR nucleic acid and/or the tracr nucleic acid may be any tracr corresponding to the appropriate Type II or Type V CRISPR nucleic acid. In some embodiments, an extended guide nucleic acid comprises: (i) a Type V CRISPR nucleic acid or a Type II CRISPR nucleic acid (e.g., a Type II or Type V CRISPR RNA, Type II or Type V CRISPR DNA, Type II or Type V crRNA, or Type II or Type V crDNA) and/or a CRISPR nucleic acid and a tracr nucleic acid (e.g., a Type II or Type V tracrRNA, Type II or Type V tracrDNA); and (ii) an extended portion comprising a primer binding site and

a reverse transcriptase template (RT template), wherein the Type V CRISPR nucleic acid or Type II CRISPR nucleic acid comprises a spacer that binds to a first strand (e.g., the target strand) of a target nucleic acid (e.g., the spacer is complementary to a portion of consecutive nucleotides in the first strand of the target nucleic acid) and the primer binding site binds to the first strand (e.g., target strand). In some embodiments, the extended portion can be fused to either the 5' end or 3' end of the CRISPR nucleic acid (e.g., from 5' to 3': repeat-spacer-extended portion or extended portion-repeat-spacer) and/or to the 5' or 3' end of the tracr nucleic acid. In some embodiments, the extended portion of an extended guide nucleic acid comprises, 5' to 3', an RT template (RTT) and a primer binding site (PBS) (e.g., 5'-crRNA-spacer-RTT(edit encoded)-PBS-3') or comprises 5' to 3' a PBS and RTT, depending on the location of the extended portion relative to the CRISPR nucleic acid of the extended guide nucleic acid (e.g., 5'-crRNA-spacer-PBS-RTT(edit encoded)-3'). For example, in some embodiments, an extended portion of the extended guide nucleic acid may comprise, 5' to 3', an RT template and a primer binding site (when the extended guide is linked to the 3' end of the CRISPR nucleic acid). In some embodiments, an extended portion of the extended guide may comprise, 5' to 3', a primer binding site and an RT template (when the extended guide is linked to the 5' end of the CRISPR nucleic acid).

**[0138]** In some embodiments, a target nucleic acid is double stranded and comprises a first strand and a second strand and a primer binding site of an extended guide nucleic acid binds to the second strand (e.g., the non-target, top strand) of the target nucleic acid. In some embodiments, a target nucleic acid is double stranded and comprises a first strand and a second strand and a primer binding site of an extended guide nucleic acid binds to the first strand (e.g., binds to the target strand, optionally the same strand to which a CRISPR-Cas effector protein is recruited, bottom strand) of the target nucleic acid. In some embodiments, a target nucleic acid is double stranded and comprises a first strand and a second strand and the primer binding site of an extended guide nucleic acid binds to the second strand (e.g., the non-target strand, optionally the opposite strand from that to which the CRISPR-Cas effector protein is recruited) of the target nucleic acid. In some embodiments, a reverse transcriptase (RT) may add to the target strand of a target nucleic acid (e.g., the strand to which the spacer of the CRISPR nucleic acid of the extended guide nucleic acid is complementary and to which the CRISPR-Cas effector protein is recruited). In some embodiments, the reverse transcriptase (RT) adds to the non-target strand of a target nucleic acid (e.g., the strand that is complementary to the strand to which the spacer of the CRISPR nucleic acid is complementary and to which the CRISPR-Cas effector protein is recruited). Example methods and editing systems are described in International Patent Publication No. WO 2021/092130, International Patent Publication No. WO 2022/098993, and U.S. Patent Application Publication Nos. 2021/0147862, 2021/0130835, 2021/0147862, and 2022/0145334, each of which are incorporated herein by reference in their entirety.

**[0139]** The RT template of an extended guide nucleic acid may encode one or more modification(s) (e.g., edit(s)) to be incorporated into a target nucleic acid. The one or more modification(s) may be located in any position within an RT template (e.g., where the position location may be relative to

the position of a protospacer adjacent motif (PAM) of the target nucleic acid). In some embodiments, an RT template has a modification at one or more positions from -1 to 23 (e.g., -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23) relative to the position of a protospacer adjacent motif (PAM) (e.g., TTTG) in a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23. In some embodiments, an RT template may comprise a modification located at nucleotide position 4 to nucleotide position 17 (e.g., position 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17) of the RT template relative to the position of a PAM of a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position 10 to nucleotide position 17 (e.g., position 10, 11, 12, 13, 14, 15, 16, or 17) of the RT template relative to the position of a PAM of a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position 12 to nucleotide position 15 (e.g., position 12, 13, 14, or 15) of the RT template relative to the position of a PAM of a target nucleic acid.

**[0140]** In some embodiments, an extended portion of an extended guide nucleic acid may comprise, 5' to 3', an RT template and a primer binding site (e.g., when the extended portion is linked to the 3' end of a CRISPR nucleic acid). In some embodiments, an extended portion of an extended guide nucleic acid may comprise, 5' to 3', a primer binding site and an RT template (RTT) (e.g., when the extended portion is linked to the 5' end of the CRISPR nucleic acid). In some embodiments, an RT template may have a length of about 1 nucleotide to about 100 nucleotides (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides, and any range or value therein), e.g., about 1 nucleotide to about 10 nucleotides, about 1 nucleotide to about 15 nucleotides, about 1 nucleotide to about 20 nucleotides, about 1 nucleotide to about 25 nucleotides, about 1 nucleotide to about 30 nucleotides, about 1 nucleotide to about 35, 36, 37, 38, 39 or 40 nucleotides, about 1 nucleotide to about 50 nucleotides, about 5 nucleotides to about 15 nucleotides, about 5 nucleotides to about 20 nucleotides, about 5 nucleotides to about 25 nucleotides, about 5 nucleotides to about 30 nucleotides, about 5 nucleotides to about 35, 36, 37, 38, 39 or 40 nucleotides, about 5 nucleotides to about 50 nucleotides, about 8 nucleotides to about 15 nucleotides, about 8 nucleotide to about 20 nucleotides, about 8 nucleotide to about 25 nucleotides, about 8 nucleotide to about 30 nucleotides, about 8 nucleotide to about 35, 36, 37, 38, 39 or 40 nucleotides, about 8 nucleotide to about 50 nucleotides in length, about 8 nucleotides to about 100 nucleotides, about 10 nucleotide to about 15 nucleotides, about 10 nucleotide to about 20 nucleotides, about 10 nucleotide to about 25 nucleotides, about 10 nucleotide to about 30 nucleotides, about 10 nucleotide to about 36 nucleotides, about 10 nucleotide to about 40 nucleotides, about 10 nucleotide to about 50 nucleotides, about 10 nucleotides to about 100 nucleotides in length and any range or value therein. In some embodiments, the length

of an RT template may be at least 8 nucleotides, optionally about 8 nucleotides to about 100 nucleotides. In some embodiments, the length of an RT template is 36, 37, 38, 39 or 40 nucleotides or less (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length, or any value or range therein (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides in length to about 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length). In some embodiments, the length of an RT template may be at least 30 nucleotides, optionally about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides in length to about 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides in length, or any range or value therein. In some embodiments, the length of an RT template may be about 36, 40, 44, 47, 50, 52, 55, 63, 72 or 74 nucleotides.

**[0141]** Within the length of the RTT one or more modification(s) may be present. The one or more modification(s) may be located anywhere within the RTT, wherein the position of the modification may be described relative to the position of a protospacer adjacent motif (PAM) of a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position -1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23. In some embodiments, an RT template may comprise a modification located at nucleotide position 4 to nucleotide position 17 (e.g., position 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17) of the RT template relative to the position of a protospacer adjacent motif (PAM) of a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position 10 to nucleotide position 17 (e.g., position 10, 11, 12, 13, 14, 15, 16, or 17) of the RT template relative to the position of a protospacer adjacent motif (PAM) of a target nucleic acid. In some embodiments, an RT template may comprise a modification located at nucleotide position 12 to nucleotide position 15 (e.g., position 12, 13, 14, or 15) of the RT template relative to the position of a protospacer adjacent motif (PAM) of a target nucleic acid.

**[0142]** As used herein, a “primer binding site” (PBS) of an extended portion of an extended guide nucleic acid (e.g., a tagRNA) refers to a sequence of consecutive nucleotides that can bind to a region or “primer” on a target nucleic acid, e.g., is complementary to the target nucleic acid primer. As an example, a CRISPR Cas effector protein (e.g., a Type II or Type V, e.g., Cas 9 or Cas12a) may nick/cut the DNA and the 3' end of the cut DNA acts as a primer for the PBS portion of the extended guide nucleic acid. The PBS may be complementary to the 3' end of a strand of the target nucleic acid and may bind and/or may be configured to bind to either the target strand or non-target strand. A primer binding site can be fully complementary to the primer or it may be substantially complementary (e.g., at least 70% complementary (e.g., 70% or about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more)) to the primer of a target nucleic acid. In some embodiments, the length of a primer binding site of an extended portion may be about 1 nucleotide to about 100 nucleotides in length (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,

11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides, or any value or range therein), or about 4 nucleotide to about 85 nucleotides, about 10 nucleotide to about 80 nucleotides, about 20 nucleotide to about 80 nucleotides, about 25 nucleotides to about 80 nucleotides about 30 nucleotide to about 80 nucleotides, about 40 nucleotide to about 80 nucleotides, about 45 nucleotide to about 80 nucleotides, about 45 nucleotide to about 75 nucleotides, or about 45 nucleotide to about 60 nucleotides, or any range or value therein. In some embodiments, the length of a PBS may be at least 30 nucleotides, optionally about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 nucleotides to about 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleotides in length, or any range or value therein. In some embodiments, the length of a PBS may be about 8, 16, 24, 32, 40, 48, 56, 64, 72, or 80 nucleotides.

**[0143]** In some embodiments, an RTT may have a length of about 35 nucleotides to about 75 nucleotides and a PBS may have a length of about 30 nucleotides to about 80 nucleotides, optionally wherein the PBS may comprise a length of about 8, 16, 24, 32, 40, 48, 56, 64, 72, or 80 nucleotides and the RTT may comprise a length of about 36, 40, 44, 47, 50, 52, 55, 63, 72 or 74 nucleotides, or any combination thereof of the RTT length and/or PBS length.

**[0144]** In some embodiments, an extended portion of an extended guide nucleic acid may be fused to either the 5' end or 3' end of a Type II or a Type V CRISPR nucleic acid (e.g., 5' to 3': repeat-spacer-extended portion, or extended portion-repeat-spacer) and/or to the 5' or 3' end of the tracr nucleic acid. In some embodiments, when an extended portion is located 5' of the crRNA, a Type V CRISPR-Cas effector protein is modified to reduce (or eliminate) self-processing RNase activity.

**[0145]** In some embodiments, the extended portion of an extended guide nucleic acid may be linked to the Type II or Type V CRISPR nucleic acid and/or the Type II or Type V tracrRNA via a linker. In some embodiments, a linker have a length of about 1 to about 100 nucleotides or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more nucleotides in length, and any range therein (e.g., about 2 to about 40, about 2 to about 50, about 2 to about 60, about 4 to about 40, about 4 to about 50, about 4 to about 60, about 5 to about 40, about 5 to about 50, about 5 to about 60, about 9 to about 40, about 9 to about 50, about 9 to about 60, about 10 to about 40, about 10 to about 50, about 10 to about 60, about 40 to about 100, about 50 to about 100, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 nucleotides to about 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more

nucleotides in length (e.g., about 105, 110, 115, 120, 130, 140 150 or more nucleotides in length).

**[0146]** A guide nucleic acid and/or an extended guide nucleic acid may comprise one or more recruiting motifs as described herein, which may be linked to the 5' end and/or the 3' end of the guide nucleic acid and/or it may be inserted into the guide nucleic acid (e.g., within a hairpin loop of the guide nucleic acid). In some embodiments, an extended guide nucleic acid may be linked to an RNA recruiting motif. An extended guide nucleic acid and/or guide nucleic acid may be linked to one or to two or more RNA recruiting motifs (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more motifs; e.g., at least 10 to about 25 motifs), optionally wherein the two or more RNA recruiting motifs may be the same RNA recruiting motif or different RNA recruiting motifs. In some embodiments, an RNA recruiting motif may be located on the 3' end of the extended portion of an extended guide nucleic acid (e.g., 5'-3', repeat-spacer-extended portion (RT template-primer binding site)-RNA recruiting motif). In some embodiments, an RNA recruiting motif may be embedded in the extended portion of an extended guide nucleic acid.


**[0147]** In some embodiments, an editing system comprises an extended guide nucleic acid that is linked to an RNA recruiting motif and a reverse transcriptase that is a reverse transcriptase fusion protein, wherein the reverse transcriptase fusion protein comprises a reverse transcriptase polypeptide fused to an affinity polypeptide that binds to the RNA recruiting motif, wherein the extended guide nucleic acid binds to a target nucleic acid and the RNA recruiting motif binds to the affinity polypeptide, thereby recruiting the reverse transcriptase fusion protein to the extended guide nucleic acid and contacting the target nucleic acid with the reverse transcriptase. In some embodiments, two or more reverse transcriptase fusion proteins may be recruited to an extended guide nucleic acid, thereby contacting the target nucleic acid with two or more reverse transcriptase fusion proteins.

**[0148]** A “target nucleic acid”, “target DNA,” “target nucleotide sequence,” “target region,” and “target region in the genome” are used interchangeably herein and refer to a region of an organism’s (e.g., a plant’s) genome that comprises a sequence that is fully complementary (100% complementary) or substantially complementary (e.g., at least 70% complementary (e.g., 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more)) to a spacer sequence in a guide nucleic acid as defined herein. A target nucleic acid is targeted by an editing system (or a component thereof) as described herein. A target region useful for a CRISPR-Cas system may be located immediately 3' (e.g., Type V CRISPR-Cas system) or immediately 5' (e.g., Type II CRISPR-Cas system) to a PAM sequence in the genome of the organism (e.g., a plant genome or mammalian (e.g., human) genome). A target region may be selected from any region of at least 15 consecutive nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides, and the like) located immediately adjacent to a PAM sequence.

**[0149]** A “protospacer sequence” or “protospacer” as used herein refer to a sequence that is fully or substantially complementary to (and can hybridize to) a spacer sequence of a guide nucleic acid. In some embodiments, the protospacer is all or a portion of a target nucleic acid as defined

herein that is fully or substantially complementary (and hybridizes) to the spacer sequence of the CRISPR repeat-spacer sequences (e.g., guide nucleic acids, CRISPR arrays, crRNAs).

**[0150]** In the case of Type V CRISPR-Cas (e.g., Cas12a) systems and Type II CRISPR-Cas (Cas9) systems, the protospacer sequence is flanked by (e.g., immediately adjacent to) a protospacer adjacent motif (PAM). For Type IV CRISPR-Cas systems, the PAM is located at the 5' end on the non-target strand and at the 3' end of the target strand (see below, as an example).



**[0151]** In the case of Type II CRISPR-Cas (e.g., Cas9) systems, the PAM is located immediately 3' of the target region. The PAM for Type I CRISPR-Cas systems is located 5' of the target strand. There is no known PAM for Type III CRISPR-Cas systems. Makarova et al. describes the nomenclature for all the classes, types and subtypes of CRISPR systems (Nature Reviews Microbiology 13:722-736 (2015)). Guide structures and PAMs are described in R. Barrangou (*Genome Biol.* 16:247 (2015)).

**[0152]** Canonical Cas12a PAMs are T rich. In some embodiments, a canonical Cas12a PAM sequence may be 5'-TTN, 5'-TTTN, or 5'-TTTV. In some embodiments, canonical Cas9 (e.g., *S. pyogenes*) PAMs may be 5'-NGG-3'. In some embodiments, non-canonical PAMs may be used but may be less efficient.

**[0153]** Additional PAM sequences may be determined by those skilled in the art through established experimental and computational approaches. Thus, for example, experimental approaches include targeting a sequence flanked by all possible nucleotide sequences and identifying sequence members that do not undergo targeting, such as through the transformation of target plasmid DNA (Esvelt et al. 2013. *Nat. Methods* 10:1116-1121; Jiang et al. 2013. *Nat. Biotechnol.* 31:233-239). In some aspects, a computational approach can include performing BLAST searches of natural spacers to identify the original target DNA sequences in bacteriophages or plasmids and aligning these sequences to determine conserved sequences adjacent to the target sequence (Briner and Barrangou. 2014. *Appl. Environ. Microbiol.* 80:994-1001; Mojica et al. 2009. *Microbiology* 155:733-740).

**[0154]** In some embodiments, the present invention provides expression cassettes and/or vectors comprising the nucleic acid constructs of the invention (e.g., one or more components of an editing system of the invention). In some embodiments, expression cassettes and/or vectors comprising the nucleic acid constructs of the invention and/or one or more guide nucleic acids may be provided. In some embodiments, a nucleic acid construct of the invention encodes a fusion protein, and/or a deaminase, and each may be comprised on the same or on a separate expression cassette or vector from that comprising the one or more guide nucleic acids. When the nucleic acid construct encoding a fusion protein or the components of an editing system is/are comprised on separate expression cassette(s) or vector(s) from that comprising the guide nucleic acid, a target nucleic acid may be contacted with (e.g., provided with) the expres-

sion cassette(s) or vector(s) encoding the fusion protein or components of an editing system in any order from one another and the guide nucleic acid, e.g., prior to, concurrently with, or after the expression cassette comprising the guide nucleic acid is provided (e.g., contacted with the target nucleic acid).

**[0155]** Methods of recruiting one or more components of an editing system to each other and/or to a target nucleic acid are known in the art and may include the use of a peptide tag or an affinity polypeptide that interacts with the peptide tag. In some embodiments, a guide nucleic acid may be linked to an RNA recruiting motif and a deaminase may be linked to an affinity polypeptide capable of interacting with the RNA recruiting motif, thereby recruiting the deaminase to the target nucleic acid. Alternatively, chemical interactions may be used to recruit a polypeptide (e.g., a deaminase) to a target nucleic acid.

**[0156]** A “recruiting motif” as used herein refers to one half of a binding pair that may be used to recruit a compound to which the recruiting motif is bound to another compound that includes the other half of the binding pair (i.e., a “corresponding motif”). The recruiting motif and corresponding motif may bind noncovalently. In some embodiments, a recruiting motif is an RNA recruiting motif (e.g., an RNA recruiting motif that is capable of binding and/or configured to bind to an affinity polypeptide), an affinity polypeptide (e.g., an affinity polypeptide that is capable of binding and/or configured to bind an RNA recruiting motif and/or a peptide tag), or a peptide tag (e.g., a peptide tag that is capable of binding and/or configured to bind an affinity polypeptide). For example, when a recruiting motif is an RNA recruiting motif, the corresponding motif for the RNA recruiting motif may be an affinity polypeptide that binds the RNA recruiting motif. A further example is that when a recruiting motif is a peptide tag, the corresponding motif for the peptide tag may be an affinity polypeptide that binds the peptide tag. Thus, a compound comprising a recruiting motif (e.g., an affinity polypeptide) may be recruited to another compound (e.g., a guide nucleic acid) comprising a corresponding motif for the recruiting motif (e.g., an RNA recruiting motif).

**[0157]** A peptide tag (e.g., epitope) useful with this invention may include, but is not limited to, a GCN4 peptide tag (e.g., Sun-Tag), a c-Myc affinity tag, an HA affinity tag, a His affinity tag, an S affinity tag, a methionine-His affinity tag, an RGD-His affinity tag, a FLAG octapeptide, a strep tag or strep tag II, a V5 tag, and/or a VSV-G epitope. Any epitope that may be linked to a polypeptide and for which there is a corresponding affinity polypeptide that may be linked to another polypeptide may be used with this invention as a peptide tag. In some embodiments, a peptide tag may comprise 1 or 2 or more copies of a peptide tag (e.g., repeat unit, multimerized epitope (e.g., tandem repeats)) (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more repeat units. In some embodiments, an affinity polypeptide that interacts with/binds to a peptide tag may be an antibody. In some embodiments, the antibody may be a scFv antibody. In some embodiments, an affinity polypeptide that binds to a peptide tag may be synthetic (e.g., evolved for affinity interaction) including, but not limited to, an affibody, an anticalin, a monobody and/or a DARPIn (see, e.g., Sha et al., *Protein Sci.* 26(5): 910-924 (2017)); Gilbreth (*Curr Opin Struct Biol* 22(4):413-420 (2013)), U.S. Pat. No. 9,982,053, each of which are

incorporated by reference in their entireties for the teachings relevant to affibodies, anticalins, monobodies and/or DARPin.

**[0158]** In some embodiments, a guide nucleic acid may be linked to an RNA recruiting motif, and a polypeptide to be recruited (e.g., a deaminase) may be fused to an affinity polypeptide that binds to the RNA recruiting motif, wherein the guide binds to the target nucleic acid and the RNA recruiting motif binds to the affinity polypeptide, thereby recruiting the polypeptide to the guide and contacting the target nucleic acid with the polypeptide (e.g., deaminase). In some embodiments, two or more polypeptides may be recruited to a guide nucleic acid, thereby contacting the target nucleic acid with two or more polypeptides (e.g., deaminases).

**[0159]** In some embodiments of the invention, a guide RNA may be linked to one or to two or more RNA recruiting motifs (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more motifs; e.g., at least 10 to about 25 motifs), optionally wherein the two or more RNA recruiting motifs may be the same RNA recruiting motif or different RNA recruiting motifs. In some embodiments, an RNA recruiting motif and corresponding affinity polypeptide may include, but is not limited, to a telomerase Ku binding motif (e.g., Ku binding hairpin) and the corresponding affinity polypeptide Ku (e.g., Ku heterodimer), a telomerase Sm7 binding motif and the corresponding affinity polypeptide Sm7, an MS2 phage operator stem-loop and the corresponding affinity polypeptide MS2 Coat Protein (MCP), a PP7 phage operator stem-loop and the corresponding affinity polypeptide PP7 Coat Protein (PCP), an SfiMu phage Com stem-loop and the corresponding affinity polypeptide Com RNA binding protein, a PUF binding site (PBS) and the affinity polypeptide Pumilio/fem-3 mRNA binding factor (PUF), and/or a synthetic RNA-aptamer and the aptamer ligand as the corresponding affinity polypeptide. In some embodiments, the RNA recruiting motif and corresponding affinity polypeptide may be an MS2 phage operator stem-loop and the affinity polypeptide MS2 Coat Protein (MCP). In some embodiments, the RNA recruiting motif and corresponding affinity polypeptide may be a PUF binding site (PBS) and the affinity polypeptide Pumilio/fem-3 mRNA binding factor (PUF). Exemplary RNA recruiting motifs and corresponding affinity polypeptides that may be useful with this invention can include, but are not limited to, SEQ ID NOs:86-96.

**[0160]** In some embodiments, the components for recruiting polypeptides and nucleic acids may include those that function through chemical interactions that may include, but are not limited to, rapamycin-inducible dimerization of FRB-FKBP; Biotin-streptavidin; SNAP tag; Halo tag; CLIP tag; DmrA-DmrC heterodimer induced by a compound; bifunctional ligand (e.g., chemically induced dimerization).

**[0161]** As described herein, a “peptide tag” may be employed to recruit one or more polypeptides. A peptide tag may be any polypeptide that is capable of being bound by a corresponding motif such as an affinity polypeptide. A peptide tag may also be referred to as an “epitope” and when provided in multiple copies, a “multimerized epitope.” Example peptide tags can include, but are not limited to, a GCN4 peptide tag (e.g., Sun-Tag), a c-Myc affinity tag, an HA affinity tag, a His affinity tag, an S affinity tag, a methionine-His affinity tag, an RGD-His affinity tag, a FLAG octapeptide, a strep tag or strep tag II, a V5 tag, and/or a VSV-G epitope. In some embodiments, a peptide

tag may also include phosphorylated tyrosines in specific sequence contexts recognized by SH2 domains, characteristic consensus sequences containing phosphoserines recognized by 14-3-3 proteins, proline rich peptide motifs recognized by SH3 domains, PDZ protein interaction domains or the PDZ signal sequences, and an AGO hook motif from plants. Peptide tags are disclosed in WO2018/136783 and U.S. Patent Application Publication No. 2017/0219596, which are incorporated by reference for their disclosures of peptide tags. Peptide tags that may be useful with this invention can include, but are not limited to, SEQ ID NO:97 and SEQ ID NO:98. An affinity polypeptide useful with peptide tags includes, but is not limited to, SEQ ID NO:99.

**[0162]** A peptide tag may comprise or be present in one copy or in 2 or more copies of the peptide tag (e.g., multimerized peptide tag or multimerized epitope) (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 9, 20, 21, 22, 23, 24, or 25 or more peptide tags). When multimerized, the peptide tags may be fused directly to one another or they may be linked to one another via one or more amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acids, optionally about 3 to about 10, about 4 to about 10, about 5 to about 10, about 5 to about 15, or about 5 to about 20 amino acids, and the like, and any value or range therein). Thus, in some embodiments, a CRISPR-Cas effector protein of the invention may comprise a CRISPR-Cas effector protein fused to one peptide tag or to two or more peptide tags, optionally wherein the two or more peptide tags are fused to one another via one or more amino acid residues. In some embodiments, a peptide tag useful with the invention may be a single copy of a GCN4 peptide tag or epitope or may be a multimerized GCN4 epitope comprising about 2 to about 25 or more copies of the peptide tag (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more copies of a GCN4 epitope or any range therein).

**[0163]** In some embodiments, a peptide tag may be fused to a CRISPR-Cas polypeptide or domain. In some embodiments, a peptide tag may be fused or linked to the C-terminus of a CRISPR-Cas effector protein to form a CRISPR-Cas fusion protein. In some embodiments, a peptide tag may be fused or linked to the N-terminus of a CRISPR-Cas effector protein to form a CRISPR-Cas fusion protein. In some embodiments, a peptide tag may be fused within a CRISPR-Cas effector protein (e.g., a peptide tag may be in a loop region of a CRISPR-Cas effector protein). In some embodiments, peptide tag may be fused to a cytosine deaminase and/or to an adenine deaminase.

**[0164]** An “affinity polypeptide” (e.g., “recruiting polypeptide”) refers to any polypeptide that is capable of binding to its corresponding peptide tag, peptide tag, or RNA recruiting motif. An affinity polypeptide for a peptide tag may be, for example, an antibody and/or a single chain antibody that specifically binds the peptide tag, respectively. In some embodiments, an antibody for a peptide tag may be, but is not limited to, an scFv antibody. In some embodiments, an affinity polypeptide may be fused or linked to the N-terminus of a deaminase (e.g., a cytosine deaminase or an adenine deaminase). In some embodiments, the affinity polypeptide is stable under the reducing conditions of a cell or cellular extract.

**[0165]** The nucleic acid constructs of the invention and/or guide nucleic acids may be comprised in one or more expression cassettes as described herein. In some embodi-

ments, a nucleic acid construct of the invention may be comprised in the same or in a separate expression cassette or vector from that comprising a guide nucleic acid and/or an extended guide nucleic acid.

**[0166]** In some embodiments, a nucleic acid construct, expression cassette, or vector of the invention that is optimized for expression in an organism (e.g., a human or plant) may be about 70% to 100% identical (e.g., about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5% or 100%) to a nucleic acid construct, expression cassette or vector comprising the same polynucleotide(s) but which have not been codon optimized for expression in the organism.

**[0167]** When used in combination a guide nucleic acid, a nucleic acid construct of the invention (and expression cassette and/or vector comprising the same) may be used to modify a target nucleic acid and/or its expression. A target nucleic acid may be contacted with a nucleic acid construct of the invention and/or expression cassettes and/or vectors comprising the same prior to, concurrently with or after contacting the target nucleic acid with the guide nucleic acid/recruiting guide nucleic acid (and/or expression cassettes and vectors comprising the same).

**[0168]** According to embodiments of the present invention, provided herein are fusion proteins (e.g., engineered proteins) that include an intein polypeptide. In some embodiments, a fusion protein of the present invention includes a Cas12a polypeptide and an intein polypeptide. In some embodiments, a fusion protein of the present invention includes a polypeptide of interest and an intein polypeptide. In some embodiments, a fusion protein of the present invention includes a reverse transcriptase polypeptide and an intein polypeptide. An “engineered protein” as used herein is a polypeptide or protein that is not found naturally in nature. A fusion protein of the present invention may comprise a Cas12a polypeptide and/or a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to (e.g., linked and/or attached to) an intein polypeptide. A Cas12a polypeptide and an intein polypeptide may be directly fused (e.g., no amino acid residue or linker between the two polypeptides) or indirectly fused (e.g., a linker (e.g., an amino acid or peptide) or another polypeptide is between the two polypeptides). Similarly, a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and an intein polypeptide may be directly fused or indirectly fused. In some embodiments, a Cas12a polypeptide is directly fused (e.g., via a peptide bond) to an intein polypeptide. In some embodiments, a Cas12a polypeptide is indirectly fused (e.g., via a peptide linker) to an intein polypeptide. A Cas12a polypeptide and an intein polypeptide may be fused in any orientation. For example, in some embodiments, the N-terminus of the Cas12a polypeptide is fused to the C-terminus of the intein polypeptide or to the N-terminus of the intein polypeptide. In some embodiments, the C-terminus of the Cas12a polypeptide is fused to the C-terminus of the intein polypeptide or to the N-terminus of the intein polypeptide. A polypeptide of interest (e.g., a reverse transcriptase polypeptide) and an intein polypeptide may be fused in any orientation. In some embodiments, a fusion protein of the present invention has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to one or more of SEQ ID NOs:100-109 or 187-188. According

to some embodiments, provided is a nucleic acid molecule that encodes a polypeptide that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to one or more of SEQ ID NOs:100-109 or 187-188. In some embodiments, a nucleic acid molecule comprises a polynucleotide that has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to one or more of SEQ ID NOs:185-186.

**[0169]** In some embodiments, an intein polypeptide is a portion (e.g., a fragment such as a N-terminal intein fragment or a C-terminal intein fragment) of an intein such as a portion of a molecular scaffold formed from two corresponding portions (e.g., two corresponding fragments or a pair of intein polypeptides) that together can or are configured to catalyze both the cleavage and formation of a peptide bond. An “intein” as used herein refers to a catalytically active complex formed from two polypeptides (e.g., a pair of intein polypeptides) that are associated with each other, wherein the complex can or is configured to excise itself (e.g., the two polypeptides) from a larger precursor polypeptide and can or is configured to ligate the ends flanking the two polypeptides with a peptide bond, optionally wherein the excising and ligating occur concurrently. In some embodiments, an intein polypeptide is a portion of a split intein such as a trans-splicing split intein. A “split intein” as used herein can perform protein trans-splicing in which two fragments of the intein (e.g., two intein polypeptides or a pair of intein polypeptides) associate (e.g., non-covalently bind) to form a catalytically competent complex or molecular scaffold that catalyzes excision of the two intein fragments and the ligation of their flanking sequences. In some embodiments, an intein polypeptide is an autocatalytic polypeptide that together with a corresponding intein polypeptide to form an intein (e.g., a split intein) is capable of excising the intein polypeptide from a larger precursor protein (e.g., a fusion protein of the present invention) and enable the flanking polypeptide sequences (e.g., the sequence adjacent to the excised intein polypeptide) to be ligated through the formation of a new peptide bond. A fusion protein of the present invention may include an intein polypeptide that is one part of two total parts such that the intein polypeptide together with another intein polypeptide (e.g., the second part) together form an intein such as a trans-splicing split intein. In some embodiments, a split intein and/or an intein polypeptide thereof may be able to function (e.g., perform protein trans-splicing) without any assistance and/or conditions other than the two portions of the split intein (e.g., the two intein polypeptides that together provide the split intein). For example, two intein polypeptides may spontaneously associate to form the intein and may spontaneously catalyze their own excision and the ligation of their flanking sequences without assistance (e.g., an external condition and/or cofactor). In some embodiments, an intein may be used for which protein trans-splicing is controlled (e.g., the intein undergoes conditional trans-splicing). For example, certain conditions (e.g., light and/or a cofactor) may be required for an intein to function. In some embodiments, a split intein and/or an intein polypeptide is a light inducible intein (e.g., as described in Wong S, et al. (2015) An Engineered Split Intein for Photoactivated Protein Trans-Splicing. *PLoS ONE* 10(8): e0135965) that uses light in order to control the association of the two intein polypeptides that together provide the intein (e.g., the catalytically active complex). In

some embodiments, a cofactor (e.g., a small molecule) and/or activator is used to bring together two intein polypeptides that together provide the intein and thereby control protein trans-splicing such as described in Gramespacher, Josef A., et al. *J Am Chem Soc.* 2019 Sep. 4; 141(35): 13708-13712. In some embodiments, an intein polypeptide of a fusion protein of the present invention may be configured to be removed (e.g., excised) from the fusion protein and fused with another intein polypeptide (e.g., an intein polypeptide that is a portion of a different fusion protein of the present invention) in situ and/or in vivo.

**[0170]** In some embodiments, an intein of the present invention is an intein present in a DNA polymerase III gene (DnaE) in cyanobacteria and/or an intein as described in Pinto, F., Thornton, E. L. & Wang, B. An expanded library of orthogonal split inteins enables modular multi-peptide assemblies. *Nat Commun* 11, 1529 (2020). Further exemplary inteins include, but are not limited, *Nostoc punctiforme* (Npu) inteins and mutants thereof (e.g., NpuGEP, a mutant that contains 3 amino acid residue mutations). In some embodiments, an intein polypeptide is a portion of a *Nostoc punctiforme* (Npu) intein and/or a portion of a mutant Npu intein (e.g., a portion of NpuGEP). An intein polypeptide may be an N-terminal portion of an intein in that the intein polypeptide includes the N-terminus of the full-length intein and/or active complex. In some embodiments, an intein polypeptide may be a C-terminal portion of an intein in that the intein polypeptide includes the C-terminus of the full-length intein and/or active complex. An intein polypeptide that is an N-terminal portion of an intein and an intein polypeptide that contains the remaining portion of the intein (e.g., the C-terminal portion of the intein) together are an intein pair and form the intein and/or the active complex. An intein polypeptide of the present invention may have at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to one or more of SEQ ID NOs: 110-112.

**[0171]** A Cas12a polypeptide of the present invention may be a portion of a Cas12a protein, optionally a portion of a Cas12a fusion protein. In some embodiments, a Cas12a protein and/or Cas12a fusion protein may be a protein as described in U.S. Patent Application Publication No. 2022/0112473, the contents of which are incorporated herein by reference in its entirety. In some embodiments, a Cas12a polypeptide is portion of a sequence of SEQ ID NO:38-60, 113-149, 192-195, or 196-259. In some embodiments, a Cas12a polypeptide is about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or more consecutive amino acids of the sequence of SEQ ID NO:38-60, 113-149, 192-195, or 196-259. In some embodiments, a Cas12a polypeptide is one part of two total parts that together form the Cas12a protein. For example, a first Cas12a polypeptide that is present in a first fusion protein of the present invention together with a second Cas12a polypeptide that is present in a second fusion protein of the present invention together form a Cas12a protein. In some embodiments, a Cas12a polypeptide is a N-terminal portion of a Cas12a protein in that the Cas12a polypeptide includes the N-terminus of the full-length Cas12a protein. In some embodiments, a Cas12a polypeptide is a C-terminal portion of a Cas12a protein in that the Cas12a polypeptide includes the C-terminus of the full-length Cas12a protein. Two Cas12a polypeptides that are individually present in two different fusion proteins of the

present invention may, upon fusing together of the two Cas12a polypeptides, provide a Cas12a protein that is part of an editing system as described herein such as a CRISPR-Cas editing system. The editing system may be used to modify a target nucleic acid. In some embodiments, a fusion protein of the present invention comprises a Cas12a polypeptide that is a N-terminal portion of a Cas12a protein and an intein polypeptide that is a N-terminal portion of an intein, wherein the intein polypeptide is at the C-terminus of the fusion protein and/or at the C-terminus of the Cas-12a polypeptide. In some embodiments, a fusion protein of the present invention comprises a Cas12a polypeptide that is a C-terminal portion of a Cas12a protein and an intein polypeptide that is a C-terminal portion of an intein, wherein the intein polypeptide is at the N-terminus of the fusion protein and/or at the N-terminus of the Cas-12a polypeptide.

**[0172]** In some embodiments, a Cas12a protein is split into two portions and a fusion protein of the present invention comprises one of the portions. For example, a Cas12a protein may be split into two portions between amino acid residues 173 and 174, 174 and 175, 175 and 176, 309 and 310, 310 and 311, 405 and 406, 406 and 407, 440 and 441, 441 and 442, 549 and 550, or 550 and 551 such that a Cas12a polypeptide includes 173, 174, 175, 309, 310, 405, 406, 440, 441, 549, or 550 consecutive amino acids of a Cas12a protein and another Cas12a polypeptide includes the remaining portion of the Cas12a protein (e.g., from amino acid residue 174, 175, 176, 310, 311, 406, 407, 441, 442, 549, or 551 to the end of the protein). In some embodiments, a Cas12a polypeptide has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to one or more of SEQ ID NOs:150-159 and 175-184.

**[0173]** In some embodiments, a fusion protein of the present invention comprises all or a portion of a polypeptide of interest. In some embodiments, a polypeptide of interest is fused (directly or via a linker) to a Cas12a polypeptide and/or to an intein polypeptide. In some embodiments, a polypeptide of interest is fused (directly or via a linker) to a Cas12a polypeptide and intein polypeptide such that the polypeptide of interest is between the Cas12a polypeptide and the intein polypeptide. In some embodiments, a polypeptide of interest is fused (directly or via a linker) to a Cas12a polypeptide and intein polypeptide such that the Cas12a polypeptide is between the polypeptide of interest and the intein polypeptide. In some embodiments, a fusion protein of the present invention comprises a polypeptide of interest that is fused (directly or via a linker) to an intein polypeptide and the fusion protein is devoid of a Cas12a polypeptide. In some embodiments, a polypeptide of interest is fused (directly or via a linker) to the N-terminus of an intein polypeptide. In some embodiments, a polypeptide of interest is fused (directly or via a linker) to the C-terminus of an intein polypeptide.

**[0174]** A fusion protein of the present invention may comprise a reverse transcriptase. A reverse transcriptase polypeptide of the present invention may be all or a portion of a reverse transcriptase. In some embodiments, a reverse transcriptase has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to one or more of SEQ ID NOs:160-171. In some embodiments, a reverse transcriptase is fused (directly or via a linker) to a Cas12a polypeptide such that the Cas12a polypeptide is between the reverse transcriptase and the intein polypeptide. In some embodiments, a reverse transcriptase is fused (di-

rectly or via a linker) to a Cas12a polypeptide and intein polypeptide such that the reverse transcriptase is between the Cas12a polypeptide and the intein polypeptide. In some embodiments, a reverse transcriptase is fused (directly or via a linker) to the N-terminus of a Cas12a polypeptide. In some embodiments, a reverse transcriptase is fused (directly or via a linker) to the C-terminus of a Cas12a polypeptide. In some embodiments, a reverse transcriptase polypeptide is fused (directly or via a linker) to an intein polypeptide to provide a fusion protein. In some embodiments, a fusion protein comprising a reverse transcriptase polypeptide and an intein polypeptide is devoid of a Cas12a polypeptide.

**[0175]** A fusion protein of the present invention may comprise a nuclear localization signal. In some embodiments, a nuclear localization signal has at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to one or more of SEQ ID NOs:172-174.

**[0176]** In some embodiments, a nucleic acid molecule encoding a fusion protein of the present invention is provided. The nucleic acid molecule may be operably associated with a promoter. In some embodiments, an expression cassette or vector comprising a nucleic acid molecule encoding a fusion protein of the present invention is provided. In some embodiments, an AAV vector comprising a nucleic acid molecule encoding a fusion protein of the present invention is provided.

**[0177]** A complex comprising a Cas12a protein, a guide nucleic acid (e.g., a guide RNA and/or an extended guide nucleic acid), optionally a reverse transcriptase, and optionally a deaminase may be provided according to embodiments of the present invention. In some embodiments, a complex comprises a Cas12a protein, an extended guide nucleic acid, and a reverse transcriptase. In some embodiments, a complex comprises a Cas12a protein, a guide nucleic acid, and a deaminase. The Cas12a protein of a complex of the present invention may be prepared from a first fusion protein of the present invention and a second fusion protein of the present invention, wherein the first fusion protein comprises a first Cas12a polypeptide fused to a first intein polypeptide and the second fusion protein comprises a second Cas12a polypeptide fused to a second intein polypeptide. Upon contact of the first fusion protein and the second fusion protein (e.g., the first and second fusion proteins being provided together (e.g., in the same composition or cell) under conditions suitable for carrying out the excision of the first and second intein polypeptides, association of the first and second intein polypeptides, and fusion of the first and second Cas12a polypeptides), the first and second intein polypeptides may associate to form an intein (e.g., an active complex), and the intein may excise the intein (e.g., the first and second intein polypeptides) and fuse the first and second Cas12a polypeptides together optionally with a linker (e.g., a peptide linker) between the first and second Cas12a polypeptides.

**[0178]** In some embodiments, a complex of the present invention comprises an engineered protein (e.g., a fusion protein, a base editor, a templated editor, etc.) and a guide nucleic acid (e.g., a guide RNA). A base editor may comprise a CRISPR-Cas effector protein (e.g., a Cas12a) and a deaminase. In some embodiments, a templated editor may comprise a CRISPR-Cas effector protein (e.g., a Cas12a) and a reverse transcriptase. In some embodiments, a templated editor may be referred to as a REDRAW editor. In some embodiments, a complex of the present invention



comprises an engineered protein that is prepared from a first fusion protein of the present invention and a second fusion protein of the present invention, wherein the first fusion protein comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the second fusion protein comprises a Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA). In some embodiments, a first fusion protein of the present invention and a second fusion protein of the present invention together provide and/or form an engineered protein, wherein the first fusion protein comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the second fusion protein comprises a Cas12a polypeptide fused to a second intein polypeptide. In some embodiments, a fusion protein of the present invention comprises, optionally in the N- to C-direction, all or a portion of a polypeptide of interest (e.g., a reverse transcriptase polypeptide), a linker, and an intein polypeptide, optionally wherein the linker comprises a sequence of SEQ ID NO:189. In some embodiments, a fusion protein of the present invention comprises, optionally in the N- to C-direction, an intein polypeptide, a linker, and all or a portion of a Cas12a, optionally wherein the linker comprises a sequence of SEQ ID NO:190.

**[0179]** In some embodiments, a composition is provided that comprises: a first fusion protein of the present invention that comprises a first Cas12a polypeptide fused to a first intein polypeptide; and a second fusion protein of the present invention that comprises a second Cas12a polypeptide fused to a second intein polypeptide. The first fusion protein and the second fusion protein may be different from each other. In some embodiments, the first intein polypeptide of the first fusion protein and the second intein polypeptide of the second fusion protein together form an intein and/or are two parts that make up a full-length intein and/or the first Cas12a polypeptide of the first fusion protein and the second Cas12a polypeptide of the second fusion protein together form a Cas12a protein and/or are two parts that make up a full-length Cas12a protein. In some embodiments, the first and second fusion proteins are present in the same cell and may optionally be delivered to the cell using separate compositions or a composition comprising both the first and second fusion proteins.

**[0180]** In some embodiments, a composition of the present invention comprises: a first fusion protein of the present invention that comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second fusion protein of the present invention that comprises a Cas12a polypeptide fused to a second intein polypeptide. The first fusion protein and the second fusion protein may be different from each other. In some embodiments, the first intein polypeptide of the first fusion protein and the second intein polypeptide of the second fusion protein together form an intein and/or are two parts that make up a full-length intein and/or the polypeptide of interest of the first fusion protein and the Cas12a polypeptide of the second fusion protein together form a fusion protein (e.g., an engineered protein and/or a templated editor) and/or are two parts that make up a full-length fusion protein (e.g., an engineered protein and/or a templated editor). In some embodiments, the first and second fusion proteins are present in the same cell and may optionally be

delivered to the cell using separate compositions or a composition comprising both the first and second fusion proteins.

**[0181]** In some embodiments, a composition of the present invention comprises a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide. The first nucleic acid molecule may encode a fusion protein of the present invention and the second nucleic acid molecule may encode a fusion protein of the present invention. In some embodiments, the first nucleic acid molecule is present in a first expression cassette and/or vector and the second nucleic acid molecule is present in a second expression cassette and/or vector, wherein the first and second expression cassettes and/or vectors are separate from each other and/or are different.

**[0182]** In some embodiments, a composition of the present invention comprises a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide. The first nucleic acid molecule may encode a fusion protein of the present invention and the second nucleic acid molecule may encode a fusion protein of the present invention. In some embodiments, the first nucleic acid molecule is present in a first expression cassette and/or vector and the second nucleic acid molecule is present in a second expression cassette and/or vector, wherein the first and second expression cassettes and/or vectors are separate from each other and/or are different.

**[0183]** A kit may be provided according to some embodiments of the present invention. A kit of the present invention may comprise a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide. In some embodiments, a kit of the present invention comprises a first nucleic acid molecule encoding a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide; and a second nucleic acid molecule encoding a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide. In some embodiments, the first nucleic acid molecule of the present invention is present in a first expression cassette and/or vector and the second nucleic acid molecule of the present invention is present in a second expression cassette and/or vector, wherein the first and second expression cassettes and/or vectors are separate from each other and/or are different.

**[0184]** A complex and/or method of the present invention may use and/or include a Cas12a protein that is provided by (e.g., prepared from) two different fusion proteins of the present invention. For example, when the two different fusion proteins are in contact (with each fusion protein comprising a Cas12a polypeptide), the intein polypeptides

of the two fusion proteins may associate to form an intein (e.g., an active complex), and the intein may excise the intein (e.g., the first and second intein polypeptides) and fuse the first and second Cas12a polypeptides together optionally with a linker (e.g., a peptide linker) between the first and second Cas12a polypeptides, to form the Cas12a protein. The two different fusion proteins may be provided by and/or be present in a composition and/or kit of the present invention. In some embodiments, a method of the present invention uses an editing system (e.g., a CRISPR-Cas editing system) in which a Cas12a protein of the present invention (e.g., a Cas12a protein formed by a composition and/or method of the present invention) is part of the editing system and is provided by (e.g., prepared from) two different fusion proteins of the present invention. The editing system may be used to modify a target nucleic acid.

**[0185]** In some embodiments, a complex and/or method of the present invention may use and/or include a fusion protein (e.g., an engineered protein) that is provided by (e.g., prepared from) two different fusion proteins of the present invention. For example, when a first fusion protein that comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and a first intein polypeptide is in contact with a second fusion protein that comprises a Cas12a polypeptide and a second intein polypeptide, the intein polypeptides of the two fusion proteins may associate to form an intein (e.g., an active complex), and the intein may excise the intein (e.g., the first and second intein polypeptides) and fuse the polypeptide of interest and Cas12a polypeptide together optionally with a linker (e.g., a peptide linker) between the polypeptide of interest and Cas12a polypeptide, to form a fusion protein (e.g., an engineered protein). The two different fusion proteins may be provided by and/or be present in a composition and/or kit of the present invention. In some embodiments, a method of the present invention uses an editing system (e.g., a CRISPR-Cas editing system) in which a fusion protein of the present invention (e.g., an engineered protein (e.g., a templated editor) formed by a composition and/or method of the present invention) is part of the editing system and is provided by (e.g., prepared from) two different fusion proteins of the present invention. The editing system may be used to modify a target nucleic acid.

**[0186]** According to some embodiments, provided is a method of modifying a target nucleic acid, the method comprising contacting the target nucleic acid with: a Cas12a protein prepared from a first fusion protein of the present invention and a second fusion protein of the present invention, wherein the first fusion protein comprises a first Cas12a polypeptide fused to a first intein polypeptide and the second fusion protein comprises a second Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA). The Cas12a protein and the guide nucleic acid may form a complex or may be comprised in a complex. The target nucleic acid may be present in a cell (e.g., a eukaryotic cell). In some embodiments, the target nucleic acid is present in a plant cell or a human cell. A method of modifying a target nucleic acid may comprise introducing a first nucleic acid molecule encoding the first fusion protein into the cell and introducing a second nucleic acid molecule encoding the second fusion protein into the cell, and expressing the first fusion protein and the second fusion protein in the cell. The first and second nucleic acid molecules may be present in the same composition such that the

first and second nucleic acid molecules may be introduced together. In some embodiments, the first and second nucleic acid molecules are in different compositions such that the first and second nucleic acid molecules are introduced together in different, separate compositions or are introduced sequentially in any order. In some embodiments, the first nucleic acid molecule and/or the second nucleic acid molecule is/are present in an expression cassette and/or vector. In some embodiments, the expression cassette and/or vector is an AAV vector. In some embodiments, the target nucleic acid is present in a cell, optionally in a cell of an organism (e.g., a plant, human, etc.). In some embodiments, the method of modifying a target nucleic acid is carried out *in vitro*, *in vivo*, or *ex vivo*.

**[0187]** In some embodiments, a method of modifying a target nucleic acid of the present invention comprises contacting the target nucleic acid with: an engineered protein (e.g., a templated editor) that is prepared from a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide and the second fusion protein comprises a Cas12a polypeptide fused to a second intein polypeptide; and a guide nucleic acid (e.g., a guide RNA). The engineered protein and the guide nucleic acid may form a complex or may be comprised in a complex. The target nucleic acid may be present in a cell (e.g., a eukaryotic cell). In some embodiments, the target nucleic acid is present in a plant cell or a human cell. A method of modifying a target nucleic acid may comprise introducing a first nucleic acid molecule encoding the first fusion protein into the cell and introducing a second nucleic acid molecule encoding the second fusion protein into the cell, and expressing the first fusion protein and the second fusion protein in the cell. The first and second nucleic acid molecules may be present in the same composition such that the first and second nucleic acid molecules may be introduced together. In some embodiments, the first and second nucleic acid molecules are in different compositions such that the first and second nucleic acid molecules are introduced together in different, separate compositions or are introduced sequentially in any order. In some embodiments, the first nucleic acid molecule and/or the second nucleic acid molecule is/are present in an expression cassette and/or vector. In some embodiments, the expression cassette and/or vector is an AAV vector. In some embodiments, the target nucleic acid is present in a cell, optionally in a cell of an organism (e.g., a plant, human, etc.). In some embodiments, the method of modifying a target nucleic acid is carried out *in vitro*, *in vivo*, or *ex vivo*.

**[0188]** According to some embodiments, provided is a method of modifying a target nucleic acid, the method comprising: introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide; contacting the target nucleic acid in the cell with a protein comprising at least a portion of the first Cas12a polypeptide and at least a portion of the second Cas12a polypeptide and a guide nucleic acid (e.g., a guide RNA and/or an extended guide nucleic acid). In some embodiments, the guide nucleic acid and the protein com-

prising at least a portion of the first Cas12a polypeptide and at least a portion of the second Cas12a polypeptide form a complex or are comprised in a complex. The method may comprise expressing the first fusion protein and the second fusion protein in the cell. In some embodiments, following the introducing step, the method comprises cleaving (e.g., excising) the first intein polypeptide from the first fusion protein and cleaving (e.g., excising) the second intein polypeptide from the second fusion protein. The method may also comprise prior to, during, and/or after cleaving, associating the first intein polypeptide and the second intein polypeptide to form an intein. The cleaving step may cleave the first Cas12a polypeptide from the first fusion protein and the second Cas12a polypeptide from the second fusion protein and/or the method may further comprise cleaving the first Cas12a polypeptide from the first fusion protein and the second Cas12a polypeptide from the second fusion protein. Prior to, during, and/or after cleaving of the first and second intein polypeptides, the method may comprise fusing the first and second Cas12a polypeptides together (e.g., via a peptide bond between the first and second Cas12a polypeptides) to form a Cas12a protein, wherein the protein that contacts the target nucleic acid in the cell is the Cas12a protein. In some embodiments, the intein fuses the first and second Cas12a polypeptides together. In some embodiments, cleaving of the first intein polypeptide from the first fusion protein and cleaving the second intein polypeptide from the second fusion protein occurs concurrently with fusing the first and second Cas12a polypeptides together. The introducing step may comprise introducing a first expression cassette and/or vector that comprises the first nucleic acid molecule and introducing a second expression cassette and/or vector that comprises the second nucleic acid molecule into the cell. The first and/or second expression cassette and/or vector may comprise the guide nucleic acid, or the method may comprise introducing into the cell a third expression cassette and/or vector that comprises the guide nucleic acid. In some embodiments, a first, second, and/or third expression cassette and/or vector is an AAV vector.

**[0189]** In some embodiments, a method of modifying a target nucleic acid of the present invention comprises introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) fused to a first intein polypeptide, and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide; contacting the target nucleic acid in the cell with a protein (e.g., a templated editor) comprising at least a portion of the polypeptide of interest and at least a portion of the Cas12a polypeptide and a guide nucleic acid (e.g., a guide RNA). In some embodiments, the guide nucleic acid and the protein comprising at least a portion of the polypeptide of interest and at least a portion of the Cas12a polypeptide form a complex or are comprised in a complex. The method may comprise expressing the first fusion protein and the second fusion protein in the cell. In some embodiments, following the introducing step, the method comprises cleaving (e.g., excising) the first intein polypeptide from the first fusion protein and cleaving (e.g., excising) the second intein polypeptide from the second fusion protein. The method may also comprise prior to, during, and/or after cleaving, asso-

ciating the first intein polypeptide and the second intein polypeptide to form an intein. The cleaving step may cleave the polypeptide of interest from the first fusion protein and the Cas12a polypeptide from the second fusion protein and/or the method may further comprise cleaving the polypeptide of interest from the first fusion protein and the Cas12a polypeptide from the second fusion protein. Prior to, during, and/or after cleaving of the first and second intein polypeptides, the method may comprise fusing the polypeptide of interest and the Cas12a polypeptide together (e.g., via a peptide bond that is between the polypeptide of interest and the Cas12a polypeptide) to form a fusion protein (optionally wherein the fusion protein is a templated editor), wherein the fusion protein contacts the target nucleic acid in the cell. In some embodiments, the intein fuses the polypeptide of interest and Cas12a polypeptide together. In some embodiments, cleaving of the first intein polypeptide from the first fusion protein and cleaving the second intein polypeptide from the second fusion protein occurs concurrently with fusing the polypeptide of interest and Cas12a polypeptide together. The introducing step may comprise introducing a first expression cassette and/or vector that comprises the first nucleic acid molecule and introducing a second expression cassette and/or vector that comprises the second nucleic acid molecule into the cell. The first and/or second expression cassette and/or vector may comprise the guide nucleic acid, or the method may comprise introducing into the cell a third expression cassette and/or vector that comprises the guide nucleic acid. In some embodiments, a first, second, and/or third expression cassette and/or vector is an AAV vector.

**[0190]** In some embodiments, a method of the present invention has increased efficiency in modifying a target nucleic acid compared to the efficiency of a control method. An exemplary control method includes a method that contacts a target nucleic acid with a wild-type CRISPR-Cas effector protein that is not fused together via protein splicing (e.g., from two different proteins) optionally using an intein. Another exemplary control method includes a method that contacts a target nucleic acid with a fusion protein (e.g., an engineered protein and/or a templated editor) that is not fused together via protein splicing (e.g., from two different proteins) optionally using an intein. A method of the present invention may generate increased indels and/or increased levels of modification (e.g., precise modifications) compared to a control method. In some embodiments, an editing system used in a method of the present invention is a Redraw editing system such as described in U.S. Patent Application Publication No. 2021/0130835 and/or in U.S. Patent Application Publication No. 2022/0145334, the contents of each of which are incorporated herein by reference in their entirety, but optionally wherein the CRISPR-Cas effector protein is a Cas12a protein that is fused together via protein splicing from two fusion proteins of the present invention and/or wherein the templated editor is a protein that is fused together via protein splicing from two fusion proteins of the present invention.

**[0191]** According to embodiments of the present invention, a Cas12a protein may be split into two parts (e.g., two Cas12a polypeptides) and each part may individually be fused to a portion (e.g., a fragment) of a trans-splicing split intein (e.g., an intein polypeptide) to provide two different fusion proteins. Each of the two fusion proteins may be separately packaged in an AAV vector. For example, a

nucleic acid molecule encoding a fusion portion comprising a Cas12a polypeptide and an intein polypeptide may be provided in an AAV vector. In some embodiments, the two fusion proteins (the Cas12a polypeptide of each form the full-length Cas12a protein and the intein polypeptide of each form the full-length intein) are individually packaged in separate AAV vectors and when both AAV vectors are introduced into (e.g., infect) the same cell, both fusion proteins can be expressed and the two Cas12a polypeptides can be fused (e.g., spliced) together in situ.

**[0192]** In some embodiments, an engineered protein (e.g., a base editor, templated editor, etc.) may be split into two parts (e.g., one part comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and a second part comprising a Cas12a polypeptide) and each part may individually be fused to a portion (e.g., a fragment) of a trans-splicing split intein (e.g., an intein polypeptide) to provide two different fusion proteins. Each of the two fusion proteins may be separately packaged in an AAV vector. For example, a nucleic acid molecule encoding a fusion portion comprising a polypeptide of interest (e.g., a reverse transcriptase polypeptide) and an intein polypeptide may be provided in an AAV vector. In some embodiments, the two fusion proteins (of which together form the engineered protein and the intein polypeptides of each form a full-length intein) are individually packaged in separate AAV vectors and when both AAV vectors are introduced into (e.g., infect) the same cell, both fusion proteins can be expressed and the polypeptide of interest and Cas12a polypeptide can be fused (e.g., spliced) together in situ.

**[0193]** In some embodiments, an editing system of the present invention utilizes the Redraw editing system. Further details on the Redraw editing system can be found in U.S. Patent Application Publication No. 2021/0130835 and/or in U.S. Patent Application Publication No. 2022/0145334, the contents of each of which are incorporated herein by reference in their entirety.

**[0194]** As described herein, the fusion proteins, nucleic acids, expression cassettes, and/or vectors of the present invention may be codon optimized for expression in an organism. An organism useful with this invention may be any organism or cell thereof for which nucleic acid modification may be useful. An organism can include, but is not limited to, any animal (e.g., a mammal), any plant, any fungus, any archaeon, or any bacterium. In some embodiments, the organism may be a plant or cell thereof. In some embodiments, the organism is an animal such as a mammal (e.g., a human).

**[0195]** The target nucleic acid may be a genomic sequence from any organism (e.g., eukaryote such as a mammal or a plant). In some embodiments, the target nucleic acid is a genomic sequence from a model organism such as, but not limited to, *Escherichia coli*, an immortalized human cell line (e.g., HEK293, HeLa, etc.), *Caenorhabditis elegans*, *Arabidopsis thaliana*, and/or *Drosophila Melanogaster*. In some embodiments, the target nucleic acid is a genomic sequence from a non-model organism. Exemplary non-model organisms include, but are not limited to crop plants (e.g., fruit crop plants, vegetable crop plants, and/or field crop plants) and/or animals such as humans, primates and/or mice. In some embodiments, the non-model organism is a crop plant such as corn, soybean, wheat, or canola. In some embodiments, the non-model organism is an animal for testing and/or use of a human therapeutic.

**[0196]** A target nucleic acid of any plant or plant part may be modified using the nucleic acid constructs of the invention. Any plant (or groupings of plants, for example, into a genus or higher order classification) may be modified using a fusion protein of the invention including an angiosperm, a gymnosperm, a monocot, a dicot, a C3, C4, CAM plant, a bryophyte, a fern and/or fern ally, a microalgae, and/or a macroalgae. A plant and/or plant part useful with this invention may be a plant and/or plant part of any plant species/variety/cultivar. The term "plant part," as used herein, includes but is not limited to, embryos, pollen, ovules, seeds, leaves, stems, shoots, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers, plant cells including plant cells that are intact in plants and/or parts of plants, plant protoplasts, plant tissues, plant cell tissue cultures, plant calli, plant clumps, and the like. As used herein, "shoot" refers to the above ground parts including the leaves and stems. Further, as used herein, "plant cell" refers to a structural and physiological unit of the plant, which comprises a cell wall and also may refer to a protoplast. A plant cell can be in the form of an isolated single cell or can be a cultured cell or can be a part of a higher-organized unit such as, for example, a plant tissue or a plant organ.

**[0197]** Non-limiting examples of plants useful with the present invention include turf grasses (e.g., bluegrass, bentgrass, ryegrass, fescue), feather reed grass, tufted hair grass, miscanthus, arundo, switchgrass, vegetable crops, including artichokes, kohlrabi, arugula, leeks, asparagus, lettuce (e.g., head, leaf, romaine), malanga, melons (e.g., muskmelon, watermelon, crenshaw, honeydew, cantaloupe), cole crops (e.g., brussels sprouts, cabbage, cauliflower, broccoli, collards, kale, Chinese cabbage, bok choy), cardoni, carrots, napa, okra, onions, celery, parsley, chick peas, parsnips, chicory, peppers, potatoes, cucurbits (e.g., marrow, cucumber, zucchini, squash, pumpkin, honeydew melon, watermelon, cantaloupe), radishes, dry bulb onions, rutabaga, eggplant, salsify, escarole, shallots, endive, garlic, spinach, green onions, squash, greens, beet (sugar beet and fodder beet), sweet potatoes, chard, horseradish, tomatoes, turnips, and spices; a fruit crop such as apples, apricots, cherries, nectarines, peaches, pears, plums, prunes, cherry, quince, fig, nuts (e.g., chestnuts, pecans, pistachios, hazelnuts, pistachios, peanuts, walnuts, macadamia nuts, almonds, and the like), citrus (e.g., clementine, kumquat, orange, grapefruit, tangerine, mandarin, lemon, lime, and the like), blueberries, black raspberries, boysenberries, cranberries, currants, gooseberries, loganberries, raspberries, strawberries, blackberries, grapes (wine and table), avocados, bananas, kiwi, persimmons, pomegranate, pineapple, tropical fruits, pomes, melon, mango, papaya, and lychee, a field crop plant such as clover, alfalfa, timothy, evening primrose, meadow foam, corn/maize (field, sweet, popcorn), hops, jojoba, buckwheat, safflower, quinoa, wheat, rice, barley, rye, millet, sorghum, oats, triticale, sorghum, tobacco, kapok, a leguminous plant (beans (e.g., green and dried), lentils, peas, soybeans), an oil plant (rape, canola, mustard, poppy, olive, sunflower, coconut, castor oil plant, cocoa bean, groundnut, oil palm), duckweed, *Arabidopsis*, a fiber plant (cotton, flax, hemp, jute), *Cannabis* (e.g., *Cannabis sativa*, *Cannabis indica*, and *Cannabis ruderalis*), lauraceae (cinnamon, camphor), or a plant such as coffee, sugar cane, tea, and natural rubber plants; and/or a bedding plant such as a flowering plant, a cactus, a succulent and/or an ornamental plant (e.g., roses,

tulips, violets), as well as trees such as forest trees (broad-leaved trees and evergreens, such as conifers; e.g., elm, ash, oak, maple, fir, spruce, cedar, pine, birch, cypress, eucalyptus, willow), as well as shrubs and other nursery stock. In some embodiments, the nucleic acid constructs of the invention and/or expression cassettes and/or vectors encoding the same may be used to modify maize, soybean, wheat, canola, rice, tomato, pepper, sunflower, raspberry, blackberry, black raspberry and/or cherry.

**[0198]** In some embodiments, the invention provides cells (e.g., plant cells, animal cells, bacterial cells, archaeon cells, and the like) comprising the polypeptides, polynucleotides, nucleic acid constructs, expression cassettes or vectors of the invention.

**[0199]** The present invention further comprises a kit or kits to carry out the methods of this invention. A kit of this invention can comprise reagents, buffers, and apparatus for mixing, measuring, sorting, labeling, etc., as well as instructions and the like as would be appropriate for modifying a target nucleic acid.

**[0200]** In some embodiments, the invention provides a kit for comprising one or more fusion proteins of the present invention, nucleic acid constructs of the present invention, and/or expression cassettes and/or vectors and/or cells comprising the same as described herein, with optional instructions for the use thereof. In some embodiments, a kit may further comprise a CRISPR-Cas guide nucleic acid (corresponding to a Cas12a protein as provided herein, which may be encoded by a polynucleotide of the invention) and/or expression cassettes and/or vectors and/or cells comprising the same. In some embodiments, a guide nucleic acid may be provided on the same expression cassette and/or vector as one or more nucleic acid constructs of the invention. In some embodiments, the guide nucleic acid may be provided on a separate expression cassette or vector from that comprising the one or more nucleic acid constructs of the invention.

**[0201]** Accordingly, in some embodiments, kits are provided comprising a nucleic acid construct comprising (a) a polynucleotide(s) as provided herein and (b) a promoter that drives expression of the polynucleotide(s) of (a). In some embodiments, the kit may further comprise a nucleic acid construct encoding a guide nucleic acid, wherein the construct comprises a cloning site for cloning of a nucleic acid sequence identical or complementary to a target nucleic acid sequence into backbone of the guide nucleic acid.

**[0202]** In some embodiments, the nucleic acid construct of the invention may be an mRNA that may encode one or more introns within the encoded polynucleotide(s). In some embodiments, the nucleic acid constructs of the invention, and/or an expression cassettes and/or vectors comprising the same, may further encode one or more selectable markers useful for identifying transformants (e.g., a nucleic acid encoding an antibiotic resistance gene, herbicide resistance gene, and the like).

**[0203]** A polypeptide, polynucleotide, nucleic acid construct, expression cassette, vector, composition, kit, system and/or cell of the present invention may comprise all or a portion of a sequence of one or more of SEQ ID NOs:1-259. In some embodiments, a polypeptide, polynucleotide, nucleic acid construct, expression cassette, vector, composition, kit, system and/or cell of the present invention may comprise at least about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%,

96%, 97%, 98%, 99%, or more consecutive amino acids of a sequence of one or more of SEQ ID NOs:1-259.

**[0204]** The invention will now be described with reference to the following examples. It should be appreciated that these examples are not intended to limit the scope of the claims to the invention, but are rather intended to be exemplary of certain embodiments. Any variations in the exemplified methods that occur to the skilled artisan are intended to fall within the scope of the invention.

## EXAMPLES

### Example 1: Validation of Split Intein Protein Reconstitution with mCherry

**[0205]** The trans-splicing activity of wildtype Npu (SEQ ID NOs:110 and 111, the N- and C-terminal portions, respectively) and NpuGEP (a mutant that contains 3 residue mutations; SEQ ID NOs:110 and 112, the N- and C-terminal portions, respectively) in HEK293T cells was evaluated. For each of the wildtype (WT) Npu and NpuGEP, the N-terminal half of the mCherry protein was fused to the N-terminal portion of the Npu intein (NpuN) and the C-terminal half of the mCherry was fused to the C-terminal portion of the Npu intein (NpuC) (FIG. 1). After transfecting plasmids encoding two halves of mCherry, their splicing and reconstitution was measured via flow cytometry after 3 days (FIG. 2). Robust fluorescence was detected from dual plasmid setups approaching the fluorescence intensity of native mCherry (FIG. 2). Cells where only one half of the mCherry fragments was provided did not show any fluorescence, which demonstrated that both halves of the protein must be present for function (FIG. 2). This shows that the split intein is functional in human cells and allows rapid splicing of proteins from transient plasmid transfection of each component.

### Example 2: Split Intein Protein Reconstitution with Redraw Editors

**[0206]** Fusion proteins were prepared using a Redraw editor (RE2; SEQ ID NO:113) and the NpuGEP system. Several sites within RE2 were used to introduce a split site (FIG. 3). In particular, RE2 includes a reverse transcriptase (RT) and Cas12a sequence and fusion proteins were prepared in which a portion of RE2 was included with the split occurring in the Cas12a sequence. Accordingly, some fusion proteins included an N-terminal portion of the Cas12a sequence, which included amino acid residues 1-175, 1-310, 1-406, 1-441, or 1-550 of the Cas12 sequence, and other fusion proteins included the remaining C-terminal portion of the Cas-12a sequence (e.g., amino acid residues 176, 311, 407, 442, or 551 to the end of Cas12a). Fusion proteins having a sequence of SEQ ID NOs:100-109 were prepared. In some cases, two amino acids (cysteine and alanine (CA) or cysteine and phenylalanine (CF)) were inserted between the C-terminal portion of the Npu intein (NpuC) and the C-terminal portion of RE2 (e.g., a C terminal portion of Cas12a), which will leave a "CA" or "CF" scar within the reconstituted RE2 protein. Insertion of the 2 amino acid "scar" residues (here, "CA" or "CF") was confirmed in mature mCherry protein and it was confirmed that the scar did not affect the protein's ability to fluoresce (FIG. 4).

Example 3: Intein-Mediated Reconstitution of the Redraw Editor in HEK293T Cells

**[0207]** HEK293T cells were transfected with a plasmid encoding a fusion protein with an N-terminal component of RE2, a plasmid encoding a fusion protein with a C-terminal component of RE2, and a plasmid encoding a stagRNA or crRNA targeting endogenous sites as described in Example 2. After 3 days, high throughput amplicon sequencing was conducted to quantify the Redraw activity at the target sites. It was observed that several split RE2 forms are capable of being spliced together in cotransfected HEK293T cells to enable Redraw activity. Robust indel activity was observed (FIGS. 5-6) as well as precise editing activity (FIG. 7) that was comparable to the single polypeptide RE2 construct. In addition, it was observed that both halves of RE2 must be expressed in the cell to enable indel and Redraw activity.

**[0208]** These results demonstrate that the Redraw editor can be separated into two halves (e.g., one half that comprises a reverse transcriptase polypeptide (such as RT(5M)-NpuN) and another half that comprises a Cas12a polypeptide (such as NpuC-Cas12a-Brex27) or e.g., one half that comprises a first Cas12a polypeptide and another half that comprises a second Cas12a polypeptide (such as a RE2 split, for example at 175) and reconstituted in a cell effectively. This can allow the Redraw editor to be separately packaged into viral delivery vehicles (such as adeno associated virus (AAV) vectors) and co-infected to effect Redraw editing in cells targeted by the viral delivery vehicles.

**[0209]** The foregoing is illustrative of the present invention, and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

---

SEQUENCE LISTING

Sequence total quantity: 259

SEQ ID NO: 1                   moltype = AA   length = 36  
 FEATURE                    Location/Qualifiers  
 source                      1..36  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 1  
 EKSKNDRSKP QPSDDRRQP PSGEDYPEWK APGEYE                   36

SEQ ID NO: 2                   moltype = AA   length = 34  
 FEATURE                    Location/Qualifiers  
 source                      1..34  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 2  
 QEPKPDQSS EVPPPPGSQK PGTKEPHDSK SSGP                   34

SEQ ID NO: 3                   moltype = AA   length = 34  
 FEATURE                    Location/Qualifiers  
 source                      1..34  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 3  
 PDNSSGQKLQ LPQPSDKPQD SREKSDSLPS DKRD                   34

SEQ ID NO: 4                   moltype = AA   length = 36  
 FEATURE                    Location/Qualifiers  
 source                      1..36  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 4  
 PDNSTLQTLQ LPQPTPSSTD TQQTSDTDPE DTTDVI                   36

SEQ ID NO: 5                   moltype = AA   length = 30  
 FEATURE                    Location/Qualifiers  
 source                      1..30  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 5  
 STSQSDGSSV PADIDQSSDS DQSSSQGQPG                   30

SEQ ID NO: 6                   moltype = AA   length = 14  
 FEATURE                    Location/Qualifiers  
 source                      1..14  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 6  
 AKPDDESQKP PQDD                   14

SEQ ID NO: 7                   moltype = AA   length = 14  
 FEATURE                    Location/Qualifiers  
 source                      1..14  
                               mol\_type = protein

-continued

---

SEQUENCE: 7 LQLEPGPTTP EYPI	organism = synthetic construct	14
SEQ ID NO: 8 FEATURE source	moltype = AA length = 14 Location/Qualifiers 1..14 mol_type = protein organism = synthetic construct	
SEQUENCE: 8 IQLPPSDTTP ENPI		14
SEQ ID NO: 9 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein organism = synthetic construct	
SEQUENCE: 9 ESDNSQVPP SL		12
SEQ ID NO: 10 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein organism = synthetic construct	
SEQUENCE: 10 SEQQEYPGSG		10
SEQ ID NO: 11 FEATURE source	moltype = AA length = 10 Location/Qualifiers 1..10 mol_type = protein organism = synthetic construct	
SEQUENCE: 11 NNSEQQENPA		10
SEQ ID NO: 12 FEATURE source	moltype = AA length = 12 Location/Qualifiers 1..12 mol_type = protein organism = synthetic construct	
SEQUENCE: 12 STDGSGQPKH KP		12
SEQ ID NO: 13 FEATURE source	moltype = AA length = 20 Location/Qualifiers 1..20 mol_type = protein organism = synthetic construct	
SEQUENCE: 13 PKPSESSEGER YEQQPEPPPP		20
SEQ ID NO: 14 FEATURE source	moltype = AA length = 16 Location/Qualifiers 1..16 mol_type = protein organism = synthetic construct	
SEQUENCE: 14 KGGGGEPDEK RPSQSS		16
SEQ ID NO: 15 FEATURE source	moltype = AA length = 14 Location/Qualifiers 1..14 mol_type = protein organism = synthetic construct	
SEQUENCE: 15 YAGGTPKEPP PPNS		14
SEQ ID NO: 16 FEATURE source	moltype = AA length = 14 Location/Qualifiers 1..14 mol_type = protein organism = synthetic construct	
SEQUENCE: 16 PLVAGGTPFE PPPP		14

-continued

---

SEQ ID NO: 17	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
source	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 17		
PQPDERSQIP DNKE		14
SEQ ID NO: 18	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 18		
YTDEKPLPRS		10
SEQ ID NO: 19	moltype = AA length = 12	
FEATURE	Location/Qualifiers	
source	1..12	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 19		
SHPPQEPPQS NL		12
SEQ ID NO: 20	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 20		
SESPSKQQPE PKSSKG		16
SEQ ID NO: 21	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 21		
SESPTNQQPE PQWTTD		16
SEQ ID NO: 22	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 22		
GGSKGPPSP PPPQE		16
SEQ ID NO: 23	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 23		
GPLPAPPQP PPPQPN		16
SEQ ID NO: 24	moltype = AA length = 14	
FEATURE	Location/Qualifiers	
source	1..14	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 24		
RPLPHDNNKQ DYSK		14
SEQ ID NO: 25	moltype = AA length = 61	
FEATURE	Location/Qualifiers	
source	1..61	
	mol_type = protein	
	organism = synthetic construct	
VARIANT	5..61	
	note = Residues are present or absent	
SEQUENCE: 25		
SGSGSGSGS GSGSGSGS GSGSGSGS SGGSGSGS GSGSGSGS GSGSGSGS		60
S		61
SEQ ID NO: 26	moltype = AA length = 4	



-continued

---

FEATURE	Location/Qualifiers	
source	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 26		
SGGS		4
SEQ ID NO: 27	moltype = AA length = 100	
FEATURE	Location/Qualifiers	
source	1..100	
	mol_type = protein	
	organism = synthetic construct	
VARIANT	6..100	
	note = Residues are present or absent	
SEQUENCE: 27		
GGGSGGGGS GGGSGGGGS GGGSGGGGS GGGSGGGGS GGGSGGGGS		60
GGGSGGGGS GGGSGGGGS GGGSGGGGS GGGSGGGGS		100
SEQ ID NO: 28	moltype = AA length = 10	
FEATURE	Location/Qualifiers	
source	1..10	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 28		
SGSGSGSGGS		10
SEQ ID NO: 29	moltype = AA length = 16	
FEATURE	Location/Qualifiers	
source	1..16	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 29		
SGSETPGTSE SATPES		16
SEQ ID NO: 30	moltype = AA length = 32	
FEATURE	Location/Qualifiers	
source	1..32	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 30		
SGGSSGGSSG SETPGTSESA TPSSGGSSG GS		32
SEQ ID NO: 31	moltype = AA length = 4	
FEATURE	Location/Qualifiers	
source	1..4	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 31		
GSSG		4
SEQ ID NO: 32	moltype = AA length = 6	
FEATURE	Location/Qualifiers	
source	1..6	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 32		
GSSGSS		6
SEQ ID NO: 33	moltype = AA length = 8	
FEATURE	Location/Qualifiers	
source	1..8	
	mol_type = protein	
	organism = synthetic construct	
SEQUENCE: 33		
GSSGSSGS		8
SEQ ID NO: 34	moltype = AA length = 60	
FEATURE	Location/Qualifiers	
source	1..60	
	mol_type = protein	
	organism = synthetic construct	
VARIANT	4..60	
	note = Residues are present or absent	
SEQUENCE: 34		
GSSGSSGSSG SSSGSSGSSG SGSSGSSGSS GSSGSSGSSG SSSGSSGSSG SSSGSSGSSG		60

-continued

---

```

SEQ ID NO: 35      moltype = AA length = 62
FEATURE           Location/Qualifiers
source            1..62
                  mol_type = protein
                  organism = synthetic construct
VARIANT          4..60
                  note = Residues may be present or absent
SEQUENCE: 35
GSSGSSGSSG SSGSSGSSGS SGSSGSSGSS GSSGSSGSSG SSGSSGSSGS SGSSGSSGSS 60
GS                                                    62

SEQ ID NO: 36      moltype = DNA length = 1592
FEATURE           Location/Qualifiers
source            1..1592
                  mol_type = other DNA
                  organism = Medicago truncatula
SEQUENCE: 36
actgttaata atttttaaac gtcagcgcac taaaaaacg aaaagacgga cacgtgaaaa 60
taaaaaacac acactagttt atgacgcaat actattttac ttatgatttg ggtacattag 120
acaaaaccgt gaaagagatg tatcagctat gaaacctgta tacttcaata cagagactta 180
ctcatatcgg atacgtacgc acgaaagtac atattaatta ttttaatfff taataaatat 240
tttatcggat acttatgtga tactctacat atacacaagg atatttctaa gatactttat 300
agatacgtat cctagaaaaa catgaagagt aaaaagtgta gacaatgttg taaaaattca 360
ttataaatgt atatgattca attttagata tgcacagta taattgattc tcgatgaaac 420
acttaaaatt atatttcttg ttgaagaacg tagcgagaga ggtgattcag ttagacaaca 480
ttaaaaaaaa ttaatgttaa gttcttttaa tgatgtttct ctcaatatca catcatatga 540
aaatgtaata tgaattataa gaaaatffff aaaaaattta ttttaataat cacatgtact 600
attttttaaa aattgtatct ttataataaa tacaataata aagagtaatc agtgttaatt 660
tttcttcaaa tataagtttt attataaatc attgttaacg tatcataagt cattaccgta 720
tcgatcttta attttttttt aaaaaccgct aattcacgta cccgtattgt attgtaccgg 780
cacctgtatc acaatcgatc tttagtagaa gaattgtctc gaggcgggtg aagacagcat 840
ataatagacg tggactctct tataccaaaac gttgtcgtat cacaaaagggt taggtaacaa 900
gtcacagttt gtccacgtgt cacgttttaa ttggaagagg tgccgtttgg gtaataaac 960
agccaatcga tttttgctat aaaagcaaat caggtaaaact aaacttcttc attcttttct 1020
tccccatcgc tacaaaaacc gttcctttgg aaaagagatt cattcaaacc tagcacccea 1080
ttccgtttca aggtataatc tactttctat tcttcgatta ttttattatt attagctact 1140
atcgtttaat cgatcttttc ttttgatcgc tcaaatftaa attcaattag ggttttgttc 1200
ttttctttca tctgattgaa atccttctga attgaaccgt ttacttgatt ttactgttta 1260
ttgtatgatt taatcctttg tttttcaaag acagtcttta gattgtgatt aggggttcat 1320
ataaatffff agatttggat ttttgtattg tatgattcaa aaaatcgtc ctttaattag 1380
attagatcat ggaatatttt tacccgattt attgattgtc agggagaatt tgatgagcaa 1440
gtttttttga tgtctgttgt aaattgaatt gattataatt gctgatctgc tgcctccagt 1500
tttcataacc catattcttt taaccttggg gtacacacaa tgaaaaattg gtgattgatt 1560
catttgtttt tctttgtttt ggattataca gg 1592

SEQ ID NO: 37      moltype = DNA length = 2000
FEATURE           Location/Qualifiers
source            1..2000
                  mol_type = other DNA
                  organism = Zea mays
SEQUENCE: 37
gtcgtgcccc tctctagaga taaagagcat tgcattgtcta aagtataaaa aattaccaca 60
tatttttttg tcacacttat ttgaagtgta gtttatctat ctctatacat atattttaa 120
ttcactctac aaataatata gtctataata ctaaaataat attagtgttt tagaggatca 180
tataaataaaa ctgctagaca tggctaaag gataattgaa tattttgaca atctacagtt 240
ttatcttttt agtgtgcatg tgatctctct gttttttttg caaatagctt gacctatata 300
atacttcatc cattttatta gtacatccat ttaggattta gggttgatgg tttctataga 360
ctaattttta gtacatccat tttattcttt ttagtctcta aattttttaa aactaaaact 420
ctatttttagt tttttattta ataatttaga tataaaaatga aataaaaata attgactaca 480
aataaaaaca atacccttta agaaataaaa aaactaaagca aacatttttc ttgtttcgag 540
tagataatga caggctgttc aacgccgtcg acgagtctaa cggacaccaa ccagcgaacc 600
agcagcgtcg cgtcgggcca agcgaagcag acggcacggc atctctgtag ctgcctctgg 660
acccctctcg agagtctcgc tccaccgttg gacttgctcc gctgtcgcca tccagaatt 720
gcgtggcgga gcggcagacg tgaggcgga cggcaggcgg cctcttctct ctctcacggc 780
accggcagct accggggatt cctttccacc cgctcctctg ctttcccttc ctgcgccgc 840
gtaataaata gacaccocct ccacaccctc tttccccaac ctctgtttcg ttcggagcgc 900
acacacacgc aaccagatct cccccaatc cagccgtcgg cacctccgct tcaaggtacg 960
ccgtccatcc tccccccccc cctctctcta ccttctctag atcggcgatc cggttccatgg 1020
ttagggcccg gtatgtctac ttctgttcat gtttgtgtta gagcaaacat gttcatgttc 1080
atgttttgta tgaattgggt ttggtgggag gtcgttctag atcggagtag gatactgttt 1140
caagctacct ggtggattta ttaattttgt atctgtatgt gttgcccata catctcata 1200
gttacagatt taagatgatg gatggaataa tcatctagg ataggatata atgttgatgc 1260
gggttttact gatgcataa cagagatgct tttttctctg cttgggtgtg atgatatggt 1320
ctggttgggc ggtcgttcta gatcggagta gaatactgtt tcaaacacc ttggtggattt 1380
atataaggat aagggtcgt tctagatcgg agtagaatac tgtttcaaac tacctgggtg 1440
atattataaa ggaatctgat gtatgtgcct acatcttcat agttacagag ttaagatgat 1500

```

-continued

ggatggaaat	atcgatctag	gataggtata	catgttgatg	cggtttttac	tgatgcata	1560
acagagatgc	tttttttgcg	ttggttgatg	tgatgtggtc	tggttggcg	gtcgttctag	1620
atcggagtag	aatactgttt	caaaactacct	ggtggattta	ttaattttgt	atctttatgt	1680
gtgtgccata	catcttcata	gttacagagt	taagatgatg	gatggaaata	ttgatctagg	1740
ataggtatac	atgttgatgt	gggtttttact	gatgcatata	catgatggca	tatgcgcat	1800
ctattcatat	gctctaacct	tgagtacct	tctattataa	taaacaga	tgttttataa	1860
ttattttgat	ctgatatac	ttggatgatg	gcatatgcag	cagctatag	tggatttttt	1920
agcctgct	tcatacgcta	tttatttgc	tggtactg	tcttttgc	gatgctcacc	1980
ctggtggttg	gtgatacttc					2000

SEQ ID NO: 38           moltype = AA   length = 1227  
 FEATURE                Location/Qualifiers  
 REGION                 1..1227  
                        note = Lachnospiraceae bacterium  
 source                 1..1227  
                        mol\_type = protein  
                        organism = unidentified

SEQUENCE: 38

SKLEKFTNCY	SLSKTLRFKA	IPVGTKQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELLENLEINL	RKEIAKAPKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAlFKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAl	240
GGFVTESEGE	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGYTSDEEVL	300
EVFRNTLNKN	SEIFSS1KKL	EKLFPNFDEY	SSAGIFVKN	PAISTISKDI	FGAWNVRDK	360
WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	IGSFSLEQLQ	EYADADLSV	EKLKEIIQK	420
VDEIYKVYGS	SEKLFADDFV	LEKSLKKKND	VVAIMKDLLD	SVKSFENYIK	APFGEKGTN	480
RDESFYGFV	LAYDILLKVD	HIYDAIRNV	TQKPYSKDKF	KLYFQNPQFM	GGWDDKDKETD	540
YRATILRYGS	KYLAINDKK	YAKCLQKIDK	DDVNGNYEKI	NYKLLPGFNK	MLPKVFFSKK	600
WMAYYNPSED	IQKIYKNGTF	KKGDMFNLND	CHKLIDFFPK	SISRYPKWSN	AYDFNPFSETE	660
KYKDIAGPYR	EVEEQGYKVS	FESASKEVD	KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	720
MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	KKEELVVHPA	NSPIANKNPD	NPKKTTLTSLY	780
DVYDKRPFSE	DQYELHIPIA	INKCPKNIFK	INTEVRVLLK	HDDNPYVIGI	ARGERNLLYI	840
VVVDGKGNIV	EQYSLNEIIN	NPNGIRIKTD	YHSLLDKKEK	ERPEARQNW	SIENIKELKA	900
GYISQVVHKI	CELVEKYDAV	IALEDLNSGF	KNSRVKVEKQ	VYQKFEKMLI	DKLNMYMVDKK	960
SNPCATGGAL	KGYQITNKPE	SFKSMSTQNG	FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	1020
ADSKFISSE	DRIMYVPEED	LFEPALDYKN	FSRTDADYIK	KWKLYSYGNR	IRIFRNPKKN	1080
NVFDWEEVCL	TSAYKELFNK	YGINYQQGDI	RALLCEQSDK	AFYSSFALM	SMLQMRNSI	1140
TGRTDVDFLI	SPVKNSDGIF	YDSRNYEAQE	NAILPKNADA	NGAYNIARKV	LWAIGQFKKA	1200
EDEKLDVKVI	AISNKEWLEY	AQTSVKH				1227

SEQ ID NO: 39           moltype = AA   length = 1307  
 FEATURE                Location/Qualifiers  
 source                 1..1307  
                        mol\_type = protein  
                        organism = Acidaminococcus sp.

SEQUENCE: 39

MTQFEGFTNL	YQVSKTLRFE	LIPQKTLKH	IQEQGFIEED	KARNDHYKEL	KPIIDRIYKT	60
YADQCLQLVQ	LDWENLSAAI	DSYRKEKTEE	TRNALIEBQA	TYRNAIHDFY	IGRTDNLDTA	120
INKRHAETIK	GLPKAELFNG	KVLKQLGTVT	TTEHENALLR	SFDKFTTYFS	GFYENRKNVF	180
SAEDISTAIP	HRIVQDNFPK	FKENCHIFTR	LITAVPSLRE	HFENVKKAIG	IFVSTSIIEV	240
FSFPFYNQLL	TQTQIDLQNG	LLGGISREAG	TEKIKGLNEV	LNLAIQKND	TAHIIASLPH	300
RFIPLFKQIL	SDRNTLSFIL	EEFKSDEEVI	QSFCKYKTL	RNENVLETA	ALFNELNSID	360
LTHIFISHKK	LETISSALCD	HWDTLRNALY	ERRISELTGK	ITKSAKEKVQ	RLSKHEDINL	420
QEIIISAAGKE	LSEAFKQKTS	EILSHAHAA	DQPLPTLKK	QEEKEILKSQ	LDSLLGLYHL	480
LDWFAVDESN	EVDPEFSARL	TGIKLEMEPS	LSFYNKARNY	ATKPKYSVEK	FKLNFMQPTL	540
ASGWDVNKEK	NNGAILFVK	GLYYLGIMP	KKGRYKALSF	EPTEKTSEGF	DKMYDYFPD	600
AAKMIPKCS	QLKAVTAHFQ	THTTPIILSN	NFIEPLEITK	EIYDLNNEPK	EPKFKQTAYA	660
KKTGDQKGYR	EALCKWIDFT	RDFLSKYTKT	TSIDLSSLRP	SSQYKDLGEY	YAEINPLLYH	720
ISFQRIAEKE	IMDAVETGKL	YLFQIYNKDF	AKGHGKPNL	HTLYWTGLFS	PENLAKTSIK	780
LNGQAEFPYR	PKSRMKRMAH	RLGKMLNKK	LKDQKTPID	TLYQELYDYV	NHRLSHDLS	840
EARALLPNVI	TKEVSHETIK	DRRFTSDKFF	FHVPIITLNYQ	AANSPSKFNQ	RVNAYLKEHP	900
ETPIIGIDRG	ERNLIYITVI	DSTGKILEQR	SLNTIQQFDY	QKKLDNREKE	RVAARQAWSV	960
VGTIKDLKQG	YLSQVIHEIV	DLMIHYQAVV	VLENLNFQFK	SKRTGIAEKA	VYQQFEKMLI	1020
DKLNCLVLKD	YPAKVGGLV	NPYQLTDQFT	SFAKMGTSQ	FLFVVPAPYT	SKIDPLTGFV	1080
DPFVWKTIKN	HESRKHFLEG	DFPLHYDVKT	GDFILHFKN	RNLSFQGLP	GFMPAWDIV	1140
EKNETQFPAK	GTPPIAGKRI	VPVIENHRFT	GRYRDLYPAN	ELIALLEKKG	IVFRDGSNIL	1200
PKLENDSDH	AIDTMVALIR	SVLQMRNSNA	ATGEDYINSP	VRDLNGVCFD	SFRQNPWPM	1260
DADANGAYHI	ALKGQLLNH	LKESKDLKLQ	NGISNQDWLA	YIQELRN		1307

SEQ ID NO: 40           moltype = AA   length = 1241  
 FEATURE                Location/Qualifiers  
 source                 1..1241  
                        mol\_type = protein  
                        organism = Butyrivibrio proteoclasticus

SEQUENCE: 40

MLLYENYTKR	NQITKSLRLE	LRPQKTLRN	IKELNLLQD	KAIYALLERL	KPVIDEGIKD	60
------------	------------	-----------	-----------	------------	------------	----

-continued

IARDTLKNCE	LSFEKLYEHF	LSGDKKAYAK	ESERLKKKEIV	KTLLIKNLPEG	IGKISEINSA	120
KYLNGLVLYDF	IDKTHKDSSE	KQNILSDILE	TKGYLALPSK	FLTSRITTLE	QSMPCRVIEN	180
FEIYAANIPK	MQDALERGAV	SPAIEYESIC	SVDYYNQILS	QEDIDSYNRL	ISGIMDEGGA	240
KEKGINQITIS	EKNIKIKSEH	LEEKPPRILK	QLHKQILEER	EKAPTIDHID	SDEEVVQVTK	300
EAFEQTKEQW	ENIKKINGFY	AKDPGDITLF	IVVGNQTHV	LSQLIYGEHD	RIRLLLEEYE	360
KNTLEVLPRR	TKSEADARYDK	FVNAVPKKVA	KESHTFDGLQ	KMTGDDRLFI	LYRDELARNY	420
MRIKEAYGTF	ERDILKSRRG	IKGNRDVQES	LVSFYDELTK	FRSALRIINS	GNDEKADPIF	480
YNTFDGIFEK	ANRTYKAENL	CRNYVTKSPA	DDARIMASCL	GTPARLRTHW	WNGEENFAIN	540
DVAMIRRGDE	YYYFVLTPDV	KPVDLKTKE	TDAQIFVQRK	GAKSFLGLPK	ALFKCILEPY	600
FESPEHKNDK	NCVLEEYVSK	PLTIDRRAYD	IFKNGTFKKT	NIGIDGLTEE	KFKDDCRYLI	660
DVYKEFIAVY	TRYSCFNMSG	LKRADEYNDI	GEFFSDVDTR	LCTMEWIPVS	FERINDMVDK	720
KEGLLFLVRS	MFLYNRPRKP	YERTFIQLFS	DSNMEHTSML	LNSRAMIQYR	AASLPRRVTH	780
KKGSILVALR	DSNGEHIPMH	IREAIYMKKN	NFDISSEDFI	MAKAYLAEHD	VAIKKANEDI	840
IRNRRYTEDK	PFLSLSYTKN	ADISARTLDY	INDKVEEDTQ	DSRMAVIVTR	NLKDLYTVAV	900
VDEKNNVLEE	KSLNEIDGVN	YRELLKERTK	IKYHDKTRLW	QYDVSSKGLK	EAYVELAVTQ	960
ISKLATKYNA	VVVVESMST	FKDKFSFLDE	QIFKAPEARL	CARMSDLSPN	TIKEGEGASI	1020
SNPIQVSNNN	GNSYQDGVYI	FLNNAYTRTL	CPDTGFVDVF	DKTRLITMQS	KRQFFAKMKD	1080
IRIDGEMLFP	NFLNLEEYPTK	RLLDRKEWTV	KIAGDGSYFD	KDKGEYVYVN	DIVREQIIPA	1140
LLEDKAVFDG	TMAEKFLDKT	AISGKSVELI	YKWFANALYG	IITKKDGEKI	YRSPITGTEI	1200
DVSKNTTYNF	GKKFMFKQEQ	RGDGFLLDAP	LNYMQAQDIA	V		1241

SEQ ID NO: 41                   moltype = AA   length = 1238  
 FEATURE                        Location/Qualifiers  
 source                         1..1238  
                               mol\_type = protein  
                               organism = Methanoplasma termitum

SEQUENCE: 41

MNNYDEFTKL	YPIQKTIRFE	LKPQGRTEH	LETFNFFEED	RDRAEKYKIL	KEAIDEYHKK	60
FIDEHLTNMS	LDWNSLKQIS	EKYYKSREEK	DKKVFLSEQK	RMRQEI VSEF	KKDDRFKDLF	120
SKKLFSELLK	EELIYKGNHQ	EIDALKSPDK	FSGYFGLHE	NRKNMYSDDG	EITAI SNRIV	180
NENFPKFLDN	LQKYQEARKK	YPEWIIKAES	ALVAHNIKMD	IVFSLEYFNK	VLNQEGLQRY	240
NLALGGYVTK	SGEKMMGLND	ALNLAHQSEK	SSKGRIHMTF	LFKQILSEKE	SFSYIPDVFT	300
BDSQLLPISG	GFFAQIENDK	DGMIPDRALE	LISSYAEYDT	ERIYI RQADI	NRVSNVIFGE	360
WGTLLGLMRE	YKADSIINDI	LERTCKKVDK	WLDKKEFALS	DVLEAIDRTG	NNDANEYIS	420
KMRTAREKID	AARKEMKFIS	EKISGDEESI	HIKTLDSV	QQFLHFFNLF	KARQDIPLDG	480
AFYAEFDEVH	SKLFAIVPLY	NKVRNVLTKN	NLNTKKIKLN	FKNPTLANGW	DQNKVVDYAS	540
LIFLRDGNYY	LGIINPKRKK	NIKFEQSGSN	GPFYRKMVYK	QIPGPNKILP	PVPLTSTKKG	600
KEYKPSKEII	EGYEADKHIR	GDKPDLDFCH	KLIDPFKESI	EKHKDWSKFN	FYFSPTESYG	660
DISEFYLDVE	KQGYRMHFEN	ISAETIDEVY	EKGDLFLPQI	YKDFVKAAT	GKDMHTIYW	720
NAAFSPENLQ	DVVYKLNSEA	ELFYRDKSDI	KEIVHREGEI	LVNRTYNGRT	PVPDKIHKKL	780
TDYHNGRTKD	LGEAKEYLDK	VRYFKAHYDI	TKDRRYLNDK	IYFHVPLTLN	FKANGKKNLN	840
KMVI EKPLSD	EKAHIIGIDR	GERNLLYYSI	IDRSKGIIDQ	QSLNVIDGDF	YREKLNQREI	900
EMKDARQSWN	AIGIKIDLKE	GYLSKAVHEI	TKMAIQYNAI	VVMEELNYGF	KRGRFKVEKQ	960
IYQKFENMLI	DKMNYLVFKD	APDESPGGVL	NAYQLTNPLE	SFAKLGKQTG	ILFYVPAAYT	1020
SKIDPTTFGV	NLFNTSCKTN	AQERKEFLQK	FESISYSKAD	GGIFAPAFDY	RKFGTSKTDH	1080
KNVWTAYTNG	ERMRYYIKKK	RNELFDPSKE	IKEALTSSTG	KYDGGQNILP	DILRSNNNGL	1140
IYTMYSFPIA	AIQMRVYDVK	EDYIISPIKN	SKGEPFRTPD	KRELPIPAD	ANGAYNIALR	1200
GELTMRATAE	KFPDSEKMA	KLELKHKDFW	EFMQTRGD			1238

SEQ ID NO: 42                   moltype = AA   length = 1281  
 FEATURE                        Location/Qualifiers  
 source                         1..1281  
                               mol\_type = protein  
                               organism = Eubacterium eligens

SEQUENCE: 42

MNGNRSIVYR	EFVGVIPVAK	TLRNELRPVG	HTQEHIIQNG	LIQEDELROE	KSTELKNIMD	60
DYYREYIDKS	LSGVTDLDFD	LLFELMNLVQ	SSPSKDNKKA	LEKEQSKMRE	QICTHLQSDS	120
NYKNIFNAKL	LKEILPDFIK	NYNQYDVVKD	AGKLETLALF	NGFSTYPTDF	FEKRKNVFTK	180
EAVSTSIAYR	IVHENSILFL	ANMTSYKKIS	EKALDEIEVI	EKNQDKMGD	WELNQIFNPD	240
FYNMVLIQSG	IDFYNEICGV	VNAHMNLYCQ	QTKNNYNLFK	MRKHLKQILA	YTSTSFEVPK	300
MFEDDMSVYN	AVNAFIDETE	KGNIIIGLLK	IVNKYDELDE	KRIYISKDFY	ETLSCFMSGN	360
WNLITGCVEN	FYDENIHAKG	KSKEEKVKA	VKEDKYKSIN	DVNDLVEKYI	DEKERNEFKN	420
SNAKQYIREI	SNITDTETA	HLEYDDHISL	I ESEEKADEM	KKRLDMYMNM	YHWAKAFIVD	480
EVLDRDEMPY	SIDIDIYNIL	ENIYPLYNRV	RNYVTQKPYN	SKKIKLNFQS	PTLANGWSQS	540
KEFDNNAIIL	IRDNKYLAII	FNAKNKPKDK	IIQGNSDKKN	DNDYKMYVYN	LLPGANKMLP	600
KVFLSKKGLI	TFKPSDYIIS	GYNNAKHIKT	SENFDISFCR	DLIDYFKNSI	EKHAERWKYE	660
FKFSATDSYS	DISEFYREVE	MQGYRIDWTY	ISEADINKLD	EEGKIYLFQI	YKDFPAENST	720
GKENLHTMYF	KNIFSEENLD	KIIKLNQOAE	LFYRRASVKN	PVKHKKDSVL	VNKTYKNQLD	780
NGDVVRIPIP	DDIYNEIYKM	YNGYIKESDL	SEAAKEYLDK	VEVRTAQKDI	VKDYYRYTVDK	840
YFIHTPITIN	YKVTARNNVN	DMVVKYIAQN	DDIHVIGIDR	GERNLIYHSI	IDSHGNIVKQ	900
KSYNILNNYD	YKKKLVEKEK	TREYARKNWK	SIGNIKELKE	GYISGVVHEI	AMLIVYEYNAI	960
IAMEDLNRYG	KRGRFKVERQ	VYQKFESMLI	NKLNYPASKE	KSVDEPGGLL	KGQLYTYVPD	1020
NIKNLGKQCG	VIFVYVPAFT	SKIDPSTGFI	SAFNFKSIST	NASRKQPFMQ	FDEIRYCAEK	1080
DMFSPGFIDY	NFDTYNITMG	KTQWTVYTNQ	ERLQSEFNNA	RRTGKTKSIN	LTETIKLLLE	1140
DNEINYADGH	DIRIDMEKMD	EDKKEBFFAQ	LLSLYKLTVO	MRNSYTEAE	QENGISYDKI	1200
ISPVINDEGE	FFSDSNYKES	DDKECKMPKD	ADANGAYCIA	LKGLYEVLKI	KSEWTEGDFD	1260

-continued

RNCLKLPHAE WLDPIQNKRY E 1281

SEQ ID NO: 43 moltype = AA length = 1300  
 FEATURE Location/Qualifiers  
 source 1..1300  
 mol\_type = protein  
 organism = Francisella tularensis

SEQUENCE: 43

MSIYQEFVVK	YLSKTLRFE	LIPQGGKLTEN	IKARGLILD	EKRAKDYKKA	KQIIDKYHQF	60
FIEEILSSVC	ISEDLLQNY	DVYFKLKKSD	DDNLQKDFKS	AKDTIKKQIS	EYIKDSEKFK	120
NLFNQNLIDA	KKQESDLIL	WLKQSKDNGI	ELFKANSDIT	DIDEALETIK	SFKGWTTYFK	180
GFHENRKVNY	SSNDIPTSII	YRIVDDNLPK	FLENKAKYES	LKDKAPEAIN	YEQIKKDLAE	240
ELTFDIDYKT	SEVNQRVFSL	DEVFEIANFN	NYLNQSGITK	FNTIIGGKVF	NGENTKRRGI	300
NEYINLYSQQ	INDKTLKKYK	MSVLFKQILS	DTEKSFVID	KLEDDSDVVT	TMQSFYEQIA	360
AFKTVEEKSI	KETLSLLFDD	LKAQKLDLSK	IYFKNDKSLT	DLSQQVFPDY	SVIGTAVLEY	420
ITQQIAPKNL	DNPSKKEQEL	IAKKTEKAKY	LSLETIKLAL	EEFNKHRDID	KQCRFEEILA	480
NFAAIPMIFD	EIAQNKDNLA	QISIKYQNGG	KDQLLQASAE	DDVKAIKDLL	DQTNLLHLK	540
KIFHISQSED	KANILDKDEH	FYLVFEECYF	ELANIVPLYN	KIRNYITQKP	YSDEKPKLNF	600
ENSTLANGWD	KNKEPDNTAI	LFIKDDKYVL	GVMNKKNNKI	FDDKAIKENK	GEGYKIVYK	660
LLPGANKMLP	KVFPFSAKSIK	FYNPSEDILR	IRNHSTHTKN	GSPQKGYEKF	EFNIEDCRKF	720
IDFYKQSISK	HPWKDFGFR	FSDTQRYSNI	DEFYREVENQ	GYKLTFFENIS	ESYIDSVVNG	780
GKLYLFQIYN	KDFSAYSKGR	PNLHTLYWKA	LFDERNLQDV	VYKLNGEAEL	FYRKQSIPIK	840
ITHPAKEAIA	NKNKDNPKKE	SVFEYDLIKD	KRFTEDKFFF	HCPITINFKS	SGANKFNDEI	900
NLLLKEKAND	WHILSIDRGE	RHLAYTYLVD	KGKNIKQDT	FNIGNDRMK	TNYHDLAAI	960
EKDRDSARKD	WKKTNNIKEM	KEGYLSQVVH	EIAKLVIEYN	AIVVFEDLNF	GFKRGRFKVE	1020
KQVYQKLEKM	LIEKLNLYLVP	KDNEPDKTGG	VLRAYQLTAP	FETPKKMGKQ	TGIYYVPAG	1080
PTSKICPVTG	FVNQLYPKYE	SVSKSQEFPF	KFDKICYNLD	KGYFEFSFDY	KNFGDKAAKG	1140
KWTIASFGSR	LINFNRNDDN	HNWDTREVYP	TKELEKLLKD	YSIEYGHGEC	IKAAICGESD	1200
KKFFAKLTSV	LNTILQMRNS	KTGTLDYLI	SPVADVNGNF	PDSRQAPKMN	PQDADANGAY	1260
HIGLKGLMLL	GRIKNNQEGK	KLNLVIKNEE	YFEFVQNRNN			1300

SEQ ID NO: 44 moltype = AA length = 1206  
 FEATURE Location/Qualifiers  
 REGION 1..1206  
 note = Lachnospiraceae bacterium  
 source 1..1206  
 mol\_type = protein  
 organism = unidentified

SEQUENCE: 44

MYEYSLTRQY	PVSKTIRNEL	IPIGKTLDNI	RQNNILESDV	KRKQNYEHVK	GILDEYHKQL	60
INEALDNCTL	PSLKIAAEIY	LKNQKEVSDR	EDFNKTQDLL	RKEVVEKLKA	HENFTKIGKK	120
DILDLEKLP	SISEDYNAL	ESFRNFYTYF	TSYKQVRENL	YSDKEKSTV	AYRLINENFP	180
KFLDNVKSYP	FVKTAGILAD	GLGEEQDSL	FIVETFNKTL	TQDGDITVNS	QVGKINSIN	240
LYNQKNQKAN	GFRKIPKMKM	LYKQILSDRE	ESFIDEFQSD	EVLIDNVESY	GSVLIESLKS	300
SKVSAPPDAL	RESKGIIVYV	KNDLAKTAMS	VIVFENWRFT	DDLLNQEYDL	ANENKKKDDK	360
YFEKRQKELK	KNKSYSLEHL	CNLSSEDSCLN	IENYIHQISD	DIENIINNE	TFLRIVINEH	420
DRSRKLAKNR	KAVKAIKDFL	DSIKVLEREL	KLINSSGQEL	EKDLIVYSAH	EELLVELKQV	480
DSLYNMTRNY	LTKKPFSTEK	VKLNPNRSTL	LNGWDRNKET	DNLGVLLKDK	GKYLYGLMNT	540
SANKAFVNP	VAKTEKVFVK	VDYKLLPVPN	QMLPKVFFAK	SNIDFYNPSS	EIYSNYKKG	600
HKKGNMFSLE	DCHNLIDFFK	ESISKHEDWS	KFGFKFDTQA	SYNDISEFYR	EVEKQGYKLT	660
YTDIDETYIN	DLIERNELYL	FQIYNKDFSM	YSKGLKLNHT	LYPMLLDQD	NIDVVYKLN	720
GEAEVYRPA	SISEDELIH	KAGEEIKNKN	PNRARTKETS	TFSYDIVDK	RYSKDKFTLH	780
IPITMNFVGD	EVKRFNDAVN	SAIRIDENVN	VIGIDRGERN	LLYVVVIDSK	GNILEQISLN	840
SIINKEYDIE	TDYHALDER	EGGRDKARKD	WNTVENIRD	KAGLYLQVNV	VVAKLVLYKN	900
AICLEDLNF	GFKRGRQKVE	KQVYQKFEKM	LIDKLNLYLVI	DKSREQTSK	ELGGALNALQ	960
LTSKFKSFK	LGKQSGVIYY	VPAYLTSKID	PTTGPFANLFY	MKCENVEKSK	RFFDGFDFIR	1020
FNALENVPEF	GFDYRSPYR	ACGINSKWTV	CTNGERIIKY	RNPKNNMFD	EKVVVVTD	1080
KNLFEQYKIP	YEDGRNVKDM	IISNEEAEPY	RRLYRLLQOT	LQMRNSTSDG	TRDYIISPVK	1140
NKREAYFNSE	LSDGSPVKDA	DANGAYNIAR	KGLWVLEQIR	QKSEGEKINL	AMTNAEWLEY	1200
AQTHLL						1206

SEQ ID NO: 45 moltype = AA length = 1233  
 FEATURE Location/Qualifiers  
 REGION 1..1233  
 note = Lachnospiraceae bacterium  
 source 1..1233  
 mol\_type = protein  
 organism = unidentified

SEQUENCE: 45

MDYNGQFER	RAPLTKTITL	RLKPIGETRE	TIREQKLEQ	DAAFRKLIVET	VTPIVDDCIR	60
KIADNALCHF	GTEYDFSCLG	NAISKNDKA	IKKETEKVEK	LLAKVLTENL	PDGLRKVNDI	120
NSAAFIQDTL	TSPVQDDADK	RVLIQELKGG	TVLMQRFLTT	RITALTVWLP	DRVFENFNIF	180
IENAEKMRIL	LDSPLNEKIM	KFPDPAEQYA	SLEFYGQCLS	QKQIDSYNLI	ISGIYADDEV	240
KNPGINEIVK	EYNQQIRGDK	DESPLPKLLK	LHKQILMPVE	KAFFVRVLSN	DSDARSILEK	300
ILKDEMLPS	KIIEAMKEAD	AGDIAVYGSR	LHELSHVIYG	DHGKLSQIIY	DKESKRISL	360
METLSPKERR	ESKRLRLEGL	EHIRKSTYTF	DELNRYAEKN	VMAAYIAAVE	ESCAEIMRKE	420

-continued

KDLRTLSSKE	DVKIRGNRHN	TLIVKNYFNA	WTVFRNLIRI	LRRKSEAEID	SDPYDVLDDS	480
VEVLSLTYKG	ENLCRSYITK	KIGSDLKPEI	ATYGSALRPN	SRWWSPEGEK	NVKFHTIVRR	540
DGRLYYFILP	KGAKPVELED	MDGDI ECLQM	RKIPNPTIFL	PKLVPKDEPA	FFRDNPEADE	600
FVFLSGMKAP	VTITRETYEA	YRYKLYTVGK	LRDGEVSEEE	YKRALLQVLT	AYKEFLENRM	660
IYADLNFGFK	DLBEEKDSSE	FIKQVETHNT	PMCWAKVSSS	QLDDLKSGN	GLLFEIWSER	720
LESYKYKNE	KVLRGYEGLV	LSILKDNLV	SMRTLLNSRP	MLVYRPKES	KPMVVHRDGS	780
RVVDRFDKDG	KYIPPEVHDE	LYRFFNNLLI	KEKLGKARK	ILDNKKVKVK	VLESERVKWS	840
KFYDEQFAVT	FSVKKNADCL	DTTKDLNAEV	MEQYSESNRL	ILIRNTTDIL	YYLVLDKNGK	900
VLKQRSNLII	NDGARDVDWK	ERFRQVTKDR	NEGYNEWDS	RTSNDLKEVY	LNALKEIAE	960
AVIEYNAILI	IEKMSNAFKD	KYSFLDDVTF	KGFETKLLAK	LSDLHFRGIK	DGEPCSFTNP	1020
LQLCQNSDNK	ILQDGVIFMV	PNSMTRSLDP	DTGFIFAIND	HNIRTKKAKL	NFLSKFDQLK	1080
VSSGCLIMK	YSGDSLPTHN	TDNRVWNC	NHPITNDRE	TKKVEFIEEP	VEELSRVLEE	1140
NGIETDTELN	KLNERENVP	KVVDIAYSLV	LNYLRTGTVS	VAGQRAVYYS	PVTGKKYDIS	1200
FIQAMNLNRK	CDYYRIGSKE	RGEWTFVAQ	LIN			1233

SEQ ID NO: 46                   moltype = AA   length = 1227  
FEATURE                        Location/Qualifiers  
REGION                         1..1227  
                                note = Lachnospiraceae bacterium  
source                         1..1227  
                                mol\_type = protein  
                                organism = unidentified

SEQUENCE: 46

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNNLNNYISL	FRKKTRETEK	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSBEAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDALFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGE	KIKGLNEYIN	LYNQTKQKL	PKFKPLYKQV	LSDRESLSFY	GEGYTSDEEV	300
LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKV	GPAISTISKD	IFGEWNVIRD	360
KWNAEYDDIH	LKKKAVYTEK	YEDDRKSPK	KIGSFLSLEQL	QEYADADLSV	VEKLKEIIIQ	420
KVDEIKVYVG	SSEKLPDADF	VLEKSLKND	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	480
NRDESFYGF	VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	540
DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGN	KMLPKVFFSK	600
KWMAYNPSSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDPFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVEEQGYKV	SPESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYFKLLFDE	NNHQIIRLSG	GAEFLMRRAS	LKKEELVHP	ANSPIANKNP	DNPKKTTLTS	780
YDVYKDKRFS	EDQYELHPI	ANINKCPKNI	FKINTEVRVL	LKHDDNPYVI	GIDRGERNLL	840
YIVVVDGKGN	IVEQYSLNEI	INNFNGIRIK	TDYHSLDDK	EKERFEARQN	WTSIENIKEL	900
KAGYSQVHV	KICBELYKDY	AVIALEDLNS	GFKNRSRVKE	KQVYQKPEKM	LIDKLNMYVD	960
KKSNPCATGG	ALKGYIITNK	VESFKSMSTQ	NGFIFYIPAW	LTSKIDPSTG	FVNLLKTKYT	1020
SIADKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPKK	1080
NNVPDWEVVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQQFKK	1200
AEDEKLDKVK	IASNKEWLEY	AQTSVKKH				1227

SEQ ID NO: 47                   moltype = AA   length = 1264  
FEATURE                        Location/Qualifiers  
source                         1..1264  
                                mol\_type = protein  
                                organism = Leptospira inadai

SEQUENCE: 47

MEDYSGFVNI	YSIQKTLRFE	LKPVGKTLEH	IEKKGFLKGD	KIRAEDYKAV	KKIIDKYHRA	60
YIEEVFDSVL	HQKKKDKDTR	FSTQFIKEIK	EFSELYYKTE	KNIPDKERLE	ALSEKLRKML	120
VGAPKGEFSE	EVAEKYKNL	FSKELIRNEI	EKFCETDEER	KQVSNFKSFT	TYFTGPHSNR	180
QNIYSDEKKS	TAIGYRIHQ	NLPKFLDNLK	IIESIQRRFK	DPPWSDLKKN	LKKIDKNIKL	240
TEYFSIDGFV	NVLNQKGIDA	YNTILGGKSE	ESGEKIQGLN	EYINLYRQKN	NIDRKNPLNV	300
KILFKQILGD	RETKSFIPEA	FPDDQSVLNS	ITFAKYLYKL	DKKKKSTIAE	LKKFLSSFNR	360
YELDGIYLAN	DNSLASISTF	LFDDWSFIKK	SVSFKYDESV	GDPKKKI KSP	LKYEKEKEKW	420
LKQKYTTISF	LNDIAESYSK	SQDEKRVKIR	LEAYFAEPKS	KDDAKKQFDL	LERIEBAYAI	480
VEPLLGAEYP	RDRNLKADKK	EVGKI KDFLD	SIKSLQFFPK	PLLSAEIFDE	KDLGFYNQLE	540
GYEEIDISG	HLYNKVRNYL	TGKIYSKEKE	KLNFNENSTLL	KGWDENREVA	NLCVIFREDQ	600
KYYLVGMDKE	NNTILSDIPK	VKPNELFYEK	MVYKLIPTPH	MQLPRIIFSS	DNLSIYNPSK	660
SILKIREAKS	FKEGKNFKLK	DCHKFIDFYK	ESISKNEWDS	RFDFPKFKSTS	SYENISEFYR	720
EVERQGYNLD	GAAEMFFRKK	SINYDEKRR	EGHHPPELFEK	LKYPILKDKR	YSEDKQPFHL	780
NLKDVCLELN	FKEAMFFRKK	SINYDEKRR	EGHHPPELFEK	LKYPILKDKR	YSEDKQPFHL	840
PISLNFKSK	RLNENLKVNE	FLKRNKDINI	IGIDRGERNL	LYLVMINQKG	EILKQTLTDS	900
MQSGKGRPEI	NYKEKLOQE	IERDKARKSW	GTVENIKELK	EGYLSIVIHQ	ISKLMVENNA	960
IVVLEDNLIG	FKRGRQKVER	QVYQKPEKML	IDKLNFLVFK	ENKPEPGGV	LKAYQLTDEF	1020
QSFEKLSQKT	GFLPYVPSWN	TSKIDPRTGF	IDFLHPAYEN	IEKAKQWINK	FDSIRFNSKM	1080
DWFPTADTR	KFSENLMGK	NRVWVICTTN	VERYFTSKTA	NSSIQYNSIQ	ITEKLEKELFV	1140
DIPFNGQDL	KEPILRNDA	VFKSLLFYI	KTTLSLRQNN	GKKGEEEKDF	ILSPVVDKSG	1200
RFFNSLEASD	DEPKDADANG	AHYHALKGLM	NLLVLNETKE	ENLSRPKWKI	KNKDWLEFVW	1260
ENNR						1264

SEQ ID NO: 48                   moltype = AA   length = 1373  
FEATURE                        Location/Qualifiers

-continued

```

source          1..1373
                mol_type = protein
                organism = Moraxella bovoculi

SEQUENCE: 48
MLFQDFTHLY  PLSKTVRFEL  FIDRTLEHII  AKNFLSQDET  MADMHQKVKV  ILDDYHRDFI  60
ADMMGEVKLT  KLAEFYDVYL  KFRKNPKDDE  LQKAQLKDLQ  AVLKRKEIVKP  IGGNGKYKAG  120
YDRLFGAKLF  KDGKELGDLA  KFVIAQEGES  SPKLAHLAHF  EKFSTYFTGF  HDNRKNMYS  180
EDKHTAIAYR  LIHENLPRFI  DNLQILTTIK  QKHSALYDQI  INELTASGLD  VSLASHLDGY  240
HKLLTQEGIT  AYNLLGGIS  GEAGSPKIQQ  INELINSHHN  QHCHKSERIA  KLRPLHKQIL  300
SDGMSVSLPL  SKFADDSFEMC  QAVNEFYRHY  ADVFAKVQSL  FDGPDHQQKD  GIYVEHKNLN  360
ELSKQAFGDF  ALLGRVLDGY  YVDVVNPEFN  ERFKAKAKTDN  AKAKLTKEKD  KFIKGVHSLA  420
SLEQAIEHYT  ARHDDSEVQA  GKLGQYFKHG  LAGVDNPIQK  IHNNHSTIKG  FLERERPAGE  480
RALPKIKSGK  NPMTQLRQL  KELLDNALNV  AHFAKLLTTK  TTLDNQDGNF  YGFEFVLYDE  540
LAKIPTLYNK  VRDYLSQLPF  STEKYKLNFG  NPTLLNGWDL  NKEKDNFVGI  LQKDGCCYLA  600
LLDKAHKLVF  DNAPNTGKSI  YQKMIYKYLE  VRKQFPKVF  SKEAIAINYH  PSKELVEIKD  660
KGRQRSDDER  LKLRYFLEIC  LKIHPKYDKK  FEGAIQDIQL  FKDKKGGREV  PISEKDLFKD  720
INGIFSSKPK  LEMEDFFIGE  FKRYNPSQDL  VDQYNIYKKI  DSNDNRKKN  FYNHHPKFKK  780
DLVRYYYESM  CKHEEWEESE  EFSKLLQDIG  CVYDVNLEFT  EIETRRLLNYK  ISPCNINADY  840
IDELVEQQQL  YLFIQYNKDF  SPKAHGKPNL  HTLYPKALFS  EDNLADPIYK  LNGEAQIFYR  900
KASLDMNETT  IHRAGEVLEN  KNPDNPKKRQ  FVYDIKDKR  YTQKDFMLHV  PITMNFVQVG  960
MTIKEFNKVV  NQSIQQYDEV  NVIGIDRGER  HLLYLTVINS  KGEILEQCCL  NDI TTASANG  1020
TQMTTPYHKI  DLKREIERLN  ARVWGGEIET  IKELKSGYLS  HVVHQISQLM  LKYNAIVVLE  1080
DLNFGFKRGR  FKVEKQIYQN  FENALIKKLN  HVLVKDKADD  EIGSYKNALQ  LTNNFTDLKS  1140
IGKQTGFLFY  VPAWNTSKID  PETGFVDLLK  PRYENIQASQ  AFFGKFKDIC  YNADKDYFEF  1200
HIDYAKFTDK  AKNSRQIWTI  CSHGDKRYVY  DKTANQNKGA  AKGINVNDIL  KSLFARHHIN  1260
EKQPNLVMDI  CQNNDKBFHK  SLMYLLKTL  ALRYSNASSD  EDFILSPVAN  DEGVFPNSAL  1320
ADDTQPQNAD  ANGAYHIALK  GLWLLNELKN  SDDLNKVKLA  IDNQTWLNFA  QNR  1373

```

```

SEQ ID NO: 49      moltype = AA length = 1352
FEATURE           Location/Qualifiers
REGION           1..1352
                 note = Parcubacteria bacterium
source          1..1352
                mol_type = protein
                organism = unidentified

SEQUENCE: 49
MENIFDQFIG  KYSLSKTLRF  ELKPVGKTED  FLKINKVFEK  DQTIDDSYNQ  AKFYFDSLHQ  60
KFIDAALASD  KTSSELSQNF  ADVLEKQNKI  ILDKKREMG  LRKRDKNAV  IDRLLQKEIN  120
AEDI IQEKE  KIIKDVTRLF  DNEAESWKTY  YQEREVDGKK  ITESKADLKQ  KGADFLTAAG  180
ILKVLKYEFP  EEKEKEFQAK  NQPSLFEVEK  ENPGQKRYIF  DSPDKFAGYL  TKFQQTKKNL  240
YAADGTSTAV  ATRIADNFII  FHQNTKVFRD  KYKNNHTDLG  FDEENIFEIE  RYKNCLLQRE  300
IEHIKNENSY  NKI IGRINKK  IKEYRDQKAK  DTKLTKSDFP  FPKNLDKQIL  GEVEKEKQLI  360
EKTRKTEDED  VLIERFKEFI  ENNEERFTAA  KKLMMNAFCNG  EFSEYEYGIY  LKNKAINTIS  420
RRWFVSDRDF  ELKLPQQKSK  NKSEKNEPKV  KKFISIAEBK  NAVBELDGI  FKAVPYDCKI  480
IAQGGSKLEQ  FLVIWKYEF  YLFRDIEREN  GEKLLGYDSC  LKIAKQLGIF  PQEKEAREKA  540
TAVIKNYADA  GLGIFQMMKY  FSLDDKDRKN  TPGQLSTNFI  AEYDGYKDF  EFIKYNEFR  600
NFITKKPFDE  DKIKLNFENG  ALLKGWDENK  EYDFMGVILK  KEGRLYLGIM  HKNHRKLFQS  660
MGNAKGDNAN  RYQKMIYKQI  ADASKDVPR  LLTSKKAMEK  FKPSQELIRI  KKEKTPKRES  720
KNFSLRDLHA  LIEYRNCIP  QYSNWSFYDF  QFQDTGKYQN  IKEPTDDVQK  YGYKISFRDI  780
DDEYINQALN  EGKMYLFEVV  NKDIYNTKNG  SKNLHTLYFE  HILSAENLND  PVFKLSGMAE  840
IFQRPVSNE  REKITTQKNQ  CILDKGDRA  KYRRYTEKKI  MFHMSLVLNT  GKGEIQVQVF  900
NKIINQRISI  SDNEMRVKVI  GIDRGEKNLL  YYSVVKQNGE  IIEQASLNEI  NGVNYRDKLI  960
BREKERLKNR  QSWKPVVKIK  DLKGGYISHV  IHKICQLIEK  YSAIVVLEDL  NMRFKQIRGG  1020
IERSVYQQFE  KALIDKLGYL  VPKDNRDLRA  PGGVLNGYQL  SAPPVSPPEK  RKQGTGLFYT  1080
QAEYTSKTD  ITGFRKNVYI  SNSASLDKIK  EAVKKFDAIG  WDGKESYFF  KYNPNLADE  1140
KYKNSTVSKE  WAIFASAPRI  RRQKGEDGYW  KYDRVKVNEE  FEKLLKVVNF  VNPKATDIKQ  1200
EIKKIKAGD  LQGEKELDGR  LRNFWSFTY  LFNLVLEL  SFSLQIKIKA  GEVIAVDEGV  1260
DFIASPVKPF  FTTNPNYIPS  NLCWLAVENA  DANGAYNIAR  KGMILKKIR  EHAKKDEPEK  1320
KLPNLFISNA  EWDEAARDWG  KYAGTTALNL  DH  1352

```

```

SEQ ID NO: 50      moltype = AA length = 1260
FEATURE           Location/Qualifiers
source          1..1260
                mol_type = protein
                organism = Porphyromonas crevioricanis

SEQUENCE: 50
MDSLKDFTNL  YPVSKTLRPE  LKPVGKTLEN  IEKAGILKED  EHRAESYRRV  KKIIDTYHKV  60
FIDSSLENMA  KMGLENIEKA  MLQSFCELYK  KDHRTEGEDK  ALDKIRAVLR  GLIVGFTGV  120
CGRRENTVQN  EKYESLPEK  LIKEILPDFV  LSTEAESLFP  SVEEATRSK  EPDSFTSYFA  180
GFYENRKNY  STKPSQTAIA  YRLIHENLPK  FIDNIVLPQK  IKEPIAKELE  HIRADFSAGG  240
YIKKDERLED  LIEYRNCIP  LSQAGIEKYN  ALIGKIVTEG  DGMKGLNEH  INLYNQQRGR  300
EDRLPLFRPL  YKQILSDREQ  LSYLPESFEK  DEELLRALKE  FYDHIAEDIL  GRTQQLMSTI  360
SEYDLSRLY  RNSQLTDIS  KMLGDWNAI  YMARERAYDH  EQAPKRITAK  YERDRKALK  420
GEESISLANL  NSCIAFLDNV  RDCRDVTYLS  TLGQKEGPHG  LSNLVENVFA  SYHEAEQLLS  480
FPYPEENLNI  QDKDNVYLV  NLLDNISDLQ  RFLKPLWGMG  DEPDKDERFY  GEYNYIRGAL  540
DQVIPLYNKV  RNYLTRKPY  TRKVKLNFGN  SLLSGWDRN  KEKDNSCVIL  RKGQNFYLA  600

```

-continued

```
MNMRHKRSFE NKMLPEYKEG EPYFEKMDYK FLDPDNKMLP KVFLSKKGGIE IYKPSPKLLE 660
QYGHGTHKKG DTFMSDDLHE LIDFFKHSIE AHEDWKQPGF KFSDTATYEN VSSFYREVED 720
QGYKLSFRKV SESYVYSLID QGKLYLFQIY NKDFSPCSKG TPNLHTLYWR MLFDERNLAD 780
VIYKLDGKAE IFFREKSLKN DHPHPAGKP IKKKSQRKKG EESLFEYDLV KDRRYTMDKF 840
QPHVPIITMNF KCSAGSKVND MVNAHIREAK DMHVIGIDRG ERNLLYICVI DSRGTILDQI 900
SLNTINDIDY HDLLESRDKD RQOEHRNWQT IEGIKELKQG YLSQAVHRIA ELMVAYKAVV 960
ALEDLNMGFK RGRQVSESSV YQQFEKQLID KLNLYLVDKKK RPEDIGLLR AYQFTAPFKS 1020
FKEMGKQNGF LFYIPAWNTS NIDPTTGFVN LFHVQYENVD KAKSFFQKFD SISYNPKKDW 1080
PEFADFYKNF TKKAEGSRSM WILCTHGSRI KNFRNSQKNG QWDSEEPALT EAFKSLFVRY 1140
EIDYTADLKT AIVDEKQKDF FVDLLKLFKL TVQMRNSWKE KDLDYLI SPV AGADGRFFDT 1200
REGNKS LPKD ADANGAYNIA LKGLWALRQI RQTSSEGGKIK LAISNKEWLQ FVQERSYEKD 1260
```

```
SEQ ID NO: 51          moltype = AA length = 1324
FEATURE              Location/Qualifiers
source               1..1324
                    mol_type = protein
                    organism = Prevotella disiens
```

```
SEQUENCE: 51
MENYQEFNTL FQLNKT LRFE LKPIGKTCEL LEEGKIFASG SFLEKDKVRA DNVSYVKKEI 60
DKKHKIPIIE TLSSFSISND LLKQYFDCYN ELKAFKKDCK SDEBEVKKTA LRNKCTSIQR 120
AMREAI SQAF LKSPQKKLLA IKNL IENVFK ADENVQHPSE FTSYFSGFET NRENFYSDEE 180
KSTSIAYRLV HDNLP IPIKN IYIFEKLEKEQ FDAKTLSEIF ENYKLYVAGS SLDEVPSLEY 240
FMNTLTQKGI DNYNAVIGKI VKEDKQEIQQ LNEHINLYNQ KHKDRRLPPF ISLKKQILSD 300
REALSWLPDM FKNDSVIDA LKGFYIEDGF ENNVLTPLAT LLSSLDKYNL NGIFIRNNEA 360
LSSLSQNVYR NFSIDEAIDA QNAELQTFNN YELIANALRA KIKKETKQGR KSFEKYEEYI 420
DKKVK AIDSL SIQEINELVE NYVSEFNSNS GNMPRKVEDY FSLMRKGDGF SNDLIENIKT 480
KLSAAEKLLG TKYQETAKDI FKKDENS KLI KELLDATQF QHF I KPLLGT GEEADRLVLF 540
YGDFLPLYEK FEELTL LYNK VRNRLTQKPY SKDKIRLCFN KPCLMTGWVD SKTEKSDNGT 600
QYGGYLPRKK NEIGEYDYFL GISSKAQLPR KNEAVIGDYE RLDYYPKAN TIYGSAYEGE 660
NSYKEDKKRL NKV I IAYIEQ IKQTNIKKSI IESISKYPNI SDDDKVTPSS LLEKIKKVS I 720
DSYNGILSFK SFQSVNKEVI NLLKKTISPL KNKAEFLDLI NKDYQIPTEV QAVIDEICKQ 780
KTFIYFPISN VELEKEMGDK DKPLCLFQIS NKDLSFAKTF SANLRKKRGA ENLHTMLFKA 840
LMEGNQDNLG LGSGAI PYRA KSLDGNKPTH PANEAIKCRN VANKDKVSLF TYDIYKNRRY 900
MENKFLPHLS IVQNYKAAND SAQLNSSATE YIRKADDLHI IGIDRGERFN LYYSVIDMKG 960
NIVEQDSLNI IRNNDLETDY HDLLDKREKE RKANRQNWEA VEGIKDLKKG YLSQAVHQIA 1020
QLMLKYNAII ALEDLGMQFV TRGQKIEKAV YQQEKS LVD KLSYLVDKRR PYNELGGILK 1080
AYQLASSITK NNSDKQNGFL FYVPAWNTSK IDPVTGFTDL LRPKAMTIKE AQDFFGAFDN 1140
ISYNDKGYFE PETNYDKFKI RMKSAQTRWT ICTFGNRIKR KDKKNYWNVE EVELTEEFKK 1200
LFPKSNIDYE NCNLKEEIQN KDNRPFFDDL IKLQLTLQM RNSDDKGNDY IISPVANAEG 1260
QFFDSRNGDK KLPLDADANG AYN IARKGLW NIRQIKQTKN KDDLNLNLISS TEWLDFVREK 1320
PYLK 1324
```

```
SEQ ID NO: 52          moltype = AA length = 1484
FEATURE              Location/Qualifiers
REGION             1..1484
                    note = Peregrinibacteria bacterium
SITE              1073
                    note = misc_feature - Xaa can be any naturally occurring
                    amino acid
source           1..1484
                    mol_type = protein
                    organism = unidentified
```

```
SEQUENCE: 52
MSNFFKNFTN LYELSKTLRF ELKPVGD TLT NMKDHLEYDE KLQTF LKQDN IDDAYQALKP 60
QFDEIH EEFI TDSLESKKAK EIDFSEYLDL FQEKKELNDS EKKL RNKIGE TFNKAGEKWK 120
KEKYPOYEWK KGSKIANGAD ILSQDMLQF IKYKNPEDEK IKNYIDDTLK GFPTYFGGPN 180
QNRANYETK KEASTAVATR IVHENLPKPC DNVIQFKHII KRKDKGTVEK TERKTEYLN A 240
YQYLKNNNKI TQIKDAETEK MIESTPIAEK IFDVYFSSC LSQKQIEEYN RII GHYNLLI 300
NLYNQAKRSE GKHL SAN EKK YKDLPKFKTL YKQIGCGKKK DLFYTIKCDT EEEANKSRNE 360
GKESHV EEEI INKAQEAINK YPKSNND CEN INTVPDFINY ILTKENYEGV YWSKAAMNTI 420
SDKYFANYHD LQDR LKEAKV FQKADKKS ED DIK IPEAIEL SGLPGVLDL ADWQTLFKS 480
SILSNEK LKI ITDSQTPSEA LLKMI FNDIE KNMESFLKET NDIITLKKYK GNKEGTEKIK 540
QWFDYTLAIN RMLKYFLVKE NKIKGNSLDT NISEALKTLI YSDDAEWFVK YDALRNLYLTQ 600
KPQDEAKENK LKLNFDNPSL ACGWVKNKEC SNFCVILKDK NEKKYLAMIK KGENTLFQKE 660
WTEGRGKNLT KKS NPLFEIN NCEI LSKMEY DFWADVSKMI PKCSTQLKAV VNHFKQSDNE 720
FIFPIGYKVT SGEKFREECK ISKQDFELNN KVFNKNELSV TAMRYDLSST QEKQYIKAFQ 780
KEYWELLPKQ EKRDTKL TNN EIFNEWINFC NKKYSELLSW ERKYKDALTN WINFCKYFLS 840
KYPKTTLFNY SFKESENYNS LDEFYRDVDI CSYKLNINTT INKSIDRLV EEGKTLFPEI 900
KNQDSNDGKS IGHKNNLHTI YWNAIFENPD NRPKLNGEAE IFYRKAI SKD KLGIVKGGKT 960
KNGTWI IKNY RFSKEKPI LH VPITLNFCSN NEYVNDIVNT KFYNF SNLHF LGIDRGEKHL 1020
AYYSLVNKNG EIVDQGLTNL PFTDKDGNQR SIKKEKYFYN QKEDKWEAVE VDXWNNYDNL 1080
DAMASNRDMA RKNWQRIGTI KEAKNGYVSL VIRKIADLAV NNERPAPIVL EDLNTGFKRS 1140
RQKIDKSVYQ KPELALAKKL NFLVDKNAKR DEIGSPTKAL QLT PPVNNYQ DIENKKQAGI 1200
MLYTRANYS TSQDPATGWRK TIYLKAGPEE TTYKDKGKIK NKS VKDQIEE TFTDIGDFGK 1260
DYFFEYDKGE FVD EKTGEIK PKKWRLYSGE NGKSLDRFRG EREKDKYEWK IDKIDIVKIL 1320
DDL FVNF DKN ISLLKQLKEG VELTRNNEHG TGESLRFAIN LIQIRNTGN NERDNDPILS 1380
```



-continued

PVRDENGKHF DSREYWDKET KGEKISMPSS GDANGAFNIA RKGIIIMNAHI LANSDSKDLS 1440  
 LFFVDEEWDL HLNKTEWKK QLNIFSSRKA MAKRRKKRPA ATTK 1484

SEQ ID NO: 53 moltype = AA length = 1245  
 FEATURE Location/Qualifiers  
 source 1..1245  
 mol\_type = protein  
 organism = Porphyromonas macacae

SEQUENCE: 53  
 MKTQHFFEDF TSLYLSKTI RFELKPIGKT LENIKKNGLI RRDEQRLLDY EKLKKVIDEY 60  
 HEDFIANILS SFSFSEELQ SYIQNLSISE ARAKIEKTMR DTLAKAFSED ERYKSIFKKE 120  
 LVKKDIPVWC PAYKSLCKKF DNFTTSLVPP HENRKNLYTS NEITASIPYR IVHVNLPKFI 180  
 QNIEALCELQ KKMGGADLYE MMENLRNVWP SFVKTPDDLK NLKTYNHLMV QSSISEYNRF 240  
 VGGYSTEDGT KHQGINEWIN IYRQRNKEMR LPGLVFLHKQ ILAKVDSSSF ISDTLENDQ 300  
 VPCVLRQPRK LFWNTVSSKE DDAASLKDLE CGLSGYDPEA IYVSDAHLAT ISKNI PDRWN 360  
 YISDAIRRKT EVLMPRKES VERYAEKISK QIKKRQSYSL AELDDLLAHY SEESLPAGFS 420  
 LLSYFTSLGG QKYLVSDEGEV ILYEEGSNIW DEVLIAFRDL QVILDKDFTE KKLKGDDEAV 480  
 SVIKKALDSA LRLRKFDFLL SGTGAEIRRD SSFYALYTDK MDKLLGGLKM YDKVRNYLTK 540  
 KPYSIEKFKL HFDNPSLLSG WDKNKELNLL SVIFRQNGY YLGMTPKGG NLFKTLPKLG 600  
 AEEMFYEKME YKQIAEPLML LPKVFFPKKT KPAPAPDQSV VDIYNNKTFK TGQKGFNKKD 660  
 LYRLIDFYKE ALTVHEWKLF NFSFSPTEQY RNIGEFFDEQ REQAYKVMV NVPASYIDEA 720  
 VENGKLYLFQ IYNKDFSPYS KGIPNLHTLY WKALFSEQNQ SRVYKLCGGG ELFYRKASLH 780  
 MQDTTVHPPK ISIHKKNLNL KGETSLFNVD LVKDKRFTED KFPFHPVPI NIYKNNKTI 840  
 NQMVRYDIAQ NDDLQHSIDR GERNLLYISR IDTRGNLEQ FSLNVIIESDK GDLRTDYQKI 900  
 LGDREQERLR RRQEWKIES IKDLKDGYS QVVKICNMV VEHKAIIVLE NLNLSFMKGR 960  
 KKVEKSVYEK FERMLVDKLN YLVVDKKNLS NEPPGLYAY QLTNPLFSFE ELHRYPSQSI 1020  
 LFFVDPWNTS LTDPTSTFVN LLGRINYTNV GDARKFFDRF NAIRYDGGKN ILFDLDSRF 1080  
 DRRVETQRKL WTLTTFGSRI AKSKKSGKWM VERIENSLC FLELFEQFNI GYRVEKDLKK 1140  
 AILSQDRKEF YVRLIYLFNL MMQIRNSDGE EDYILSPALN EKNLQFDSRL IEAKDLPVDA 1200  
 DANGAYNVAR KGLMVVQRIK RGDHESIHR I GRAQWLRVYQ EGIVE 1245

SEQ ID NO: 54 moltype = AA length = 1250  
 FEATURE Location/Qualifiers  
 source 1..1250  
 mol\_type = protein  
 organism = Smithella sp.

SEQUENCE: 54  
 MQTLFENFTN QYPVSKTLRF ELIPQGKTKD FIEQKGLLKK DEDRAEKYKK VKNIIIDEYHK 60  
 DFIEKSLNGL KLDGLEKYKT LYLKQEKDDK DKKAFDKEKE NLRKQIANAF RNNEKPKTLF 120  
 AKELIKNDLM SFACEEDKKN VKEFEAFTTY FTGFHQNRAN MYVADEKRRTA IASRLIHENL 180  
 PKFIDNIKIF EKMKKEAPEL LSPFNQTLKD MKDVIKGTTL EEIIFSLDYFN KTLTQSGIDI 240  
 YNSVIGGRTP EEGKTKIKGL NEYINTDFNQ KQTDKDKRQP KFKQLYKQIL SDRQSLSFIA 300  
 EAFKNDTEIL EAIKEFYVNE LHFHSNEGKS TNVLDAIKNA VSNLSEPNLT KMYFRSGASL 360  
 TDVSRKVPEG WSIINRALDN YYATTYPIKP REKSEKYBER KEKWLKQDFN VSLIQTIDE 420  
 YDNETVKGNK SGKVIADYFA KPCDDKETDL IQKVNIEGYIA VKDLLNTPCP ENKLGSKND 480  
 QVKQIKAFMD SIMDIMHVR PLSLKDTEKE KDETFFYSLEF PLYDHLTQTI ALYKVRNYL 540  
 TQKPYSTEKI KLNFNSTLL GGWDLNKETD NTAIILRKN LYYLGMIDKR HNRIFRNVPK 600  
 ADKDFCYEK MUYKLLPGAN KMLPKVFFSQ SRIQEFTPSA KLENYANET HKKGDNFNLN 660  
 HCHKLIDFFK DSINKHEDWK NDFRFRSATS TYADLSGFYH EVEHQGYKIS FQSVADSFID 720  
 DLVNEGKLYL FOIYNKDFSP FSKGKPNLHT LYWKMLFDEN NLKDVVYKLN GEAEVYFRKK 780  
 STAEKNTTIIH KANESINKN PDMPKATSTF NYDIVKDKRY TIDKQFPHI ITMNFKAEGI 840  
 FMNQVRVQF LKANPDIINII GIDRGERHLL YYALINQKGG ILKQDTLNV I ANEKQKVDYH 900  
 NLLDKKEGDR ATARQEWGVI ETIKELKEGY LSQVIHKLTD LMIENNAIIV MEDLNFGFKR 960  
 GRQKVEKQVY QKF EKMLIDK LNYLVDKNNK ANELGGLLNA FQLANKPESF QKMGKQNGFI 1020  
 FYVPAWNTSK TDPATGDFID LKPRYENLNQ AKDFFEKFD IRLNSKADYF EFADFKNFT 1080  
 EKADGGRTKW TVCTTNEEDRY QWNRALNNR GSQEKYDITA ELKSLFDGKV DYKSGKDLKQ 1140  
 QIASQESADF FKALMKNLSI TSLRHNNGE KGDNEQDYIL SPVADSKGRF FDSRKADDDM 1200  
 PKNADANGAY HIALKGLWCL EQISKTDLTK KVKLAISNKE WLEFVQTLKG 1250

SEQ ID NO: 55 moltype = AA length = 1228  
 FEATURE Location/Qualifiers  
 REGION 1..1228  
 note = Lachnospiraceae bacterium  
 source 1..1228  
 mol\_type = protein  
 organism = unidentified

SEQUENCE: 55  
 MSKLEKFTNC YLSKTLRFX AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60  
 FINDVLHSIK LKNLNNYISL FRKKTRETEKE NKELENLEIN LRKEIAKAFK GNEGYSKSLFK 120  
 KDIIITILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSBEAKSTS IAFRCINENL 180  
 TRYISNMDF EKVDAIFDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGDYNVAI 240  
 IGGFVTESEGE KIKGLNEYIN LYNQKTKQKL PKFKPLYKQV LSDRESLSFY GEGYTSDEEV 300  
 LEVFRNTLNK NSEIFSSIKK LEKLFKNFDE YSSAGIFVKN GPAISTISKD IFGEWNVIRD 360  
 KWNAEYDDIH LKKKAVVTEK YEDDRRKSFK KIGSFSLEQL QEYADADLSV VEKLEI IIQ 420  
 KVDEIYKVVYG SSEKLPDADF VLEKSLKND AVVAIMKDLL DSVKSFENYI KAFFGEGKET 480  
 NRDESFYGDF VLAYDILKLV DHIYDAIRNY VTQKPYSKDK FKL YFQNPQF MGGWDKDKET 540

-continued

DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGN	KMLPKVFFSK	600
KWMAYNPSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVVEEQGYKV	SPESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYPKLLPDE	NNHGQIRLSG	GAEFLMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTTLT	780
YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IDRGERNLLY	840
IVVVDGKGNL	VEQYSLNEII	NNFNGIRIKT	DYHSLDDKKE	KERFEARQNW	TSIENIKELK	900
AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	960
KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	1020
IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPKK	1080
NNVPDWEEVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	1200
AEDEKLDKVK	IAISNKWELE	YAQTSVKH				1228

SEQ ID NO: 56                   moltype = AA   length = 1228  
FEATURE                        Location/Qualifiers  
source                         1..1228  
                                  mol\_type = protein  
                                  note = Lachnospiraceae bacterium  
                                  organism = unidentified

SEQUENCE: 56

MSKLEKFTNC	YSLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKLNLNYSISL	FRKKTRETEK	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEEAKSTS	IAFRGINENL	180
TRYISNMDF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTESE	KIKGLNEYIN	LYNQKTKQKL	PKFKPLYKQV	LSDRESLSFY	GEGYTSDEEV	300
LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKV	GPAISTISKD	IFGEWNVIRD	360
KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QEYADADLSV	VEKLKEIIQ	420
KVDEIYKVG	SSEKLFADDF	VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	480
NRDESFGDF	VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	540
DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGN	KMLPKVFFSK	600
KWMAYNPSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVVEEQGYKV	SPESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYPKLLPDE	NNHGQIRLSG	GAEFLMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTTLT	780
YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IDRGERNLLY	840
IVVVDGKGNL	VEQYSLNEII	NNFNGIRIKT	DYHSLDDKKE	KERFEARQNW	TSIENIKELK	900
AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	960
KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	1020
IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPKK	1080
NNVPDWEEVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	1200
AEDEKLDKVK	IAISNKWELE	YAQTSVKH				1228

SEQ ID NO: 57                   moltype = AA   length = 1228  
FEATURE                        Location/Qualifiers  
source                         1..1228  
                                  mol\_type = protein  
                                  organism = synthetic construct

SEQUENCE: 57

MSKLEKFTNC	YSLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKLNLNYSISL	FRKKTRETEK	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEEAKSTS	IAFRGINENL	180
TRYISNMDF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTESE	KIKGLNEYIN	LYNQKTKQKL	PKFKPLYKQV	LSDRESLSFY	GEGYTSDEEV	300
LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKV	GPAISTISKD	IFGEWNVIRD	360
KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QEYADADLSV	VEKLKEIIQ	420
KVDEIYKVG	SSEKLFADDF	VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	480
NRDESFGDF	VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	540
DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGN	KMLPKVFFSK	600
KWMAYNPSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVVEEQGYKV	SPESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYPKLLPDE	NNHGQIRLSG	GAEFLMRRAS	LKKEELVVAP	ANSPIANKNP	DNPKKTTLT	780
YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IDRGERNLLY	840
IVVVDGKGNL	VEQYSLNEII	NNFNGIRIKT	DYHSLDDKKE	KERFEARQNW	TSIENIKELK	900
AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	960
KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	1020
IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPKK	1080
NNVPDWEEVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	1200
AEDEKLDKVK	IAISNKWELE	YAQTSVKH				1228

SEQ ID NO: 58                   moltype = AA   length = 1307  
FEATURE                        Location/Qualifiers  
source                         1..1307  
                                  mol\_type = protein  
                                  organism = synthetic construct

SEQUENCE: 58

-continued

MTQFEGFTNL	YQVSKTLRFE	LIPQGKTLKH	IQEQGFIEED	KARNDHYKEL	KPIIDRIYKT	60
YADQCLQLVQ	LDWENLSAAI	DSYRKEKTEE	TRNALIEEQA	TYRNAIHDFY	IGRTDNLDTA	120
INKRHAEIYK	GLFKAELFNG	KVLKQLGTVT	TTEHENALLR	SFDKFTTYFS	GFYRNKQNVF	180
SAEDISTAIP	HRIVQDNFPK	FKENCHIFTR	LITAVPSLRE	HFENVKKAIG	IFVSTSIIEV	240
FSFPFYNQLL	TQTQIDLYNQ	LLGGISREAG	TEKIKGLNEV	LNLAIQKNDE	TAHIIASLPH	300
RFIPLFKQIL	SDRNTLSFIL	EEFKSDEEVI	QSFCKYKTL	RNENVLETAE	ALFNELSID	360
LTHIFISHKK	LETISSALCD	HWDTLRNALY	ERRISELTGK	ITKSAKEKVQ	RSLKHEDINL	420
QEIISAAGKE	LSEAFKQKTS	EILSHAHAAL	DQPLPTTLKK	QEEKEILKSQ	LDSLLGLYHL	480
LDWFAVDESN	EVDPEFSARL	TGIKLEMEPS	LSFYNKARNY	ATKKPYSVEK	FKLNFQMPTL	540
ARGWDVNRK	NNGAILFVKI	GLYYLGIMPK	QKGRYKALSF	EPEKTSSEGF	DKMYDYDFPD	600
AAKMIPKCS	QLKAVTAHFQ	THTTPILLSN	NFIEPLEITK	EIYDLNNPEK	EPKFKQTAYA	660
KKTGDQKGYR	EALCKWIDFT	RDFLSKYTKT	TSIDLSSLRP	SSQYKDLGEY	YAEINPLLYH	720
ISFQRIAEKE	IMDAVETGKL	YLPQIYNKDF	AKGHHGKPNL	HTLYWTGLFS	PENLAKTSIK	780
LNGQAEFLFYR	PKSRMKRMAA	RLGKMLNKK	LKDQKTPIPD	TLYQELDYDV	NHRLSHDLS	840
EARALLPNVI	TKEVSHIIEK	DRRFTSDKPF	FHVPIITLNYQ	AANSPSKFNQ	RVNAYLKEHP	900
ETPIIGIDRG	ERNLIYITVI	DSTGKILEQR	SLNTIQQFDY	QKKLDNREKE	RVAARQAWSV	960
VGTIKDLKQG	YLSQVIHEIV	DLMIHYQAVV	VLENLNFQFK	SKRTGIAEKA	VYQQFEKMLI	1020
DKLNCLVLKD	YPAEKVGGVL	NPYQLTDQFT	SFAKMGTSQG	FLFYVPAPYT	SKIDPLTGFV	1080
DPFVWKTIKN	HESRKHFLFEG	FDPLHYDVKT	GDFILHFQMN	RNLSFQRGLP	GFMPAWDIVF	1140
EKNETQFPAK	GTPPIAGKRI	VPVIENHRFT	GRYRDLYPAN	ELIALLEEKG	IVFRDGSNIL	1200
PKLENDSDH	AIDTMVALIR	SVLQMRNSNA	ATGEDYINSP	VRDLNGVCFD	SRFQNPWPM	1260
DADANGAYHI	ALKGQLLNH	LKESKDLKQ	NGISNQDWLA	YIQELRN		1307

SEQ ID NO: 59                   moltype = AA   length = 1307  
 FEATURE                        Location/Qualifiers  
 source                         1..1307  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 59

MTQFEGFTNL	YQVSKTLRFE	LIPQGKTLKH	IQEQGFIEED	KARNDHYKEL	KPIIDRIYKT	60
YADQCLQLVQ	LDWENLSAAI	DSYRKEKTEE	TRNALIEEQA	TYRNAIHDFY	IGRTDNLDTA	120
INKRHAEIYK	GLFKAELFNG	KVLKQLGTVT	TTEHENALLR	SFDKFTTYFS	GFYRNKQNVF	180
SAEDISTAIP	HRIVQDNFPK	FKENCHIFTR	LITAVPSLRE	HFENVKKAIG	IFVSTSIIEV	240
FSFPFYNQLL	TQTQIDLYNQ	LLGGISREAG	TEKIKGLNEV	LNLAIQKNDE	TAHIIASLPH	300
RFIPLFKQIL	SDRNTLSFIL	EEFKSDEEVI	QSFCKYKTL	RNENVLETAE	ALFNELSID	360
LTHIFISHKK	LETISSALCD	HWDTLRNALY	ERRISELTGK	ITKSAKEKVQ	RSLKHEDINL	420
QEIISAAGKE	LSEAFKQKTS	EILSHAHAAL	DQPLPTTLKK	QEEKEILKSQ	LDSLLGLYHL	480
LDWFAVDESN	EVDPEFSARL	TGIKLEMEPS	LSFYNKARNY	ATKKPYSVEK	FKLNFQMPTL	540
ARGWDVNRK	NNGAILFVKI	GLYYLGIMPK	QKGRYKALSF	EPEKTSSEGF	DKMYDYDFPD	600
AAKMIPKCS	QLKAVTAHFQ	THTTPILLSN	NFIEPLEITK	EIYDLNNPEK	EPKFKQTAYA	660
KKTGDQKGYR	EALCKWIDFT	RDFLSKYTKT	TSIDLSSLRP	SSQYKDLGEY	YAEINPLLYH	720
ISFQRIAEKE	IMDAVETGKL	YLPQIYNKDF	AKGHHGKPNL	HTLYWTGLFS	PENLAKTSIK	780
LNGQAEFLFYR	PKSRMKRMAA	RLGKMLNKK	LKDQKTPIPD	TLYQELDYDV	NHRLSHDLS	840
EARALLPNVI	TKEVSHIIEK	DRRFTSDKPF	FHVPIITLNYQ	AANSPSKFNQ	RVNAYLKEHP	900
ETPIIGIDRG	ERNLIYITVI	DSTGKILEQR	SLNTIQQFDY	QKKLDNREKE	RVAARQAWSV	960
VGTIKDLKQG	YLSQVIHEIV	DLMIHYQAVV	VLENLNFQFK	SKRTGIAEKA	VYQQFEKMLI	1020
DKLNCLVLKD	YPAEKVGGVL	NPYQLTDQFT	SFAKMGTSQG	FLFYVPAPYT	SKIDPLTGFV	1080
DPFVWKTIKN	HESRKHFLFEG	FDPLHYDVKT	GDFILHFQMN	RNLSFQRGLP	GFMPAWDIVF	1140
EKNETQFPAK	GTPPIAGKRI	VPVIENHRFT	GRYRDLYPAN	ELIALLEEKG	IVFRDGSNIL	1200
PKLENDSDH	AIDTMVALIR	SVLQMRNSNA	ATGEDYINSP	VRDLNGVCFD	SRFQNPWPM	1260
DADANGAYHI	ALKGQLLNH	LKESKDLKQ	NGISNQDWLA	YIQELRN		1307

SEQ ID NO: 60                   moltype = AA   length = 1107  
 FEATURE                        Location/Qualifiers  
 source                         1..1107  
                                mol\_type = protein  
                                organism = Bacillus hisashii

SEQUENCE: 60

ATRSFILKIE	PNEEVKKGLW	KTHEVLNNGI	AYYMNILKLI	RQEAIEYEHHE	QDPKPKKVS	60
KAEIQAEALWD	FVLKMQKCN	FTHEVDKDEV	FNILRELYEE	LVPSSVEKKG	EANQLSNKPL	120
YPLVDPNSQS	GKGKLLKSGI	PRWYNLKIAG	DPSWEEEEKK	WEEDKKKDP	AKILGLKLAEY	180
GLIPLFIPYT	DSNEPIVKEI	KWMEKSRNQS	VRRLDKDMFI	QALERFLSWE	SWNLKVKKEY	240
EKVEKEYKTL	EERIKEDIQA	LKALEQYKE	RQEQLLRDTL	NTNEYRLSKR	GLRGWREIIQ	300
KWLKMDENEP	SEKYLEVFKD	YQRKHPREAG	DYSVYEFLSK	KENHFIWRNH	PEYPYATF	360
CEIDKKKKA	KQQAFTFLAD	PINHPWVRF	EERSGSNLNK	YRIILTEQLHT	EKLKLLTVQ	420
LDRLIYPTES	GGWEEKKVD	IVLLPSRQFY	NQIFLDIEEK	GKHAFTYKDE	SIKFPKGLTL	480
GGARVQFDRD	HLRRYPHKVE	SGNVGRIYPN	MTVNIPTES	PVSKSLKIHR	DDPPKVVNFK	540
PKELTEWIKD	SKGKLLKSGI	ESLEIGLRVM	SIDLQGRQAA	AASIFEVDQ	KPDIEGKLF	600
PIKGTELYAV	HRASFNIKLP	GETLVKSREV	LRKAREDNLK	LMNQKLNFLR	NVLHFQQFED	660
ITEREKRVTK	WISRQENSVD	PLVYQDELIQ	IRELMYKPYK	DWVAFKQLH	KRLEVEIGKE	720
VKHWRKSLSD	GRKGLYIGSL	KNIDEIDRTR	KFLLRWSLRP	TEPGEVRRLE	PGQRFADQL	780
NHLNALKEDR	LKKMANTIIM	HALGYCYDVR	KKKQAKNPA	CQIILFEDLS	NYNYPGERSR	840
FENSRLMKWS	RREIPRQVAL	QGEIYGLQVG	EVGAQFSSRF	HAKTGSPIR	CRVVTKEKLG	900
DNRFFKNLQR	EGRILTLDKIA	VLKEGDLYPD	KGGEKFISSL	KDRKCVTTHA	DINAAQNLOK	960
RFWTRTHGFY	KRYTCAQVD	GQTVYIPESK	DQKQKIIIEF	GEGYFILDKG	VYEWVNAGKL	1020
KIKKSSKQS	SSELVSDIL	KDSFDLASEL	KGEKMLLYRD	PSGNVFP	SDK WMAAGVFFGK	1080

-continued

LERILISKLT NQYSISTIED DSSKQSM 1107

SEQ ID NO: 61 moltype = DNA length = 3987  
 FEATURE Location/Qualifiers  
 source 1..3987  
 mol\_type = other DNA  
 organism = synthetic construct

SEQUENCE: 61  
 atggccggga gcaagaagcg ccggataaag caggacacgc agttcggagg cttcaccacac 60  
 ctgtaccaag tctccaagac gctccgggtc gagcttatcc cgcaagggaa gaccctgaaa 120  
 cacatccagg aacaagggtt catcgaggag gacaaggccc gcaacgacca ctacaaggag 180  
 ctcaagccca taatcgatcg gatctacaag acgtacgccc accagtgccct ccaactgggtg 240  
 cagctcgact gggagaacct gagcgcggcc attgacagct accgcaagga aaagacggag 300  
 gagacgcgca acgccccttat tgaggagcaa gccacctacc gcaacgccat ccacgactac 360  
 ttcatcgggc gcaaccgaaa cctgacggac gcgatcaaca agcgcaccgc ggaatctac 420  
 aagggccttt tcaaggccga gctctcaac gggaaaggtcc taaaacagct cgggactgtc 480  
 acgacaaccg agcatgagaa gcgccctcct cgcagcttcg acaagttcac cacatacttc 540  
 tccggctctc accggaaccg caagaacgct ttcagcggcc aggcacatctc caccgccatc 600  
 ccgcacagga tccgccaagga caacttcccc aagttcaagg agaactgcca catcttcacg 660  
 cgcctgatta cagccgtacc ttcacttcgt gagcacttcg agaactgcaa aaagggccatc 720  
 gggatctctc gctccaagtc catcgaggag gtattctctt tcccgttcta taaccagctc 780  
 ctgaccacaga ccgagatcga cctctacaac cagctactgg gcggcatcag ccgggaggcc 840  
 gggaccgaga aataaaaggg cctcaacgaa gttctcaacc tggccatcca gaagaacgac 900  
 gagaccgcgc atatcatcgc atccctgccc catcgcttca ttcctttggt caagcagata 960  
 ttgagcgacc ggaacaccct ctcgctcatc ctcaagaagt tcaagagcga cggagggttc 1020  
 attcagctct tctgcaagta caagacgctc ctacggaatg agaatgtgct ggagaccgag 1080  
 gaggcactct tcaatgagct gacctccatt gacctgaccc acatcttcat tagccacaag 1140  
 aaactggaga cagctccagc gcacctgtgc gacctctcgg acactctccg caacgccctc 1200  
 tacgaacgccc ggtatctcga acttaccgag aagataacta agtccggtaa ggagaagggtg 1260  
 caacggagccc tcaagcagca ggcacccaac cttcaggaaa tcatctcagc ccggggcaag 1320  
 gagctgagcg acccggttaa gcagaaaaca tccgagatag tgagccacgc gcaccgccc 1380  
 ctggatcaac cgtgcccgcac gactctcaag aagcaagagg agaaggaat ccttaagtcc 1440  
 cagctcgact cgtgctcggc cctctatcac ttgctcgact ggttcggggtg tgatgagtc 1500  
 aacgaggtgg acccgaggtt ctccgcgcgc ctccagggta ttaagctgga gatggagcca 1560  
 agcttaagct tctacaacaa ggcccgcacac tacgcgacca aaaaaccgta ctcagtcgag 1620  
 aaatcaagc tgaatttcca gatgctaca ttggcgaggg ggtgggagct gaaccgcgag 1680  
 aagaacaatg ggcctatcct gttcgtcaaa aatgggttgt actacctggg catctgccc 1740  
 aagcagaagg ccggttcaaa ggcccctgca ttcgagccta ccgagaagac ctccgggggc 1800  
 ttcgacaaga tgtactacga ctatttcccg gacgcgccca agatgatccc gaagtgtccc 1860  
 accgagctca aagccgtcac gcccacttc cagacgcata ccacgccgat actcttgagc 1920  
 aacaacttca ttgagccgct agagatcacg aaggagatat acgacctaaa caaccgccga 1980  
 aaggagccca agaagttcca gacagcctac gctaagaaga caggtgatca gaagggatat 2040  
 agggagggcac tctgcaagtg gatcgacttc acgcgcgact tcctgtcgaa atatacaag 2100  
 acgaccagca ttgacctaa gttctctccc ccatctccc agtacaagga tctggggcag 2160  
 tattatcgcg agctgaaccc attgctgtac cacatcagct tccagaggat ccgagagaag 2220  
 gagattatgg acccggttga gacggggaaa ctataacctgt tccaaatata taacaaggac 2280  
 ttctgtaaa ggcaccacgg gaagcccaac ctgacacac tctactggac gggcttggtt 2340  
 tccgcagaaa atttggccaa gacttcgac aagctcaacg gccagggcga gttgttttac 2400  
 cgtcccaagt ctgcctgaaa gcgcctggcg catcgccctc gagagaaaat gcttaacaag 2460  
 aagctcaagg atcagaagac gcccatacct gatacgttgt accaggaat gtacgactac 2520  
 gtgaaccacc gccctatcga cagcctctca gacgagccc gcgcccctcc cccaaacgtg 2580  
 attactaagg aggttttcca tgaataatc aaggaccgac ggttccaccg cgacaattt 2640  
 tttttccag tgcctatcac gctcaattac caggcggcca actcccctc gaagttcaac 2700  
 cagcgcgtga accgctacct taaggagcac ccggagaccc caatcatcgg gatcgaccgt 2760  
 ggcgagcggga acctgatcta tattacgggt atcgatagca ccgggaagat cctggagcag 2820  
 cgctccctga acacaatcca gcagtttgac taccagaaga aactcgacaa ccggggagaag 2880  
 gagcgcgtcg cagcccggca agcatggagt gtggtcgcca ccataaagga cctgaaacag 2940  
 ggttacctaa gtcgaagttat ccacagatc gttgacctga tgatacacta tcaagccgta 3000  
 gtcgtgctgg agaacctcaa cttcgggttt aagttcaagc gcaccggcat ccgggagaag 3060  
 gcggtgtacc agcagttcga gaagatgctg atcgacaagc tgaactgcct ggtgctcaag 3120  
 gactacctcg ccgagaaggt cggcggggtc ttgaaccctg accagctaac cgaccagttc 3180  
 acgagcttcg ccaaaatggg cacgcagctc ggattcttgt tttatgtccc ggctccatat 3240  
 acaagtaaga tccaccgct gacagggttt gttgacctat cctgtgggaa gacctcaag 3300  
 aaccacgaga gcaggaaaa cttcttagag ggcttcgact tccctgatta cgacgttaag 3360  
 acagccgact tcatcctgca cttcaagatg aaccgcaacc tgtcgtcca gaggggccc 3420  
 cccggcttca tgcgccctg ggatatcgtc ttgagaaga atgagacgca gttcagacgg 3480  
 aaggggacgc cgttcctcgc tggaaagcgg atcgtgcggc tcatcgagaa ccaccgcttc 3540  
 accggctcgt accgagattt ataccgcccc aacgaactaa ttgctgctgt ggaggagaag 3600  
 gggatcgtgt tccgagatgg cagcaacatt ctcccgaagc tgctggagaa cgacgactcg 3660  
 cagctatctg acacgatggt ccgccctcata cggagcgtgc ttcagatgag gaacagtaac 3720  
 gctgccacgg tccagggact cattaactcc cccgtcccgc acctcaacgg ggttgccttc 3780  
 gatagccgct gccagaaccc ggagtgccct atggatgcgg acgcgaacgg ggcctaccac 3840  
 atcgcctcca agggccaact cctgctcaac cacttgaagg aaagcaaga cctcaaatg 3900  
 cagaatggca tcaagtaaca ggactggctc gcgtacatcc aggaactgag aaacgggtcc 3960  
 aagaagcggc gatatcaagca agattga 3987

-continued

```

SEQ ID NO: 62          moltype = DNA length = 3987
FEATURE              Location/Qualifiers
source               1..3987
                    mol_type = other DNA
                    organism = synthetic construct

SEQUENCE: 62
atggcgggaa gcaaaaagcg ccggattaag caagacacgc agttcggagg cttcacgaa 60
ctctaccaag tcagcaagac cctccgggtc gagctgatac cacagggaaa gacgctcaag 120
cacatccagg aacagggtct catcggagg gacaaggcgc gcaacgacca ctacaaggag 180
ttgaaaccga tcatcgaccg catctacaag acgtacgccc accagtgcct ccagctcgtg 240
cagctcgact gggagaacct ctccgcccgc attgactcgt accggaagga gaagactgag 300
gagaccgcca acgcccctgat cggaggagca gcaacctacc ggaacgcat ccacgactac 360
ttcatcggcc gcaccgcaa cctcaccgac cgtatcaaca agcggcacgc ggagatatac 420
aaagggctgt tcaaggcgga gctgttcaac ggcaagggtc tcaagcagct agggacgggtg 480
accacgaccg agcagcagaa cgcgctcctc cgcagcttcg acaagttcac cacctacttc 540
agcggcttct accggaaccg caagaatgtg ttcagcggcg aggacatcag cacggccatc 600
ccgacccgca tcgtccagga caactcccgc aagttcaagg agaactgcca catcttcacc 660
cgcctgataa ccgcccctcc ctcccctggg gagcacttcg agaactgcaa aaaggaatt 720
gggatcttgc tctcgaccag catctgaggag gtgttcagct tccccttcta caaccagctc 780
ctcaccaga ctcagatcga cctgtacaat cagttgctcg gcgggataag ccgagggcg 840
ggaaaccgaa aaatcaaggg gctgaacgaa gtgttgaacc tcgcatcca gaagcagcag 900
gagaccgccc acatcatcgc ctcccctgcc caccggttca tcccgtgtt caagcagatc 960
ctctctgaac ggaacacctc gtccttcatt cttgaggagt tcaagtcgga cgaggaggtc 1020
atccagagct tctgcaagta caagacgctg ctacggaaagc agaactgctt ggagacggcg 1080
gaggcactgt tcaacgacgc aaacagcatc gacctcacgc acatcttcat cagtcaaacg 1140
aaactggaga ccatctcctc cgcgctgtgc gaccactggg acacgctcag gaacgctc 1200
tacgagcggc gaatcagtga gctgacgggc aagatcacga agtccgcaa ggagaagggtg 1260
cagcggctcc tcaagcagca ggacatcaac ctcccaggaga tcctctcagc ggctgggaaa 1320
gagctgtccg aggcgttcaa gcagaaaacg agcgaatcc tgtcccacgc gcacgcccgc 1380
ctggatcagc ctctcggcag caccctcaag aaacaagaag aaaaggaatt cctcaagctc 1440
cagctcagct ccctgctggg cctgtacctc ctcccctgact ggttcgcccgt ggacgagagc 1500
aacgaggtgg accccgagtt ctccgcccgc cttacgggga tcaagctgga gatggagccc 1560
agcctgtcct tctacaacaa ggcgcgcaac tacgccacca agaagccta cagcgtggag 1620
aagtccaagc tcaacttcca gattgccact ctccgacgtg ggtgggact caaccgcaa 1680
aaaaataatg gggcgatcct gttcgtcaag aacggcctgt actacttggg catcatgccc 1740
aaacagaagg gccgctacaa gcccctgagc ttcgaaccga ccgagaaaac gagcaggggg 1800
ttcgacaaga tctactcaga ctacttccc gacgcccgca agatgatccc aaagtgtccc 1860
acgcagctta aggcgctgca ggcaccttc cagacgcaca cgaccccgat cctcctcagc 1920
aacaacttca tcgagcccct ggagatcacg aaggagatat acgacctgaa caaccgggag 1980
aaggagccca ggaatcca gaccgctac gccaaagaaga caggcgaaca aaagggttac 2040
agggaggccc tctgcaagtg gatcgacttc actagggact tcctgtccaa gtacaccaag 2100
actacctcta tcgacctgtc cagcctccgc ccgtcgtccc agtcaaaaaga tttggggcag 2160
tattacgccc agcagttcca aactgtctac cacatcagct tccagcgcac cgcggagaag 2220
gagatcatgg acgagtgga gacgggcaag ctatacctat ttcagatata caacaaagac 2280
ttcgctaagg gacaccacgg caagcctaac ctgcacacccc tctactggag ggggctcttc 2340
agcccggaaga acctcgcgca gacctcgatc aagctcaacg gccaggccca gctgttctac 2400
cggcccagat cccgcatgaa gccgatggcc caccggctcg gggagaaaaa gctcaacaag 2460
aaattgaagg accaaaaaac ccgcgataccc gacacctat accaggagct gtacgactat 2520
gtgaaccacc gctcgagcca gcacctcagc gacgagggcg gggccctcct gccgactc 2580
atcaaaaagg ggctcagcca cgagatcatc aaggaccggc gcttcacctc cgacaagttt 2640
ttctttcacg tgcccatacc gctcaactac caggcccgca actcgcgcgc caagttcaac 2700
cagcgcgtga acgctacctc caaggagcac cccgagacccc cgateatcgg gattgaccga 2760
ggggagcggg acctcatcta catcacctgc atcgacagca cccgggaagat ccttgaacag 2820
cggctcgtca accacctcca gcagttcgac taccagaaga aactcgacaa ccgggagaag 2880
gagagagtgg ccgcccgcca ggcttggccc gtcgtcggga cgattaagga cttgaaacaa 2940
ggttacctgt cgcaagtgat ccacgagatc gttgacctga tgatccacta ccaagccgtc 3000
gtggtcctgg agaacctcaa cttcggcttc aagagcaaac gaaccggcat cgcggagaag 3060
gccgtgtacc agcagttcca aaaaatgctg atcgacaagc tgaactgctc cgtgctcaag 3120
gactaccocg ctgagaaggt cggcgggggtg ctgaacctgt accagctcac tgaccagttc 3180
accagcttcg caaagatggg caccocagtc ggtctcctgt tctactgtgc tcgcccatac 3240
acctcgaaga tcgaccctgc caccgggttc gtggaccctc tcgtctggaa gaccatcaag 3300
aaccacgaga gccgcaagca cttcctggag ggtctcagct tcctccacta cgactcaag 3360
accggggact tcatcctgca cttcaagatg aaccgcaacc tcagtttcca gcgcccctg 3420
ccgggggtca tgcctcgttg ggateatgtc ttcgagaaga atgagacgca gttcgacgcg 3480
aaagggacccc cgttcactgc cgggaagcgc atcgtgcccg tcatcgagaa ccaccggttc 3540
accggcgctc accgagacct ataccggcgc aacgagttga tcgcccctcct ggagagaag 3600
ggcatcgtgt tccgagcagg ctccaacatc ctcccgaagc tgctcgaaaa cgacgactcc 3660
cacgccatcg acacgatggc cgcgctgac cggtegggtc tccagatgag gaactccaac 3720
gccgagcagg gcgaggacta catcaacagt ccggctccgc atctgaacgg cgtctgtctc 3780
gactcccgtg tccagaacct cgagtggcgc atggacggcg acgcaaacgg cgcataccac 3840
atcgccctaa agggcaattg gctgctcaac cacctcaagg aatccaaaga cctaaagctc 3900
cagaacggca tctccaacca ggaactggctg gcgtacatcc aggaactcgc gaacgggagc 3960
aaaaaacgtc ggatecaagca agattga 3987

```

```

SEQ ID NO: 63          moltype = DNA length = 3987
FEATURE              Location/Qualifiers

```

-continued

```

source          1..3987
                mol_type = other DNA
                organism = synthetic construct

SEQUENCE: 63
atggcgggct ccaagaaacg cgggattaag caagataccc agttcggagg gttcacgaac 60
ctctaccaag tgagcaagac cctccgattc gaactgattc ctcaggggaa gaccctcaag 120
cacatccagg agcaagggtt catcggagg gacaaggcgc ggaacgacca ctacaaggaa 180
ctcaaaccca tcatcgaccg catctacaag acctacgccg atcagtgcc tccagctcgtg 240
cagttggact gggagaacct cagcgcggcc attgactcct accggaagga gaaaacggag 300
gagacgcgca acgcgctcat cagggaacag gcaacctatc gcaacgacct ccacgactac 360
ttcatcggga ggactgacaa cctcaactgac gcgattaaca agcgcacgc ggagatatac 420
aagggactct tcaagcgga gctgtttaac ggcaaggttc tcaagcaact cggcactgtg 480
accacgcggc agcatgagaa gccctctctc cgctccttcg acaagttcac cacctacttc 540
tccgggtctc accgcaaccg caagaatgtc ttcagcggcg aggacatcag cacggccatt 600
ccacatcgaa tcgtccaaga taacttcccg aagttcaagg agaactgcca catcttcacc 660
cgactcatta tctgtgtacc gtcgttacgc gaaccttcg agaactgcca gaaggcaatt 720
ggaatctctc tctctactgc atatagagg gtgttcagct tccctttcta caaccagctc 780
cttacgcaga cccagataga cctgtacaat cagctcctcg gtgggacag cggggaggcg 840
gggactgaga agattaaagg gctcaacgag gtcttgaacc tggccatcca aaaaaacgat 900
gagacggcgc acatcatcgc ctcgctgccc caccggttca tcccgctgt caaacgagatc 960
ctcagtgaca ggaacaacct gagctttatc ctgagggagt tcaagagcga cggagggtg 1020
atccagagac tctgcaagta gctgacccct ctgaggaacg agaactgcca ggaacggcg 1080
gaggcgtctg tcaacgagct gaactctatc gacttaactc acatattcat ctgcacaaag 1140
aagctggaga ctattagctc tgcactctgc gaccactggg acacctccg caacgcgctc 1200
tacgagcgcc gcatctcgga gctgaccggg aagatcacca aatcgcgcaa ggaacgggtc 1260
cagcgttccc tcaaacacga ggatattaac ttacaggaga ttatctcagc ggctgggaaag 1320
gagttgtcag agtcgttcaa gcagaaaaat tccgagatcc tgagccacgc gcacgcagcg 1380
ctcgaccagc cctctgcccac caccctcaaa aagcaggaag aaaaagagat cctcaagagc 1440
cagttggact cctctgctgg gctctatcac cttctcagc gggttcgctg cgatgagctg 1500
aacgaggtgg accccgagtt ctcggcccggt ctgaccggca tcaagctaga gatggagccg 1560
tccctcagct tctacaataa ggcccgcacac tacgcgacca aaaaacccta cagcgtggag 1620
aagttcaagc tgaacttcca gatgcccagc ttgacacgcg gttgggacgt aaacagggag 1680
aagaacaatg gagccatcct gttcgtcaag aacgggcttt actacctcgg gataatgccc 1740
aagcagaagg gccgtacaaa ggccctttcc ttcgagccga cggagaaaac ctccgagggg 1800
ttcgacaaga tgtactacga ctacttcccc gagcgcgcca agatgatccc gaagtgtctc 1860
acgcagctaa aagccgtgac gcgccacttc cagaccacca cgacgcgatc cctgctgagc 1920
aacaacttca tcgagccctc tgagatcact aaggagatag acgacctgaa caaccocgag 1980
aaggagccca agaagtttca aaccgcctac gccaaaaaaa ctggcgacca aaagggttac 2040
agggaggcgc tgtgtaagtg gatcgacttc acacgcgact tcccttcgaa gtatacgaag 2100
acaacctcta ttgacctgag cagcctgctc cctagctccc agtacaagaa tttggcgag 2160
tactacgagg agcttaatcc actactctac cacatctcat tccagcgcac cgctgagaag 2220
gaaatcatgg acgctgtgga gacaggcaaa ctgtacctct tccagatata caacaagac 2280
ttcgtaagg ggccaccagg gaagcccacac cttcatacgc tctactggac gggccatttc 2340
agccccgaaa atctggccaa gaacctccatc aagctgaacg gccaaagcga gctgttctac 2400
agaccacaag gccggatgaa gcgggatggc cacaggctcg gcgagaaaaa gcttaacaaa 2460
aagttgaagg accagaaaac cctatcccc gacacctctc accaggaact gtaacctac 2520
gtgaaccaca ggtctctgca cgacctttcc gagcaggccc gtgcccact cccgaacgtc 2580
attaccaaa aggtttcgca cgagatcctc aaggaccggc gggtcaccag cgacaagttt 2640
ttctttcag tccccatcac ccttaactac caggcggcca actccccat caagttcaac 2700
cagcgtgtga atgctacct caaggagcac ccagagaccc cgatcattgg gatcgaccgg 2760
ggcgagcggg acctgatota catcacctgc atcgactcga cgggcaagat tcttgagcag 2820
agatcgttga ataccataca gccagttcag taccagaaga aactcgacaa ccgcgagaag 2880
gagcgcgtgg cggcccgcga gccgtgggtc gtcgttggga cgattaagga cttgaaacaa 2940
ggttatctgt cccaagatct ccacgagatc gttgatctga tgatccacta tcaggcagtg 3000
gtggtgctgg agaactctca cttcggcttc aagagtaagc ggaacgggaa cgcgcgagaag 3060
gccgtgtacc agcagttcga gaagatgctg atcgacaagc tcaactgctc tgtgctgaaa 3120
gactaccgag ccagagaaggt cggcggcgtc ctcaaccctg accaacttac cgaccagttc 3180
acctcctcgg ccaagatggg cactcagttc gggttctgt tctacgtccc cgcaccttac 3240
accttaaga tcgacctctc gactggcttc gtagatccat tcgtgtggaa gaccattaag 3300
aaccacgaga gccgcaagca cttcctggag ggtctcgact tccctgacta cgactgtaag 3360
accggggact tcatccttca cttcaagatg aaccggaacc tcagcttcca cggggcctcg 3420
ccggggttca tgcccgcctg ggacatcgtg ttcgagaaga acgagaccca gttcgacgcg 3480
aagggcacgc ccttcatcgc cgggaagcgt atcgtgccgg tgatcgagaa ccatcgtttc 3540
acgggtcgtc acctggaact ctaccggcg aacgagctta tcgcaactcc ggaggagaag 3600
ggcatcgtct tccgggaagg ctccaacatc ctcccgaac tgctggaaaa cgacgactct 3660
cacgccatcg acacgatggg gccctcctac cgggtccgtg tccaaatgcg gaacagcaac 3720
gccgccaccg gtgaggacta catcaacagc ccggtccggg atctgaaacg ggtgtgcttc 3780
gattcgggt tccagaatcc tgagtgccg atggacggcg atgcaaacgg ggcgtaacc 3840
atcgcgctca agggccagtt acttctgaac cacctaaagg agtctaaga tttgaaactc 3900
cagaacggga tctcgaacca ggactggctg gctcatatcc aagagttgcg gaacggcagc 3960
aagaagcggc ggattaagca agattag 3987

```

```

SEQ ID NO: 64      moltype = AA length = 228
FEATURE           Location/Qualifiers
source            1..228
                 mol_type = protein

```

-continued

---

```

                                organism = Rattus norvegicus
SEQUENCE: 64
SSETGPVAVD PTLRRRIEPH EFEVFFDPRE LRKETCLLYE INWGGRHSIW RHTSQNTNKH 60
VEVNFIEKFT TERYFCPNTR CSITWFLSWS PCGECSSRAIT EFLSRYPHVT LFIYIARLYH 120
HADPRNRQGL RDLISSGVTI QIMTEQESGY CWRNRFVNYSP SNEAHWPYP HLWVRLYVLE 180
LYCIIILGLPP CLNILRRKQP QLTFFTIALQ SCHYQLRPPH ILWATGLK 228

SEQ ID NO: 65                moltype = AA length = 199
FEATURE                      Location/Qualifiers
source                       1..199
                               mol_type = protein
                               organism = Homo sapiens

SEQUENCE: 65
MEASPASGPR HLMDFPHIFTS NFNNGIGRHK TYLCYEVERL DNGTSVKMDQ HRGFLHNQAK 60
NLLCGFYGRH AELRFLDLVP SLQLDPAQIY RVTWFISWSP CFSWGCAGEV RAFLQENTHV 120
RLRIFAARIY DYDPLYKEAL QMLRDAGAQV SIMTYDEFKH CWDTFVDHQG CPPQPWDGLD 180
EHSQALSGLR RAILQNQGN 199

SEQ ID NO: 66                moltype = DNA length = 621
FEATURE                      Location/Qualifiers
source                       1..621
                               mol_type = other DNA
                               organism = Petromyzon marinus

SEQUENCE: 66
acagatgcag agtatgtgag aattcacgaa aagctggaca tctatacctt caagaagcag 60
ttctttaaca ataagaagtc tgtgagccat aggtgctacg tgctgttcga gctgaagaga 120
aggggtgaaa gaagggcatg tttttggggg tatgctgtga acaagcccca gtctggaact 180
gagagaggca ttcacgcca aatttcacg atcagaaagg tggaggaata cctgagggat 240
aacctggac agtttacaat taattggtat tctagctggt ctcctatgctg tgactgtgcc 300
gagaagatcc tggaaatgta caaccaggag ctgagaggaa atggccatac cctgaagatt 360
tgggcctgca agctgtacta tgaaaagaac gcaagaaatc agatcggact gtggaactg 420
agggataatg gtgtggggct gaacgtgatg gtgtccgagc actatcagtg ctgtagaaaag 480
atthtcattc agtcctcaca taatcagctg aacgagaata gatggctgga aaagactctg 540
aagagggctg agaagagaag gtccgaactg tcaattatga tccaggtgaa gatcctgcac 600
accactaagt cacctgcccgt g 621

SEQ ID NO: 67                moltype = AA length = 160
FEATURE                      Location/Qualifiers
source                       1..160
                               mol_type = protein
                               organism = synthetic construct

SEQUENCE: 67
FERNYDPREL RKETYLLYEI KWKSGKGLWR HWCQNNRTQH AEVYFLENIF NARRFNPSTH 60
CSITWYLSWS PCAECSQKIV DFLKEHPNVL EIYVARLYYH EDERNRQGLR DLVNSGVTIR 120
IMDLDPDNYC WKTFFVSDQGG DEDYWPGHFA PWIKQYSLKL 160

SEQ ID NO: 68                moltype = AA length = 229
FEATURE                      Location/Qualifiers
source                       1..229
                               mol_type = protein
                               organism = Rattus norvegicus

SEQUENCE: 68
MSSETGPVAV DPTLRRRIEP HEFEVFFDPR ELRKETCLLY EINWGGRHSI WRHTSQNTNK 60
HVEVNFIEKF TTERYFCPNT RCSITWFLSW SPCGECSSRAI TEFLSRYPHV TLFYIARLY 120
HHADPRNRQG LRDLISSGVT IQIMTEQESG YCWRNRFVNY PSNEAHWPYP PHLWVRLYVL 180
ELYCIIILGLP PCLNILRRKQ PQLTFFTIAL QSCHYQLRPP HILWATGLK 229

SEQ ID NO: 69                moltype = AA length = 198
FEATURE                      Location/Qualifiers
source                       1..198
                               mol_type = protein
                               organism = Homo sapiens

SEQUENCE: 69
MDSLMLNRRK FLYQFKNVRW AKGRRETYLC YVVKRRDSAT SFSLDFGYLR NKNKGHVVELL 60
FLRYISDWDL DPGRCYRVTV FTSWSPCYDC ARHVADFLRG NPNLSLRIFT ARLYFCEDRK 120
AEPEGLRRLH RAGVQIAIMT FKDYFYCWNT FVENHERTEFK AWEGLHENS VRLSRQLRRIL 180
LPLYEVDDL R DAFRTLGL 198

SEQ ID NO: 70                moltype = AA length = 197
FEATURE                      Location/Qualifiers
REGION                       1..197
                               note = Synthetic polypeptide
source                       1..197
                               mol_type = protein
                               organism = synthetic construct

SEQUENCE: 70

```

-continued

---

MDSLMLNRR E FLYQFKNVRW AKGRRETYLC YVVKRRDSAT SFSLDFGYLR NKNGCHEVELL 60  
 FLRYISDWDL DPGRCYRVTW FISWSPCYDC ARHVADFLRG NPNLSLRIFT ARLYFCEDRK 120  
 AEPEGLRRLH RAGVQIAIMT FKDYFYCWNT FVENHGRTPK AWEGLHENS SV RLSRQLRRL 180  
 LPLYEVDDL R DAFRTCT 197

SEQ ID NO: 71 moltype = AA length = 207  
 FEATURE Location/Qualifiers  
 source 1..207  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 71  
 TDAEYVRIHE KLDIYTFKKQ FSNKKKSVSH RCYVLFELKR RGERRACFWG YAVNKPQSGT 60  
 ERGIHAEIFS IRKVEEYLRD NPGQFTINWY SSWSPCADCA EKILEWYNQE LRGNHGLTKI 120  
 WVCKLYYEKN ARNQIGLWNL RDNGVGLNVM VSEHYQCCRK IFIQSSHNQL NENRWLEKTL 180  
 KRAEKRRSEL SIMFQVKILH TTKSPAV 207

SEQ ID NO: 72 moltype = AA length = 228  
 FEATURE Location/Qualifiers  
 source 1..228  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 72  
 SSKTGPVAVD PTLRRRIEPH EFEVFFDPRE LRKETCLLYE INWGGRRHSIW RHTSQNTNKH 60  
 VEVNFIEKFT TERYFCPNTR CSITWFLSWS PCGECSSRAIT EFLSRYPNVT LFIYIARLYH 120  
 LANPRNRQGL RDLISSGVTI QIMTEQESGY CWHNFPVYSP SNESHWPYPY HLWVRLYVLE 180  
 LYCIILGLPP CLNILRRKQS QLTSTPTALQ SCHYQLRPPH ILWATGLK 228

SEQ ID NO: 73 moltype = AA length = 162  
 FEATURE Location/Qualifiers  
 source 1..162  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 73  
 SFERNYDPRE LRKETYLLYE IKWKGSGKLW RHCQNNRTQ HAEVYFLENI FNARRFPST 60  
 HCSITWYLSW SPCAECQKI VDFLKEHPNV NLEIYVARLY YPENERNRQG LRDLVNSGVT 120  
 IRIMDLDPYN YCWKTFVSDQ GGDYWPVGH FAPWIKQYSL KL 162

SEQ ID NO: 74 moltype = AA length = 166  
 FEATURE Location/Qualifiers  
 source 1..166  
 mol\_type = protein  
 organism = Escherichia coli

SEQUENCE: 74  
 SEVEFSHEYW MRHALTLAKR AWDEREVPVG AVLVLNRRVI GEGWNRPIGR HDPTAHAEIM 60  
 ALRQGGVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGARDAKT GAAGSLMDVL 120  
 HHPGMNHRVE ITEGILADEC AALLSDFFRM RRQEIKAQKK AQSSTD 166

SEQ ID NO: 75 moltype = AA length = 166  
 FEATURE Location/Qualifiers  
 source 1..166  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 75  
 SEVEFSHEYW MRHALTLAKR ARDEREVPVG AVLVLNRRVI GEGWNRAIGL HDPTAHAEIM 60  
 ALRQGGVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNAKT GAAGSLMDVL 120  
 HHPGMNHRVE ITEGILADEC AALLCYFFRM PRQVFNAQKK AQSSTD 166

SEQ ID NO: 76 moltype = AA length = 166  
 FEATURE Location/Qualifiers  
 source 1..166  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 76  
 SEVEFSHEYW MRHALTLAKR AWDEREVPVG AVLVLNRRVI GEGWNRISGL HDPTAHAEIM 60  
 ALRQGGVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNAKT GAAGSLMDVL 120  
 HHPGMNHRVE ITEGILADEC AALLCYFFRM RRQVFNAQKK AQSSTD 166

SEQ ID NO: 77 moltype = AA length = 166  
 FEATURE Location/Qualifiers  
 source 1..166  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 77  
 SEVEFSHEYW MRHALTLAKR ALDEREVPVG AVLVLNRRVI GEGWNRAIGL HDPTAHAEIM 60  
 ALRQGGVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNAKT GAAGSLMDVL 120  
 HHPGMNHRVE ITEGILADEC NALLCYFFRM RRQVFNAQKK AQSSTD 166



-continued

```

SEQ ID NO: 78      moltype = AA length = 166
FEATURE           Location/Qualifiers
source           1..166
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 78
SEVEFSHEYW MRHALTLAKR ALDEREVPVG AVLVLNRRVI GEGWNRAIGL HDPTAHAEIM 60
ALRQGGLVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNAKT GAAGSLMDVL 120
HYPGMNHRVE ITEGILADEC NALLCYFFRM PRQVFNAQKK AQSSTD 166

SEQ ID NO: 79      moltype = AA length = 1763
FEATURE           Location/Qualifiers
source           1..1763
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 79
SEVEFSHEYW MRHALTLAKR AWDEREVPVG AVLVHNNRVI GEGWNRPIGR HDPTAHAEIM 60
ALRQGGLVMQ NYRLIDATLY VTLEPCVMCA GAMIHSRIGR VVFGARDAKT GAAGSLMDVL 120
HHPGMNHRVE ITEGILADEC AALLSDFFRM RQEIKAQKK AQSSTDSGGS SGGSSGSETP 180
GTSESATPES SGGSSGSSSE VEFSEYWMR HALTLAKRAR DEREVPVGAV LVLNRRVIGE 240
GWNRAIGLHD PTAHAEMAL RQGGLVMQNY RLIDATLYVT FEPCEMCA GAMIHSRIGRV 300
FGVRNAKTGA AGSLMDVLHY PGMNHRVEIT EGILADECAA LLCYFFRMPR QVFNAQKKAQ 360
SSTDSSGSSG SSSGSETPGT SESATPESG SSSGSDKKY SIGLAIGTNS VGWAVITDEY 420
KVPSKKFKVL GNTDRHSIKK NLIGALLFDS GETAEATRLK RTARRRYTRR KNRCYLQEI 480
FSNEMAKVDD SFFHRLEESF LVEEDKKHER HPIFGNIVDE VAYHEKYPTI YHLRKKLVDS 540
TDKADRLIY LALAHMIKFR GHFLIEGDLN PDNSDVDFKL IQLVQTYNQL FEENPINASG 600
VDKAILSAR LSKSRRLENL IAQLPGEKKN GLFGNLIALS LGLTPNPKSN FDLAEDAQLQ 660
LSKDTYDDDL DNLLAQIGDQ YADLFLAAKN LSDAILLSDI LRVNTEITKA PLSASMIKRY 720
DEHHQDLTLL KALVRQQLPE KYKEIFFDQS KNGYAGYIDG GASQEEFYKF IKPILEKMDG 780
TEELLVKLNR EDLLRKQRTF DNGSIPHQIH LGELHAILRR QEDFYPLKD NREKIEKILT 840
FRIPYVVGPL ARGNSRFAMW TRKSEETITP WNFEEVVDKG ASAQSFIERM TNFDKNLPNE 900
KVLPHKSLLY EYFTVYNELT KVKYVTEGMR KPAPLSGQEK KAIVDLLFKT NRKVTVKQLK 960
EDYFKKIECF DSVETISGVED RFNASLGTYH DLLKIKDKD FLDNEENEDI LEDIVLTLTL 1020
FEDREMIER LKTYAHLFDD KVMQKLRKR YTGWRGRLSRK LINGIRDKQS GKTILDPLKS 1080
DGFANRNFPMQ LIHDDSLTFK EDIQKAQVSG QGDSLHEHIA NLAGSPAICK GILQTVKVV 1140
ELVKVMGRHK PENIVIMAR ENQTTQKQK NSRERMKRIE EGIKELGSQI LKEHPVENTQ 1200
LQNEKLYLYY LQNGRDMYVD QELDINRLSD YVDVHIVPQS FLKDDSIDNK VLTRSDKNRG 1260
KSDNVPSSEV VKLMKNYWRQ LLNAKLITQR KFDNLTKAER GGLSELDKAG FIKRQLVETR 1320
QITKHVAQIL DSRMNTKYRE NDKLIREVKV ITLKSKLVSD FRKDFQFYKV REINNYHHAH 1380
DAYLNAVVG TALIKKYKPLE SEFVYGDYKV YDVRKMIAS EQEIGKATAK YFFYSNIMNF 1440
FKTEITLANG EIKRPLIET NGETGEIVWD KGRDFATVRK VLSMPQVNI V KKTVEVQTGGF 1500
SKESILPKRN SKDLIARKND WDPKYGQGG SPTVAYSVLV VAKVEKQKSK KLSKVKELLG 1560
ITIMERSFFE KNPIDFLEAK GYKEVKKDLI IKLPKYSLFE LENGKRMLA SAGELQKGN 1620
LALPSKYVNF KYTLASHYKEL KSPEDNEQK QLFVEQHKHY LDEIIEQISE FSKRVILADA 1680
NLDKVLSAYN KHRDKPIREQ AENIIHLFTL TNLGAPAAFK YPDTTIDRRK YTSKTEVLDA 1740
TLIHQSITGL YETRIDLSQL GGD 1763

SEQ ID NO: 80      moltype = AA length = 1565
FEATURE           Location/Qualifiers
source           1..1565
                 mol_type = protein
                 organism = synthetic construct

SEQUENCE: 80
SEVEFSHEYW MRHALTLAKR ARDEREVPVG AVLVLNRRVI GEGWNRAIGL HDPTAHAEIM 60
ALRQGGLVMQ NYRLIDATLY VTFEPCVMCA GAMIHSRIGR VVFGVRNSKR GAAGSLMNVL 120
NYPGMNHRVE ITEGILADEC AALLCDFYRM PRQVFNAQKK AQSINSGGS SGGSSGSETP 180
GTSESATPES SGGSSGSSDK KYSIGLAIGT NSVGWAVITD EYKVPKFKFK VLGNTRHSI 240
KKNLIGALLF DSGETAETAR LKRTARRRYT RKNRCICYLQ EIFSNEMAKV DDSFFHRLEE 300
SFLVEEDKKH ERHPIFGNIV DEVAYHEKYP TIYHLRKKLV DSTDKADLRL IYLALAHMIK 360
FRGHFLIEGD LNPDNSVDVK LFIQLVQTYN QLFEEENPINA SGVDKAILS ARLSKSRLE 420
NLIAQLPGEK KNGLFGNLIA LSLGLTPNFK SNFDLAEDAK LQLSKDTYDD DLNLLAQIG 480
DQYADLFLAA KNLSDAILLS DILRVNTEIT KAPLSASMIK RYDEHHQDLT LLKALVRQQL 540
PEKYKEIFFD QSKNGYAGYI DGGASQEEFY KFIKPILEKM DGTBELLVKL NREDLLRKQR 600
TFDNGSIPHQ IHLGELHAIL RRQEDFYFPL KDNREKIEKI LTFRIPYVYG PLARGNSRFA 660
WMTRKSEETI TPWNFEEVVD KGASAQSFI E RMTNFDKNLP NEKVLPHKSL LYEFYTYNE 720
LTKVKYVTEG MRKPAPLSGE QKKAIVDLLF KTNRKVTVKQ LKEDYFKKIE CDFSVEISGV 780
EDRFNASLGT YHLLKIKID KDFLDNEENE DILEDIVLTL TLFEDREMI ERLKTYAHLF 840
DDKVMQKLR RRYTGWRGRLS RKLINGIRDK QSGKTILDPL KSDGFANRNF MQLIHDDSLT 900
FKEDIQKAQV SQGQDSLHEH IANLAGSPA I KKGILQTVKV VDELVKVMGR HKPENIVIM 960
ARENQTTQKQ KNSRERMRKH IEBGIKELGS QILKEHPVEN TQLQNEKLYL YYLQNGRDMY 1020
VDQELDINRL SDYVDVHIVP QSFLKDDSID NKVLTRSDKN RGKSDNVPS E EVVKMKQNYW 1080
RQLLNAKLIT QRKFDNLTKA ERGGLSELDK AGFIKRLVE TRQITKHVAQ ILDSRMNTKY 1140
DENDKLIREV KVI TLKSKLV SDFRKFQFY KVREINNYHH AHDAYLNAV GTALIKKYPK 1200
LESEFVYGDY KYVDVRKMLA KSBQETGKAT AKYFFYSNIM NPFKTEITLA NGEIRKPLI 1260
ETNGETGEIV WDKGRDFATV RKVLSMPQVN IVKKEVQQTG GFSKESILPK RNSDKLIARK 1320

```

-continued

KDWDPKKYGG	FDSPTVAYSV	LVVAKVEKGG	SKKLSVKEL	LGITIMERSS	FEKNPIDFLE	1380
AKGYKEVKKD	LIIKLPKYSL	FELNGRKRK	LASAGELQKG	NELALPSKYV	NFLYLASHYE	1440
KLKGSPEPNE	QKQLFVEQHK	HYLDEIIEQI	SEFSKRVIDA	DANLDKVLSA	YNKHRDKPIR	1500
EQAENIIHLF	TLTNLGAAPAA	FKYFDTTIDR	KRYTSTKEVL	DATLIHQISIT	GLYETRIDL	1560
QLGGD						1565

SEQ ID NO: 81                   moltype = AA   length = 1565  
 FEATURE                        Location/Qualifiers  
 source                         1..1565  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 81

SEVEFSHEYW	MRHALTLAKR	ARDEREVPVG	AVLVLNNRVI	GEGWNRAIGL	HDPTAHAEIM	60
ALRQGGGLVMQ	NYRLYDATLY	STFEPVCVMA	GAMIHSRIGR	VVFGVRNAKT	GAAGSLMDVL	120
HHPGMNHRVE	ITEGILADEC	AALLCRFFRM	PRRVFNAQKK	AQSSTDSGGS	SGGSSGSETP	180
GTSESATPES	SGGSSGSDK	KYSIGLAIGT	NSVGWAVITD	EYKVPKPKFK	VLGNTDRHSI	240
KKNLIGALLF	DSGETAEATR	LKRTARRRYT	RRKNRICYLQ	EIFSNEMAKV	DDSFHRLLEE	300
SFLVEEDKKH	ERHPIFGNIV	DEVAYHEKYP	TIYHLRKKLV	DSTDKADLRL	IYLALAHMIK	360
FRGHFLIEGD	LNPDNSDVDK	LFIQLVQTYN	QLFEENPINA	SGVDAKALS	ARLSKSRRL	420
NLIAQLPGEK	KNLGFNLIA	LSLGLTPNFK	SNFDLAEDAK	LQLSKDITYDD	DLNLLAQIG	480
DQYADLFLAA	KNLSDAILLS	DILRVNTEIT	KAPLSASMIK	RYDEHHQDLT	LLKALVRQQL	540
PEKYKEIFFD	QSKNGYAGYI	DGGASQEEFY	KFIKPILEKM	DGTEELVKL	NREDLLRKQR	600
TFDNGSIPHQ	IHLGELHAIL	RRQEDFYPPF	KDNREKIEKI	LTFRIPYYVG	PLARGNSRFA	660
WMTRKSEETI	TPWNFEVVD	KGASAQSFIE	RMTNFDKNLP	NEKVLPKHSL	LYEYFTVYNE	720
LTKVKYVTEG	MRKPAFLSGE	QKKAIVDLLE	KTRNRKVTVKQ	LKEDYFKKIE	CFDSVEISGV	780
EDRFNASLGT	YHDLKIIKD	KDFLDNEENE	DILEDIVLTL	TLFEDREMIE	ERLKYAHLP	840
DDKVMKQLKR	RRYTGWRSL	RKLLINGIRDK	QSGKTILDFL	KSDGFANRNF	MQLIHDDSLT	900
FKEDIQKQV	SGQDLSLHEH	IANLAGSPAI	KKGILQTVKV	VDELVKVMGR	HKPENIVIEI	960
ARENQTTQKG	QKNSRERMR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	1020
VDQELDINRL	SDYDVIDHVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKMKKNYW	1080
RQLLNAKLIT	QRKFDNLTKA	ERGGLSLKD	AGFIKRQLVE	TRQITKHVAQ	ILDSRMNTKY	1140
DENDKLIREV	KVITLKSCLV	SDPRKDFQFY	KVREINNYHH	AHDAYLNAV	GTALIKKYPK	1200
LESEFVYGDY	KVYDVRKMLA	KSQEIGKAT	AKYFPYSNIM	NFPKTEITLA	NGEIRKRPLI	1260
ETNGETGIV	WDKGRDFATV	RKVLSPQVN	IVKKTVEVQTG	GFSKESILPK	RNSDKLIARK	1320
KDWDPKKYGG	FDSPTVAYSV	LVVAKVEKGG	SKKLSVKEL	LGITIMERSS	FEKNPIDFLE	1380
AKGYKEVKKD	LIIKLPKYSL	FELNGRKRK	LASAGELQKG	NELALPSKYV	NFLYLASHYE	1440
KLKGSPEPNE	QKQLFVEQHK	HYLDEIIEQI	SEFSKRVIDA	DANLDKVLSA	YNKHRDKPIR	1500
EQAENIIHLF	TLTNLGAAPAA	FKYFDTTIDR	KRYTSTKEVL	DATLIHQISIT	GLYETRIDL	1560
QLGGD						1565

SEQ ID NO: 82                   moltype = AA   length = 364  
 FEATURE                        Location/Qualifiers  
 source                         1..364  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 82

SEVEFSHEYW	MRHALTLAKR	AWDEREVPVG	AVLVHNNRVI	GEGWNRPIGR	HDPTAHAEIM	60
ALRQGGGLVMQ	NYRLIDATLY	VTLEPCVMA	GAMIHSRIGR	VVFGARDAKT	GAAGSLMDVL	120
HHPGMNHRVE	ITEGILADEC	AALLSDFFRM	RRQEIKAQKK	AQSSTDSGGS	SGGSSGSETP	180
GTSESATPES	SGGSSGSSSE	VEFSHEYWMR	HALTLAKRAR	DEREVPVGAV	LVLNNRVI	240
GWNRAIGLHD	PTAHAEIMAL	RQGGGLVMQNY	RLIDATLYVT	FEPCVMCAGA	MIHSRIGRVV	300
FGVRNAKTGA	AGSLMDVLHY	PGMNHVEIT	EGILADECAA	LLCYFFRMPR	QVFNAQKKAQ	360
SSTD						364

SEQ ID NO: 83                   moltype = AA   length = 167  
 FEATURE                        Location/Qualifiers  
 source                         1..167  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 83

MSEVEFSHEY	WHRHALTLAK	RARDEREVPV	GAVLVLNNRV	IGEGWNRAIG	LHDPTAHAEI	60
MALRQGGGLVM	QNYRLIDATL	YSTFEPVCVM	AGAMIHSRIG	RVVFGVRNAK	TGAAGSLMDV	120
LHHPGMNHRV	EITEGILADE	CAALLCRFFR	MPRRVFNAQK	KAQSST		167

SEQ ID NO: 84                   moltype = AA   length = 167  
 FEATURE                        Location/Qualifiers  
 source                         1..167  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 84

MSEVEFSHEY	WHRHALTLAK	RARDEREVPV	GAVLVLNNRV	IGEGWNRAIG	LHDPTAHAEI	60
MALRQGGGLVM	QNYRLIDATL	YVTFEPCVM	AGAMIHSRIG	RVVFGVRNSK	RGAAGSLMNV	120
LNYPGMNHRV	EITEGILADE	CAALLCDFYR	MQRQVFNAQK	KAQSSIN		167

SEQ ID NO: 85                   moltype = AA   length = 83  
 FEATURE                        Location/Qualifiers

-continued

---

source 1..83  
mol\_type = protein  
note = Bacillus phage AR9  
organism = unidentified

SEQUENCE: 85  
TNLSDIIEKE TGKQLVIQES ILMPEEVEE VIGNKPESDI LVHTAYDEST DENVMLLTSD 60  
APEYKPWALV IQDSNGENKI KML 83

SEQ ID NO: 86 moltype = DNA length = 66  
FEATURE Location/Qualifiers  
source 1..66  
mol\_type = other DNA  
organism = Saccharomyces bayanus

SEQUENCE: 86  
ttcttgctg acttatagat cgctacgta tttcaat ttt gaaaatctga gtctctggag 60  
tgcgga 66

SEQ ID NO: 87 moltype = AA length = 605  
FEATURE Location/Qualifiers  
source 1..605  
mol\_type = protein  
organism = Homo sapiens

SEQUENCE: 87  
MSGWESYYKT EGDEEAEEEQ EENLEASGDY KYSGRDSLIF LVDASKAMFE SQSEDELTPF 60  
DMSIQCIQSV YISKIISDR DLLAWPYGTE KDKNSVNFKI YVLQELDNPQ AKRILELDQF 120  
KGQQGQKRFQ DMMGHGSDYS LSEVLWVCAN LPSDVQFKMS HKRIMLFTNE DNPNGNDSAK 180  
ASRARTKAGD LRDTGIFLDL HLKPKGGFDI SLFYRDIISI AEDEDLRVHF EESSKLEDDL 240  
RKVRAKETRK RALSRLKLLK NKDIVISVGI YNLVQKALKP PPIKLYRETN EPVTKTRTF 300  
NTSTGGLLLP SDTKRSQIYG SRQIILEKEE TEELKRFDDP GLMLMGFKPL VLLKHHHYLR 360  
PSLFVYPEES LVIGSSTLFS ALLIKCLEKE VAALCRYTPR RNIPYPFVAL VPQEEELDDQ 420  
KIQVTPPGFQ LVFLPFADDK RKMPTTEKIM ATPEQVGKMK AIVEKLRFTY RSDSFENPVL 480  
QQHFRNLEAL ALDLMEPEQA VDLTLPKVEA MNKRLGSLVD EFKELVYPPD YNPEGKVTKR 540  
KHDNEGSGSK RPKVEYSEEE LKTHISKGTL GKFTVPLKEA CRAYGLKSGL KQELLEALT 600  
KHFQD 605

SEQ ID NO: 88 moltype = AA length = 482  
FEATURE Location/Qualifiers  
REGION 1..482  
note = Synthetic polypeptide  
source 1..482  
mol\_type = protein  
organism = synthetic construct

SEQUENCE: 88  
MVRSGNKAAM LCMVDVGFTMS NSIPGIESPF EQAKKVITMF VQRQVFAENK DEIALVLFGT 60  
DGTDNPLSGG DQYQNTVHR HMLPDPFDLL EDIESKIQPG SQQADFLDAL IVSMDVIQHE 120  
TIGKKFEKRH IEIFDLSSR FSKSQLDIII HSLKKCDISE RHSIHWPCRL TIGSNLSIRI 180  
AAYKSILQER VKKTTWDAKT LKKEDIQKET VYCLNDDDET EVLKEDIQG FRYGSDIVPF 240  
SKVDEEQMKY KSEGKCFSVL GPKSSQVQR RFFMGQVQLK VFAARDDEAA AVALSSLIHA 300  
LDDLDIWAIV RYAYDKRANP QGVVAFPHIK HNYECLVYVQ LPFMEDLRQY MFSCLKNSKK 360  
YAPTEAQLNA VDALIDMSML AKKDEKDTL EDLFPPTKIP NPRFQRLFOC LLHRALHPRE 420  
PLPPIQQHIW NMLNPPAEVT TKSQIPLSKI KTLFPLIEAK KKDQVTAQEI FQDNHEDGPT 480  
AK 482

SEQ ID NO: 89 moltype = DNA length = 10  
FEATURE Location/Qualifiers  
source 1..10  
mol\_type = other DNA  
organism = Methanobacterium thermoautotrophicum

SEQUENCE: 89  
aatttttggga 10

SEQ ID NO: 90 moltype = AA length = 83  
FEATURE Location/Qualifiers  
source 1..83  
mol\_type = protein  
organism = Methanobacterium thermoautotrophicum

SEQUENCE: 90  
GSVIDVSSQR VNVQRPLDAL GNSLNSPVII KLKGDREPRG VLKSFDLHMN LVLNDAEELE 60  
DGEVTRRLGT VLIRGDNIVY ISP 83

SEQ ID NO: 91 moltype = DNA length = 25  
FEATURE Location/Qualifiers  
source 1..25  
mol\_type = other DNA  
organism = Emesvirus zinderi

SEQUENCE: 91

-continued

---

gcgcacatga ggatcaccca tgtgc 25

SEQ ID NO: 92 moltype = AA length = 116  
 FEATURE Location/Qualifiers  
 source 1..116  
 mol\_type = protein  
 organism = Emesvirus zinderi

SEQUENCE: 92  
 MASNFTQFVL VDNNGTGDVT VAPSNFANGI AEISSNSRSQ AYKVTCSVRQ SSAQNRKYTI 60  
 KVEVPKGAWR SYLNMELTIP IFATNSDCEL IVKAMQGLLK DGNPIPSAIA ANSGIY 116

SEQ ID NO: 93 moltype = DNA length = 26  
 FEATURE Location/Qualifiers  
 source 1..26  
 mol\_type = other DNA  
 organism = Pepevirus rubrum

SEQUENCE: 93  
 ataaggagtt tatatggaaa ccctta 26

SEQ ID NO: 94 moltype = AA length = 127  
 FEATURE Location/Qualifiers  
 source 1..127  
 mol\_type = protein  
 organism = Pepevirus rubrum

SEQUENCE: 94  
 MSKTIVLSVG EATRTEIQ STADRQIFEE KVGPLVGRLR LTASLRQNGA KTAYRVNLKL 60  
 DQADWDCSTS VCGELPKVRY TQVWSDVTI VANSTEASRK SLYDLTKSLV ATSQVEDLVV 120  
 NLVPLGR 127

SEQ ID NO: 95 moltype = DNA length = 19  
 FEATURE Location/Qualifiers  
 source 1..19  
 mol\_type = other DNA  
 organism = Shigella flexneri

SEQUENCE: 95  
 ctgaatgcct gcgagcatc 19

SEQ ID NO: 96 moltype = AA length = 62  
 FEATURE Location/Qualifiers  
 source 1..62  
 mol\_type = protein  
 organism = Shigella flexneri

SEQUENCE: 96  
 MKSIRCKNKN KLLFKADSPD HIEIRCPCK RHIIMLNACE HPTEKHCGKR EKITHSDETV 60  
 RY 62

SEQ ID NO: 97 moltype = AA length = 24  
 FEATURE Location/Qualifiers  
 source 1..24  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 97  
 BELLSKNYHL ENEVARLKKG SGSG 24

SEQ ID NO: 98 moltype = AA length = 241  
 FEATURE Location/Qualifiers  
 source 1..241  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 98  
 EEELLSKNYH LENEVARLKK GSGSGEELLS KNYHLENEVA RLKKGSGSGE ELLSKNYHLE 60  
 NEVARLKKGS GSGEELLSKN YHLENEVARL KKGSGSGEEL LSKNYHLENE VARLKKGSGS 120  
 GEELLSKNYH LENEVARLKK GSGSGEELLS KNYHLENEVA RLKKGSGSGE ELLSKNYHLE 180  
 NEVARLKKGS GSGEELLSKN YHLENEVARL KKGSGSGEEL LSKNYHLENE VARLKKGSGS 240  
 G 241

SEQ ID NO: 99 moltype = AA length = 277  
 FEATURE Location/Qualifiers  
 source 1..277  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 99  
 MGPDIIVMTQS PSSLSASVGD RVTITCRSST GAVTTSNYAS WVQEKPGKLF KGLIGGTNNR 60  
 APGVPSRFSG SLIGDKATLT ISSLQPEDFA TYFCALWYSN HWVFGQGTKV ELKRGGGGSG 120  
 GGGSGGGSS GGGSEVKLLE SGGGLVQPGG SLKLSCAVSG FSLTDYGVNW VRQAPGRGLE 180  
 WIGVIWGDGI TDYNSALKDR FIISKDNGKN TVYLQMSKVR SDDTALYYCV TGLFDYWGQG 240

-continued

---

 TLVTVSSYPY DVPDYAGGGG GSGGGGSGGG GSGGGGS 277

SEQ ID NO: 100 moltype = AA length = 1030  
 FEATURE Location/Qualifiers  
 source 1..1030  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 100  
 MKRTADGSEF ESPKPKRVRT LNIIDEHRLH ETSKEPDVSL GSTWLSDFPQ AWAETGGMGL 60  
 AVRQAPLIIP LKATSTPVS I KQYPMSEQEAR LGIKPHIQRL LDQGILVPCQ SPWNTPLLPV 120  
 KKP GTNDYRP VQDLREV NKR VEDIHPTVPN PYNLLSGLPP SHQWYTVL DL KDAFFCLR LH 180  
 PTSQPLFAFE WRDPEMGI SG QLTWTRL PQG FKN SPTLFNE ALHRDLADFR IQHPDLILLQ 240  
 YVDDLLLAAT SELDCQQGTR ALLQTLGNLG YRASAKKAI CQKQVKYLG Y LLKEGQRWLT 300  
 EARKETVMGQ PTPKTPRQLR EFLGKAGFCR LFIPGFAEMA APLYPLTKPG TLFNWGPDQQ 360  
 KAYQEI KQAL LTAPALGLPD LTKPFELFVD EKQGYAKGVL TQKLGWRRP VAYLSKKLDP 420  
 VAAGWPPCLR MVAIAVLT K DAGKLTMGQP LVILAPHAVE ALVKQPPDRW LSNARMTHYQ 480  
 ALLLDTDRVQ FGPVVALNPA TLLPLPEEGL QHNCLDILAE AHGTRPDLTD QPLPDADHTW 540  
 YTDGSSLLQE GQRKAGAAVT TETEVIWAKA LPAGTSAQRA ELIALTQALK MAEGKKNLVY 600  
 TDSRYAFATA HIHGEIYRRR GWLTSEKKEI KNKDEILALL KALFLPKRRLS I IHCPGHQKG 660  
 HSAEARGNRM ADQAARAAI TETPDSTLL IENSSPNSRL INSGGSSGGS SGSETPGTSE 720  
 SATPSSGGS SGGSSKLEKF TNCYLSKTL RFKAI PVGKT QENIDNKRL VEDEKRAEDY 780  
 KGVKKLLDRY YLSFINDVLK SIKLKNLNNY ISLFRKTRT EKENKELENL EINLRKEIAK 840  
 AFKGN EGYKS LFKKDIETI LPEFLDDKDE IALVNSFNFG TTAFTGFFDN RENMFSEEA K 900  
 STSIAFRCLS YETBILTVEY GLLPIGKIVE KRIECTVYSV DNNGNIYTQP VAQWHDGRGEQ 960  
 EVFEYCLEDDG SLIRATKDHK FMTVDGQMLP IDEIFERELD LMRVDNL PNS GSKRTADGS 1020  
 EFEPKPKRKV 1030

SEQ ID NO: 101 moltype = AA length = 1197  
 FEATURE Location/Qualifiers  
 source 1..1197  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 101  
 MKRTADGSEF ESPKPKR KVI KIATRKYLGK QNVYDIGVGE PHNFALKNGF IASNCINENL 60  
 TRYISNMDIF EKVD AIFDKH EVQEI KEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 120  
 IGGVTESEGE KIKGLNEYIN LYNQKTQKQL PKFKPLYKQV LSDRESLSFY GEGYTSDEEV 180  
 LEVFRNTLNK NSEIFSSIKK LEKLFKNFDE YSSAGIFVKV GPAISTISKD IFGEWNVIRD 240  
 KWNAEYDDIH LKKKAVVTEK YEDDRRKSFK KIGSFSLEQL QEYADADLSV VEKLEKIIQ 300  
 KVDEIYKYVG SSEKLPADF VLEKSLKKN AVVAIMKDLL DSVKSFENYI KAFFGEGKET 360  
 NRDESFGDF VLAYDILLKV DHIYDAIRNY VTQKPYSKDK FKL YFQNPQF MGGWMDKET 420  
 DYRATILRYG SKYYLAIMDK KYAKCLQKID KDDVNGNYEK INYKLLPGPN KMLPKVFFSK 480  
 KWMA YNPSE DIQIYKNGT FFKGDMFNLM DCHKLIDPFK DSISRYPKWS NAYDFNFSET 540  
 EKYKDIAGFY REVEEQGYK VSEFASAKKEV DLKVEEGKLY MFQIYNKDFS DKSHGTPNLH 600  
 TMYFKLLPDE NNHGQIRLSG GAELFMRRAS LKKEELV VHP ANSPIANKNP DNPKKT T TLS 660  
 YDVKDKRFS EDQYELHPI ANKCPKNIF KINTEVRVLL KHDDNPYVIG IDRGERNLLY 720  
 IVVVDGKGN I VEQYSLNEII NNFNGIRIKT DYHSLDDKKE KERFEARQNW TSIENIKELK 780  
 AGYISQV VHK ICELV EKYDA VIALEDLNSG FKNSRVKVEK QVYQKFEKML IDKLN YMVDK 840  
 KSNPCATGGA LKGQI TNKF ESFKSMSTQN GFIFYIPAWL TSKIDPSTGF VNLKTKTYTS 900  
 IADSKKFIS DRIMYVPEE DLPEFALDYK NFRSDADYI KKWKLYSYGN RIRIFRNPCK 960  
 NNVPDWEEVC LTSAYKELFN KYGINYQQGD IRALLCEQSD KAFYSSFMAL MSLMLQMRNS 1020  
 ITGR TDVDFL ISPVKNSDGI FYDSRNYEAQ ENAILPKNAD ANGANIARK VLWAIQFQFK 1080  
 ADEKLDKVK IAI SNKEWLE YAQTSVKHSG GSSGGSSGSE TPGTSESAT ESSGGSSGGS 1140  
 ALDFLSRLPL PPPVSPICTF VSPAQAQAFQ PPRSCGSGGS KRTADGSEFE PKKPKRKV 1197

SEQ ID NO: 102 moltype = AA length = 1166  
 FEATURE Location/Qualifiers  
 source 1..1166  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 102  
 MKRTADGSEF ESPKPKRVRT LNIIDEHRLH ETSKEPDVSL GSTWLSDFPQ AWAETGGMGL 60  
 AVRQAPLIIP LKATSTPVS I KQYPMSEQEAR LGIKPHIQRL LDQGILVPCQ SPWNTPLLPV 120  
 KKP GTNDYRP VQDLREV NKR VEDIHPTVPN PYNLLSGLPP SHQWYTVL DL KDAFFCLR LH 180  
 PTSQPLFAFE WRDPEMGI SG QLTWTRL PQG FKN SPTLFNE ALHRDLADFR IQHPDLILLQ 240  
 YVDDLLLAAT SELDCQQGTR ALLQTLGNLG YRASAKKAI CQKQVKYLG Y LLKEGQRWLT 300  
 EARKETVMGQ PTPKTPRQLR EFLGKAGFCR LFIPGFAEMA APLYPLTKPG TLFNWGPDQQ 360  
 KAYQEI KQAL LTAPALGLPD LTKPFELFVD EKQGYAKGVL TQKLGWRRP VAYLSKKLDP 420  
 VAAGWPPCLR MVAIAVLT K DAGKLTMGQP LVILAPHAVE ALVKQPPDRW LSNARMTHYQ 480  
 ALLLDTDRVQ FGPVVALNPA TLLPLPEEGL QHNCLDILAE AHGTRPDLTD QPLPDADHTW 540  
 YTDGSSLLQE GQRKAGAAVT TETEVIWAKA LPAGTSAQRA ELIALTQALK MAEGKKNLVY 600  
 TDSRYAFATA HIHGEIYRRR GWLTSEKKEI KNKDEILALL KALFLPKRRLS I IHCPGHQKG 660  
 HSAEARGNRM ADQAARAAI TETPDSTLL IENSSPNSRL INSGGSSGGS SGSETPGTSE 720  
 SATPSSGGS SGGSSKLEKF TNCYLSKTL RFKAI PVGKT QENIDNKRL VEDEKRAEDY 780  
 KGVKKLLDRY YLSFINDVLK SIKLKNLNNY ISLFRKTRT EKENKELENL EINLRKEIAK 840  
 AFKGN EGYKS LFKKDIETI LPEFLDDKDE IALVNSFNFG TTAFTGFFDN RENMFSEEA K 900  
 STSIAFRCLN ENLTRYISNM DIFEKVD AIF DKHEVQEIKE KILNSDYDVE DFFEGEFFNF 960

-continued

VLTQEGIDVY	NAIIGGFVTE	SGEKIKGLNE	YINLYNQTK	QKLPKFKPLY	KQVLSDRSL	1020
SFYGEGYTS	EEVLEVRNT	LNKCLSYTE	ILTVYGLLP	IGKIVEKRIE	CTVYSVDNNG	1080
NIYTQVPAQW	HDRGEQVFE	YCLEDGSLIR	ATKDHKFMVT	DGQMLPIDEI	FERELDLMRV	1140
DNLPSGGSK	RTADGSEFEP	KKRKKV				1166

SEQ ID NO: 103           moltype = AA   length = 1063  
 FEATURE                Location/Qualifiers  
 source                 1..1063  
                       mol\_type = protein  
                       organism = synthetic construct

SEQUENCE: 103

MKRTADGSEF	ESPKKKRVI	KIATRKYLGK	QNVYDIGVGE	PHNFALKNGF	IASNCANSEI	60
FSSIKKLEKL	FKNFDEYSSA	GIPVKNPAPAI	STISKDIFGE	WNVIRDKWNA	EYDDIHLKKK	120
AVVTEKYEDD	RRKSFKKIGS	FSLEQLQEYA	DADLSVVEKL	KEIIIQKQVDE	IYKVGYSSEK	180
LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	SFENYIKAFF	GEGKETNRDE	SFYGDVFLAY	240
DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	DKDKETDYRA	TILRYGSKYY	300
LAIMDKKYAK	CLQKIDKDDV	NGNYEKINYK	LLPGPNKMLP	KVFFSKKQMA	YYNPSEDIQK	360
IYKNGTFKKG	DMPNLDCHK	LIDFPKDSIS	RYPKWSNAYD	FNFSETEKYK	DIAGFYREVE	420
EQGYKVSFES	ASKKEVDKLV	EEGKLYMFQI	YNKDFSDKSH	GTPNLHTMYF	KLLFDENNHG	480
QIRLSGGAE	FMRRASLKE	ELVVHPANSP	IANKNPDNPK	KTTTLYSDVY	KDKRFSEDOY	540
ELHIPIAANK	CPKNIFKINT	EVVRLKHDD	NPYVIGIDRG	ERNLLYIVVV	DGKGNIVEQY	600
SLNEIINNFN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	660
VEKYDAVIAL	EDLNSGFKNS	RVKVEKQVYQ	KFEKMLIDKL	NYMVDKKSNP	CATGGALKGY	720
QITNKFESFK	SMSQNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTKYTSIADS	KKFISSFDRI	780
MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKNNVVF	DWEEVCLTSA	840
YKELFNKYGI	NYQQGDIAL	LCEQSDKAFY	SSFMALMSLM	LQMRNSITGR	TDVDFLISPV	900
KNSDGI FYDS	RNYEAQENAI	LPNADANGA	YNIARKVLWA	IGQPKKAED	KLDKVKLAIS	960
NKEWLEYAQT	SVKHSGGSSG	GSSGSETPGT	SESATPESSG	GSSGGSALDF	LSRPLPLPPV	1020
SPICTFVSPA	AQKAFQPPRS	CGSGGSKRTA	DGSEFEPKKK	RKV		1063

SEQ ID NO: 104           moltype = AA   length = 1262  
 FEATURE                Location/Qualifiers  
 source                 1..1262  
                       mol\_type = protein  
                       organism = synthetic construct

SEQUENCE: 104

MKRTADGSEF	ESPKKKRVT	LNIIDEHRLH	ETSKEPDVSL	GSTWLSDFPQ	AWAETGGMGL	60
AVRQAPLIIP	LKATSTPVS	KQYPMSQEAR	LGIKPHIQRL	LDQGILVPCQ	SPWNTPLLPV	120
KKPGTNDYRP	VQDLREVNKR	VEDIHTVPN	PYNLLSGLFP	SHQWYTVLDD	KDAFFCLRHL	180
PTSQPLFAFE	WRDPEMISG	QLTWTRLPQG	FKNSPTLFNE	ALHRDLADFR	IQHPDLILLQ	240
YVDDLLLAAT	SELDCQOQTR	ALLQTLGNLG	YRASAKKQI	CQKQVKYLYG	LLKEGQRWLT	300
BARKETVMGQ	PTPKTPRQLR	EPLGKAGFCR	LFIGPFAEMA	APLYPLTKPG	TLFNWGPDDQ	360
KAYQEIQAAL	LTAPALGLPD	LTKPFELFVD	EKQGYAKGVL	TQKLGWRRR	VAYLSKLLDP	420
VAAGWPPCLR	MVAIAVLT	DAGKLTMGQP	LVILAPHAVE	ALVKQPPDRW	LSNARMTHYQ	480
ALLLDTDRVQ	FGPVVALNPA	TLPLPEEGL	QHNCLDILAE	AHGTRPDLTD	QPLPADADHTW	540
YTDGSSLLQE	GQRKAGAAVT	TEVEIWAKA	LPAGTSAQRA	ELIALTQALK	MAEGKKNVY	600
TDSRYAFATA	HIHGEIYRR	GWLTSSEKKEI	KNKDEILALL	KALFLPKRLS	IHCPCGHQKG	660
HSAEARGNRM	ADQAARAAI	TETPDTSTLL	IENSSPNSRL	INSGSSGSGS	SGSETPGTSE	720
SATPESSGGS	SGSSKLEKF	TNCYLSKTL	RFKAI PVGKT	QENIDNKRLL	VEDEKRAEDY	780
KGVKKLLDRY	YLSFINDVLH	SIKLNLNLY	ISLFRKTRT	EKENKELENL	EINLRKEIAK	840
AFKNGEYKNS	LFKKDIETI	LPEFLDDKDE	IALVNSPFGF	TTAFTGPFDD	RENMFSEEA	900
STSIAPRCIN	ENLTRYISNM	DIFEKVDIAIF	DKHEVQEIKE	KILNSDYDVE	DFPEGEFFNF	960
VLTQEGIDVY	NAIIGGFVTE	SGEKIKGLNE	YINLYNQTK	QKLPKFKPLY	KQVLSDRSL	1020
SFYGEGYTS	EEVLEVRNT	LNKNSEIFSS	IKKLEKLPKN	FDEYSSAGIF	VKNPASTI	1080
SKDIFGEWNV	IRDKWNAEYD	DIHLKKKAVV	TEKYEDDRK	SFKKIGSFSL	EQLQVEYADAC	1140
LSYETEILTV	EYGLLPIGKI	VEKRIECTVY	SVDNNGNIYT	QVPAQWHDG	EQEVFPCYCLE	1200
DGSLIRATKD	HKFMVTVDQM	LPIDEIFERE	LDLMRVDNLP	NSGSKRTAD	GSEFEPKKK	1260
KV						1262

SEQ ID NO: 105           moltype = AA   length = 967  
 FEATURE                Location/Qualifiers  
 source                 1..967  
                       mol\_type = protein  
                       organism = synthetic construct

SEQUENCE: 105

MKRTADGSEF	ESPKKKRVI	KIATRKYLGK	QNVYDIGVGE	PHNFALKNGF	IASNCADLSV	60
VEKLEKIIIQ	KVDEIYKVG	SSEKLPDADF	VLEKSLKND	AVVAIMKDLL	DSVKSFENYI	120
KAFFGEGKET	NRDESFGYDF	LAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	180
MGGWDKDKET	DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYKLLPGPN	240
KMLPKVFFSK	KWMAYNPSE	DIQKIYKNGT	FKKGDMPNLL	DCHKLIDFFK	DSISRYPKWS	300
NAYDFNFSET	EKYFDIAGFY	REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	360
DKSHGTPNLH	TMYFKLLFDE	NNHQIRLSG	GAELFMRRAS	LKKEELVVHP	ANSPIANKNP	420
DNPKTTTLS	YDVYKDRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	480
IDRGERNLLY	IVVVDGKGN	VEQYSLNEII	NNFNGIRIKT	DYHSLDDKKE	KERFEARQNW	540
TSIENIKELK	AGYTSQVVKH	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKPEKML	600
IDKLNMYMVDK	KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYPYPAWL	TSKIDPSTGF	660

-continued

```

VNLKTKYKTS IADSKKFISS FDRIMVPEE DLFEPALDYK NFSRTDADYI KKWKLYSYGN 720
RIRIFRNPCK NNVFDWEEVC LTSAYKELFN KYGINYQQGD IRALLCEQSD KAFYSSFMAL 780
MSMLLQMRNS ITGRTDVDFL ISPVKNSDGI FYDSRNYEAQ ENAILPKNAD ANGAYNIARK 840
VLWAIQGPKK AEDEKLDKVK IAINSKEWLE YAQTSVKHSG GSSGSSGSGE TPGTSESATP 900
ESSGSSGSGS ALDFLSLRPL PPPVSPICTF VSPAAQKAFQ PPRSCGSGGS KRTADGSEPE 960
PKKKRKV 967

```

```

SEQ ID NO: 106      moltype = AA length = 1297
FEATURE            Location/Qualifiers
source             1..1297
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 106
MKRTADGSEF ESPKKKRKVT LNIIEDEHRLH ETSKEPDVSL GSTWLSDFPQ AWAETGGMGL 60
AVRQAPLIIP LKATSTPVS I KQYPMSQEAR LGIKPHIQRL LDQGILVPCQ SPWNTPLLPV 120
KKPGTNDYRP VQDLREVNKR VEDIHPTVFN PYNLLSGLPP SHQWYTVLDL KDAFFCLRHL 180
PTSQPLFAFE WRDPEMGISG QLTWTRLPQG FKNSPTLFNE ALHRDLADFR IQHPDLILLQ 240
YVDDLLLAAT SELDCQQGTR ALLQTLGNLG YRASAKKAI CQKQVKYLYG LLKEGQRWLT 300
EARKETVMGQ PTPKTPRQLR EFLGKAGFCR LFIPGFAEMA APLYPLTKPG TLFNWWGPDQ 360
KAYQEIQQAL LTAPALGLPD LTKPFELFVD EKQGYAKGVL TQKLGWRRP VAYLSKKLDP 420
VAAGWPPCLR MVAIAVLTG DAGKLTMGQP LVILAPHAVE ALVKQPPDRW LSNARMTHYQ 480
ALLLDTDRVQ FGPVVALNPA TLLPLPEEGL QHNCLDILAE AHGTRPDLTD QPLPDADHTW 540
YTDGSSLLQE GQRKAGAAVT TETEVIWAKA LPAGTSAQRA ELIALTQALK MAEGKKNLVY 600
TDSRYAFATA HIHGEIYRRR GWLTSSEKKEI KNKDEILALL KALFLPKRRLS IIHCPGHQKG 660
HSAEARGNRM ADQARAKAAI TETPDTSTLL IENSSPNSRL INSGSSGSGS SGSETPGTSE 720
SATPESSGGS SGGSSKLEKF TNCYSLSKTL RPKAIPVGKT QENIDNKRL VEDEKRAEDY 780
KGVKLLDRY YLSPINDVLH SIKLKNLNNY ISLFRKTRT EKENKELENL EINLRKEIAK 840
AFKGNEGYKS LFKKDIETI LPEFLDDKDE IALVNSFNFG TTAFTGFDFN RENMFSEEA 900
STSIAPRCIN ENLTRYISNM DIFEKVDAIF DKHEVQEIKE KILNSDYDVE DPFEGEFFNF 960
VLTQEGIDVY NAIIGGFVTE SGKEIKGLNE YINLYNQTK QKLPKFKPLY KQVLSDRSLE 1020
SFYGEYTS D EHVLEVRFRNT LNKNSEIFSS IKKLEKLFKN FDEYSSAGIF VKNPASTI 1080
SKDIFGEWNV IRDKWNAEYD DIHLKKKAVV TEKYEDDRK SFKKIGSFSL EQLQEYADAD 1140
LSVVEKLEKI IIQKVDIYK VYGSSEKLPD ADFVCLSYET EILTVEYGLL PIGKIVEKRI 1200
ECTVYSVDNN GNIYTQVAQ WHDRGEQEVF EYCLEGSLI RATDKHKFMT VDGQMLPIDE 1260
IFERELDLMR VDNLPNSGGS KRTADGSEPE PKKKRKV 1297

```

```

SEQ ID NO: 107      moltype = AA length = 932
FEATURE            Location/Qualifiers
source             1..932
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 107
MKRTADGSEF ESPKKKRKVI KIATRKYLGK QNVYDIGVGE PHNFALKNGF IASNCALEKS 60
LKKNDVAVAI MKDLLDSVKS FENYIKAPFG EGKETNRDES FYGDFVLAYD ILLKVDHIYD 120
AIRNYVTQKP YSKDKFKLYF QNPQFMGGWD KDKETDYRAT ILRYSKYYL AIMDKKYAK 180
LQKIDKDDVN GNYEKINYKL LPGPNKMLPK VFFSKWMAY YNPSEDIQI YKNGTPKKGD 240
MFNLNDCHKL IDFFKDSISR YPKWSNAYDF NPSETEKYKD IAGFYREVVE QGYKVSFESA 300
SKKEVDLIVE EGKLYMPQIY NKDFSDKSHG TPNLHTMYFK LLPDENNHGQ IRLSGGAELE 360
MRRASLKKEE LVVHPANSPI ANKNPDNPKK TTLSYDVYK DKRFSEDEYE LHIPIAINKC 420
PKNIFKINTE VRVLLKHHDDN PYVIGIDRGE RNLLYIVVVD GKGNIIVEQYS LNEIINNFG 480
IRIKTDYHSL LDKKEKERFE ARQNWTSIEN IKELKAGYIS QVWHKICELV EKYDAVIALE 540
DLNSGFKNR VVKFKQVYQK FEKMLIDKLN YMVDKKSNPC ATGGALKGYQ ITNKFESFKS 600
MSTQNGFIFY IPAWLTSKID PSTGFVNLK TKYTSIADSK KFISDFRIM YVPEEDLFEP 660
ALDYKNFSRT DADYIKKWL YSYGNRIRIF RNPKNNVFPD WEEVCLTSAY KELFNKYGIN 720
YQQGDIRALL CEQSDKAFYS SFMALMSLML QMRNSITGRT DVDFLISPVK NSDGIYDSR 780
NYEAQENAIL PKNADANGAY NIARKVLWAI GQFKKADEK LDKVKIAISN KEWLEYAQT 840
VKHSGSSGG SSGSETPGTS ESATPESSGG SSGSALDFL SRLPLPPPV PICTFVSPAA 900
QKAFQPPRSC GSGSKRTAD GSEFEPKKR KV 932

```

```

SEQ ID NO: 108      moltype = AA length = 1406
FEATURE            Location/Qualifiers
source             1..1406
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 108
MKRTADGSEF ESPKKKRKVT LNIIEDEHRLH ETSKEPDVSL GSTWLSDFPQ AWAETGGMGL 60
AVRQAPLIIP LKATSTPVS I KQYPMSQEAR LGIKPHIQRL LDQGILVPCQ SPWNTPLLPV 120
KKPGTNDYRP VQDLREVNKR VEDIHPTVFN PYNLLSGLPP SHQWYTVLDL KDAFFCLRHL 180
PTSQPLFAFE WRDPEMGISG QLTWTRLPQG FKNSPTLFNE ALHRDLADFR IQHPDLILLQ 240
YVDDLLLAAT SELDCQQGTR ALLQTLGNLG YRASAKKAI CQKQVKYLYG LLKEGQRWLT 300
EARKETVMGQ PTPKTPRQLR EFLGKAGFCR LFIPGFAEMA APLYPLTKPG TLFNWWGPDQ 360
KAYQEIQQAL LTAPALGLPD LTKPFELFVD EKQGYAKGVL TQKLGWRRP VAYLSKKLDP 420
VAAGWPPCLR MVAIAVLTG DAGKLTMGQP LVILAPHAVE ALVKQPPDRW LSNARMTHYQ 480
ALLLDTDRVQ FGPVVALNPA TLLPLPEEGL QHNCLDILAE AHGTRPDLTD QPLPDADHTW 540
YTDGSSLLQE GQRKAGAAVT TETEVIWAKA LPAGTSAQRA ELIALTQALK MAEGKKNLVY 600
TDSRYAFATA HIHGEIYRRR GWLTSSEKKEI KNKDEILALL KALFLPKRRLS IIHCPGHQKG 660

```

-continued

HSAEARGNRM	ADQAARKAAI	TETPDTSTLL	IENSSPNSRL	INSGGSSGGS	SGSETPGTSE	720
SATPSSGGS	SGGSSKLEKF	TNCYLSKTL	RFKAI PVGKT	QENIDNKRL	VEDEKRAEDY	780
KGVKLLDRY	YLSFINDVLH	SIKLNLNLY	ISLFRKTRT	EKENKELENL	EINLRKEIAK	840
AFKGNEGYKS	LFKKDIIETI	LPEFLDDKDE	IALVNSFNGF	TTARTGFDFN	RENMFSEEA	900
STSIAFRCIN	ENLTRYISNM	DIFEKVDAIF	DKHEVQEIKE	KILNSDYDVE	DFPEGEFFNF	960
VLTQBGIDVY	NAIIGGFVTE	SGEKI KGLNE	YINLYNQTK	QKLPKFKPLY	KQVLSDRSL	1020
SFYGGYTS	EVLEVPFRNT	LKNSEIFSS	IKKLEKLPKN	FDEYSSAGIF	VKNPASTI	1080
SKDIFGEWNV	IRDKWNAEYD	DIHLKKKAVV	TEKYEDDRK	SFKKIGSFSL	EQLQEYADAD	1140
LSVVEKLKEI	IIQKVDEIYK	VYGSSEKLPD	ADFVLEKSLK	KNDAVVAIMK	DLSDSVKSFE	1200
NYIKAFPEG	KETNRDESFY	GDFVLAYDIL	LKVDHIYDAI	RNYVTQKPYS	KDKFKLYFQN	1260
PQFMGGWDK	KETDYRATIL	RYGCLSYETE	ILTVEYGLLP	IGKIVEKRIE	CTVYSVDNNG	1320
NIYTQVPAQW	HDRGEQEVFE	YCLEGSLIR	ATKDHKFMVT	DGQMLPIDEI	FERELDMRV	1380
DNLPSGGSK	RTADGSEFEP	KKRKYV				1406

SEQ ID NO: 109           moltype = AA   length = 823  
 FEATURE                Location/Qualifiers  
 source                  1..823  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 109

MKRTADGSEF	ESPKKKRVI	KIATRKYLGK	QNVYDIGVGE	PHNFALKNGF	IASNCASKYY	60
LAIMDKKYAK	CLQKIDKDDV	NGNYEKINYK	LLPGPNKMLP	KVFFSKKMA	YYPSEDIQK	120
IYKNGTFKKG	DMPNLNDCHK	LIDFFKDSIS	RYPKWSNAYD	PNFSETEKYK	DIAGFYREVE	180
BQGYKVPES	ASKKEVDKLV	EEGKLYMFOI	YNKDFSDKSH	GTPNLHTMYF	KLLFDENNHG	240
QIRLSGGAEL	FMRRASLKEE	ELVVHPANSP	IANKNPDNPK	KTTLSYDVY	KDKRFSEDQY	300
ELHIPIAINK	CPKNIFKINT	EVVLLKHDD	NPYVIGIDRG	ERNLLYIVVV	DGKGNIVEQY	360
SLNEIINNFN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	420
VEKYDAVIAL	EDLNSGPKNS	RKVKVKQVYQ	KFEKMLIDKL	NYVDDKSNP	CATGGALKGY	480
QITNKFESFK	SMSTQNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTKYTSIADS	KKFISSFDR	540
MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKKNVVF	DWEEVCLTSA	600
YKELFNKYGI	NYQQDIRAL	LCEQSDKAFY	SSFALMSLM	LQMRNSITGR	TDVDFLISPV	660
KNSDGIIFYDS	RNYEAQENAI	LPKNADANGA	YNIARKVLWA	IGQPKKAED	KLDKVKIAIS	720
NKEWLEYAQT	SVKHSGGSSG	GSSGSETPGT	SESATPSSG	GSSGGSALDF	LSRLPLPPP	780
SPICTFVSPA	AQKAFQPPRS	CGSGGSKRTA	DGSEFEPKKK	RKV		823

SEQ ID NO: 110           moltype = AA   length = 102  
 FEATURE                Location/Qualifiers  
 source                  1..102  
                           mol\_type = protein  
                           organism = Nostoc punctiforme

SEQUENCE: 110

CLSYETEILT	VEYGLLPIGK	IVEKRIECTV	YSVDNNGNIY	TQPVAQWHDR	GEQEVFEYCL	60
EDGSLIRATK	DHKFMTVDGQ	MLPIDEIFER	ELDLMRVDNL	PN		102

SEQ ID NO: 111           moltype = AA   length = 35  
 FEATURE                Location/Qualifiers  
 source                  1..35  
                           mol\_type = protein  
                           organism = Nostoc punctiforme

SEQUENCE: 111

IKIATRKYLG	KQNVYDIGVG	EPHNFALKNG	FIASN			35
------------	------------	------------	-------	--	--	----

SEQ ID NO: 112           moltype = AA   length = 35  
 FEATURE                Location/Qualifiers  
 source                  1..35  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 112

IKIATRKYLG	KQNVYDIGVG	EPHNFALKNG	FIASN			35
------------	------------	------------	-------	--	--	----

SEQ ID NO: 113           moltype = AA   length = 2010  
 FEATURE                Location/Qualifiers  
 source                  1..2010  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 113

TLNIEDEHRL	HETSKEDVVS	LGSTWLSDFP	QAWAETGGMG	LAVRQAPLII	PLKATSTPVS	60
IKQYPMSEQE	RLGKPKHQ	LLDQGILVPC	QSPWNTPLP	VKKPGTNDYR	PVQDLREVNK	120
RVEDIHPTVP	NPYNLLSGLP	PSHQWYTVLD	LKDAFFCLRL	HPTSQPLFAF	EWRDPPEMGI	180
GQLTWTRLPQ	GFKNSPTLFN	EALHRDLADF	RIQHPDLILL	QYVDDLLAA	TSELDCQOQT	240
RALLQTLGNL	GYRASAKKAQ	ICQKQVKYLG	YLLKEGQRWL	TEARKETVMG	QPTPKTPRQL	300
REFLGKAGFC	RLFIPGFAEM	AAPLYPLTKP	GTLFNWGPDQ	QKAYQEIQA	LLTAPALGLP	360
DLTKPFELFV	DEKQGYAKGV	LTKLGPWRR	PVAYLSKLD	PVAAGWPPCL	RMVAIAVLT	420
KDAGKLTMGQ	PLVILAPHAV	EALVKQPPDR	WLSNARMTHY	QALLDTPDRV	QFGPVVALNP	480
ATLLPLPEEG	LQHNCLDILA	EAHGTRPDLT	DQPLPADADHT	WYTDGSSLLQ	EGQRKAGAAV	540
TTETEVIWAK	ALPAGTSAQR	AELIALTQAL	KMAEGKMLNV	YTDSRYAFAT	AHIHGEIYRR	600



-continued

RGWLTSEGKE	IKNKDEILAL	LKALFLPKRL	SIHCPGHQK	GHSABARGNR	MADQAARKAA	660
ITETPDSTL	LIENSSPNSR	LINSGGSSGG	SSGSETPGTS	ESATPESGG	SSGGSSKLEK	720
FTNCYSLSKT	LRFKAIPVGK	TQENIDNKRL	LVEDEKRAED	YKGVKLLDR	YYLSFINDVL	780
HSIKLKNLNN	YISLFRKKTR	TEKENELEN	LEINLRKEIA	KAFKNGEGYK	SLFKKDIET	840
ILPEFLDDKD	EIALVNSFNG	FTTAFTGFFD	NRENMFSEEA	KSTSIAFRCI	NENLTRYISN	900
MDIFEKVDAI	FDKHEVQEI	EKILNSDYDV	EDFPEGEFPN	FVLTOEGIDV	YNAIIGGFVT	960
ESGEKIKGLN	EYINLYQKT	QKQLPKFKPL	YKQVLSDRS	LSFYGEGYTS	DEEVLEVFRN	1020
TLNKNSEIFS	SIKKLELKF	NFDEYSSAGI	FVKNGPAIST	ISKDIFGEWN	VIRDKWNAEY	1080
DDIHLKKKAV	VTEKYEDDR	KSPFKIGSFS	LEQLQYADA	DLSVVEKLKE	IIIQKVEIY	1140
KVYGSSEKLF	DADFVLEKSL	KKNDAVVAIM	KDLLDSVKSF	ENYIKAFPE	GKETNRDES	1200
YGDVFLAYDI	LLKVDHIYDA	IRNYVTQKPY	SKDKFKLYFQ	NPQFMGGWDK	DKETDYRATI	1260
LRYGSKYYLA	IMDKKYAKCL	QKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	FFSKKWMAYY	1320
NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	DFFKDSISRY	PKWSNAYDFN	FSETEKYKDI	1380
AGFYREVVEEQ	GYKVSFESAS	KKEVDKLVVEE	GKLYMFQIYN	KDFSDKSHGT	PNLHTMYFKL	1440
LPDENNHGQI	LRASGABELFM	RRASLKKEEL	VVHPANSPIA	NKNPDNPKKT	TTLSYDVYKD	1500
KRFSEDQVEL	HPIAINKCP	KNIKFINTEV	RVLKHDNDP	YVIGIDRGER	NLLYIVVDG	1560
KGNIVEQYSL	NEIINNNGI	RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	KELKAGYISQ	1620
VVHKICELVE	KYDAVIALED	LNSGFKNSRV	KVEKQVYQK	EKMLIDKLN	MVDKKSNPCA	1680
TGGALKGYQI	TNKFESPKSM	STQNGPIFYI	PAWLTSKIDP	STGPNLLKT	KYTSIADSKK	1740
FISSFDRIMY	VPEEDLPEFA	LDYKNFSRTD	ADYIKKWKLY	SYGNRIRIFR	NPKKNNVFDW	1800
EEVCLTSAYK	ELFNKYGINY	QQGDIRALLC	EQSDKAFYSS	FMALMSMLQ	MRNSITGRD	1860
VDFLISPVKN	SDGFYDSRN	YEAQENAILP	KNADANGAYN	IARKVLWAI	QFKKAEDKL	1920
DKVKIAISNK	EWLEYAQTSV	KHSGGSSGG	SGSETPGTSE	SATPESGG	SGGSALDFLS	1980
RLPLPPVSP	ICTFVSPAQ	KAEQPPRSCG				2010

SEQ ID NO: 114                   moltype = AA   length = 1373  
 FEATURE                        Location/Qualifiers  
 source                           1..1373  
                                   mol\_type = protein  
                                   organism = synthetic   construct

SEQUENCE: 114

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKTRTEK	ENKELLENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEAKST	SIAFRGINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGENQTTQK	300
QKNSRERMKR	IEEGIKELSG	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VQQLDINRL	360
SDYVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEBGT	SDEEVLEVFR	NLTKNSSEIF	SSIKKLEKLF	KNFDEYSSAG	480
IFVKNPDAIS	TISKDIFGEW	NVIRDKNWAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQYAD	ADLSVVEKLE	EIIIQKVEI	YKVGSEKLE	FDADFVLEKS	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFPE	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKFKLYF	NPQFMGGWD	DKKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	720
GNYEKINYKL	LPQPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	YKNGTFKKGD	MFNLNDCHKL	780
IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVEE	QGYKVSFESA	SKKEVDKLV	840
EGLKLYMFQIY	NKDFSDKSDS	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELE	MRRASLKKEE	900
LVVHPANSPI	ANKNPDNPKK	TTLSYDVYK	DKRFSEDQYE	LHPIAINKC	PKNIFKINTE	960
VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	LNELINNNGI	IRIKTDYHSL	1020
LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVKICELV	EKYDAVIALE	DLNSGFKNSR	1080
VKVEKQVYQK	FEKMLIDKLN	YMVDKKSNPC	ATGGALKGYQ	ITNKFESPKS	MSTQNGFIFY	1140
IPAWLTSKID	STGPNLLKT	KYTSIADSK	KFISSFDRIM	YVPEEDLPEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNNVDF	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	1260
CEQSDKAFYS	SFMALMSML	QMRNSITGR	DVDFLISPVK	NSDGIFYDSR	NYEAQENAIL	1320
PKNADANGAY	NIARKVLWAI	GQFKKAEDK	LDKVKIAISN	KEWLEYAQTS	VKH	1373

SEQ ID NO: 115                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                           1..1375  
                                   mol\_type = protein  
                                   organism = synthetic   construct

SEQUENCE: 115

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKTRTEK	ENKELLENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEAKST	SIAFRGINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YSGENQTTQ	300
KGQKNSRERM	KRIEIKEL	GSQILKEHPV	ENTQLQNEKL	YLYLQNGRDMY	MYVDQELDIN	360
RLSDYVDVHI	VPQSFLLKDS	IDNKVLTRSD	KNRGKSDNVP	SEEVVKKMKN	YWRQLLNAKL	420
ITQRKFDNLT	KAERGGLSEG	YTSDEEVLEV	FRNTLNKNS	IFSSIKKLEK	LFPNFDEYSS	480
AGIFVKNPDA	ISTSKDIFG	EMNVIRDKN	AEYDDIHLK	KAVVTEKYED	DRRKSFKKIG	540
SFSLQEQY	ADADLSVVEK	LKEIIQKVD	EIYKVGSS	KLPDADFVLE	KSLKKNDAV	600
AIMKDLLDSV	KSPENYIKAF	FGEGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQMG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPSEDIQ	KIYKNGTFK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKNSNAY	DNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMFQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRRASLKK	900

-continued

EELVVHPANS	PIANKNDPNP	KKTTTLYSDV	YKDKRFSEDO	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIAR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVKVEKQVY	QKFEKMLIDK	LNVMVDKKS	PCATGGALKG	YQITNKFESE	KSMSTQNGFI	1140
FYIPAWLTSK	IDPSTGFVNL	LKTKYTSIAD	SKKFISSPDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSPMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGI FYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQFKKAED	EKLDKVKIAI	SNKEWLEYAQ	TSVKH	1375

SEQ ID NO: 116           moltype = AA   length = 1377  
 FEATURE                Location/Qualifiers  
 source                 1..1377  
                        mol\_type = protein  
                        organism = synthetic   construct

SEQUENCE: 116

MGSKLEKPTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHST	KLKLNLYIS	LFRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDI IETILP	EFLDDKDEIA	LVNSPFGFT	AFTGFFDNRE	NMFSEEAKST	SIAPRCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKI KGLNEIY	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGGSSGENQT	300
TQKGQKNSRE	RMKRIEIEGK	ELGSQILKEH	PVENTQLQNE	KLYLYYLQNG	RDYVVDQELD	360
INRLSDYDVD	HIVPQSPFKD	DSIDNKVLR	SDKNRKGSDN	VPSEEVVKM	KNYWRQLLNA	420
KLITQRKFDN	LTKAERGGLS	EGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLFKPNFDEY	480
SSAGIFVKNG	PAISTISKDI	FGEWNVIRK	WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	540
IGSFSLEQLQ	EYADADLSV	EKLKEII IQK	VDEIYKVYGS	SEKLFDAFV	LEKSLKNDNA	600
VVAIMKDLLD	SVKSFENYIK	APFGGKETN	RDESFYGFV	LAYDILLKVD	HIYDAIRNYV	660
TQKPYSKDKF	KLYFQNPQFM	GGWDDKDET	YRATILRYGS	KYLAIMDKK	YAKCLQKIDK	720
DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYYNPSED	IQKIYKNGTF	KKGDMFNLND	780
CHKLIDFFPKD	SISRYPKWSN	AYDFNPFSETE	KYKDIAGFYR	EVVEEQYKVS	FESASKKEVD	840
KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	900
KKEELVVHPA	NSPIANKNDP	NPKKTTLTSLY	DVYDKRFSE	DQYELHIPIA	INCKPKNIPK	960
INTEVRVLLK	HDDNPYVIGI	ARGERNLLYI	VVDGKGNIV	EQYSLNEIIN	NFNIRIKTD	1020
YHSLLDKKEK	VEFEARQNW	SIENIKELKA	GYISQVVKI	CELVEKYDVA	IALEDLNSGF	1080
KNSRVKVEKQ	YQKFEKMLI	DEKLNVMVDK	SNPCATGGAL	KGYQITNKFE	SFKSMSTQNG	1140
FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSF	DRIMYVPEED	LFEPALDYKN	1200
FSRTDADYIK	KWKLYSYGNR	IRIFRNPKN	NVDFWEEVCL	TSAYKELFNK	YGINYQQGDI	1260
RALLCEQSDK	AFYSSFMALM	LMLQMRNSI	TGRTDVDFLI	SPVKNSDGI F	YDSRNYEAQE	1320
NAILPKNADA	NGAYNIARKV	LWAIGQFKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH	1377

SEQ ID NO: 117           moltype = AA   length = 1379  
 FEATURE                Location/Qualifiers  
 source                 1..1379  
                        mol\_type = protein  
                        organism = synthetic   construct

SEQUENCE: 117

MGSKLEKPTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHST	KLKLNLYIS	LFRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDI IETILP	EFLDDKDEIA	LVNSPFGFT	AFTGFFDNRE	NMFSEEAKST	SIAPRCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKI KGLNEIY	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGGSSGENQT	300
TQKGQKNSRE	RMKRIEIEGK	ELGSQILKEH	PVENTQLQNE	KLYLYYLQNG	RDYVVDQELD	360
INRLSDYDVD	HIVPQSPFKD	DSIDNKVLR	SDKNRKGSDN	VPSEEVVKM	KNYWRQLLNA	420
KLITQRKFDN	LTKAERGGLS	GSEGYTSDEE	VLEVFRNTLN	KNSEIFSSIK	KLEKLPKNFD	480
BYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKAVVTE	KYEDDRRKS	540
KKIGSFSLEQ	LQYADADLS	VVEKLKEIII	QKVDEIYKVY	GSSEKLPDAD	FVLEKSLKKN	600
DAVVAIMKDL	LDSVKSFENY	IKAFFGEGKE	TNRDESFYGD	FVLAYDILLK	VDHIYDAIRN	660
YVTQKPYSKD	KFKLYFQNPQ	FMGGWDKDK	TDYRATILRY	GSKYLAIMD	KKYAKCLQKI	720
DKDDVNGNYE	KINYKLLPGP	NKMLPKVFFS	KKWMAYYNPS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDFNPFSE	TEKYKDIAGF	YREVEEQYK	VSFESASKKE	840
VDKLVVEEGK	YMFQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAEELPMRRA	900
SLKKEELVVH	PANSPIANKN	PDNPKKTTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	960
FKINTEVRVL	LKHDDNPYVI	GIARGERNLL	YIVVVDGKGN	IVEQYSLNEI	INNFNGIRIK	1020
TDYHSLDKK	EKERFEARQ	WTSIENIKEL	KAGYISQVVK	KICELVEKYD	AVIALDELNS	1080
GFKNRSRVKVE	KQVYQKFEKM	LIDKLNMYMD	KKSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140
NGFIFYIPAW	LTSKIDPSTG	FVNLLKTKYT	SIADSKKPI	SFDRIMYVPE	EDLFEFALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRIFRNP	KNNVDFWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIGQFK	KADEKLDKVK	KIAISNKEWL	EYAQTSVKH	1379

SEQ ID NO: 118           moltype = AA   length = 1373  
 FEATURE                Location/Qualifiers  
 source                 1..1373  
                        mol\_type = protein  
                        organism = synthetic   construct

SEQUENCE: 118

MGSKLEKPTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
------------	-----------	------------	-----------	-----------	------------	----

-continued

SFINDVLHSI	KLKLNLYNIS	LFRKKTTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRESLSF	YGEENQTTQK	300
GQKNSRERMK	RIEBEIKELG	SQILKEHPVE	NTQLQNEKLY	LYYLQNGRDM	YVDQELDINR	360
LSDYDVDHIV	PQSFLKDDSI	DNKVLTRSDK	NRGKSDNVPS	EEVVKMKMNY	WRQLLNAKLI	420
TQRKFDNLTK	AERGLSGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	KNPDEYSSAG	480
IFVKNPAPIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQEQYAD	ADLSVVEKLE	EIIIQKVDEI	YKVYGSSEKL	PDADPVLKES	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFPG	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	720
GNYEKINYKL	LPGNKMLPK	VFFSKWMAY	YNPSEDIQKI	YKNGTFPKGD	MFNLNDCHKL	780
IDFFKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVEE	QGYKVSFESA	SKKEVDKLV	840
EGKLYMFIQY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELEF	MRRASLKKKE	900
LVVHPANSPI	ANKNPDNPKK	TTTSLYDVYK	DKRFSDEQYE	LHIPIAINKC	PKNIFPKINTE	960
VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNFF	IRIKTDYHSL	1020
LDKKEKERFE	ARQNWTSTIEN	IKELKAGYIS	QVVHKICELV	EKYDAVIALE	DLNSGFKNSR	1080
VKVEKQVYQK	FEKMLIDKLN	YVMDKKS NPC	ATGGALKGYQ	ITNKFESFKS	MSTQNGFIFY	1140
I PAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSFDRI	YVPEEDLFEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNKNNVFD	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	1260
CEQSDKAFYS	SFMALMSLML	QMRNSITGR	DVDPLISPVK	NSDGI FYDSR	NYEAQENAIL	1320
PKNADANGAY	NIARKVLWAI	GQPKKAEDK	LDKVKIAISN	KEWLEBYAQT	VKH	1373

SEQ ID NO: 119                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                         1..1375  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 119

MGSKLEKPTN	CYLSKTLTRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKKTTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRESLSF	YGESENQTT	300
QKQKNSRER	MKRIEIKEKE	LGSQILKEHP	VENTQLQNEK	LYLYLQNGR	DMYVDQELDI	360
NRLSDYDVDH	IVPQSFLKDD	SIDNKVLT	DKNRGKSDNV	PSEEVVKMK	NYWRQLLNAK	420
LITQRKFDNL	TKAERGLSG	YTSDEEVLE	FRNTLNKNS	IFSSIKKLEK	LRFKNFDEYSS	480
AGIFVKNPAP	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLK	KAVVTEKYED	DRRKSFKKIG	540
SFSLBQLQEQ	ADADLSVVEK	LKEIIIQKVD	EYKVYGSSE	KLPDADPVL	KSLKKNDAVV	600
AIMKDLLDSV	KSPFENYIKAF	FGEKGTNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYKDKFKPL	YFQNPQFMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFFSKWM	AYNPNSEDIQ	KIYKNGTFPK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DNFSETEKY	KDIAGFYREV	EEQYKVSFE	SASKKEVDKL	840
VEEGKLYMFI	QYKDFSDKSH	HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRRASLKK	900
EELVHPANS	PIANKNPDNP	KKTTLTSDYV	YDKRFSDEQ	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPVIGIARG	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVHKICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVVEKQVYQ	KQFQKMLIDK	LNYVMDKKS	PCATGGALKG	YQITNKFESF	KSMSTQNGFI	1140
FYIPAWLTSK	YVSTGFVNLK	LKTKYTSIAD	SKKFISSFDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNKNN	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSFMALMSL	MLQMRNSITG	RTDVDPLISP	VKNSDGI FYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQPKKAED	EKLKVKIAI	SNKEWLEBYA	QTSVKH	1375

SEQ ID NO: 120                   moltype = AA   length = 1377  
 FEATURE                        Location/Qualifiers  
 source                         1..1377  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 120

MGSKLEKPTN	CYLSKTLTRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKKTTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRESLSF	YGESSGENQ	300
TTQKQKNSR	ERMRKIEE	KELGSQLKE	HPVENTQLQ	EKLYLYLQ	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGLG	SGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLKFNPFDEY	480
SSAGIFVKNP	PAISTISKDI	FGEWNVIRDK	WNAEYDDIHL	KKKAVVTEKY	EDDRRSFKK	540
IGSFSLEQLQ	EYADADLSV	EKLKEIIQK	VDEIYKVYGS	SEKLPDADFV	LEKSLKKNDA	600
VVAIMKDLLD	SVKSPFENYIK	AFPGEGKETN	RDESPYGFV	LAYDILLKVD	HIYDAIRNYV	660
TQKPYKDKFK	KLIPSTGFVNL	GWDKDKKETD	YRATILRYGS	KYLLAIMDKK	YAKLQKIDK	720
DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYNPNSED	IQKIYKNGTF	KKGDMFNLD	780
CHKLIDFFPK	SISRYPKWSN	AYDFNFSETE	KYKDIAGPYR	EVEREQYKVS	FESASKKEVD	840
KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	900
KKEELVHPA	NSPIANKNPD	NPKKTTLSY	DVYKDKRFS	DQYELHIPIA	INCKPKNIFK	960
INTEVRVLLK	HDDNPVIGI	ARGERNLLYI	VVVDGKGNIV	BOYSLNEIIN	NFNGIRIKTD	1020

-continued

YHSLLDKKEK	ERFEARQNTW	SIENIKELKA	GYISQVHVKI	CELVEKYDAV	IALEDLNSGF	1080
KNSRVKVEKQ	VYQKFEKMLI	DKLNYMVDKK	SNPCATGGAL	KGYQITNKFE	SFKSMSTQNG	1140
FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSE	DRIMYVPEED	LFEFALDYKN	1200
FSRTDADYIK	KWKLYSYGMR	IRIFRNPKKN	NVFDWEEVCL	TSAYKELFNK	YGINYQQGDI	1260
RALLCEQSDK	AFYSSFMALM	SLMLQMRNSI	TGRTDVFPLI	SPVKNSDGIF	YDSRNYEAQE	1320
NAILPKNADA	NGAYNIARKV	LWAIQGFKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH	1377

SEQ ID NO: 121                   moltype = AA   length = 1379  
 FEATURE                        Location/Qualifiers  
 source                         1..1379  
                               mol\_type = protein  
                               organism = synthetic   construct

SEQUENCE: 121

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LPRKKTRETEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFDFNRE	NMFSEEAKEST	SIAPRCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVFL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGENQTTQKG	300
TTQKGQKNSR	ERMKRIEEGI	KELGSQILKE	HPVENTQLQN	EKLYLYLQON	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGG	SGSGYTSDEE	VLEVFRNTLN	KNSEIFSSIK	KLEKLPKNPD	480
EYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKKAVVTE	KYEDDRRKS	540
KKIGSFSLEQ	LQEYADADLS	VVEKLEKII	QKVDEIYKVY	GSSEKLPDAD	FVLEKSLKKN	600
DAVVAIMKDL	LDSVKSFENY	IKAFPEGEGE	TNRDESFGYD	FVLYADILLK	VDHIYDAIRN	660
YVTQKPYSKD	KFKLYFPQNP	FMGGWDKDK	TDYRATILRY	GSKYLLAAMD	KKYAKCLQKI	720
DKDDVNGNYE	KINYKLLPGP	NKMLPKVFP	KKWMAYNPS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDFNFSE	TEKYKDIAGF	YREVEEQYK	VSPESASKKE	840
VDKLVEEGKL	YMFQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAEYLMRRA	900
SLKKEELVVH	PANSPIANKN	PDNPKKTTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	960
PKINTEVRVL	LKHDDNPYVI	GIARGERLL	YIVVVDGKGN	IVEQYSLNEI	INNFNGIRIK	1020
TDYHSLDDKK	EKERFEARQN	WTSIENIKEL	KAGYISQVHH	KICELVEKYD	AVIALEDLNS	1080
GPKNSRVKVE	KQVYQKPEKM	LIDKLNMYVD	KKSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140
NGFIYIPAW	LTSKIDPSTG	FVNLKTKYT	SIADSKKPI	SFDRIMYVPE	EDLFEPALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRIFRNPK	KNNVFDWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIQGFK	KADEKLDKVK	KIAISNKEWL	EYAQTSVKH	1379

SEQ ID NO: 122                   moltype = AA   length = 1373  
 FEATURE                        Location/Qualifiers  
 source                         1..1373  
                               mol\_type = protein  
                               organism = synthetic   construct

SEQUENCE: 122

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LPRKKTRETEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFDFNRE	NMFSEEAKEST	SIAPRCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVFL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YLLQNGRDMY	VQQLDINRL	360
SDYDVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEBEGT	SDEEVLVFR	NLTKNSSEIF	SSIKKLEKLF	KNFDEYSAG	480
IFVKNGPAS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQYAD	ADLSVVEKLE	EIIIQKVDEI	YKVYGSSEKL	FDADFVLEKS	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFPG	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAK	LQKIDKDDVN	720
GNYEKINYKL	LPQPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	YKNGTFKKGD	MFNLNDCHKL	780
IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVE	QGYKVSPEA	SKKEVDKLE	840
EGKLYMFQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELE	MRRASLKKEE	900
LVVHPANSPI	ANKNPDNPKK	TTTLYSDVYK	DKRFSEDOYE	LHIPIAINK	PKNIFKINTE	960
VRVLLKHDND	PYVIGIDRGE	RNLLYIVVVD	GKGNIVEQYS	LNELINNFG	IRIKTDYHSL	1020
LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVHKICELV	EKYDAVIALE	DLNSGPFKNSR	1080
VKVEKQVYQK	FEKMLIDKLN	YMDVKKSNPC	ATGGALKGYQ	ITNKFESFKS	MSTQNGFIFY	1140
IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSEFDRIM	YVPEEDLFEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNVDF	WEEVCLTSAY	KELPNKYGI	YQGDIDRALL	1260
CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	DVDFLISPVK	NSDGI FYDSR	NYEAQENAIL	1320
PKNADANGAY	NIARKVLWAI	GQFKKAEDK	LDKVKIAISN	KEWLEYAQT	VKH	1373

SEQ ID NO: 123                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                         1..1375  
                               mol\_type = protein  
                               organism = synthetic   construct

SEQUENCE: 123

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LPRKKTRETEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFDFNRE	NMFSEEAKEST	SIAPRCINEN	180

-continued

LTRYISNMDI	FEKVDALFDK	HEVQEIKEKI	LNSDYDVEDE	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGGSSGENQT	300
KGQKNSRERM	KRIEEDIKEL	GSQILKEHPV	ENTQLQNEKL	YLYYLQNGRD	MYVDQELDIN	360
RLSDYDVVHI	VPQSFLKDDS	IDNKVLTRSD	KNRGKSDNVP	SEEVVKKMKQ	YWRQLLNAKL	420
ITQRKFDNLT	KAERGGLESEG	YTSDEEVLEV	FRNTLNKNSE	IFSSIKKLEK	LFRNFDEYSS	480
AGIFVKNQPA	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLK	KAVVTEKYED	DRRKSFKKIG	540
SFSLBQLQEQY	ADADLSVVEK	LKEIIIQKVD	EIYKYVGSSE	KLFDADFVLE	KSLKKNDAVV	600
AIMKDLLDSV	KSPFENYIKAF	FGEGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQFMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPSEDIQ	KIYKNGTFKK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DFNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMFO	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENN	HQIRLSGGAE	LPMRRASLKK	900
EELVVHPANS	PIANKNPDP	KKTTTLYSYD	YKDKRFSDEQ	YELHIPAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIDR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINN	NGIRIKTDYH	1020
SLLDKKKEKER	FEARQNQTSI	ENIKELKAGY	ISQVVKICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVKVEKQVY	QKPFKMLD	LNVMVDKSN	PCATGGALKG	YQITNKFEF	KSMSTQNGFI	1140
FYIPAWLTSK	IDPSTGFVNL	LKTKYTSIAD	SKKFISSFDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKKNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSFMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGI FYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQPKKAE	EKLDKVKIAI	SNKEWLEYAQ	TSVKH	1375

SEQ ID NO: 124           moltype = AA   length = 1377  
 FEATURE                Location/Qualifiers  
 source                  1..1377  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 124

MGSKLEKPTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYLL	60
SPINDVLHSI	KLKLNLYNIS	LFRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIITETILP	EFLDDKDEIA	LVNSPFGFT	AFTGFFDNRE	NMFSEEAKST	SIAPRCINEN	180
LTRYISNMDI	FEKVDALFDK	HEVQEIKEKI	LNSDYDVEDE	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGGSSGENQT	300
TQKGGKNSRE	RMKRIEEDIK	ELGSQILKEH	PVENTQLQNE	KLYLYYLQNG	RDYVDQELD	360
INRLSDYDVD	HIVPQSLPKD	DSIDNKVLT	SDKNRGKSDN	VPEEVVKKM	KNYWRQLLNA	420
KLITQRKFDN	LTKAERGGLES	EGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLKFNPFDEY	480
SSAGIFVKNQ	PAISTISKDI	FGWNVIRDK	WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	540
IGSFSLBQLQ	EYADADLSV	EKLKEIIIQK	VDEIYKYVGS	SEKLFDAFV	LEKSLKKNDA	600
VVAIMKDLLD	SVKSPFENYIK	AFPGEGKETN	RDESFYGFV	LAYDILLKVD	HIYDAIRNYV	660
TQKPYSKDKF	KLYFQNPQFM	GGWDDKDET	YRATILRYGS	KYLLAIMDKK	YAKCLQKIDK	720
DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYNPSED	IQKIYKNGTF	KKGMDFMND	780
CHKLIDFFPKD	SISRYPKWSN	AYDFNFSETE	KYKDIAGFYR	EVEEQGYKVS	FESASKKEVD	840
KLVEEGKLYM	FQYINKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	900
KKEELVVHPA	NSPIANKNPD	NPKTTTLYS	DVYKDKRFS	DQYELHIPAI	INKCPKNIFK	960
INTEVRVLLK	HDDNPYVIGI	DRGERNLLYI	VVDGKGNIV	EQYSLNEIIN	NFNIRIKTD	1020
YNSLLDKKEK	EFARQNQTSI	SINI KELA	GYISQVVKH	CELVEKYDAV	IALEDLNSGF	1080
KNSRVKVEKQ	VYQKPFKML	DKLNYMVDK	SNPCATGGAL	KGYQITNKFE	SFKSMSTQNG	1140
FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSF	DRIMYVPEED	LFEFALDYKN	1200
FRSDADYIK	KWLYSYGNR	IRIFRNPKKN	NVDFWEEVCL	TSAYKELFNK	YGINYQQGDI	1260
RALLCEQSDK	AFYSSFMALM	SMLQMRNSIT	TGRDVFLLISP	SPVKNSDGIF	YDSRNYEAQE	1320
NAILPKNADA	NGAYNIARKV	LWAIGQPKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH	1377

SEQ ID NO: 125           moltype = AA   length = 1379  
 FEATURE                Location/Qualifiers  
 source                  1..1379  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 125

MGSKLEKPTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYLL	60
SPINDVLHSI	KLKLNLYNIS	LFRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIITETILP	EFLDDKDEIA	LVNSPFGFT	AFTGFFDNRE	NMFSEEAKST	SIAPRCINEN	180
LTRYISNMDI	FEKVDALFDK	HEVQEIKEKI	LNSDYDVEDE	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGGSSGENQT	300
TQKGGKNSRE	RMKRIEEDIK	ELGSQILKEH	PVENTQLQNE	KLYLYYLQNG	RDYVDQELD	360
INRLSDYDVD	HIVPQSLPKD	DSIDNKVLT	SDKNRGKSDN	VPEEVVKKM	KNYWRQLLNA	420
KLITQRKFDN	LTKAERGGLES	GSEGYTSDEE	VLEVFRNTLN	KNSIFSSIK	KLEKLFKNP	480
EYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKAVVTE	KYEDDRRKS	540
KKIGSFSLBQL	LQYADADLS	VVEKLEIIIQ	KVDEIYKYV	GSSEKLFDAF	FVLEKSLKKN	600
DAVVAIMKDL	LDVSKSPENY	IKAFFGEGKE	TNRDESFYGD	FVLAYDILLK	VDHIYDAIRN	660
VYTQKPYSKD	KFKLYFQNPQ	FMGGWDDKDE	TDYRATILRY	GSKYLLAIMD	KKYAKCLQKI	720
DKDDVNGNYE	KINYKLLPGP	NKMLPKVFFS	KWMAAYNPS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDFNFSE	TEKYKDIAGF	YREVEEQGYK	VSFESASKKE	840
VDKLEVEGKL	YMFQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAELPMRRA	900
SLKKEELVVH	PANSPIANKN	PDNPKTTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	960
KINTEVRVL	LKHDDNPYVI	GIDRGERNLL	YIVVVDGKGN	IVEQYSLNEI	INNFNGIRIK	1020
FDYHSLLDK	EKERFEARQN	WTSIENIKEL	KAGYISQVVK	KICELVEKYD	AVIALEDLNS	1080
GPKNSRVKVE	KQVYQKFEKM	LIDKLNMYVD	KSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140

-continued

NGFIFYPYIPAW	LTSKIDPSTG	FVNLLKTKYT	SIADSKKPFIS	SFDRIMYVPE	EDLFEFALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRIFRNP	KNNVFDWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIGQPK	KAEDEKLDKV	KIAISNKEWL	EYAQTSVKH	1379

SEQ ID NO: 126                   moltype = AA   length = 1373  
 FEATURE                        Location/Qualifiers  
 source                         1..1373  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 126

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKKTREK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGEENQTTQK	300
GQKNSRERMK	RIEBEIKELG	SQILKEHPVE	NTQLQNEKLY	LYYLQNGRDM	YVDQELDINR	360
LSDYDVDHIV	PQSFLKDDSI	DNKVLTRSDK	NRGKSDNVPS	EEVVKMKMNY	WRQLLNAKLI	420
TQRKFDNLTK	AERGGLSGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	KNFDEYSSAG	480
IPVKNPAPIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQEQYAD	ADLSVVEKLL	EIIIQKVDEI	YKVYGSSEKL	FDADFLVLEKS	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFPG	EKGKTNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQPK	660
YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	720
GNYEKINYKL	LPGPNKMLPK	VFPSSKWMAY	YNPSEDIQKI	YKNGTFPKGD	MFNLNDCHKL	780
IDFFKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVEE	QGYKVSFESA	SKKEVDKLVE	840
EGKLYMPQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELEF	MRRASLKKKE	900
LVVHPANSP	ANKNPDNPKK	TTTSLYDVYK	DKRFSDEQYE	LHIPIAINKC	PKNIPKINTE	960
VRVLLKHDDN	PYVIGIDRGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNFGN	IRIKTDYHSL	1020
LDKKEKERFE	ARQNWTSEIN	IKELKAGYIS	QVVHKICELV	EKYDAVIALE	DLNSGFKNSR	1080
VKVEKQVYQK	PEKMLIDKLN	YVMDKKSNSP	ATGGALKGYQ	ITNKFESFKS	MSTQNGFIFY	1140
IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSFDRI	YVPEEDLFEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNKNNVD	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	1260
CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	DVDPLISPVK	NSDGI FYDSR	NYEAQENAIL	1320
PKNADANGAY	NIARKVLWAI	GQPKKAEDK	LDKVKIAISN	KEWLEAYAQS	VKH	1373

SEQ ID NO: 127                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                         1..1375  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 127

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKKTREK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGEENQTTQK	300
QKQKNSRER	MKRIEIKELG	LGSQILKEHP	VENTQLQNEK	LYLYLQNGR	DMYVDQELDI	360
NRLSDYDHDH	IVPQSFLKDD	SIDNKVLTRS	DKNRGKSDNV	PSEEVVKMK	NYWRQLLNAK	420
LITQRKFDNL	TQAERGLSG	YTSDEEVLEV	FRNTLNKNSE	IFSSIKKLEK	LPKFNDEYSS	480
AGIFVKNPAP	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLK	KAVVTEKYED	DRRKSFKKIG	540
SFSLBQLQEQ	ADADLSVVEK	LKEIITQKVD	EYKVKVYGSSE	KLPDADFLVE	KSLKKNDAVV	600
AIMKDLSDSV	KSPFENYIKAF	FGEKGTNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQFMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFPSSKWM	AYNPNSEDIQ	KIYKNGTFPK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DFNFSSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMPQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRASLKK	900
EELVVHPANS	PIANKNPDNP	KKTPTTSLYDV	YDKRFSDEQY	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIDR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVKVEKQVY	QKFEKMLIDK	LNVMVDKKS	PCATGGALKG	YQITNKPESF	KSMSTQNGFI	1140
FYPAPWLTSK	IDPSTGFVNL	LKTKYTSIAD	SKKFISSFDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNKNN	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSFMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGIFYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQPKKAED	EKLKVKIAIS	SNKEWLEYAQ	TSVKH	1375

SEQ ID NO: 128                   moltype = AA   length = 1377  
 FEATURE                        Location/Qualifiers  
 source                         1..1377  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 128

MGSKLEKFTN	CYSLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKKTREK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGEENQTTQK	300

-continued

TTQKGQKNSR	ERMKRIEEGI	KELGSQILKE	HPVENTQLQN	EKLYLYLQ	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGGI	SGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLFKNFDEY	480
SSAGIFVKNG	PAISTISKIA	FGEWNVIRDK	WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	540
IGSFSLEQLQ	EYADADLSV	EKLKEIIIQK	VDEIYKVVYS	SEKLFADDFV	LEKSLKKNDA	600
VVAINMKDLLD	SVKSFENYIK	AFPGEGKETN	RDESPYGFV	LAYDILLKVD	HIYDAIRNYV	660
TQKPYSKDKF	KLYQNPQFM	GGWDDKEDT	YRATILRYGS	KYLLAIMDKK	YAKCLQKIDK	720
DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYYNPSED	IQKIYKNGTF	KKGDMFNLND	780
CHKLIDPFKD	SISRYPKWSN	AYDFNFSETE	KYKDIAGPYR	EVEREQYKVS	FESASKEVD	840
KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	900
KKEELVVHPA	NSPIANKNPD	NPKKTTTSLY	DVYKDKRFSE	DQYELHIPIA	INKCPKNIFK	960
INTEVRVLLK	HDDNPYVIGI	DRGERNLLYI	VVVDGKGNIV	EQYSLNEIIN	NFNIGIRIKTD	1020
YHSLLDKKEK	ERFPEARQNT	SINIENIKEL	GYISQVVHKI	CELVEKYDAV	IALEDLNSGF	1080
KNSRVKVEKQ	VYQKFEKMLI	DKLNMYMVDK	SNPCATGGAL	KGYQITNKFE	SFKSMSTQNG	1140
FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSE	DRIMYVPEED	LFEPALDYKN	1200
FSRTDADYIK	KKKLYSYGNR	IRIRFNPKKN	NVDFWEEVCL	TSAYKELFNK	YGINYQQGDI	1260
RALLCEQSDK	AFYSSFMALM	SLMLQMRNSI	TGRTDVDFLI	SPVKNSDGI	YDSRNYEAQE	1320
NAILPKNADA	NGAYNIARKV	LWAIGQFKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH	1377

SEQ ID NO: 129           moltype = AA   length = 1379  
 FEATURE                Location/Qualifiers  
 source                   1..1379  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 129

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKTRTEK	ENKELELEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETTLF	EFLDDKDEIA	LVNSFNGFTT	AFTGFNDRE	NMFSEAKST	SIAFRINEN	180
LTRYISNMDI	FEKVAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRLESLF	YGENQTTQKG	300
TTQKGQKNSR	ERMKRIEEGI	KELGSQILKE	HPVENTQLQN	EKLYLYLQ	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGGI	SGSGYTSDEE	VLEFRNTLN	KNSIEFSSIK	KLEKLPKNPD	480
EYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKKAVVTE	KYEDDRRKS	540
KKIGSFSLEQ	LQYADADLS	VVEKLEIII	QKVDEIYKVY	GSSEKLPDAD	FVLEKSLKKN	600
DAVVAIMKDL	LDSVKSFENY	IKAFPGEGKE	TNRDESPYGD	FVLAIDILLK	VDHIYDAIRN	660
YVTQKPYSKD	KFKLYPNQF	FMGGWDDKKE	TDYRATILRY	GSKYLLAIMD	KKYAKCLQKI	720
DKDDVNGNYE	KINYKLLPGP	NKMLPKVFFS	KKWMAYYNPS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDFNFSE	TEKYKDIAGF	YREVEEQYKS	VSPESASKE	840
VDKLVVEGKL	ERFQIYNKDF	SKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAELEFMRA	900
SLKKEELVVH	PANSPIANKN	PDNPKTTTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	960
PKINTEVRVL	LKHDNDPYVI	GDRGERNLL	YIVVDGKGN	IVEQYSLNEI	INNFNIGIRI	1020
TDYHSLLDK	KEKRFPEARQ	WTSIENIKEL	KAGYISQVVH	KICELVEKYD	AVIALEDLNS	1080
GPKNSRVKVE	KQVYQKFEKM	LIDKLNMYVD	KKSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140
NGFIYIPAW	LTSKIDPSTG	FVNLLKTKYT	SIADSKKPI	SFDRIMYVPE	EDLFEPALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRI FRNPK	KNNVDFWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIGQFK	KAEDEKLDKV	KIATSNKEWL	EYAQTSVKH	1379

SEQ ID NO: 130           moltype = AA   length = 1373  
 FEATURE                Location/Qualifiers  
 source                   1..1373  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 130

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKTRTEK	ENKELELEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETTLF	EFLDDKDEIA	LVNSFNGFTT	AFTGFNDRE	NMFSEAKST	SIAFRINEN	180
LTRYISNMDI	FEKVAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKI KGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRLESLF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YLLQNGRDMY	VDQELDNRL	360
SDYDVHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKPDNLTKA	ERGLSEBGT	SDEEVLVFR	NLTNKNSEIF	SSIKKLEKLF	KNFDEYSAG	480
IFVKNGPAIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQYAD	ADLSVVEKLE	EIIIQKVDI	YKVGSSSEKL	FDADVFLEKS	LKNDAVVAI	600
MKDLLDSVKS	FENYIKAFPG	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	720
GNYEKINYLK	LPGPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	YKNGTFPKGD	MFNLDNCHKL	780
IDFFKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVEE	QGYKVSFESA	SKKEVDKLVE	840
EGKLYMPQIY	NKDFSDKSHG	TPNLHTMYFK	LFLDENNHGQ	IRLSGGAELE	MRRASLKKEE	900
LVVHPANSPI	ANKNPDNPKK	TTTLYSDVYK	DKRFSQYQY	LHPIAIANKN	PKNIFKINTE	960
VRVLLKHDDN	PYVIGIDRGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNPNF	IRIKTDYHSL	1020
LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVKICELV	EKYDAVIALE	DLNSGPKNSR	1080
VKVEKQVYQK	EKMLIDKLN	YMVDDKSNPC	ATGKALKGYQ	ITNKFESFKS	MSTQNGFIFY	1140
IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSFDRI	YVPEEDLFEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNVDF	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	1260

-continued

CEQSDKAPYS SFMALMSLML QMRNSITGRT DVDFLISPVK NSDGIIFYDSR NYEAQENAIL 1320  
 PKNADANGAY NIARKVLWAI GQPKKAEDK LDKVKIAISN KEWLEYAQTS VKH 1373

SEQ ID NO: 131 moltype = AA length = 1375  
 FEATURE Location/Qualifiers  
 source 1..1375  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 131  
 MGSKLEKPTN CYSLSKTLRF KAIPVGKTQE NIDNKRLLE DEKRAEDYKG VKKLLDRYYL 60  
 SFINDVLHST KLKLNLNYS LFRKTRTEK ENKELENLEI NLRKEIAKAF KEGNEGYKSLF 120  
 KKDIIETILP EFLDDKDEIA LVNSPFGFTT AFTGFFDNRE NMFSEEAKST SIAFRGINEN 180  
 LTRYISNMDI FEKVDAIFDK HEVQEIKEKI LNSDYDVEDF FEGEFFNFVL TQEGIDVYNA 240  
 IIGGFVTESG EKI KGLNEYI NLYNQKTKQK LPKFKPLYKQ VLSDRSLSF YGSSGENQT 300  
 KGQKNSRERM KRIEEGIKEL GSGILKEHPV ENTQLQNEKL YLYLQNGRD MYVDQBELDIN 360  
 RLSDYDVVDH VPOQFLKDD IDNKVLTRSD KNRGKSDNVP SEEVVKKMKN YWRQLNLAKL 420  
 ITQRKFDNLT KAERGGLSEG YTSDEEVLEV FRNTLNKNS IFSSIKKLEK LFKNFDEYSS 480  
 AGIFVKNGPA ISTISKDIFG EWNVIRDKWN AEYDDIHLK KAVVTEKYED DRRKSPKKIG 540  
 SFSLEQLQEQY ADADLSVVEK LKEIIIQKVD EYKYVGSSE KLPDADFVLE KSLKNDVAV 600  
 AIMKDLDSV KSPFENYKAF FEGEKETNRD ESFYGDFVLA YDILLKVDHI YDAIRNYVTQ 660  
 KPYSKDKFKL YFQNPQFMGG WDKDKETDYR ATILRYGSKY YLAIMDKKYA KCLQKIDKDD 720  
 VNGNYEKINY KLLPGPNKML PKVFFSKKWM AYNPSEDIQ KIYKNGTFKK GDMFNLDCH 780  
 KLIDPFKDSI SRYPKWSNAY DNFSETEKY KDIAGFYREV EEQGYKVSFE SASKKEVDKL 840  
 VEKGKLYMFQ IYNKDFSDS HGTPNLHTMY FKLDFDENNH GQIRLSGGAE LFMRRASLKK 900  
 EELVHVHPNS PIANKNDPNP KKTTLTSLYDV YDKRFRSEDO YELHIPIAIN KCPKNIFKIN 960  
 TEVRVLLKHD DNPYVIGIDR GERNLIIYIV VDGKGNIVEQ YSLNEIINNF NGIRIKTDYH 1020  
 SLLDKKEKER FEARQNTSI ENIKELKAGY ISQVVKICE LVEKYDAVIA LEDLNSGFKN 1080  
 SRVKVEKQVY QKFLMLIDK LNYMVDKSN PCATGGALKG YQITNKFSF KSMSTQNGFI 1140  
 FYIPAWLTSK IDPSTGFVNL LKTKYTSIAD SKKFISSFDR IMYVPEEDLF EFALDYKNFS 1200  
 RTDADYIKKW KLYSYGNRIR IFRNPKKNV PDWEEVCLTS AYKELFNKYG INYQQGDIRA 1260  
 LLCEQSDKAF YSSFMALMSL MLQMRNSITG RTDVDFLISP VKNSDGIIFYD SRNYEAQENA 1320  
 ILPKNADANG AYNIARKVLW AIGQPKKAED EKLDKVKIAI SNKEWLEYAQ TSVKH 1375

SEQ ID NO: 132 moltype = AA length = 1377  
 FEATURE Location/Qualifiers  
 source 1..1377  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 132  
 MGSKLEKPTN CYSLSKTLRF KAIPVGKTQE NIDNKRLLE DEKRAEDYKG VKKLLDRYYL 60  
 SFINDVLHST KLKLNLNYS LFRKTRTEK ENKELENLEI NLRKEIAKAF KEGNEGYKSLF 120  
 KKDIIETILP EFLDDKDEIA LVNSPFGFTT AFTGFFDNRE NMFSEEAKST SIAFRGINEN 180  
 LTRYISNMDI FEKVDAIFDK HEVQEIKEKI LNSDYDVEDF FEGEFFNFVL TQEGIDVYNA 240  
 IIGGFVTESG EKI KGLNEYI NLYNQKTKQK LPKFKPLYKQ VLSDRSLSF YGSSGENQT 300  
 TQKQKNSRE RMKRIEIEGK ELGSGILKEH PVENTQLQNE KLYLYLQNG RDMYVDQELD 360  
 INRLSDYDVD HIVPQFLKD DSIDNKVLR SDKNRGKSDN VPSEEVVKKM KNYWRQLLNA 420  
 KLITQRKFDN LTKAERGGLS EGYTSDEEVL EVFRNTLNKN SEIFSSIKKL EKLFKNFDEY 480  
 SSAGIFVKNG PAISTISKDI FGWNVIRDK WNAEYDDIHL KKKAVVTEKY EDDRRKSPFK 540  
 IGSFLEQLQ EYADADLSV EKLKEIIQK VDEIYKYVGS SEKLPDADFV LEKSLKNDNA 600  
 VVAIMKDLDD SVKSPFENYK AFFGEGKETN RDESFGDFV LAYDILLKVD HIYDAIRNYV 660  
 TQKPYSKDKF KLYPQNPQFM GGWDKDKETD YRATILRYGS KYLLAIMDKK YAKCLQKIDK 720  
 DDVNGNYEKI NYKLLPGPNK MLPKVFFSKK WMAYNPSED IQKIYKNGTF KKGDMFNLND 780  
 CHKLIDPFKD SISRYPKWSN AYDFNFSETE KYKDIAGFYR EVBEOGYKVS FESASKKEVD 840  
 KLVEEGKLYM FQIYNKDFSD KSHGTPNLHT MYPKLLFDEN NHGQIRLSGG AELFMRRASL 900  
 KKEELVVHVA NSPIANKNDP NPKKTTLSY DVYDKRFRSE DQYELHIPIA INKCPKNIFK 960  
 INTEVRVLLK HDDNPYVIGI DRGERNLIIY VVDGKGNIV EQYSLNEIIN NFNNGIRIKTD 1020  
 YHSLLDKKEK ERFEARQNT SIENIKELKA GYISQVVKHI CELVEKYDAV IALEDLNSGF 1080  
 KNSRVKVEKQ NYKLLPGPNK MLPKVFFSKK SNPCATGGAL KGYQITNKFE SFSKSMSTQNG 1140  
 FIFYIPAWLT SKIDPSTGFV NLLKTKYTSI ADSKFISSF DRIMYVPEED LFEPALDYKN 1200  
 FSRTDADYIK KWKLYSYGNR IFRNPKKNV NVDWEEVCL TSAYKELFNK YGINYQQGDI 1260  
 RALLCEQSDK AFYSSFMALM SMLQMRNSITG TRTDVDFLI SPVKNSDGIIFYD YDSRNYEAQENA 1320  
 NAILPKNADA NGAYNIARKV LWAIGQPKKA EDEKLDKVKI AISNKEWLEY AQTSVKH 1377

SEQ ID NO: 133 moltype = AA length = 1379  
 FEATURE Location/Qualifiers  
 source 1..1379  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 133  
 MGSKLEKPTN CYSLSKTLRF KAIPVGKTQE NIDNKRLLE DEKRAEDYKG VKKLLDRYYL 60  
 SFINDVLHST KLKLNLNYS LFRKTRTEK ENKELENLEI NLRKEIAKAF KEGNEGYKSLF 120  
 KKDIIETILP EFLDDKDEIA LVNSPFGFTT AFTGFFDNRE NMFSEEAKST SIAFRGINEN 180  
 LTRYISNMDI FEKVDAIFDK HEVQEIKEKI LNSDYDVEDF FEGEFFNFVL TQEGIDVYNA 240  
 IIGGFVTESG EKI KGLNEYI NLYNQKTKQK LPKFKPLYKQ VLSDRSLSF YGSSGENQT 300  
 TQKQKNSRE RMKRIEIEGK ELGSGILKEH PVENTQLQNE KLYLYLQNG RDMYVDQELD 360  
 INRLSDYDVD HIVPQFLKD DSIDNKVLR SDKNRGKSDN VPSEEVVKKM KNYWRQLLNA 420



-continued

KLITQRKFPD	LTKAERGGSL	GSEGYTSDEE	VLEVPFRNTLN	KNSEIFSSIK	KLEKLFKPNFD	480
EYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKKAVVTE	KYEDDRRKSF	540
KKIGSFSLEQ	LQEYADADLS	VVEKLKEIII	QKVDEIYKVY	GSSKELFPDAD	FVLEKSLKKN	600
DAVVAIMKDL	LDSVKSFENY	IKAFFGEGKE	TNRDESFYGD	FVLAYDILLK	VDHIYDAIRN	660
YVTQKPYSK	KFKLYFQNPQ	FMGGWDKDK	TDYRATILRY	GSKYYLAIMD	KKYAKCLQKI	720
DKDDVNGNVE	KINYKLLPGP	NKMLPKVFFS	KKWMAYNPS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDPNFSE	TEKYKDIAGF	YREVEEQGYK	VSPESASKKE	840
VDKLVEEGKL	YMPQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAELPMRRA	900
SLKKEELVVH	PANSPIANKN	PDNPKKTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	960
FKINTEVRVL	LKHDDNPYVI	GIDRGERNLL	YIVVVDGKGN	IVEQYSLNEI	INNFNGIRIK	1020
TDYHSLDDKK	EKERFEARQN	WTSIENIKEL	KAGYISQVVH	KICELVEKYD	AVIALEDLNS	1080
GFKNRSRVKE	KQVYQKPEKM	LIDKLNVMVD	KKSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140
NGFIYFIPAW	LTSKIDPSTG	FVNLKTKTYT	SIADSKKPFIS	SFDRIMVYVE	EDLFEPALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRIFRNPK	KNNVFDWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIGQPK	KAEDEKLDKV	KIAISNKEWL	EYAQTSVKH	1379

SEQ ID NO: 134                   moltype = AA   length = 1373  
 FEATURE                        Location/Qualifiers  
 source                         1..1373  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 134

MGSKLEKFTN	CYLSKTLTRF	KAIPVGKTQE	NIDNKRLIVE	DEKRAEDYKG	VKLLDRLRYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKKTTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLE	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEBAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRRESLSF	YGEENQTTQK	300
GQKNSRERMK	RIEBEIKELG	SQILKEHPVE	NTQLQNEKLY	LYYLQNGRDM	YVDQELDINR	360
LSDYDVDHIV	PQSFLKDDSI	DNKVLTRSDK	NRGKSDNVPS	EEVVKMKMNY	WRQLLNAKLI	420
TQRKFDNLTQ	AERGGLSGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	KNFDEYSSAG	480
IPVKNPAPIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQEQYAD	ADLSVVEKLL	EIIIQKVDEI	YKVYGSSEKL	FDADPVLKES	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFFG	EKGKTNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	720
GNYEKINYKL	LPGPNKMLPK	VFPKSKWMAY	YNPSEDIQKI	YKNGTFPKGD	MFNLNDCHKL	780
IDFFKDSISR	YPKNSNAYDF	NFSETEKYKD	IAGFYREVVEE	QGYKVSFESA	SKKEVDKLV	840
EGKLYMPQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELE	MRRASLKKKE	900
LVVHPANSPI	ANKNPDNPCK	TTTLSYDVYK	DKRFSEDDQY	LHIPIAINKC	PKNIFKINTE	960
VRVLLKHDDN	PYVIGIDRGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNFRG	IRIKTVYHSL	1020
LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVHKICELV	EKYDAVIALE	DLNSGPKNSR	1080
VKVEKQVYQK	PEKMLIDKLN	YMWVKKSNPC	ATGGALKGYQ	ITNKFESFKS	MSTQNGFIFY	1140
IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSFDRIM	YVPEEDLFEF	ALDYKNFSRT	1200
DADYIKKWKL	YSYGNRIRIF	RNPKNMVPD	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	1260
CEQSDKAFYS	SFPMALMSLML	QMRNSITGRT	DVDPLISPVK	NSDGI FYDSR	NYEAQENAIL	1320
PKNADANGAY	NIARKVLWAI	GQPKKAEDK	LDKVKIAISN	KEWLEYAQT	VKH	1373

SEQ ID NO: 135                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                         1..1375  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 135

MGSKLEKFTN	CYLSKTLTRF	KAIPVGKTQE	NIDNKRLIVE	DEKRAEDYKG	VKLLDRLRYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKKTTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLE	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEBAKST	SIAFRNCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRRESLSF	YGEENQTTQK	300
QKQKNSRER	MKRIEBEIKE	LGSQILKEHP	VENTQLQNEK	LYLYLQNGR	DMYVDQELDI	360
NRLSDYDVDH	IVPQSFLKDD	SIDNKVLTRS	DKNRGKSDNV	PSEEVVKMKM	NYWRQLLNK	420
LITQRKFDNLT	TKAERGGLSG	YTSDEEVLEV	FRNTLNKNSE	IFSSIKKLEK	LFPKFNDEYSS	480
AGIFVKNPAP	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLKK	KAVVTEKYED	DRRKSFPKIG	540
SFSLBQLQEQY	ADADLSVVEK	LKEIIIQKVD	EYKVVYGSSE	KLPDADPVIH	KSLKKNDAVV	600
AIMKDLLDSV	KSFENYIKAF	FGBGKTNTRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQFMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNVEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPNSEDIQ	KIYKNGTFPK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DFNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMPQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENN	GQIRLSGGAE	LPMRRAESLKK	900
EELVVHPANS	PIANKPNPDP	KKTTLTSLYDV	YDKRFSQEDQ	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIDR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVHKICE	LVEKYDAVIA	LEDLNSGPKN	1080
SRVKVEKQVY	QKFEKMLIDK	LNYMVDKKS	PCATGGALKG	YQITNKFESF	KSMSTQNGFI	1140
FYIPAWLTSK	IDPSTGFVNL	LTKYTSIAD	SKFIFSSPDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSFPMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGI FYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQPKKAED	EKLDKVKIAI	SNKEWLEYAQ	TSVKH	1375

-continued

SEQ ID NO: 136                   moltype = AA   length = 1377  
 FEATURE                        Location/Qualifiers  
 source                         1..1377  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 136

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LPRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFDFNRE	NMFSEAKST	SIAFRGINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YEGSSGENQ	300
TTQKGQKNSR	ERMKRIEEGI	KELGSQLKE	HPVENTQLQN	EKLYLYLQN	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGG	SGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLFKPFDEY	480
SSAGIFVKNG	PAISTISKDI	FGEWNVIRDK	WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	540
IGSFSLEQLQ	EYADADLSV	EKLKEIIIQK	VDEIYKVGYS	SEKLFDAFV	LEKSLKKNDA	600
VVAIMKDLDD	SVKSFENYIK	AFGEGKETN	RDESPYGFV	LAYDILLKVD	HIYDAIRNYV	660
TQKPYSKDKF	KLYFQNPQM	GGWDDKEDT	YRATILRYGS	KYLAIMDKK	YAKCLQKIDK	720
DDVNGNYEKI	NYKLLPFPNK	MLPKVFFSKK	WMAYNPSED	IQKIYKNGTF	KKGDMFNLD	780
CHKLIDFPKD	SISRYPKWSN	AYDFNFSETE	KYKDIAGPYR	EVEEQGYKVS	FESASKKEVD	840
KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSSG	AELFMRRASL	900
KKEELVVHPA	NSPIANKNDP	NPKKTTTLYS	DVYKDKRPFSE	DQYELHIPIA	INKCPKNIFK	960
INTEVRVLLK	HDDNPYVIGI	DRGERNLLYI	VVVDGKGNIV	EQYSLNEIIN	NFNGIRIKTD	1020
YHSLLDKKEK	ERFEARQNTW	SIENIKELKA	GYISQVVKHI	CELVEKYDAV	IALEDLNSGF	1080
KNSRVKVEKQ	VYQKPEKMLI	DKLNYMVDKK	SNPCATGGAL	KGYQITNKFE	SPFKSMSTQNG	1140
FIFYIPAWLT	SKIDPSTGPFV	NLLKTKYTSI	ADSKKFISSF	DRIMYVPEED	LFEPALDYKN	1200
FSRTDADYIK	KWKLYSYGNR	IRIFRNPKKN	NVFDWEEVCL	TSAYKELFNK	YGINYQQGDI	1260
RALLCEQSDK	AFYSSFMALM	SLMLQMRNSI	TGRTDVDFLI	SPVKNSDGI	YDSRNYEAQE	1320
NAILPKNADA	NGAYNIARKV	LWAIGQFKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH	1377

SEQ ID NO: 137                   moltype = AA   length = 1379  
 FEATURE                        Location/Qualifiers  
 source                         1..1379  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 137

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYK	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LPRKTRTEK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFDFNRE	NMFSEAKST	SIAFRGINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGEFFNFVL	TQEGIDVYNA	240
IIGGFVTEG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YEGSSGENQ	300
TTQKGQKNSR	ERMKRIEEGI	KELGSQLKE	HPVENTQLQN	EKLYLYLQN	GRDMYVDQEL	360
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	420
AKLITQRKFD	NLTKAERGG	SGSGYTSDEE	VLEVFRNTLN	KNSEIFSSIK	KLEKLPKNPD	480
EYSSAGIFVK	NGPAISTISK	DIFGEWNVIR	DKWNAEYDDI	HLKKKAVVTE	KYEDDRRKS	540
KKIGSFSLEQ	LQYADADLS	VVEKLEIII	QKVDEIYKVI	GSSEKLFAD	FVLEKSLKKN	600
DAVVAIMKDL	LDSVKSFENY	IKAPFGEKKE	TNRDESPYGD	FVLAIDILLK	VDHIYDAIRN	660
YVTQKPYSKD	KFKLYFQNPQ	FMGGWDKDK	TDYRATILRY	GSKYLLAAMD	KKYAKCLQKI	720
DKDDVNGNYE	KINYKLLPFP	NKMLPKVFFS	KKWMAYNPNS	EDIQKIYKNG	TFKKGDMFNL	780
NDCHKLIDFF	KDSISRYPKW	SNAYDFNFSE	TEKYKDIAGF	YREVEEQGYS	VSPESASKKE	840
VDKLVEEGKL	YMFQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAELEPMRA	900
SLKKEELVVH	PANSPIANKN	PDPNPKTTTL	SYDVYKDKRF	SEDQYELHIP	IANKCPKNI	960
FKINTEVRVL	LKHDDNPYVI	GIDRGERNLL	YIVVDGKGN	IVEQYSLNEI	INNFNGIRIK	1020
TDYHSLLDKK	EKERFEARQN	WTSIENIKEL	KAGYISQVVK	KICELVEKYD	AVIALEDLNS	1080
GPKNSRVKVE	KQVYQKPEKM	LIDKLNVMVD	KKSNPCATGG	ALKGYQITNK	FESFKSMSTQ	1140
NGFIFYIPAW	LTSKIDPSTG	FVNLLKTKYT	SIADSKKPI	SFDRIMYVPE	EDLFEPALDY	1200
KNFSRTDADY	IKKWKLYSYG	NRIRIFRNPK	KNNVFDWEEV	CLTSAYKELF	NKYGINYQQG	1260
DIRALLCEQS	DKAFYSSFMA	LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	1320
QENAILPKNA	DANGAYNIAR	KVLWAIGQFK	KAEDEKLDKV	KIATSNKEWL	EYAQTSVKH	1379

SEQ ID NO: 138                   moltype = AA   length = 1787  
 FEATURE                        Location/Qualifiers  
 REGION                         1..1787  
                                note = Synthetic polypeptide  
 source                         1..1787  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 138

MKRTADGSEF	ESPKKKRKVS	KLEKFTNCYS	LSKTLRFKAI	PVGKTQENID	NKRLLEVEDEK	60
RAEDYKGVKK	LLDRYYLSFI	NDVLHSIKLK	NLNNYISLFR	KKTRTEKENK	ELENLEINLR	120
KEIAKAFKGN	EGYKSLFKKD	IIETILPEPL	DDKDEIALVN	SFNGFTTAFT	GFFDNRENMF	180
SEEAKSTIA	FRCINENLTR	YISNMDIFEK	VDAIFDKHEV	QEIKEKILNS	DYDVEDFFEG	240
EFFNFVLTQE	GIDVYNAIG	GFVTEGSEKI	KGLNEYINLY	NQKTKQKLPK	FKPLYKQVLS	300
DRESLDFYGE	GSSGENQTTQ	KQKNSRERM	KRIEEGIKEL	GSQILKEHPV	ENTQLQNEKL	360
YLYYLQNGRD	MYVDQELDIN	RLSDYDVDHI	VPQSPFKDDS	IDNKVLRSD	KNRGKSDNVP	420

-continued

SEEVVKMKMN	YWRQLLNAKL	ITQRKPDNLT	KAERGGLSGY	TSDEEVLEVF	RNTLNKNSEI	480
FSSIKKLEKL	FKNFDEYSSA	GIFVKNGPAI	STISKDIFGE	WNVIRDKWNA	EYDDIHLKKK	540
AVVTEKYEDD	RRKSFKKIGS	FSLEQLQEYA	DADLSVVEKL	KEIIIQKVDE	IYKVYGSSEK	600
LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	SFENYKAFK	GEGKETNRDE	SFYGDFVLAY	660
DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	DKDKETDYRA	TILRYGSKYY	720
LAIMDKKYAK	CLQKIDKDDV	NGMYEKINIK	LLPGPNKMLP	KVFFSKKQMA	YYNPSEDIQK	780
IYKNGTFPKK	DMFNLDNCHK	LIDFFKDSIS	RYPKWSNAYD	FNFSETEKYK	DIAGFYREVE	840
EQGYKVSFES	ASKKEVDKLV	EEGKLYMFQI	YNKDFSDKSH	GTPNLHTMYF	KLLFDENNHG	900
QIRLSGGAEI	FMRRASLKEE	ELVVHPANSP	IANKNPDNPK	KTTTLSYDVY	KDKRFSEDOY	960
ELHIPIAINK	CPKNIKFINT	EVRLVKHDD	NPYVIGIARG	ERNLLYIVVV	DGKGNIVEQY	1020
SLNEIINNFN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	1080
VEKYDAVIAL	EDLNSGPKNS	RVKVEKQVYQ	KFEKMLIDKL	NYMVDKSNP	CATGGALKGY	1140
QITNKFESFK	SMSQTNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTQYTSIADS	KKFISSFDRI	1200
MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKKNMVF	DWEEVCLTSA	1260
YKELFNKYGI	NYQQGDIRAL	LCEQSDKAPY	SSFMALMSLM	LQMRNSTTGR	TDVDFLISP	1320
KNSDGIIFYDS	RNYEAQENAI	LPKNADANGA	YNIARKVLWA	IGQPKKAED	KLDKVKIAIS	1380
NKEWLEYAQT	SVKHGGGGSG	GGSGGGGGSG	PKKKRKVA	AAGSEELLSK	NYHLENEVAR	1440
KGSGSGSGSG	GGSGSGSGSG	GGSGSGSGSG	LLSKNYHLEN	EVARLKKKGS	SGSGSGSGSG	1500
SGSGSGSGSG	SGSGEELLSK	NYHLENEVAR	LKKSGSGSG	GGSGSGSGSG	SGSGSGSGSG	1560
EELLSKNYHL	ENEVARLKKG	SGSGSGSGSG	SGSGSGSGSG	GGSGSGEELL	SKNYHLENEV	1620
ARLKKGSGSG	GGSGSGSGSG	SGSGSGSGSG	SGEELLSK	NYHLENEVAR	KGSGSGSGSG	1680
GGSGSGSGSG	GGSGSGSGSG	LLSKNYHLEN	EVARLKKKGS	SGSGSGSGSG	SGSGSGSGSG	1740
SGSGEELLSK	NYHLENEVAR	LKKSGSGKRT	ADGSEFEPKK	KRKGSGSG		1780

SEQ ID NO: 139      moltype = AA    length = 1787  
 FEATURE            Location/Qualifiers  
 REGION             1..1787  
                     note = Synthetic polypeptide  
 source              1..1787  
                     mol\_type = protein  
                     organism = synthetic construct

SEQUENCE: 139

MKRTADGSEF	ESPKKKRQVS	KLEKFTNCYS	LSKTLRFKAI	PVGKTQENID	NKRLLEVEDEK	60
RAEDYKGVKK	LLDRYLSFI	NDVLHSIKLK	NLNYYISLFR	KKTRTEKENK	ELENLEINLR	120
KEIAKAFKGN	EGYKSLFKKD	IIETILPEFL	DDKDEIALVN	SFNGFTTAFT	GFFDNRENMF	180
SEEAKSTIA	FRCINENLTR	YISNMDIFEK	VDAIFDKHEV	QEIKEKILNS	DYDVEDFFEG	240
EFFNFVLTQE	GIDVYNAIIG	GFVTESEGEI	KGLNEYINLY	NQKTQKQLPK	FKPLYKQVLS	300
DRESLSFYGG	SSGENQTTQK	GQKNSRERMK	RIEIEGKELG	SQILKEHPVE	NTQLQNEKLY	360
LYYLQNGRDM	VYDQELDINR	LSDYVDVHIV	PQSFLKDDSI	DNKVLTRSDK	NRGKSDNVPS	420
SEEVVKMKMN	YWRQLLNAKL	ITQRKPDNLT	KAERGGLSGY	TSDEEVLEVF	RNTLNKNSEI	480
FSSIKKLEKL	FKNFDEYSSA	GIFVKNGPAI	STISKDIFGE	WNVIRDKWNA	EYDDIHLKKK	540
AVVTEKYEDD	RRKSFKKIGS	FSLEQLQEYA	DADLSVVEKL	KEIIIQKVDE	IYKVYGSSEK	600
LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	SFENYKAFK	GEGKETNRDE	SFYGDFVLAY	660
DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	DKDKETDYRA	TILRYGSKYY	720
LAIMDKKYAK	CLQKIDKDDV	NGMYEKINIK	LLPGPNKMLP	KVFFSKKQMA	YYNPSEDIQK	780
IYKNGTFPKK	DMFNLDNCHK	LIDFFKDSIS	RYPKWSNAYD	FNFSETEKYK	DIAGFYREVE	840
EQGYKVSFES	ASKKEVDKLV	EEGKLYMFQI	YNKDFSDKSH	GTPNLHTMYF	KLLFDENNHG	900
QIRLSGGAEI	FMRRASLKEE	ELVVHPANSP	IANKNPDNPK	KTTTLSYDVY	KDKRFSEDOY	960
ELHIPIAINK	CPKNIKFINT	EVRLVKHDD	NPYVIGIARG	ERNLLYIVVV	DGKGNIVEQY	1020
SLNEIINNFN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	1080
VEKYDAVIAL	EDLNSGPKNS	RVKVEKQVYQ	KFEKMLIDKL	NYMVDKSNP	CATGGALKGY	1140
QITNKFESFK	SMSQTNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTQYTSIADS	KKFISSFDRI	1200
MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKKNMVF	DWEEVCLTSA	1260
YKELFNKYGI	NYQQGDIRAL	LCEQSDKAPY	SSFMALMSLM	LQMRNSTTGR	TDVDFLISP	1320
KNSDGIIFYDS	RNYEAQENAI	LPKNADANGA	YNIARKVLWA	IGQPKKAED	KLDKVKIAIS	1380
NKEWLEYAQT	SVKHGGGGSG	GGSGGGGGSG	PKKKRKVA	AAGSEELLSK	NYHLENEVAR	1440
KGSGSGSGSG	GGSGSGSGSG	GGSGSGSGSG	LLSKNYHLEN	EVARLKKKGS	SGSGSGSGSG	1500
SGSGSGSGSG	SGSGEELLSK	NYHLENEVAR	LKKSGSGSG	GGSGSGSGSG	SGSGSGSGSG	1560
EELLSKNYHL	ENEVARLKKG	SGSGSGSGSG	SGSGSGSGSG	GGSGSGEELL	SKNYHLENEV	1620
ARLKKGSGSG	GGSGSGSGSG	SGSGSGSGSG	SGEELLSK	NYHLENEVAR	KGSGSGSGSG	1680
GGSGSGSGSG	GGSGSGSGSG	LLSKNYHLEN	EVARLKKKGS	SGSGSGSGSG	SGSGSGSGSG	1740
SGSGEELLSK	NYHLENEVAR	LKKSGSGKRT	ADGSEFEPKK	KRKGSGSG		1780

SEQ ID NO: 140      moltype = AA    length = 1789  
 FEATURE            Location/Qualifiers  
 REGION             1..1789  
                     note = Synthetic polypeptide  
 source              1..1789  
                     mol\_type = protein  
                     organism = synthetic construct

SEQUENCE: 140

MKRTADGSEF	ESPKKKRQVS	KLEKFTNCYS	LSKTLRFKAI	PVGKTQENID	NKRLLEVEDEK	60
RAEDYKGVKK	LLDRYLSFI	NDVLHSIKLK	NLNYYISLFR	KKTRTEKENK	ELENLEINLR	120
KEIAKAFKGN	EGYKSLFKKD	IIETILPEFL	DDKDEIALVN	SFNGFTTAFT	GFFDNRENMF	180
SEEAKSTIA	FRCINENLTR	YISNMDIFEK	VDAIFDKHEV	QEIKEKILNS	DYDVEDFFEG	240
EFFNFVLTQE	GIDVYNAIIG	GFVTESEGEI	KGLNEYINLY	NQKTQKQLPK	FKPLYKQVLS	300

-continued

DRESLSFYGG	SSGENQTTQK	GQKNSRERMK	RIEEGIKELG	SQILKEHPVE	NTQLQNEKLY	360
LYYLQNGRDM	YVDQELDINR	LSDYVDHIV	PQSFLKDDSI	DNKVLTRSDK	NRGKSDNVPS	420
EEVVKMKMNY	WRQLLNAKLI	TQRKPDNLTK	AERGLSGSE	GYTSDDEEVL	VFRNTLNKNS	480
EIFSSIKKLE	KLFKNFDEYS	SAGIFVKNGP	AISTISKDIF	GEWNVIRDKW	NAEYDDIHLK	540
KKAVVTEKEYE	DDRRKSFKKI	GSFSLEQLQE	YADADLSVVE	KLKEIIQKV	DEIYKVYSS	600
EKLFPDADFVL	EKSLKKNDAV	VAIMKDLLDS	VKSPFENYKA	FFGEGKETNR	DESFYGDVFL	660
AYDILLKVDH	IYDAIRNYVT	KRPYSKDKFK	LYFQNPQPMG	GWDKDKETDY	RATILRYGSK	720
YYLAIMDKKY	AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	780
QKIYKNGTFK	KGMDFNLNDC	HKLIDFFKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGFYRE	840
VEEQGYKVSF	ESASKHEVVK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHTM	YFKLLPDENN	900
HGQIRLSGGA	ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	PKKTTLTSLYD	VYKDKRFSED	960
QYELHIPAI	NGCKPNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	1020
QYSLNEIINN	FNGIRITDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	YISQVVKIC	1080
ELVEKYDAVI	ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	1140
GYQITNKFES	FKSMSTQNGF	IFYIPAWLTS	KIDPSTGPNV	LLKTKYTSIA	DSKFFISSPD	1200
RIMYVPEEDL	FEPALDYKNF	SRTDADYIKK	WKLYSYGNRI	RIFRNPKNKN	VFDWEVCLT	1260
SAYKELFNKY	GINYQQGDIR	ALLCEQSDKA	FYSSPFMALMS	LMLQMRNSIT	GRTDVDFLIS	1320
PVKNSDGIFY	DSRNYEAQEN	AILPKNADAN	GAYNIARKVL	WAIQGFQKAE	DEKLDKVKIA	1380
ISNKEWLEYA	QTSVKHGGGG	SGGGSGGGG	SGPKKRVKA	AAGSEELLSK	NYHLENEVAR	1440
LKKGSGSGGS	SGGGSGSGG	SGGGSGSGG	EELLSKNYHL	ENEVARLKKG	SGSGSGSGG	1500
SGSGSGSGGS	SGSGSGBELL	SKNYHLENEV	ARLKKGSGSG	SGSGSGSGG	SGSGSGSGG	1560
SGBELLSKNY	HLENEVARLK	KSGSGSGSG	SGSGSGSGG	SGSGSGGEE	LLSKNYHLEN	1620
EVARLKKGSG	SGSGSGSGG	SGSGSGSGG	SGSGBELLSK	NYHLENEVAR	LKKGSGSGGS	1680
SGSGSGSGGS	SGSGSGSGG	EELLSKNYHL	ENEVARLKKG	SGSGSGSGG	SGSGSGSGG	1740
GGSGSGBELL	SKNYHLENEV	ARLKKSGGSK	RTADGSEFEP	KKRKRKVGSG		1789

SEQ ID NO: 141           moltype = AA   length = 1739  
 FEATURE                Location/Qualifiers  
 REGION                 1..1739  
                        note = Synthetic polypeptide  
 source                 1..1739  
                        mol\_type = protein  
                        organism = synthetic construct

SEQUENCE: 141

MKRTADGSEF	ESPKKKRKVE	ASPASGPRHL	MDPHIFTSNF	NNGIGRHKTY	LCYEVEERLDN	60
GTSVKMDQHR	GFLHNQAKNL	LCGFYGRHAE	LRFLDLVPSL	QLDPAQIYRV	TWFISWSPCF	120
SWGAGEVRA	FLQENTHVR	RIFAARIYDY	DPLYKEALQM	LRDAGAQVSI	MTYDEPKHCW	180
DTFVDHQGCP	FQPWDGLDEH	SQALSGRLRA	ILQNQGNSTS	QSDGSSVPAD	IDQSSSDSDQS	240
SSQGGPQSKL	EKFPTNCYLS	KTLRPFKAI	PVGTQENIDNK	RLLEVEDEKRA	EDYKGVKLL	300
DRYLLSFIND	VLHSIKLKNL	NNYISLFRKK	TRTEKENKEL	ENLEINLRKE	IAKAFKNEG	360
YKSLFKKDI	ETILPEFLDD	KDEIALVNSF	NGFTTAFTGF	FDNRENMFSE	EAKSTSIAPR	420
CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	IKEKILNSDY	DVEDFFEGEF	FNFLVTQEGI	480
DVYNALIGGF	VTESGKISRY	LNEYINLYNQ	KTKQKLPKFK	PLYKQVLSDR	ESLSFYGEYS	540
SGENQTTQK	QKNSRERMK	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	600
VDQELDINRL	SDYVDHIVP	QSFLLKDDSI	NKVLTRSDKN	RGKSDNVPS	EVVVKMKMNY	660
RQLLNAKLIT	QRKFDNLTKA	ERGLSGYTS	DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLPK	720
NFDEYSSAGI	FVKNGPAIST	ISKDIFGEWN	VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	780
KSPFKIGSFS	LEQLQEYADA	DLSVVEKLE	IIIQKVDEIY	KVYGSSEKLF	DADDFVLEKSL	840
KNDAAVVAIM	KDLLDSYKSF	ENYIKAFFGE	GKETNRDESF	YGFVFLAYDI	LLKVDHIYDA	900
IRNYVTQKPY	SKDKFKLYFQ	NPQFMGGWDK	DKETDYRATI	LRYGSKYLLA	IMDKKYAKCL	960
QKIDKDDVNG	NYEKINYLK	PGPNKMLPKV	PFKSKWMAYY	NPSEDIQKIY	KNGTFPKGDM	1020
PNLNDCHKLI	DFPKDSISRY	PKWSNAYDFN	FSETEKYKDI	AGFYREVEEQ	GYKVSFESAS	1080
KKEVDKLVVE	GKLYMPQIYN	KDFSDKSHGT	PNLHTMYFKL	LFDENNHGQI	RLSOGAELFM	1140
RRASLKKEEL	VVHPANSPIA	NKNPDNPKKT	TTLSDYVYKD	KRFSEQYEL	HIPAIANKCP	1200
KNIFKINTEV	RVLLKHDDNP	YVIGIARGER	NLLYIVVVDG	KGNIVEQYSL	NEIINNNGI	1260
RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	1320
LNSGFKNRSV	KVEKQVYQKF	EKMLIDKLN	MVDKKSNP	TGGALQYQI	TNKFESFKSM	1380
STQNGFIFYI	PAWLTSKIDP	STGFVNLLKT	KYTSIADSKK	FISSFDRIMY	VPEEDLFEFA	1440
LDYKNFSRTD	ADYIKKWKLY	SYGNRIRIFR	NPKNVDFDW	EEVCLTSAYK	ELFNKYGINY	1500
QQGDIRALLC	EQSDKAFYSS	FMALMSLMLQ	MRSNTIGRTD	VDFLISPVKN	SDGIFYDSRN	1560
YEAQENAILP	KNADANGAYN	IARKVLWAI	GQFKAEDEKL	DKVKIAISNK	EWLEYAQTSTV	1620
KHSGSGSGGS	GSTNLSDIIE	KETGKQLVIQ	ESILMLPEEV	EEVIGNKPES	DILVHTAYDE	1680
STDENVMLLT	SDAPEYKPA	LVIQDSNGEN	KIKMLSGGSK	RTADGSEFEP	KKRKRKVGSG	1739

SEQ ID NO: 142           moltype = AA   length = 1739  
 FEATURE                Location/Qualifiers  
 REGION                 1..1739  
                        note = Synthetic polypeptide  
 source                 1..1739  
                        mol\_type = protein  
                        organism = synthetic construct

SEQUENCE: 142

MKRTADGSEF	ESPKKKRKVE	ASPASGPRHL	MDPHIFTSNF	NNGIGRHKTY	LCYEVEERLDN	60
GTSVKMDQHR	GFLHNQAKNL	LCGFYGRHAE	LRFLDLVPSL	QLDPAQIYRV	TWFISWSPCF	120
SWGAGEVRA	FLQENTHVR	RIFAARIYDY	DPLYKEALQM	LRDAGAQVSI	MTYDEPKHCW	180
DTFVDHQGCP	FQPWDGLDEH	SQALSGRLRA	ILQNQGNSTS	QSDGSSVPAD	IDQSSSDSDQS	240

-continued

SSQGQPGSKL	EKFNTNCYSLS	KTLRFKAI PV	GKTQENIDNK	RLLVEDEKRA	EDYKGVKKLL	300
DRYLSFIND	VLHSIKLKNL	NNYISLFRKK	TRTEKENKEL	ENLEINLRKE	IAKAFKGNEG	360
YKSLFKKDI	ETILPEFLDD	KDEIALVNSF	NGFTTAFTGF	FDNRENMFSE	EAKSTSIAPR	420
CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	IKEKILNSDY	DVEDFFEGEF	FNFLVLTQEGI	480
DVYNAIIGGF	VTESGEIKG	LNEYINLYNQ	KTKQKLPKFK	PLYKQVLSDR	ESLSFYGGSS	540
GENQTTQKGQ	KNSRERMKRI	EEGIKELGSQ	ILKEHPVENT	QLQNEKLYLY	YLQNGRDMYV	600
DQELDINRLS	DYDVDHIVPQ	SFLKDDSIDN	KVLTRSDKNR	GKSDNVPSEE	VVKKMKNYWR	660
QLLNAKLITQ	RKFDNLTKAE	RGGLSGEGYS	DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLPK	720
NFDEYSSAGI	FKVNGPAIST	ISKDIFGEWN	VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	780
KSFKKIGSFS	LEQLQEVYADA	DLSVVEKLKE	IIIQKVDIY	KVYGSSEKLF	DADFVLEKSL	840
KNDAVVAIM	KDLLDSVKSF	ENYIKAFFGE	GKETNRDESF	YGFVFLAYDI	LLKVDHIYDA	900
IRNYVTQKPY	SKDKFKLYFQ	NPQFMGGWDK	DKETDYRATI	LRVGSKYLLA	IMDKKYAKCL	960
QKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	FFSKKMAYY	NPSEDIQKIY	KNGTFKKGDM	1020
FNLNDCHKLI	DFPKDISISRY	PKWSNAYDFN	FSETEKYKDI	AGFYREVEEQ	GYKVSFESAS	1080
KKEVDKLVVE	GKLYMPQIYN	KDFSDKSHGT	PNLHTMYPKL	LFDENNHGQI	RLSGGAEELFM	1140
RRASLKKEEL	VVHPANSPIA	NKNPDNPKKT	TLSYDVYKD	KRFSEDDQYEL	HIPAIANKCP	1200
KNIFKINTEV	RVLKHHDDNP	YVIGIARGER	NLLYIVVVDG	KGNIVEQYSL	NEIINNNGFI	1260
RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	1320
LNSGFKNSRV	KVEKQVYQF	KMLIDKLN	MVDKSNPCA	TGGALKGYQI	TNKFESFKSM	1380
STQNGFIFYI	PAWLTSKIDP	STGFVNLLKT	KYTSIADSKK	FISSFDRIMY	VPEEDLFEPFA	1440
LDYKNFSRTD	ADYKWKWLY	SYGNRIRIPR	NPKNVDFDW	EEVCLTSAYK	ELFNKYGINY	1500
QQGDIRALLC	BQSDKAFYSS	FMALMSLMQ	MRNSITGRD	VDFLISPVKN	SDGIFVDSRN	1560
YEAQENAILP	KNADANGAYN	IARKVLWAI	QFKKADEKLE	DKVKIAISNK	EWLEYAQTSTV	1620
KHSGSGSGG	GSTNLSIDIE	KETGKQLVIQ	ESILMLPEEV	EEVIGNKPEP	DILVHTAYDE	1680
STDENVMLLT	SDAPEYKPA	LVIQDSNGEN	KIKMLSGGSK	RTADGSEFEP	KKRKRKVGSG	1739

SEQ ID NO: 143                   moltype = AA   length = 1741  
 FEATURE                        Location/Qualifiers  
 REGION                         1..1741  
                                note = Synthetic polypeptide  
 source                         1..1741  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 143

MKRTADGSEF	ESPCKKRKVE	ASPASGPRHL	MDPHIFTSNF	MNGIGRHKTY	LCYEVERLND	60
GTSVKMDQHR	GFLHNQAKNL	LCGFYGRHAE	LRFLDLVPSL	QLDPAQIYRV	TWFIWSWPCF	120
SWGACAGEVRA	FLQENTHVR	RIFAARIYD	DPLYKEALQ	LRDAGAQVSI	MTYDEFKHCW	180
DTFVDHQGCP	FQPDWGLDEH	SQALSGRLRA	ILQNGNSTS	QSDGSSVPAD	IDQSSSDSDQS	240
SSQGQPGSKL	EKFNTNCYSLS	KTLRFKAI PV	GKTQENIDNK	RLLVEDEKRA	EDYKGVKKLL	300
DRYLSFIND	VLHSIKLKNL	NNYISLFRKK	TRTEKENKEL	ENLEINLRKE	IAKAFKGNEG	360
YKSLFKKDI	ETILPEFLDD	KDEIALVNSF	NGFTTAFTGF	FDNRENMFSE	EAKSTSIAPR	420
CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	IKEKILNSDY	DVEDFFEGEF	FNFLVLTQEGI	480
DVYNAIIGGF	VTESGEIKG	LNEYINLYNQ	KTKQKLPKFK	PLYKQVLSDR	ESLSFYGGSS	540
GENQTTQKGQ	KNSRERMKRI	EEGIKELGSQ	ILKEHPVENT	QLQNEKLYLY	YLQNGRDMYV	600
DQELDINRLS	DYDVDHIVPQ	SFLKDDSIDN	KVLTRSDKNR	GKSDNVPSEE	VVKKMKNYWR	660
QLLNAKLITQ	RKFDNLTKAE	RGGLSGEGYS	TSDEEVLEVFRN	TLNKNSEIFS	SIKKLEKLPK	720
FKNFDEYSSA	GIFVNGPAI	STISKDIFGE	WNVIRDKWNA	EYDDIHLKKK	AVVTEKYEDD	780
RRKSFKKIGS	FMKLEQVYQ	DADLSVVEKL	KEIIQKVDI	IYKVGSSSEK	LFPADFVLEK	840
SLKKNDAVVA	IMKDLDSVK	SFENYIKAF	GEGKETNRDE	SFYGDFVFLAY	DILLKVDHIY	900
DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	DKDKETDYRA	TILRYGSKY	LAIMDKKYAK	960
CLQKIDKDDV	NGNYEKINYK	LPLGPNKMLP	KVFFSKKMA	YNNPSEDIQK	IYKNGTFKKG	1020
DMFNLDNCHK	LIDFPKDISI	RYPKWSNAYD	FNFSETEKYK	DIAGFYREVE	EQGYKVSFES	1080
ASKKEVDKLV	EEGKLYMPQI	YNKDFSDKSH	GTPNLHTMYF	KLLFDENNHG	QIRLSGGAE	1140
FMRRASLKKE	ELVVHPANSP	IANKNPDNPK	KTTLSDYDV	KDKRFSEDDQY	ELHIPAIANK	1200
CPKNIFKINT	EVRLKHHDD	NPYVIGIARG	ERNLLYIVVV	DGKGNIVEQY	SLNEIINNPN	1260
GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	VEKYDAVIAL	1320
EDLNSGFKNS	RVKVEKQVYQ	KPEKMLIDKL	NYMVDKSNP	CATGGALKGY	QITNKFPESFK	1380
SMSTQNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTKYTSIADS	KKFISSFDRI	MYVPEEDLFE	1440
FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKNVDF	DWEEVCLTSA	YKELFNKYGI	1500
NYQQDIRAL	LCEQSDKAFY	SSFMALMSLM	LQMRNSITGR	TDVDFLISPV	KNSDGIFYDS	1560
RNYEAQENAI	LPKNADANGA	YNIARKVLWA	IQQFKKAEDE	KLDKVKIAIS	NKEWLEYAQT	1620
SVKHSGSGG	SGGSTNLSDI	IEKETGKQLV	IQESILMLPE	EVEEIGNKPE	ESDILVHTAY	1680
DESTDENVML	LTSDAPEYK	WALVIQDSNG	ENKIKMLSGG	SKRTADGSEF	EPKRRKRVGS	1740
G						1741

SEQ ID NO: 144                   moltype = AA   length = 1734  
 FEATURE                        Location/Qualifiers  
 REGION                         1..1734  
                                note = Synthetic polypeptide  
 source                         1..1734  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 144

MKRTADGSEF	ESPKKRRKVM	EASPASGPRH	LMDPHIFTSN	FNNGIGRHKTY	LYCYEVERLND	60
NGTSVKMDQHR	RGFLHNQAKN	LLCGFYGRHA	ELRFLDLVPS	LQLDPAQIYR	VTWFIWSWPC	120
SWGACAGEVRA	AFLQENTHVR	LRIFAARIYD	YDPLYKEALQ	MLRDAGAQVSI	IMTYDEFKHC	180

-continued

WDTFVDHQGC	PFQPWDGLDE	HSQALSGLRL	AILQNGNSG	SETPGTSESA	TPESMSKLEK	240
FTNCYLSLST	LRPKAIPVVK	TQENIDNKRL	LVEDEKRAED	YKGVKLLDR	YLSFINDVL	300
HSIKLKNLNM	YISLFRKTR	TEKENKELEN	LEINLRKETA	KAFKGNREGYK	SLFKKDIET	360
ILPEFLDDKD	EIALVNSFNG	FTTAFTGFPD	NRENMFSEEA	KSTSIAPRCI	NENLTRYISN	420
MDIFEKVDAI	FDKHEVQEI	EKILNSDYDV	EDFFEGEFFN	FVLTOEGIDV	YNAIIGFVVT	480
ESGEKIKGLN	EYINLYNQKT	KQKLPKFKPL	YQVLSDRS	LSFYGGSSG	ENQTTQKGQK	540
NSRERMKRIE	EGIKELGSQI	KEHPVENTQ	LQNEKLYLY	LQNGRDMYVD	QELDINRLSD	600
YDVDHIVPQS	FLKDDSIDNK	VLTRSDKNRG	KSDNVPSEEV	VKMKNYWRQ	LLNAKLITQR	660
KFDNLTKAER	GGLSGYTSDE	EVLEVFRNTL	NKNSEIFSSI	KKLEKLPKFN	DEYSSAGIFV	720
KNGPAISTIS	KDIFGEWNV	RDKNWAEYDD	IHLKKKAVVT	EKYEDDRRKS	FKKIGSFSLE	780
QLQEYADADL	SVVEKLEKII	IQKVDEIYK	YGSSEKLFDA	DFVLEKSLKK	NDAVVAIMKD	840
LLDSVKSPEN	YIKAFFGEGK	ETNRDESFG	DFVLAYDILL	KVDHIYDAIR	NYVTQKPYSK	900
DKFKLYFQNP	QFMGGWDKDK	ETDYRATILR	YGSKYLAIM	DKKYAKCLQK	IDKDDVNGNY	960
EKINYKLLPG	PNKMLPKVFF	SKKWMAYYNP	SEDIQKIYKN	GTFKKGDMFN	LNDCHKLIDF	1020
FKDISRYPK	WSNAYDFNFS	ETEKYKDIAG	FYREVEEQGY	KVSFESASK	EVDKLVVEEGK	1080
LYMFQIYNKD	FSDKSHGTPN	LHTMYPKLLF	DENNHQGI	IRL SGGAELPMRR	ASLKKELV	1140
HPANSPIANK	NPDPNPKTTT	LSYDVYKDKR	FSEDQYELHI	PIAINKCPKN	IFKINTEVRV	1200
LLKHDNDPYV	IGIARGERNL	LYIVVVDGKG	NIVEQYSLNE	IINNFGIRI	KTDYHSLLDK	1260
KEKERFEARQ	NWTSIENI	KE LKAGYISQVV	HKICELVEKY	DAVIALEDLN	SGFKNSRVKV	1320
EKQVYQKPEK	MLIDKLNMYV	DKKSNPCATG	GALKGYQITN	KPFESKSMST	QNGFIYIPA	1380
WLTSKIDPST	GFVNLKTKY	TSIADSKKFI	SSFDRIMYVP	EEDLFEPALD	YKNFSRTDAD	1440
YIKKWKLYSY	GNRIRIFRNP	KKNVFDWEE	VCLTSAYKEL	FNKYGINYQQ	GDIRALLCEQ	1500
SDKAFYSSFM	ALMSLMLQMR	NSITGRD	VDV FLISPVKNSD	GIFYDSRNYE	AQENAILPKN	1560
ADANGAYNIA	RKVLWAIQGF	KKADEKLDK	VKIAISNKEW	LEYAQT	SVKH GSPKKR	KVKS 1620
GGSTNLS	DI EKETGKQLVI	QESILMLPEE	VEEVIGNKPE	SDILVHTAYD	ESTDEN	VMLL 1680
TSDAPEYK	PW ALVIQDSNGE	NKIKMLTKYD	SGGSKRTADG	SEFEPK	KRKRK VGSG	1734

SEQ ID NO: 145           moltype = AA   length = 1734  
 FEATURE                Location/Qualifiers  
 REGION                 1..1734  
                           note = Synthetic polypeptide  
 source                 1..1734  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 145

MKRTADGSEF	ESPKKKRKM	EASPASGRH	LMDPHIFTSN	FNNGIGRHK	YLCYEVR	LD 60
NGTSVKMDQH	RGFLHNQAKN	LLCGFYGRHA	ELRFLDLVPS	LQLDPAQIYR	VTWFI	SWSPC 120
FSWGCAGEVR	AFLQENTHVR	LRIFAARIYD	YDPLYKEALQ	MLRDAGAQVS	IMTYDE	FKHC 180
WDTFVDHQGC	PFQPWDGLDE	HSQALSGLRL	AILQNGNSG	SETPGTSESA	TPESMSKLEK	240
FTNCYLSLST	LRPKAIPVVK	TQENIDNKRL	LVEDEKRAED	YKGVKLLDR	YLSFINDVL	300
HSIKLKNLNM	YISLFRKTR	TEKENKELEN	LEINLRKETA	KAFKGNREGYK	SLFKKDIET	360
ILPEFLDDKD	EIALVNSFNG	FTTAFTGFPD	NRENMFSEEA	KSTSIAPRCI	NENLTRYISN	420
MDIFEKVDAI	FDKHEVQEI	EKILNSDYDV	EDFFEGEFFN	FVLTOEGIDV	YNAIIGFVVT	480
ESGEKIKGLN	EYINLYNQKT	KQKLPKFKPL	YQVLSDRS	LSFYGGSSG	ENQTTQKGQK	540
SRERMKRIE	GIKELGSQIL	KEHPVENTQL	QNEKLYLYL	QNGRDMYVDQ	ELDINRLSDY	600
DVDHIVPQSF	LKDDSIDNKV	LTRSDKNRKG	SDNVPSEEV	VKMKNYWRQL	LNAKLITQRK	660
FDNLTKAERG	GLSEGYTSDE	EVLEVFRNTL	NKNSEIFSSI	KKLEKLPKFN	DEYSSAGIFV	720
KNGPAISTIS	KDIFGEWNV	RDKNWAEYDD	IHLKKKAVVT	EKYEDDRRKS	FKKIGSFSLE	780
QLQEYADADL	SVVEKLEKII	IQKVDEIYK	YGSSEKLFDA	DFVLEKSLKK	NDAVVAIMKD	840
LLDSVKSPEN	YIKAFFGEGK	ETNRDESFG	DFVLAYDILL	KVDHIYDAIR	NYVTQKPYSK	900
DKFKLYFQNP	QFMGGWDKDK	ETDYRATILR	YGSKYLAIM	DKKYAKCLQK	IDKDDVNGNY	960
EKINYKLLPG	PNKMLPKVFF	SKKWMAYYNP	SEDIQKIYKN	GTFKKGDMFN	LNDCHKLIDF	1020
FKDISRYPK	WSNAYDFNFS	ETEKYKDIAG	FYREVEEQGY	KVSFESASK	EVDKLVVEEGK	1080
LYMFQIYNKD	FSDKSHGTPN	LHTMYPKLLF	DENNHQGI	IRL SGGAELPMRR	ASLKKELV	1140
HPANSPIANK	NPDPNPKTTT	LSYDVYKDKR	FSEDQYELHI	PIAINKCPKN	IFKINTEVRV	1200
LLKHDNDPYV	IGIARGERNL	LYIVVVDGKG	NIVEQYSLNE	IINNFGIRI	KTDYHSLLDK	1260
KEKERFEARQ	NWTSIENI	KE LKAGYISQVV	HKICELVEKY	DAVIALEDLN	SGFKNSRVKV	1320
EKQVYQKPEK	MLIDKLNMYV	DKKSNPCATG	GALKGYQITN	KPFESKSMST	QNGFIYIPA	1380
WLTSKIDPST	GFVNLKTKY	TSIADSKKFI	SSFDRIMYVP	EEDLFEPALD	YKNFSRTDAD	1440
YIKKWKLYSY	GNRIRIFRNP	KKNVFDWEE	VCLTSAYKEL	FNKYGINYQQ	GDIRALLCEQ	1500
SDKAFYSSFM	ALMSLMLQMR	NSITGRD	VDV FLISPVKNSD	GIFYDSRNYE	AQENAILPKN	1560
ADANGAYNIA	RKVLWAIQGF	KKADEKLDK	VKIAISNKEW	LEYAQT	SVKH GSPKKR	KVKS 1620
GGSTNLS	DI EKETGKQLVI	QESILMLPEE	VEEVIGNKPE	SDILVHTAYD	ESTDEN	VMLL 1680
TSDAPEYK	PW ALVIQDSNGE	NKIKMLTKYD	SGGSKRTADG	SEFEPK	KRKRK VGSG	1734

SEQ ID NO: 146           moltype = AA   length = 1736  
 FEATURE                Location/Qualifiers  
 REGION                 1..1736  
                           note = Synthetic polypeptide  
 source                 1..1736  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 146

MKRTADGSEF	ESPKKKRKM	EASPASGRH	LMDPHIFTSN	FNNGIGRHK	YLCYEVR	LD 60
NGTSVKMDQH	RGFLHNQAKN	LLCGFYGRHA	ELRFLDLVPS	LQLDPAQIYR	VTWFI	SWSPC 120
FSWGCAGEVR	AFLQENTHVR	LRIFAARIYD	YDPLYKEALQ	MLRDAGAQVS	IMTYDE	FKHC 180

-continued

WDTFVDHQGC	PFQPWDGLDE	HSQALSGLRL	AILQNGNSG	SETPGTSESA	TPESMSKLEK	240
FTNCYLSLKT	LRPKAI PVGK	TQENIDNKRL	LVEDEKRAED	YKGVKLLDR	YYLSFINDVL	300
HSIKLKNLNN	EYISLFRKTR	TEKENKELEN	LEINLRKEIA	KAPKGNIEGK	SLFKKDIET	360
ILPEFLDDKD	EIALVNSFNG	FTTAFTGFPD	NRENMFSEEA	KSTSIAPRCI	NENLTRYISN	420
MDIFEKVDVAI	FDKHEVQEIK	EKILNSDYDV	EDFFEGEFPN	FVLTOEGIDV	YNAIIGGFVT	480
ESGEKIKGLN	EYINLYNQKT	KQKLPKFKPL	YKQVLSDRS	LSFYGGSSGE	NQTTQKGGQN	540
SRERMKRIEE	GIKELGSQL	KEHPVENTQL	QNEKLYLYYL	QNGRDMYVDQ	ELDINRLSDY	600
DVDHIVPQSF	LKDDSIDNKV	LTRSDKNRGR	SDNVPSEEVV	KMKKNYWRQL	LNAKLITQRK	660
FDNLTKAERG	GLSGSEGYS	DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLFK	NFDEYSSAGI	720
FVKNGPAIST	ISKDIFGEWN	VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	KSPFKIGSFS	780
LEQLQEYADA	DLSVVEKLKE	IIIQKVDEIY	KVYGSSEKLF	DADFVLEKSL	KNDAVVAIM	840
KDLLDSVKSF	ENYIKAFFGE	GKETNRDES	YGFVFLAYDI	LLKVDHIYDA	IRNYVTQKPY	900
SKDKFKLYFQ	NPQFMGGWDK	DKETDYRATI	LRYSKYLYLA	IMDKKYAKCL	QKIDKDDVNG	960
NYEKINYKLL	PGPNKMLPKV	FFSKKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	1020
DFPKDISRY	KFWSNADFN	FSETEKYKDI	AGFYREVEEQ	GKVSFESAS	KKEVDKLVVEE	1080
GKLYMFQIYN	PDFSDKSHGT	PNLHTMYFKL	LFDENNHGQI	RLSGGAELFM	RRASLKKEEL	1140
VVHPANSPIA	NKNPDNPCKT	TTLSDYVYKD	KRFSEDQYEL	HIPIAINKCP	KNIFKINTEV	1200
RVLLKHDDNP	YVIGIARGER	NLLYIVVVDG	KGNIVEQYSL	NEIINNPNFI	RIKTDYHSL	1260
DKKEKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNRSR	1320
KVEKQVYQKF	EKMLIDKLN	MVDKKSNPCA	TGGALKGYQI	TNKFESFKSM	STQNGFIFYI	1380
PAWLTSKIDP	STGFVNLLKT	KYTSIADSKK	FISSFDRIMY	VPEEDLFEP	LDYKNFSRTD	1440
ADYIKKWKLY	SYGNRIRIFR	NPKKNVPDW	EEVCLTSAYK	ELFNKYGINY	QQGDIRALLC	1500
EQSDKAFYSS	FMALMSLMLQ	MRNSITGRD	VDFLISPVKN	SDGIFYDSRN	YEAQENAILP	1560
KNADANGAYN	IARKVLAIG	QPKKAEDKEL	DKVKIAISNK	EWLEYAQT	SVKHSPPKRRK	1620
VSGGSTNLSD	IIEKTEGKQL	VIQESILMLP	EEVEEVIGNK	PESDILVHTA	YDESTDENVM	1680
LLTSDAPEYK	PWALVIQDSN	GENKIKMLTK	YDSGGSKRTA	DGSBEFEPK	KKVGVSG	1736

SEQ ID NO: 147                   moltype = AA   length = 1616  
 FEATURE                        Location/Qualifiers  
 REGION                         1..1616  
                                   note = Synthetic polypeptide  
 source                         1..1616  
                                   mol\_type = protein  
                                   organism = synthetic construct

SEQUENCE: 147

MKRTADGSEF	ESPKKKRQVS	EVEFSHEYWM	RHALTLAKRA	RDEREVPVGA	VLVLNRRVIG	60
EGWNRALGLH	DPTAHAEIMA	LRQGGGLVMQN	YRLIDATLYV	TFEPCVMCAG	AMIHSRIGRV	120
VFGVRNSKRG	AAGSLMNVLN	YPGMNRHVEI	TEGILADECA	ALLCDFYRMP	RQVFNAQKKA	180
QSSINSGGSS	GGSSGSETPG	TSESATPSS	GGSSGGSSKL	EKFTNCYLSL	KTLRFKAIPV	240
GKTQENIDNK	RLLEVEDEKRA	EDYKGVKKLL	DRYYLSFIND	VLHSIKLKNL	NNYISLFRKK	300
TRTEKENKEL	ENLEINLRKE	IAPKAFKNEG	YKSLFKKDI	ETILPEFLDD	KDEIALVNSF	360
NGFTTAFTGF	FDNRENMFSE	EAKSTSIAPR	CINENLTRYI	NMMDIFEKVD	AIFDKHEVQE	420
IKEKILNSDY	DVEDFFEGEF	FNFVLTQEGI	DVYNAIIGGF	VTESEKIKRG	LNEYINLYNQ	480
KTKQKLPKFK	PLYKQVLSDR	ESLSFYGEGS	SGENQTTQKG	QKNSRERMKR	IEEGIKELGS	540
QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VDQELDINRL	SDYDVIDHIV	QSFLKDDSID	600
NKVLTRSDKN	RGKSDNVPS	EVVKKMKNYW	RQLLNAKLIT	QRKFDNLTKA	ERGGLSGYTS	660
DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLFK	NFDEYSSAGI	FVKNGPAIST	ISKDIFGEWN	720
VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	KSPFKIGSFS	LEQLQEYADA	DLSVVEKLKE	780
IIIQKVDEIY	KVYGSSEKLF	DADFVLEKSL	KNDAVVAIM	KDLLDSVKSF	ENYIKAFFGE	840
GKETNRDES	YGFVFLAYDI	LLKVDHIYDA	IRNYVTQKPY	SKDKFKLYFQ	NPQFMGGWDK	900
DKETDYRATI	LRYSKYLYLA	IMDKKYAKCL	QKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	960
FFSKKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	DFPKDISRY	PKWSNADFN	1020
FSETEKYKDI	AGFYREVEEQ	GKVSFESAS	KKEVDKLVVEE	GKLYMFQIYN	KDFSDKSHGT	1080
PNLHTMYFKL	LFDENNHGQI	RLSGGAELFM	RRASLKKEEL	VVHPANSPIA	NKNPDNPCKT	1140
TTLSDYVYKD	KRFSEDQYEL	HIPIAINKCP	KNIFKINTEV	RVLLKHDDNP	YVIGIARGER	1200
NLLYIVVVDG	KGNIVEQYSL	NEIINNPNFI	RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	1260
KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNRSR	KVEKQVYQKF	EKMLIDKLN	1320
MVDKKSNPCA	TGGALKGYQI	TNKFESFKSM	STQNGFIFYI	PAWLTSKIDP	STGFVNLLKT	1380
KYTSIADSKK	FISSFDRIMY	VPEEDLFEP	LDYKNFSRTD	ADYIKKWKLY	SYGNRIRIFR	1440
NPKKNVPDW	EEVCLTSAYK	ELFNKYGINY	QQGDIRALLC	EQSDKAFYSS	FMALMSLMLQ	1500
MRNSITGRD	VDFLISPVKN	SDGIFYDSRN	YEAQENAILP	KNADANGAYN	IARKVLAIG	1560
QPKKAEDKEL	DKVKIAISNK	EWLEYAQT	SVKHSPPKRRK	DGSBEFEPK	KKVGVSG	1616

SEQ ID NO: 148                   moltype = AA   length = 1616  
 FEATURE                        Location/Qualifiers  
 REGION                         1..1616  
                                   note = Synthetic polypeptide  
 source                         1..1616  
                                   mol\_type = protein  
                                   organism = synthetic construct

SEQUENCE: 148

MKRTADGSEF	ESPKKKRQVS	EVEFSHEYWM	RHALTLAKRA	RDEREVPVGA	VLVLNRRVIG	60
EGWNRALGLH	DPTAHAEIMA	LRQGGGLVMQN	YRLIDATLYV	TFEPCVMCAG	AMIHSRIGRV	120
VFGVRNSKRG	AAGSLMNVLN	YPGMNRHVEI	TEGILADECA	ALLCDFYRMP	RQVFNAQKKA	180
QSSINSGGSS	GGSSGSETPG	TSESATPSS	GGSSGGSSKL	EKFTNCYLSL	KTLRFKAIPV	240
GKTQENIDNK	RLLEVEDEKRA	EDYKGVKKLL	DRYYLSFIND	VLHSIKLKNL	NNYISLFRKK	300

-continued

TRTEKENKEL	ENLEINLRKE	IAKAFKGN	YKSLPKKDI	ETILPEFLDD	KDEIALVNSF	360
NGFTTAPTGF	FDNRENMFSE	EAKSTSIAPR	CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	420
IKEKILNSDY	DVEDFPFEGEF	FNFLVTQEGI	DVYNAIIGGF	VTESGEKIKG	LNEYINLYNQ	480
KTKQKLPKFK	PLYKQVLSDR	ESLSFYGGSS	GENQTTQKGQ	KNSRERMKRI	EEGIKELGSQ	540
ILKEHPVENT	QLQNEKLYLY	YLQNGRDMYV	DQELDINRLS	DYDVDHIVPQ	SFLKDDSIDN	600
KVLRSDKNR	GKSDNVPSEE	VVKMKMKNYWR	QLLNAKLITQ	RKFDNLTKAE	RGGLSEGYTS	660
DEEVLEVPFR	TLNKNSEIFS	SIKKLEKLFK	NFDEYSSAGI	FVKNGPAIST	ISKDIGEWN	720
VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	KSFKKIGSFS	LEQLQEYADA	DLSVVEKLKE	780
IIIQKVDEIY	KVYGSSEKLF	DADFVLEKSL	KKNDAVVAIM	KDLLDSVKSF	ENYIKAFFGE	840
GKETNRDSF	YGDFVLAYDI	LLKVDHIYDA	IRNYVTQKPY	SKDKFKLYFQ	NPQFMGWDK	900
DKETDYRATI	LRYGSKYYLA	IMDKKYAKCL	QKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	960
PFSSKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	DFPKDSISRY	PKWSNAYDFN	1020
FSETEKYKDI	AGFYREVLEEQ	GKVKVPESAS	KKEVDKLVVEE	GKLYMFQIYN	KDFSCKSHGT	1080
PNLHTMYFKL	LFDENNHGQI	RLSGGAELEF	RRASLKKKEEL	VVHPANSPIA	NKNPDNPCKT	1140
TTLSYDVKD	KRSEDQYEL	HIPIAINKCP	KNIFKINTEV	RVLLKHDDNP	YVIGIARGER	1200
NLLYIVVVVDG	KGNIVQYSL	NEIINNENFI	RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	1260
KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNSRV	KVEKQVYQKF	EKMLIDKLN	1320
MVDDKSNPCA	TGGALKGYQI	TNKFESFKSM	STQNGFIPYI	PAWLTSKIDP	STGFVNLKKT	1380
KYTSIADSKK	FISDFRIMY	VPEEDLFEFA	LDYKNFSRTD	ADYIKKWKLY	SYGNRIRIRI	1440
NPKKNVDFW	EEVCLTSAYK	ELFNKYGINY	QQGDIRALLC	EQSDKAFYSS	FMALMSLMLQ	1500
MRNSITGRD	VDFLISPVKN	SDGIFYDSRN	YEAQENALIP	KNADANGAYN	IARKVLWAIG	1560
QPKKAEDEKL	DKVKIAISNK	EWLEYAQTSV	KHSGGSKRTA	DGSEFEPKKK	RKVGSG	1616

SEQ ID NO: 149           moltype = AA   length = 1618  
 FEATURE                Location/Qualifiers  
 REGION                 1..1618  
                        note = Synthetic polypeptide  
 source                 1..1618  
                        mol\_type = protein  
                        organism = synthetic construct

SEQUENCE: 149

MKRTADGSEF	ESPKKKRKVS	EVEFSHEYWM	RHALTLAKRA	RDEREVPVGA	VLVLNNRVIG	60
EGWNRALGLH	DPTAHAIMA	LRQGGGLVMQN	YRLIDATLYV	TFEPCVMCAG	AMIHSRIGRV	120
VFGVRNSKRG	AAGSLMNVLN	YPGMNRHVEI	TEGILADECA	ALLCDFYRMP	RQVFNAQKKA	180
QSSINSGGSS	GGSSGSETPG	TSESATPES	GGSSGGSSKL	EKFTNCYSL	KTLPFKAIPIV	240
GKTQENIDNK	RLLVDEKRA	EDYKGVKLL	DRYLSFIND	VLHISIKLNL	NNYISLFRKK	300
TRTEKENKEL	ENLEINLRKE	IAKAFKGN	YKSLPKKDI	ETILPEFLDD	KDEIALVNSF	360
NGFTTAPTGF	FDNRENMFSE	EAKSTSIAPR	CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	420
IKEKILNSDY	DVEDFPFEGEF	FNFLVTQEGI	DVYNAIIGGF	VTESGEKIKG	LNEYINLYNQ	480
KTKQKLPKFK	PLYKQVLSDR	ESLSFYGGSS	GENQTTQKGQ	KNSRERMKRI	EEGIKELGSQ	540
ILKEHPVENT	QLQNEKLYLY	YLQNGRDMYV	DQELDINRLS	DYDVDHIVPQ	SFLKDDSIDN	600
KVLRSDKNR	GKSDNVPSEE	VVKMKMKNYWR	QLLNAKLITQ	RKFDNLTKAE	RGGLSGSEGY	660
TSDEEVLEVP	RNTLNKNSI	FSSIKKLEKL	FNPFDEYSSA	GIFVKNGP	STISKDIGE	720
WNVIRDKWNA	EYDDIHLKKK	AVVTEKYEDD	RRKSPFKKIGS	PSLEQLQEYA	DADLSVVEKL	780
KEIIIQKVDE	IYKVYGSSEK	LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	SFENYIKAFP	840
GEGKETNRDE	SFYGDFVLAY	DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	900
DKDKETDYRA	TILRYGSKYY	LAIMDKKYAK	CLQKIDKDDV	NGNYEKINYK	LLPGPNKMLP	960
KVFFSKKWM	YNNPSEDIQK	IYKNGTFKKG	DMFNLDCHK	LIDFPKDSIS	RYPKWSNAYD	1020
FNFSSETEKYK	DIAGFYREVE	EQGYKVSFES	ASKKEVDKLV	EKGKLYMFQI	YNKDFSDKSH	1080
GTPNLHTMYF	KLLFDENNHG	QIRLSGGAE	FMRASLKKKE	ELVVHPANS	IANKNPDNPK	1140
KTTTTLSYDVY	KDKRPFSEDQY	ELHIPIAINK	CPKNIFKINT	EVVLLKHDD	NPYVIGIARG	1200
ERNLLYIVVV	DGKGNIVEQY	SLNEIINNEN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	1260
NIKELKAGYI	SQVVKICEL	VEKYDAVIAL	EDLNSGFKNS	RVKVEKQVYQ	KFEKMLIDKL	1320
NYMVDKSNP	CATGGALKGY	QITNKFESFK	SMSTQNGFIP	YIPAWLTSKI	DPSTGFVNL	1380
KTKYTSIADS	KKFISSFDRI	MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	1440
FRNPKKNVDF	DWEEVCLTSA	YKELFNKYGI	NYQQGDIRAL	LCEQSDKAFY	SSFALMSLML	1500
LQMRNSITGR	TDVDFLISPV	KNSDGIYDS	RNYEAQENAI	LPKNADANGA	YNIARKVLWA	1560
IGQPKKAEDE	KLDKVKIAIS	NKEWLEYAQT	SVKHSGGSKR	TADGSEFEPK	KRKRKVGSG	1616

SEQ ID NO: 150           moltype = AA   length = 173  
 FEATURE                Location/Qualifiers  
 source                 1..173  
                        mol\_type = protein  
                        note = Lachnospiraceae bacterium  
                        organism = unidentified

SEQUENCE: 150

SKLEKFTNCY	SLSKTLRFLKA	IPVGTQENI	DNKRLLEVE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNNYISLF	RKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAP	TGFPDNREN	FSEAKSTSI	APR	173

SEQ ID NO: 151           moltype = AA   length = 1053  
 FEATURE                Location/Qualifiers  
 source                 1..1053  
                        mol\_type = protein  
                        note = Lachnospiraceae bacterium  
                        organism = unidentified



-continued

SEQUENCE: 151

INENLTRYIS	NMDIFEKVIDA	IPDKHEVQEI	KEKILNSDYD	VEDFFEGEFF	NFVLTQEGID	60
VYNAIIGGFV	TESGEKIKGL	NEYINLYNQK	TKQKLPKPKP	LYKQVLSDRE	SLSFYGEGYT	120
SDEEVLEVFR	NLTKNGSEIF	SSIKKLEKLF	KNFDEYSSAG	IFVKNGPAIS	TISKDIFGEW	180
NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	SLEQLQEYAD	ADLSVVEKLL	240
EIIIQKVDEI	YKVYGSSEKL	FDADFVLEKS	LKKNDAVVAI	MKDLLDSVKS	FENYIKAFFG	300
EGKETNRDES	FYGFVFLAYD	ILLKVDHIYD	AIRNYVTQKP	YSKDKFKLYF	QNPQFMGGWD	360
KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	LQKIDKDDVN	GNYEKINYKL	LPGPNKMLPK	420
VFFSKKWMAY	YNPSEDIQKI	YKNGTFKKGD	MFNLNDCHKL	IDFFKDSISR	YPKWSNAYDF	480
NFSETEKYKD	IAGFYREVEE	QGYKVSFESA	SKKEVDKLV	EGKLYMFQIY	NKDFSDKSHG	540
TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELE	MRRASLKEE	LVVHPANSPI	ANKNPDNPKK	600
TTLSYDVYK	DKRFSEDOYE	LHIPIAINKC	PKNIFKINTE	VRVLLKHDDN	PYVIGIDRGE	660
RNLLYIVVVD	GKGNIVEQYS	LNEIINNFG	IRIKTDYHSL	LDKKEKERFE	ARQNWTSIEN	720
IKELKAGYIS	QVVHKICELV	EKYDAVIALE	DLNSGFKNRS	VKVEKQVYQK	FEKMLIDKLN	780
YMVDKKSNPC	ATGGALKGYQ	ITNKPESFKS	MSTQNGFIFY	IPAWLTSKID	PSTGFVNLLK	840
TKYTSIADSK	KFISSFDRIM	YVPEEDLFEF	ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	900
RNPKNNVFD	WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	960
QMRNSITGRT	DVDFLISPVK	NSDGIFYDSR	NYEAQENAIL	PKNADANGAY	NIARKVLWAI	1020
GQFKAEDK	LDKVIAISN	KEWLEYAQT	VKH			1053

SEQ ID NO: 152           moltype = AA   length = 310  
 FEATURE                Location/Qualifiers  
 source                 1..310  
                       mol\_type = protein  
                       note = Lachnospiraceae bacterium  
                       organism = unidentified

SEQUENCE: 152

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELNLEINL	RKEIAKAPKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEBAKTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFPNFVLTQ	EGIDVYNAII	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGYTSDEEVL	300
EVFRNTLNKC						310

SEQ ID NO: 153           moltype = AA   length = 918  
 FEATURE                Location/Qualifiers  
 source                 1..918  
                       mol\_type = protein  
                       note = Lachnospiraceae bacterium  
                       organism = unidentified

SEQUENCE: 153

NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVK	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	60
LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QYADADLSV	VEKLKEIIQ	KVDEIYKVVY	120
SSEKLFADAF	VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAPFGGKGT	NRDESFYGDF	180
VLAYDILKLV	DHIYDAIRNY	VTQKPYSKDK	PKLYFQNPQF	MGGWKDKET	DYRATILRYG	240
SKYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLLPGFN	KMLPKVFFSK	KWMAYYNPSE	300
DIQKIYKNGT	FKKGMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNPFSET	EKYKDIAGFY	360
REVEEQYK	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYPKLLFDE	420
NNHGQIRLSG	GAELEFMRAS	LKKEELVVHP	ANSPITANKP	DNPKTTLS	YDVYKDKRFS	480
EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IDRGERNLLY	IVVVDGKGN	540
VEQYSLNEII	NNPNGIRIKT	DYHSLLDKKE	KERPEARQMW	TSIENIKELK	AGYISQVVKH	600
ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	660
LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFIS	720
PDRIMYVPEE	DLFEFALDYK	NFSRTDADYI	KWKLYSYGN	RIRIFRNPCK	NNVFDWEEVC	780
LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	840
ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIGQFVK	AEDEKLDKVK	900
IAISNKWLE	YAQTSVKH					918

SEQ ID NO: 154           moltype = AA   length = 406  
 FEATURE                Location/Qualifiers  
 source                 1..406  
                       mol\_type = protein  
                       note = Lachnospiraceae bacterium  
                       organism = unidentified

SEQUENCE: 154

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELNLEINL	RKEIAKAPKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEBAKTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFPNFVLTQ	EGIDVYNAII	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGYTSDEEVL	300
EVFRNTLNKN	SEIFSSIKK	EKLFKNFDEY	SSAGIFVKNG	PAISTISKDI	FGWNVIRDK	360
WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	IGSFSLEQLQ	EYADAC		406

SEQ ID NO: 155           moltype = AA   length = 822  
 FEATURE                Location/Qualifiers  
 source                 1..822

-continued

```

mol_type = protein
note = Lachnospiraceae bacterium
organism = unidentified

SEQUENCE: 155
DLSVVEKLKE IIIQKVDEIY KVYGSSEKLF DADFVLEKSL KKNDAVVAIM KDLLDSVKSF 60
ENYIKAPFGE GKETNRDESF YGDFVLAYDI LLKVDHIYDA IRNYVTQKPY SKDKPKLYFQ 120
NPQFMGGWDK DKETDYRATI LRYGSKYYLA IMDKKYAKCL QKIDKDDVNG NYEKINYKLL 180
PGPNKMLPKV PFSKKWMAYY NPSEDIQKIY KNGTFKKGDM FNLNDCHKLI DPFKDSISRY 240
PKWSNAYDFN FSETEKYKDI AGFYREVEEQ GYKVSFESAS KKEVDKLVVEE GKLYMPQIYN 300
KDFSDKSHGT PNLHTMYFKL LFDENNHGQI RLSGGAELEFM RRASLKKKEEL VVHPANSPIA 360
NKNPDNPCKT TTSYDVYKDK KRFSEDOYEL HIPIAINKCP KNIPKINTEV RVLLKHDDNP 420
YVIGIDRGER NLLYIVVVDG KGNIVEQYSL NEIINNFMGI RIKTDYHSLD DKKEKERFEA 480
RQNWTSIENI KELKAGYISQ VVHKICECVE KYDAVIALED LNSGFKNRSV KVEKQVYQKF 540
EKMLIDKLNK MVDKKSNPCA TGGALKGYQI TNKPFESFKSM STQNGFIFYI PAWLTSKIDP 600
STGFVNLKLT KYTSIADSKK FISSPDRIMY VPEEDLFEFA LDYKNFSRTD ADYIKKWKLY 660
SYGNRIRIFR NPKKNVFDW EEVCLTSAYK ELFNKYGINY QQGDIRALLC EQSDKAFYSS 720
FMALMSLMLQ MRNSITGRTD VDFLISPVKV SDGIFYDSRN YEAQENAILP KNADANGAYN 780
IARKVLWAIG QFKKAEDKEL DKVKIAISNK EWLEYAQTSTV KH 822

```

```

SEQ ID NO: 156      moltype = AA length = 441
FEATURE           Location/Qualifiers
source           1..441
                 mol_type = protein
                 note = Lachnospiraceae bacterium
                 organism = unidentified

```

```

SEQUENCE: 156
SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYLLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYKSLFKK 120
DIIETILPEF LDDKDEIALV NSPFGPTTAP TGFFDNRENM FSEEAkstSI AFRcINENLT 180
RYISNMDIFE KVDAIFPKHE VQEIKEKILN SDYDVEDPFE GEPFNFVLTQ EGIDVYNAIL 240
GGFVTESEGE IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGYTSDEEVL 300
EVFRNTLNKN SEIFSSIKKL EKLKFNDFEY SSAGIFVKNG PAISTISKDI FGEWNVIRDK 360
WNAEYDDIHL KKAQVTEKY EDDRRKSFVK IGSFSLQQLQ EYADADLSV EKLKENIIQK 420
VDEIYKVYGS SEKLFDAADFV C 441

```

```

SEQ ID NO: 157      moltype = AA length = 787
FEATURE           Location/Qualifiers
source           1..787
                 mol_type = protein
                 note = Lachnospiraceae bacterium
                 organism = unidentified

```

```

SEQUENCE: 157
LEKSLKKKND VVAIMKDLLD SVKSFENYIK AFFGEGKETN RDESFGDFV LAYDILLKVD 60
HIYDAIRNYV TQKPYSKDKF KLYFQNPQPM GGWDKDKETD YRATILRYGS KYLAIMDKK 120
YAKCLQKIDK DDVNGNYEKI NYKLLPGPNK MLPKVFFSKK WMAYYNPSED IQKIYKNGTF 180
KKGDMFNLND CHKLDIFFKD SISRYPKWSN AYDFNFSETE KYKDIAGFYR EVEEQGYKVS 240
FESASKKEVD KLVEEGKLYM FQIYNKDFSD KSHGTPNLHT MYFKLLFDEN NHGQIRLSSG 300
AELFMRRASL KKEELVVHPA NSPIANKNDP NPKKTTLSY DVYDKRFESE DQYELHIPIA 360
INKCPKNIFFK INTEVRVLLK HHDNPPYVIGI DRGERNLLYI VVVDGKGNIV EQYSLNEIIN 420
NPNFIRIKTD YHSLLDKKEK ERFEARQNW T SIENIKELKA GYISQVVKI CELVEKYDAV 480
IALEDLNSGF KNSRVKVEKQ VYQKFEKMLI DKLNYMVDKK SNPCATGGAL KGYQITNKFE 540
SFKSMSTQNG FIFYPAWLT SKIDPSTGFV NLLKTKYTSI ADSKFFISSF DRIMYVPEED 600
LPEFALDYKN FSRTDADYIK KWKLYSYGNR IRIFRNPKKN NVFDWEEVCL TSAYKELFNK 660
YGINYQQGDI RALLCEQSDK AFYSSFMALM SLMLQMRNSI TGRTDVDFLI SPVKNSDGIF 720
YDSRNYEAQE NAILPKNADA NGAYNIARKV LWAIGQFKKA EDEKLDKVKI AISNKEWLEY 780
AQTSTVKH 787

```

```

SEQ ID NO: 158      moltype = AA length = 550
FEATURE           Location/Qualifiers
source           1..550
                 mol_type = protein
                 note = Lachnospiraceae bacterium
                 organism = unidentified

```

```

SEQUENCE: 158
SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYLLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYKSLFKK 120
DIIETILPEF LDDKDEIALV NSPFGPTTAP TGFFDNRENM FSEEAkstSI AFRcINENLT 180
RYISNMDIFE KVDAIFPKHE VQEIKEKILN SDYDVEDPFE GEPFNFVLTQ EGIDVYNAIL 240
GGFVTESEGE IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGYTSDEEVL 300
EVFRNTLNKN SEIFSSIKKL EKLKFNDFEY SSAGIFVKNG PAISTISKDI FGEWNVIRDK 360
WNAEYDDIHL KKAQVTEKY EDDRRKSFVK IGSFSLQQLQ EYADADLSV EKLKENIIQK 420
VDEIYKVYGS SEKLFDAADFV LEKSLKKKND VVAIMKDLLD SVKSFENYIK AFFGEGKETN 480
RDESFGDFV LAYDILLKVD HIYDAIRNYV TQKPYSKDKF KLYFQNPQPM GGWDKDKETD 540
YRATILRYGC 550

```

```

SEQ ID NO: 159      moltype = AA length = 678

```

-continued

```

FEATURE                               Location/Qualifiers
source                                 1..678
                                         mol_type = protein
                                         note = Lachnospiraceae bacterium
                                         organism = unidentified

SEQUENCE: 159
SKYYLAIMDK KYAKCLOKID KDDVNGNYEK INYKLLPGPN KMLPKVFFSK KWMAYYNPSE 60
DIQKIYKNGT FKKGDMFNLN DCHKLIDFFK DSISRYPKWS NAYDFNFSET EKYKDIAGFY 120
REVERQGYKV SFESASKKEV DKLVEEGKLY MFQIYNKDFS DKSHGTPNLH TMYFKLLFDE 180
NNHGQIRLSG GAELFMRRAS LKKEELVVHP ANSPTANKNP DNPKKTTLT YDVYKDKRFS 240
EDQYELHIPI AINKCPKNIF KINTEVRVLL KHDDNPYVIG IDRGERNLLY IVVVDGKGNL 300
VEQYSLNEII NNFNGIRIKT DYHSLLDKKE KERPEARQNW TSIENIKELK AGYISQVVHK 360
ICELVEKYDA VIALEDLNSG FKNSRVKVEK QVYQKFEKML IDKLNMYVDK KSNPCATGGA 420
LKGYQITNKF ESPFKSMSTQN GFIFYIPAWL TSKIDPSTGF VNLKTKYTS IADSKKFISS 480
PDRIMYVPEE DLFEFALDYK NFRSTDADYI KWKLYSYGN RIRIFRNPCK NNVFDWEEVC 540
LTSAYKELFN KYGINYQQGD IRALLCEQSD KAFYSSFML MSLMLQMRNS ITGRTDVDFL 600
ISPVKNSDGI FYDSRNYEAQ ENAILPKNAD ANGAYNIARK VLWAIGQFCK AEDEKLDKVK 660
IAISNKEWLE YAQTSVKH 678

SEQ ID NO: 160                               moltype = AA length = 683
FEATURE                               Location/Qualifiers
source                                 1..683
                                         mol_type = protein
                                         organism = synthetic construct

SEQUENCE: 160
TLNIEDEHRL HETSKEPDVS LGSTWLSDFP QAWAETGGMG LAVRQAPLII PLKATSTPVS 60
IKQYPMQEA RLGIKPHIQR LLDQGIIVPC QSPWNTPLLP VKKPGTNDYR PVQDLREVNK 120
RVEDIHPTVP NPYNLLSGLP PSHQWYTVLD LKDAFFCLRLL HPTSQPLFAF EWRDPEMGIS 180
GQLTWTRLPO GFKNSTPLFN EALHRDLADF RIQHPDLILL QYVDDLLLA TSELDCQOQT 240
RALLQTLGNL GYRASAKKAQ ICQKQVKYLG YLLKEGQRWL TEARKETVMG QPTPKTPRQL 300
REFLKGAGFC RLFIPGFAEM AAPLYPLTKP GTLFNFWGPDQ QKAYQETKQA LLTAPALGLP 360
DLTKPFELFV DEKQGYAKGV LTQKLGWRR PVAYLKSKLD PVAAGWPPCL RMVAIAVLT 420
KDAGKLTMGQ PLVILAPHAV EALVKQPPDR WLSNARMTHY QALLLDTDRV QFGPVVALNP 480
ATLLPLPEEG LQHNCLELILA EAHGTRPDLT DQPLPDADHT WYTDGSSLQ EGQRKAGAAV 540
TTETEVIWAK ALPAGTSAQR AELIALTQAL KMAEGKMLNV YTDSRYAFAT AHIHGEIYRR 600
RGWLTSEGKE IKNKDELIAL LKALFLPKRL SIIHCPGHQK GHSABARGNR MADQAARKAA 660
ITETPDTSTL LIENSSPNSR LIN 683

SEQ ID NO: 161                               moltype = DNA length = 2031
FEATURE                               Location/Qualifiers
misc_feature                           1..2031
                                         note = MMLV_M01
source                                 1..2031
                                         mol_type = other DNA
                                         organism = synthetic construct

SEQUENCE: 161
accctgaaca tcgaggacga gtatcggtt catgagacca gcaaagagcc ggacgtctcc 60
ctgggaagca cctggctgag cgaactcccg caagcctggg cggagaccgg tggatgggg 120
ctcgagtgcc ggcaggcgcc gttgataatc ccgctaagag ccaagagcac gccctgtct 180
atcaagcagt acccgatgag tcaagaggca cgcctcggtt tcaagccgca tatccagcgc 240
ctcctggacc agggcctcct cgtgccctgc cagtctccct ggaatacgcc tctgctaccc 300
gtcaagaagc cttggcaccaa cgattacagg ccggtgcaag acctgctgga ggtcaacaag 360
cgctggagg acatccaccc aacggtgccc aaccctgaca atctctatc tggccttccg 420
ccctcgacc agtggtagac ggtctgggac ctaaaggacg cattctctg tctgaggtcg 480
caacctacgt cccagcctgt gttcgcttc gagtggcgcc acccgagat gggcatctct 540
ggccagctaa cttggacgag attgccccag gggtttaaga actcgccac actcttcaac 600
gaggcactcc accgtgacct ggcgaccttt cgcatacagc accccgacct tatcctgttg 660
cagtacgtcg atgacctgct cctggcgccc acgtccgagc tggactgcca gcaaggcaac 720
cgcgccctac ttcaaacctt gggcaacctg ggttaccgtg cgtccgcaa gaaggcccaa 780
atctgcaaaa agcaagtcac gtacctcgcc tacctcttga aggagggaca gcgctggctg 840
acggaggcga ggaaggagac gttgatgggt cagcccaaac ccaagacccc gagcgagctg 900
agggagttcc tggggaagcc gggctctctc cgtctattca tccctggctt cgggagatg 960
gcgccccgcc tgtaccgctt aacgaagccg ggcacgctgt tcaactgggg cctgaccag 1020
cagaaggcgt accaggagat caagcaagcg ttgcttactg cccagcact cggcctcccc 1080
gacctcaaaa agccgctcga gctattcgtt gacgagaaac agggctacgc gaagggtgtg 1140
ctgactcaaa agctagggcc gtggcgacgc ccagtagcct acctgagcaa gaagctcgac 1200
cccgtggcgg gggctggcc accatgcctc cggatggctg cggctatcgc ggtgctcaca 1260
aaggatcggg ggaagctcac gatggggcag cccctgggta tccctggccc acacgggtg 1320
gaggcgctag tgaagcaacc tcccgaaccg ttgctgagca acgcccgcac gaccactac 1380
caggcgctcc tccctgacac cgaccgcgtg caattcgccc ctgctgctgg actgaacccc 1440
gccacgctgc tcccactgcc cgaggagggg ctacagcaca actgctcga tatactggcg 1500
gaaagccacg gcaaccgccc cgacttgagc gaccagccc tcccagcgc ggaccatagc 1560
tggtacaccg acgggagttc cttactccaa gagggcccag gaaagggcgg cgctcggtg 1620
accactgaga cggaaagtaa cttgggcaaa ggcctgctc cgggacgctc tgcccagcgg 1680
gcgagctgga tgcctctgac ccaggccctc aagatggccc agggcaagaa gctgaacgtt 1740
tacaccgaca gtcggtatgc cttcgcaact gccacatcc accggcaaat ctaccgtcgg 1800

```

-continued

```

cgcggtctggc tgacgagcga gggcaaggag atcaagaaca aggacgagat cctcgccctg 1860
ctaaaggcac tcttcctgcc caagegactg tccatcattc actgtccggg gcaccagaag 1920
ggccattccg ccgaggcgcg gggcaaccgc atggcggatc aggcgctcg gaaggcgcg 1980
atcaccgaga cgcccgatac gacgacgctc ctgattgaaa actcgtcgcc g 2031

```

```

SEQ ID NO: 162      moltype = DNA length = 2031
FEATURE            Location/Qualifiers
misc_feature        1..2031
                    note = MMLV_M02
source              1..2031
                    mol_type = other DNA
                    organism = synthetic construct

```

```

SEQUENCE: 162
accctgaaca ttgaggacga gtatcgctcg cacgagacca gcaaggagcc cgacgtgagc 60
ctcggctcaa cgtggctcag tgacttccca caagcctggg ccgagactgg tggaatgggg 120
ctggccgtgc gccaaagtcc cctcatcatt cctctcaagg ccacttcgac gcctgtctcc 180
atcaagcagt accccatgtc ccaggaggct aggtcgggca tcaagccgca catccaacgc 240
ctgttagatc aaggaatact ggtcccctgc cagtcgcccgt ggaatactcc gctactgcct 300
gtcaagaagc cgggcaacgaa cgactaccgg cctgtccaag acctgcccga ggtgaacaag 360
cgggtcagag acattcaacc caccgttccc aacccttaca acctattgtc tggcctccca 420
ccgagccatc agtggtagac cgtcctggac ctcaaggatg cgttctctcg tctgcccgtc 480
caccctacgt cgcaccactc cttcgccctc gagtggcggg atccggagat ggggatctcg 540
gggcagctca cgtggactcg gctgcctcag gggttcaaga actccccaac actctttaac 600
gaggcactgc atcgggatct ggcggacttc cgtatccagc acccagacct catcctccta 660
cagtacgtgg acgacttgct gctggccgcg accagcagc tggactgcca gcaagggaca 720
cgcgcgctgc tccagagcct gggaaacctg ggatacccg ccagcgctaa gaaggctcaa 780
atctgtcaga aacaagttaa gtacctgggt tacctgctca aggagggtca gcgttggcct 840
accgaggccc gcaaggagac cgtgatgggg caaccocagc caaagacgccc ccgacagcta 900
cgcgagttcc tgggcaaggc tgggtctctg cggttgttca tcccgggtt cgtgagatg 960
gcccgcctcc tctaccgctc gacgaaacct gggactctgt tcaactgggg cctgaccag 1020
cagaaggcgt accaggagat caagcaagcg ctgcttaccg ccccgcgctc cggattgccc 1080
gaccttacc aacctctoga cgtgtctctg gacgagaagc aaggttacgc gaaggcgctc 1140
ctgacacaaa agttggggcc ctggcgtagg ccggtcgccct acctcagcaa gaagttggac 1200
cccggtggcg ggggctggcc gccgtgctcc cgtatggtgg cagccatcgc cgttctcacc 1260
aaagacgctg gcaagctcac gatggggcag cctctggtga tccctggcacc ccatgcccgc 1320
gaggcgctcg tgaagcagcc gccctgaccgc tggctgagta acgacagcat gaccattac 1380
caagccctat tgcctagcac ggatcgctcc caatttgggc ccgtggtggc tctgaacctc 1440
gccactctcc tccccctccc tgaggagggc ttgcagcata actgcctgga catactggct 1500
gaggcccacg ggaacaaggcc ggacctaacg gaccagcctc taccggagcc ggatcacaca 1560
tggtacaccg accgctcctc tctcctacaa gaggggcagc ggaaggcggg tgcgccctgc 1620
accacggaga cggaggtgat ctgggctaag gcactgcccg cggggacttc ggcacagcga 1680
gcccagctaa tagccctcac acaagcgctg aaaatggccc agggcaagaa gctaaacctc 1740
tatacggact cccgatccgc tttcgccacc gccacattc atggcgaaat ctaccgcccg 1800
cgtggctggc tgacgtccga gggcaaggag atcaagaaca aggacgagat cctcgccctc 1860
ctgaaagccc tgttccctgcc gaaaaggctt tcgataatcc actgcccggg ccaccagaag 1920
gggcactccg ccgaggcacg cggcaaccgt atggccgacc aggcgcccgg gaaggcgcg 1980
atcacggaaa ccccgacac atccacgctc ctcatcgaga acagcagccc c 2031

```

```

SEQ ID NO: 163      moltype = DNA length = 2031
FEATURE            Location/Qualifiers
misc_feature        1..2031
                    note = MMLV_M03
source              1..2031
                    mol_type = other DNA
                    organism = synthetic construct

```

```

SEQUENCE: 163
accctcaaca tcgaggacga gtaccgtctg cacgagacgt cgaaggagcc ggatgtctca 60
ctcggctcca cgtggctcag cgacttccca caggcgtggg cggagaccgg tggcatggga 120
ctggcggctg gacaagcgcc ccttatcatt cccctaaagg cgaagctaac tctgtttcc 180
attaagcagt accctatgtc ccaggaggcc cggctcgcca tcaagccaca catccaacgg 240
ctattggacc agggatctct ggtgcccgtg caatccccgt ggaacactcc ccttctacc 300
gtcaagaagc caggcaccac cgactaccgc cccgtgcaag acctgcccga ggtcaacaag 360
cgagtggagg acatccatcc tacctgcccg aaccctgaca acctgcttcc cggcctcccg 420
cctcgcacc agtggtagac cgttctcagc ttgaaggagc cattctctctg tctgcccctc 480
caccacaacg gccagcccct ctctgcttcc gagtggcggc acccggagat gggaaatttc 540
ggccagctta catggaccgg cctcccacag gggttcaaga acagcccagc gctgttcaac 600
gaggccctgc acccgactt gccagacttc cgaatccagc atcccagact aatcctcctg 660
caatacgttg acgacttatt gctggcccgg accagcagc ttagctgcca gcaagggact 720
cgcgcgcttc tacagacgct cgggaacctg ggctaccgtg cctcagctaa gaaggcccag 780
atgtccaga agcaagttaa gtatctcgcc tacctcctca aggagggaca gcggtggctg 840
accgaggccc gcaaggagac ggtcatgggc cagccaacac cgaaacgcc cagacaactc 900
cgcgagttcc tggcaaaagc gggctctctg cggctgttta tcccggctc cgcagagatg 960
gcccgcctcc tctaccact gacgaaacct ggcaccctgt tcaactgggg cccggatcag 1020
cagaaggcgt atcaggagat caagcaagca ctcctgacac ccccgcccct gggattgccc 1080
gaccttaccg agccctcoga gttatctgtg gacgagaagc aaggctatgc gaagggtgtc 1140
ctcacgaga agctggggcc ctggaggcgg cccgtcgctg acctaaagcaa gaagctcgac 1200

```

-continued

```

ccagtggcgg cgggttgccc gccctgctc cgcattggtg ccgcgattgc ggttctcaca 1260
aaggacgccc ggaagctcac gatggggcag ccacttgcca tcctcgctcc gcaagcogtg 1320
gaggcactgg tgaagcagcc gccggatcgc tggctgtcta atgctcgcat gaccactat 1380
caggcgctgc tcctagacac tgacaggggt cagttcggcc ccgttgcgc gcttaacccc 1440
gctacactac tcccgtgccc ggaggagggt ttgcagcata actgcctcga catcctcgcc 1500
gaggcccacg gcaagcagcc cgacctaacg gaccagccgc tgcgggacgc tgaccacact 1560
tggtacaccg acggcagctc cctcctgcaa gaggagacgc ggaaggccgg tgcccgcgtg 1620
acgacggaga cggagggtgat atgggctaag gccctgcccg ctggtactgc cgcccagcga 1680
gccgagctga tccgcccagc gcaagccctc aagatggccc agggcaagaa gctaaacgctc 1740
tatacggaca gccgctacgc attcggccca gccacattc acggagagat ataccggagg 1800
cgccgctggc ttacgtccga aggcaaggag attaagaaca aagatgagat tctggcgctg 1860
ttgaaggccc tcttccctcc caagcgctt tccatcatac actgtccagg ccaccagaag 1920
ggcactcgg cggagggcgc gggcaaccgg atggccgacc agggcgccgc caaagccgcg 1980
atcacggaga ccccagacac ttccacgctc ctgatcgaga acagttagccc c 2031
    
```

```

SEQ ID NO: 164      moltype = DNA length = 2031
FEATURE            Location/Qualifiers
misc_feature       1..2031
                   note = MMLV_D01
source             1..2031
                   mol_type = other DNA
                   organism = synthetic construct
    
```

```

SEQUENCE: 164
actttgaata tcgaagatga gtaccggcta catgagacgt ctaaggagcc tgatgtttca 60
ctcgggagca ctgggctaag cgatttcca caagcgtggg ctgaaacggg cgggatgggc 120
ctcgtgttaa gacaagcgcc acttatcacc ccgcttaagc ctacttctac tcccgtctct 180
attaagcaat acccaatgct ccaggaagct cgtttggcca ttaagcctca tatacaaaag 240
ctactcgatc agggcactat gtctccctgc caatcacctg ggaatacgcc cctattacca 300
gttaagaagc ctgggactaa cgactatcgc cccgtacagg atctactgta ggtgaacaag 360
cgtgttagagg acatccatcc gaccgctccg aatccataca atttgccttc tggattacct 420
ccaagtcatc aatggatcac cgtgctggat ctcaaggacg cattctctcg tctaagatta 480
catcctacta gccagccact ttctgcattc gagtggcgag atcccagatg gggaaatttcg 540
ggccagctta catggacgag gcttcctcaa ggtctcaaga actctcctac cttgttcaat 600
gaggctctac acccgacact cgcagacttc cggatacaac atccggacct catactcta 660
caatatgtgg acgatctatt gctggccgcg acgagcgaat tggattgtca gcaaggaacc 720
cgccgcttgt tacaacgctt ggggaacttg gggatctcag catcagccaa gaaggcaca 780
atctgccaga aacaagtga  gtatttgggg tacttactga aagaggggca acgatgggtg 840
accgaagctc gcaaggaaac gtttatgggc cagccgacac ctaagaactc aagacagctc 900
cgagagctcc tggcaaggcc tgggttctgt cgcctattca ttctggggtt tgcgaaatg 960
gctgctcctc gtaaccgctt gaccaaaccc ggaacctgtg tcaattgggg accagatcaa 1020
cagaaggcgt atcaggagat caagcaagcg ctggtgactg cgctcgctgt gggcttgccg 1080
gatttgacaa aaccttttga acttttctgt gacgagaaac aaggttacgc gaaggaggtt 1140
cttacacaaa agctgggccc ctcggagacga cctgttgctt atcttagcaa gaagttagat 1200
cccgttgtg cgggggtggc gccctgcttg aggatgggtg ccgccattgc ggttctgact 1260
aaagatcgcg gcaaatgac gatgggccag ccgctcgtaa ttctcgccc gcaagcagctc 1320
gaagccctag tgaagcagcc tccctgacct tggctctcca acgctcggat gaccactat 1380
caagcgctgc tgttggatcc cgatagagtt caattcgggc cggctcgtagc gctcaatccc 1440
gcaacgctat taccctgccc tgaggaggga ctacaacata actccttgga tattctagcg 1500
gaggctcatg ggacaagacc tgaactgaca gatcagccct tgcagatgc cgaccacaca 1560
tggtacactg acggctcacc acttctacaa gagggcaaaa ggaaggccgg agctgcccgtg 1620
acgactgaaa ccagggtgat ctgggcaaaag gctttaccgc ctggaacttc tgctcagcgc 1680
gcagagctta tccgctaacc tcaagccctg aaaatggctg agggcaagaa gttgaatgctc 1740
tataccgatt cacggatgac ttctgctacc gccacattc atggagaaat ctatcggcga 1800
cgagggtggc tcacgtctga ggggaaggag attaagaaca aggacgaaat cttagctctg 1860
ctgaaagctc tattcttacc caaacgcttg tctgattacc actgcccagg acaccaaaag 1920
ggccattccg ccgaagccag gggaaaccgt atggccgacc aagctgcccg gaaggctgca 1980
ataaccgaaa cccctgacac ttccacgcta ctcatcgaaa actctagccc a 2031
    
```

```

SEQ ID NO: 165      moltype = DNA length = 2031
FEATURE            Location/Qualifiers
misc_feature       1..2031
                   note = MMLV_D02
source             1..2031
                   mol_type = other DNA
                   organism = synthetic construct
    
```

```

SEQUENCE: 165
accttgaata tcgaagatga gtacagactc catgagacca gcaaggagcc tgatgtgagc 60
ctgggaagta catggctatc tgactttcct caggcttggg cggagaccgg tggcatgggc 120
ctggctgtcc ggcaagcacc cctaatcacc ccggtgaaag caacgtccac acccgtatct 180
atcaagcagc acccagtgag ccaagaggca cggctagggg ttaagccgca catccaaaga 240
ttgttagacc aggggatact gttccctgt caatctccgt ggaacacacc gttactcct 300
gttaagaagc cgggcacaaa tgattatcgg cctgtacaag acctgcccga agtgaacaaa 360
cgagtggaa gatttaccac caccgtgccc aatccttaca acttgcctaa cggtttacca 420
cccagtcacc agtggatcac cgtcctggac ctcaaaagac cattctctcg cttgcccgtg 480
catcctacga gtcagccgct ctttgccttt gaatggagag atcccagat gggcataagt 540
ggtcagctta catggacgag gctacctcag ggattcaaga actcgcctac cttattcaat 600
    
```

-continued

gaggctctac	acagggatct	tgtcgacttt	cggatacaac	accctgactt	aattctgcta	660
caatatgttg	acgatctgct	gcttgccggc	accagtgaac	tcgactgcca	acaagggaca	720
agagccttgt	tacagacact	tggcaatctc	ggctaccgcg	cgctctgctaa	gaaggcacag	780
at ttgccaaa	agcaagtga	gtatctcgg	tacctgctga	aagagggaca	aagatggttg	840
accgaagcca	ggaaggaac	gtcatgggg	caaccaccc	ctaaaacccc	aagacagctt	900
agagagttcc	tcgggaaagc	tgggtctcgc	cgccgtgtca	ttcccggttt	cgctgaaatg	960
gctgcacctc	tataccact	gaccaaaccc	ggcacgctat	tcaattgggg	accggatcaa	1020
caaaaggctt	accaggagat	caagcaagct	ctattgacag	ctccggctct	gggtttacc	1080
gacttgacta	aacctctcga	gttggtcgtt	gacgagaac	agggctacgc	gaaaggcgta	1140
ctgacgcaga	aactgggccc	gtggcggcga	cccgctgctt	acctttccaa	gaagctggac	1200
cctgttgccg	ctggctggcc	gccctgcctt	cgcatggttg	cggccatgct	tgctcttacg	1260
aaagatgctg	ggaactaac	tatgggtcag	ccgctcgtaa	ttctcgcgcc	acacgctgtc	1320
gaggctctag	tcaacaacc	ctctgaccgc	tggctgtcga	atgcacggat	gacacattac	1380
caggcgttgc	tattggacac	tgaccgagta	caatttgac	cagtagtggc	tttaaatccc	1440
gcgacactcc	ttcccctccc	tgaggagggt	ttgcaacaca	actgtcttga	tatacttgct	1500
gagggccacg	gaacaacgac	cgatctcaca	gatcaacccc	tcccgcacgc	agatcacacc	1560
tggtacaccg	accggtcaag	ctgtttacag	gaaggccagc	gaaaggccgg	agcagccgtg	1620
acaaccgaaa	ccgaagtatt	ctgggcaaa	gccctaccag	ccgggacaag	cgcgacagag	1680
gccagctga	ccgcgctcac	acaagcactc	aaaatggccg	aaggcaagaa	gctcaatggt	1740
tacactgatt	tccgctacgc	attcgtacc	gctcatattc	acggagaaat	ctacaggagg	1800
cgagggtggc	ttactacgca	aggaaggag	attaagaaca	aagacgagat	cctggcacta	1860
tgaaagcct	tgttccctgc	aaagcgtcta	tctatcttc	actgtccggg	ccaccagaag	1920
ggccacagtg	ctaggctcgc	gggcaatcgc	atggcagatc	aggccgcacg	aaaagccgca	1980
attactgaga	cacctgacac	atctaccttg	ctgattgaga	actcgtctcc	g	2031

SEQ ID NO: 166                   moltype = DNA   length = 2073  
FEATURE                        Location/Qualifiers  
source                         1..2073  
                                 mol\_type = other DNA  
                                 organism = Soybean chlorotic mottle virus

SEQUENCE: 166

aatactgaaa	ttgtccaaaa	acaccgagtt	ttaaccaaa	gtaaccctaa	tgttactttc	60
ataaaagtta	gtataggcaa	aagaaatctc	ttggcttata	ttgatactgg	agcaactctg	120
tgctttggaa	aaagaaaaat	ttcaataaat	tgggaaatct	taaaacaacc	aaaagaat	180
atcattggag	ataaatcaaa	acactatatt	agagaagcta	tttctaattg	gtttttaaaa	240
atcgaaaata	aagaattctt	aatccctatc	atataattac	atgattcagg	attagattta	300
attataggaa	acaatttctc	aaaattatac	caacctttta	ttcagagatt	ggaacaat	360
gaattaagat	ggaaaaatct	taataacca	aaagaatctc	aatgatttc	aaccaagatt	420
cttcaaaaa	tcaagattat	aaaactttca	ttgaaaaaa	ttcatatttg	tttagaaaa	480
tatttatttt	tcaaaaacat	tgaagaacaa	ctcgaagaag	tatgttcaga	acatccactg	540
gatgaaacaa	aaaataaaaa	tggtctttta	atagaaataa	gacttaaa	cccattacaa	600
gaaataaatg	tcaaaaatag	aattccat	acaataagag	atgtacaaga	attcaaggag	660
gaaatgtgaa	accctttaa	aaagggotta	attcgagaat	ctcaaaagtc	acacagtgca	720
ccggcattct	atgtcgaaaa	tcaaatgaa	atcaagcgtg	gaaaaagacg	catggtaatt	780
aattcaaaaa	aaatgaatga	agccacaatt	ggcagttcat	ataagttacc	aagaaaagat	840
tttattctgg	aaaaaatata	aggatcttta	tggttttcaa	gcttggatgc	taaatctgga	900
tactaccagc	taaggctcca	tgaataata	aagcctctaa	cagctttttc	atgtccacct	960
cagaaacatt	acgaatggaa	tgttttaagt	ttggactta	aacaagcacc	atctatatat	1020
caagatatta	tggatcaatc	ccccaaggga	cttgaacata	tatgtttggc	atatattgat	1080
gacatcctga	tctttacaaa	aggatctaaa	gaacaacatg	taaatgatgt	tcggattggt	1140
ttgcaagaaa	tcaaaagaaa	aggaattatt	atcttaaga	aaaaatcaaa	actgattcaa	1200
cagaaatcgc	aatatctcgg	tttaaaaata	caagggaatg	gagaaattga	tttatccact	1260
catacccaag	aaaaattctg	tcaatttctc	gatgaattag	aagatagaaa	acaaatcacg	1320
cgttttcttg	gctgtattaa	ttacattgca	aatgaaggat	ttttcaaaaa	tcttgcctca	1380
gaaagaaaagc	accctcaaaa	gaaaatttct	gttaaaaacc	cctggaaatg	ggatacaata	1440
gatacaaaaa	tggttcagtc	cataaaagcc	aaaattcaaa	gcctaccaaa	attatataat	1500
gcatcgattc	aagacttttt	aatagtcgag	acagatgcat	cgcaacactc	ctggagtgga	1560
tgtttgcgag	ctttaccctaa	gggaaagcaa	aaaatcggac	tcgatgaatt	cgggataccg	1620
acagctgacc	tctgcacagg	tagcagttca	gcttcaagcg	ataattcgc	agctgagatt	1680
gacaaatgct	attcagccag	taaacaggac	actcatgtgg	ccagtaaaat	aaagaaactc	1740
gaaaacgagc	ttctactttg	caaatatggt	tcaggtacct	tcacagatac	ggaacaaga	1800
tacctatag	cagaactgga	ggttcttctg	ggagtaaaag	tcctagaaaa	atggagaatc	1860
gacctcctac	aaacgaggtt	cctcctccgc	actgacagca	agtactttgc	aggtttttgt	1920
aggtacaaca	tcaagcaga	ctaccggaac	ggacgtctaa	tcaggtggca	actacggtta	1980
caagcctatc	aaccgtacgt	ggaattaaat	aaatcagaaa	ataaccatt	cgcagatagc	2040
cttacgcgag	aatggagcaa	gccatcaagc	agt			2073

SEQ ID NO: 167                   moltype = DNA   length = 2073  
FEATURE                        Location/Qualifiers  
misc\_feature                   1..2073  
                                 note = SbcMV\_D01  
source                         1..2073  
                                 mol\_type = other DNA  
                                 organism = synthetic construct

SEQUENCE: 167

aaactgaga	ttgttcaaaa	acatagagtg	cttaccaaa	gaaatccaaa	tggtacattt	60
-----------	------------	------------	-----------	------------	------------	----

-continued

ataaaagtgt	ccatagggaa	gagaaat	ttagcttata	ttgacactgg	agccacactc	120
tgttttggaa	aaaggaaaat	atcaaataac	tgggaaatcc	ttaagcaacc	caaagaaatc	180
attatocgctg	ataagtcaaa	acactacatc	agagaagcta	taagtaacgt	attcctgaaa	240
attgaaaaaca	aggagtctct	gataccatt	atatacttc	atgattcagg	gttggatttg	300
attattggga	ataactctoc	gaagctttat	caaccattta	ttcaaagact	tgaaactatc	360
gaactcaggt	ggaaaaactt	gaacaatccc	aaagagtctc	aaatgattag	cactaaaatt	420
cttacgaaaa	atgaagtctt	taagctgagt	tttgagaaga	ttcatatttg	tctcgaaaaa	480
tacctttct	ttaaaacat	cgaggaacaa	cttgaggagg	tttgtctga	acatccactt	540
gatgagacaa	agaacaagaa	tggctctttg	attgagatc	gtctgaaaga	tcctctgcag	600
gagattaacg	tcacaatag	gattccat	accattagag	atgtacagga	attcaaggaa	660
gaatgtgaag	atttacttaa	gaaggtctc	atctgtgaat	cacaatctcc	ccacagtgca	720
cccgcatttt	acgttgaaaa	tcataatgaa	attaagagag	gcaagcgtag	aatggttatc	780
aactacaaga	agatgaatg	agcaaccata	ggagatagct	acaaactccc	gcgaaaggat	840
tttatcttag	agaagataaa	gggcagtttg	tggttttcaa	gtttagatgc	aaaatcaggt	900
tattatcagc	ttcgcttaca	tgagaacaca	aagcctctca	ctgctttctc	ttgccctcct	960
caaaaacatt	atgaatggaa	gtgtgtgagt	ttcggcttaa	aacaggcacc	ttcgatttac	1020
cagcgtctca	tggaccagtc	cttaaaagga	ttagagcaca	tttgctggc	atataatagat	1080
gatattcttaa	tctttactaa	aggctcaaag	gaacagcatg	tcaatgatgt	tcggattgtc	1140
ctgcaaaagaa	tcaaaagaaa	aggaatcota	atatactaaa	aaaaatcaaa	attgattcag	1200
caagagatgt	aatactcagg	attgaaaaat	caaggtaatg	gtgaaatgta	cctctcacca	1260
catactcaag	aaaagatcct	acagttccct	gatgaactgg	aggatagaaa	acaaatcacg	1320
aggttctag	gttgcaatga	ttcattgctg	aacgaaggat	ttttcaaaaa	tctgccccta	1380
gagagaaaagc	attgacagaa	gaagatttcc	gtgaagaatc	catggaagtg	ggatacaata	1440
gacacaaaaa	tggtgcaatc	aatcaagggc	aaaattcaat	ccctgcccga	gctctacaat	1500
gcaagtattc	aggatttctc	aattgttagag	actgacgcct	cgcaacattc	ttggtctggg	1560
tgtttgcggg	ctcttccaaa	gggcaagcag	aaaatcggtc	tggacgaatt	tgggattcca	1620
acggcagatt	atgtactcgg	tagctccagt	gcttctctg	ataattctcc	tgctgagatc	1680
gacaagtgcc	actcagctgg	gaagcaggat	acacacgtcg	cctctaaaat	aaagaaactt	1740
gagaatgagt	tacttttgtg	caagtatgtt	tcagggactt	tcacggcac	cgagactagg	1800
tatctatag	ctgaactcga	ggtgttggcg	ggtgttaaa	ttttgaaaa	atggaggata	1860
gacttggtgc	aaacacgatt	tctacttagg	acagattcca	aatattttgc	tggattttgt	1920
agatacaaca	ttaagactga	ttatcggaac	gggaggctca	taagatggca	attgcgcctt	1980
caagcttacc	agccttatgt	ggaactgatc	aagagtgaaa	ataatccttt	tcgagacacc	2040
ctaacacgag	agtggagcaa	accatcttct	agc			2073

SEQ ID NO: 168                   moltype = DNA   length = 2034  
 FEATURE                        Location/Qualifiers  
 source                         1..2034  
                                  mol\_type = other DNA  
                                  organism = Cauliflower mosaic virus

SEQUENCE: 168

gatcatctac	ttctgaagac	tcagactcag	actgagcagg	tgatgaacgt	caccaatccc	60
aattcgatct	acatcaaggc	aagactctac	ttcaagggat	acaagaagat	agaacttcac	120
tgtttcgtag	acacggggagc	aagcctatgc	atagcatcca	agttcgtcat	accagaagaa	180
cattgggtca	atgcagaaag	accaattatg	gtcaaaatag	cagatggaag	ctcaatcacc	240
atcagcaaa	tctgcaaaag	ctagactctg	atcatagccg	gcgagatatt	cagaattccc	300
accgtctatc	agcaagaag	tggcatcgat	ttcattatcg	gcaacaactt	ctgtcagctg	360
tatgaacct	ctcatcagtt	tacggataga	gttatctcca	caaagaacaa	gtcttatcct	420
gttcatattg	cgaagctaac	cgagcagctg	cgagtaggca	cgaaggattt	tcttgatcca	480
atgaagaaac	gttcaaaaac	tcacaacca	gagccagtga	acattttctc	aaacaagata	540
gaaaatccac	tagaagaaat	tgctattctt	tcagagggga	ggaggttacc	agaagaaaaa	600
ctctttatca	ctcaacaag	attgcaaaaa	atcgaagaac	tacttgagaa	agtatgtcca	660
gaaaatccat	tagatcctaa	caagactaag	caatggatga	aagcttctat	caagctcagc	720
gacccaagca	aagctatcaa	ggttaaacc	atgaagtata	gcccaatgga	tcgccaagaa	780
tttgacaagc	aaatcaaa	attactggac	ctaaaagtca	tcaagccag	taaaagccct	840
cacatggcac	cagccttctt	ggtcaacaat	gaagccgaga	agcgaagagg	aaagaaactt	900
atggttagca	actacaagc	tatgaacaaa	gctactgtag	gagatgctca	caatcttccc	960
aaacaagacg	agttacttac	actcattcga	ggaaagaaga	tcttctcttc	cttcgactgt	1020
aagtccaggt	tctggcaagt	tctgctagat	caagaatcaa	gacctctaac	ggcattcaca	1080
tgctcacaag	gtcactacga	attggaatgt	gtccctttcg	gcttaaagca	agctccatcc	1140
atattccaaa	gacacatgga	cgaagcattt	cgtgtgtcca	gaaagttctg	ttgctgttat	1200
gtcgcagaca	ttctcgtatt	cagtaacaac	gaagaagatc	atctactcca	ctgtagcaatg	1260
atcttcaaaa	agtgtaatca	acatggaatt	atcctttcca	agaagaagc	acaactcttc	1320
aagaagaaga	taaacttctc	tggtctagaa	atagatgaag	gaacacataa	gcctcaagga	1380
catatcttgg	aacacatcaa	caagttcccc	gatacccttg	aagacaagaa	gcaacttcag	1440
agattcttag	gcataactaac	atagcctcgg	gattacatcc	cgaagctagc	tcaaatcaga	1500
aagcctctgc	aagccaagct	taagaaaaac	gttccatgga	gatggacaaa	agaggatacc	1560
ctctacatgc	aaaaggtgaa	gaaaaatctg	caaggatttc	ctccaactaca	tcacccctta	1620
ccagaggaga	agctgatcat	cgagaccgat	gcatcagacg	actactgggg	aggatgttta	1680
aaagctatca	aaatataacg	aggtactaat	actgagttaa	tttgagata	cgcatctgga	1740
agctttaaag	ctgcagaaaa	gaattaccac	agcaatgaca	aagagacatt	ggcggtaata	1800
aatactataa	agaaatctag	tatttatcta	actcctgttc	atcttctgat	taggacagat	1860
aatactcatt	tcaagagttt	cgttaatctc	aattacaaag	gagattcgaa	acttggaaaga	1920
aacatcagat	ggcaagcatg	gcttagccac	tattcatttg	atggtgaaca	cattaaagga	1980
accgacaacc	actttgcgga	cttcccttca	agagaattca	ataaggttaa	ttcc	2034

-continued

SEQ ID NO: 169                   moltype = DNA   length = 2034  
 FEATURE                        Location/Qualifiers  
 misc\_feature                   1..2034  
                                   note = CaMV\_D01  
 source                         1..2034  
                                   mol\_type = other DNA  
                                   organism = synthetic construct

SEQUENCE: 169

gatcaccttc	tgcttaagac	acagacacaa	actgaacaag	ttatgaatgt	gaccaacccg	60
aattccattt	acattaaggg	acgactctac	tttaaggggt	ataagaaat	agaattacat	120
tgtttcgtcg	acactggagc	atctctctgc	atagcgcca	agtttggtat	tcctgaggaa	180
cattgggtaa	atgcagaag	gccgattatg	gttaaaattg	cagatggtag	cagcatcaca	240
atctcaaaag	tttgcagaag	cattgacttg	atcattgctg	gtgagatttt	cagaattcct	300
acagtgtatc	aacaagaatc	cggcattgat	tttataaattg	gtaataaactt	ttgtcaactt	360
tatgagccct	tcatacaaat	tacagatcga	gtcattttta	ctaaaaacaa	gagttaccct	420
gttcacattg	caaaactcac	ctgtgccgtg	agagttggaa	cggaaggatt	tctagaatct	480
atgaagaaga	gatcgaaaac	tcagcaacca	gaaccgcta	atatttctac	aaataagatt	540
gaaaatccat	tagaggaat	agccatcttg	tccaaggcc	ggcggttgag	tgaagaaaag	600
ttgtttatca	cgcagcagag	aatgcaaaaa	atagaggagc	ttctcgaaaa	ggtttgttct	660
gagaatcctt	tgatccaaaa	taaaacaaaa	caatggatga	aagctagtat	aaagctttca	720
gacctatcaa	aggcaattaa	ggtgaagcca	atgaaata	gccccatgga	tagggaggag	780
tttgacaagc	aaattaagga	gctactcgat	ctgaaagtaa	taaaaccttc	taaatcgctt	840
cacatggctc	cagcattcct	ggttaacaac	gaggctgaaa	agcgcagagg	aaaaaaaaaga	900
atggtgggtg	actcaaaagc	aatgaataag	gctactgttg	gagatgctta	taatcttctt	960
aaataagatg	agctcttgac	cttaattaga	gggaagaaaa	tttctcctc	atttgattgt	1020
aaatcaggat	tttggcaagt	ggtgctggat	caagagtctc	gtccactgac	cgcttttacg	1080
tgccctcaag	gacattatga	atggaatgct	gtaccatttg	gtctcaagca	agcaccttct	1140
attttccaga	ggcatatgga	tgaagcattt	agagtgttta	ggaattctcg	ctgtgtttat	1200
gtggatgata	tattgttatt	ctcaaaat	gaggaagacc	atttctgca	tgttgcatg	1260
atcttccaga	agtgaatc	acatggaatc	atcttatcca	agaagaagcc	tcagttgttc	1320
aagaagaaga	taattttttt	gggtctcgag	attgatgagg	ggacacataa	gcctcagggt	1380
cataactag	aacatataca	caagtttcca	gacacttgg	aagacaaaa	gcagtgtcaa	1440
agggtccttg	ggattctgac	ttatgcttca	gattatatac	caagcttgc	tcaataaaga	1500
aaacccttc	agcgaagtc	caagaaaaa	gttccttgga	ggtggactaa	ggaggatacc	1560
ttatacatgc	agaaagtcaa	gaaaaacctc	cagggtttcc	caccgctcca	ccatccttta	1620
cctgaagaaa	aactaattat	cgagacagat	gcttctgatg	actactgggg	cggcattggtg	1680
aaggccatca	aaatcaatga	agggaccaat	actgagctca	tttctgata	tgcagcggga	1740
agttttaaag	cagctgagaa	aaattatcat	agtaatgata	aagagactct	agccgttatt	1800
aacaccataa	agaaattctc	tatatatctt	acccccctcc	actttttaat	caggacagac	1860
aaactcact	tcaaatcatt	gtggaacctg	aattacaagg	gtgatagtaa	acttggccgt	1920
aacatacgtc	ggcaggcttg	gttgagccac	tactcttttg	atgtagaaca	cattaagga	1980
acagataatc	attttctgta	tttcttttct	cgcgagtcca	acaaagtaa	ttca	2034

SEQ ID NO: 170                   moltype = AA   length = 683  
 FEATURE                        Location/Qualifiers  
 source                         1..683  
                                   mol\_type = protein  
                                   organism = Moloney Murine Leukemia Virus

SEQUENCE: 170

TLNIEDEHRL	HETSKPEPVS	LGSTWLSDFP	QAWAETGGMG	LAVRQAPLII	PLKATSTPVS	60
IKQYPMQEA	RLGKPKHIQR	LLDQGLVPC	QSPWNTPLLP	VKKPGTNDYR	PVQDLREVNK	120
RVEDIHPTVP	NPYNLLSGLP	PSHQWYTVLD	LKDAFFCLR	HPTSQPLFAF	EWDRPEMGIS	180
GQLTWTRLPQ	GFKNSPTLFD	EALHRDLADF	RIQHPDLILL	QYVDDLLLA	TSELDCQQT	240
RALLQTLGNL	GYRASAKKAQ	IQQKQVKYLG	YLLKEGQRWL	TEARKETVMG	QPTPKTPRQL	300
REFLGTAGFC	RLWIPGFAEM	AAPLYPLTKT	GTLFNWGPDQ	QKAYQEIQA	LLTAPALGLP	360
DLTKPFELFV	DEKQGYAKGV	LTQKLGWRR	PVAYLSKKLD	PVAAGWPPCL	RMVAIAVLT	420
KDAGKLTMGQ	PLVILAPHAV	EALVKQPPDR	WLSNARMTHY	QALLLDTDRV	QFGPVVALNP	480
ATLLPLPEEG	LQHNCLDILA	EAHGTRPDLT	DQPLPADDHT	WYTDGSSLLQ	EGQRKAGAAV	540
TTETEVIWAK	ALPAGTSAQR	ABELIALTQAL	KMAEGKMLNV	YTDSRYAFAT	AHIHGEIYRR	600
RGLLTSEGKE	IKNKDEILAL	LKALFLPKRL	SIHCPGHQK	GHSABARGNR	MADQAARKAA	660
ITETPDTSTL	LIENSSPNRS	LIN				683

SEQ ID NO: 171                   moltype = AA   length = 717  
 FEATURE                        Location/Qualifiers  
 source                         1..717  
                                   mol\_type = protein  
                                   organism = Moloney Murine Leukemia Virus

SEQUENCE: 171

MKRTADGSEF	ESPKKKRKVT	LNIEDEHRLH	ETSKPEPVS	GSTWLSDFPQ	AWAETGGMGL	60
AVRQAPLIIP	LKATSTPVS	IKQYPMQEAR	LGKPKHIQRL	LDQGLVPCQ	SPWNTPLLPV	120
KKPGTNDYR	VQDLREVNKR	VEDIHPTVNP	PYNLLSGLFP	SHQWYTVLDL	KDAFFCLRHL	180
PTSQPLFAFE	WRDPEMGISG	QLTWTRLPQG	FKNSTPLFNE	ALHRDLADFR	IQHPDLILLQ	240
YVDDLLLAAT	SELDCQQT	ALLQTLGNLG	YRASAKKAI	CQKQVKYLG	LLKEGQRWLT	300
EARKETVMGQ	PTPKTPRQLR	EFLGKAGFCR	LFIPGFAEMA	APLYPLTKPG	TLFNWGPDQ	360
KAYQEIQAAL	LTAPALGLPD	LTGPFELFVD	EKQGYAKGVL	TQKLGWRRP	VAYLSKKLDP	420
VAAGWPPCLR	MVAIAVLT	DAGKLTMGQP	LVLILAPHAVE	ALVKQPPDRW	LSNARMTHYQ	480



-continued

ALLLDTDRVQ	FGPVVALNPA	TLLPLPEEGL	QHNCLDILAE	AHGTRPDLTD	QPLPDADHTW	540
YTDGSSLLQE	GQRKAGAAVT	TETEVIWAKA	LPAGTSAQRA	ELIALTQALK	MABGKKNLVY	600
TDSRYAFATA	HIHGEIYRRR	GWLTSEGKEI	KNKDEILALL	KALFLPKRLS	IIHCPGHQKG	660
HSAEARGNRM	ADQAARKAAI	TETPDTSTLL	IENSSPSGGS	KRTADGSEFE	PKKKRKV	717
SEQ ID NO: 172	moltype = AA length = 19					
FEATURE	Location/Qualifiers					
source	1..19					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 172						
MKRTADGSEF	ESPKKKRKV				19	
SEQ ID NO: 173	moltype = AA length = 21					
FEATURE	Location/Qualifiers					
source	1..21					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 173						
SGGSKRTADG	SEFEPKKKRK V				21	
SEQ ID NO: 174	moltype = AA length = 7					
FEATURE	Location/Qualifiers					
source	1..7					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 174						
PKKKRKV				7		
SEQ ID NO: 175	moltype = AA length = 175					
FEATURE	Location/Qualifiers					
source	1..175					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 175						
MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLIVE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKKTREK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEAKST	SIAFR	175
SEQ ID NO: 176	moltype = AA length = 1198					
FEATURE	Location/Qualifiers					
source	1..1198					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 176						
CINENLTRYI	SNMDIFEKVD	AIFDKHEVQE	IKEKILNSDY	DVEDFFEGEF	FNFVLTQEGI	60
DVYNAIIGGF	VTEGSEKIKG	LNEYINLYNQ	KTKQKLPKFK	PLYKQVLSDR	ESLSFYGENQ	120
TTQKGQKNSR	ERMKRIEEGI	KELGSQLKE	HPVENTQLQN	EKLYLYLQN	GRDMYVDQEL	180
DINRLSDYDV	DHIVPQSFLK	DDSIDNKVLT	RSDKNRGKSD	NVPSEEVVKK	MKNYWRQLLN	240
AKLITQRKFD	NLTKAERGG	SEGYTSDEEV	LEVFRNTLNK	NSEIFSSIKK	LEKLPKNFDE	300
YSSAGIFVKI	GPAISTISKD	IPGEWNVIRD	KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	360
KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	KVDEIYKVVY	SSEKLPDADF	VLEKSLKKN	420
AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	NRDESFGYGF	VLAYDILLKV	DHIYDAIRNY	480
VTKQPYSKDK	FKLYFQNPQF	MGGWDDKDKET	DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	540
KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYNPSE	DIQKIYKNGT	FKKGDMPNLN	600
DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	660
DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYFKLLPDE	NNHGQIRLSG	GAELFMRRAS	720
LKKEELVVHP	ANSPIANKNP	DNPKKTTLT	YDVYKDKRES	EDQYELHIPI	AINKCPKNIF	780
KINTEVRVLL	KHDDNPPYVIG	IARGERNLLY	IVVVDGKGN	VEQYSLNEII	NNFNGIRIKT	840
DYHSLDDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVKH	ICELVEKYDA	VIALEDLNSG	900
FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	LKGQYITNKF	ESFKSMSTQN	960
GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	FDRIMYVPEE	DLFEPALDYK	1020
NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	NNVPDWEVVC	LTSAYKELFN	KYGINYQQGD	1080
IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	ITGRTDVDFL	ISPVKNSDGI	FYDSRNVEAQ	1140
ENAILPKNAD	ANGAYNIARK	VLWAIQFKK	AEDEKLDKVK	IAISNKEWLE	YAQTSVKH	1198
SEQ ID NO: 177	moltype = AA length = 455					
FEATURE	Location/Qualifiers					
source	1..455					
	mol_type = protein					
	organism = synthetic construct					
SEQUENCE: 177						
MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLIVE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYIS	LFRKKTREK	ENKELENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETILP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEAKST	SIAFR	180
LTRYISNMDI	FEKVDIAFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240

-continued

IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VDQELDINRL	360
SDYDVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEGYT	SDEEVLEVFR	NLTK			455

SEQ ID NO: 178                   moltype = AA   length = 918  
 FEATURE                        Location/Qualifiers  
 source                         1..918  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 178

NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKN	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	60
LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QFYADADLSV	VEKKEIIIQ	KVDEIYKVVY	120
SSEKLFDAF	VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAPFGGKGT	NRDESPYGF	180
VLAYDILKLV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWKDKET	DYRATILRYG	240
SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGFN	KMLPKVFFSK	KWMAYVNPSE	300
DIQKIYKNGT	FKKGDMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNPFSET	EKYKDIAGFY	360
REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYPKLLFDE	420
NNHQQIRLSG	GAELEFMRAS	LKKEELVVHP	ANSPIANKNP	DNPKTTTLS	YDVYKDKRFS	480
EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGN	540
VEQYSLNII	NNFNGIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVK	600
ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	660
LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	720
PDRIMYVPEE	DLFEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	NNVFDWEEVC	780
LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	840
ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIGQPKK	AEDEKLDKVK	900
IAISNKEWLE	YAQTSVKH					918

SEQ ID NO: 179                   moltype = AA   length = 551  
 FEATURE                        Location/Qualifiers  
 source                         1..551  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 179

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKTRTEK	ENKELLENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIIETLLP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAkst	SIAFRGINEN	180
LTRYISNMDI	FEKVDAlFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRSLSF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VDQELDINRL	360
SDYDVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEGYT	SDEEVLEVFR	NLTKNSEIF	SSIKKLEKLF	KNFDEYSAG	480
IFVKNGPAlS	TISKDIPGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSPKKIGSF	540
SLEQLQEYAD	A					551

SEQ ID NO: 180                   moltype = AA   length = 822  
 FEATURE                        Location/Qualifiers  
 source                         1..822  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 180

DLSVVEKLKE	IIIQKVDIYI	KVYGSSEKLF	DADFVLEKSL	KKNDAVVAIM	KDLLDSVKSF	60
ENYIKAPFGE	GKETNRDES	YGFVFLAYDI	LLKVDHIYDA	IRNYVTQKPY	SKDKFKLYFQ	120
NPQFMGGWDK	DKETDYRATI	LRYSKYLYA	IMDKKYAKCL	QKIDKDDVNG	NYEKINYLK	180
PGPNKMLPKV	FFSKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	DFPKDSISRY	240
PKWSNAYDFN	FSETEKYKDI	AGFYREVVEQ	GKVSFESAS	KKEVDKLVVE	GKLYMPQIYN	300
KDFSDKSHGT	PNLHTMYFKL	LPDENNHGQI	RLSGGAELFM	RRASLKKKEEL	VVHPANSPIA	360
NKNPDNPKKT	TTLSYDVYKD	KRFSEDQYEL	HIPIAINKCP	KNIFKINTEV	RVLLKHDDNP	420
YVIGIARGER	NLLYIVVVDG	KGNIVEQYSL	NEIINNPNFI	RIKTDYHSL	DKKEKERFEA	480
RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNRSV	KVEKQVYQKF	540
EKMLIDKLN	MVDKSNPCA	TGGALKGYQI	TNKFESFKSM	STQNGFIFYI	PAWLTSKIDP	600
STGFVNLLKT	KYTSIADSKK	FISSFDRIMY	VPEEDLFEFA	LDYKNFSRTD	ADYIKKWKLY	660
SYGNRIRLFR	NPKKNNVFDW	EEVCLTSAYK	ELFNKYGINY	QQGDIRALLC	EQSDKAFYSS	720
FMALMSLMLQ	MNSITGRTD	VDLISPVKN	SDGIFYDSRN	YEAQENAILP	KNADANGAYN	780
IARKVLWAlG	QFKKADEKEL	DKVKIAISNK	EWLEYAQTSV	KH		822

SEQ ID NO: 181                   moltype = AA   length = 586  
 FEATURE                        Location/Qualifiers  
 source                         1..586  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 181

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKTRTEK	ENKELLENLEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETLLP	EFLDDKDEIA	LVNSFNGFTT	AFTGFFDNRE	NMFSEEAkst	SIAFRGINEN	180
LTRYISNMDI	FEKVDAlFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240

-continued

IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRRESLSF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VDQELDINRL	360
SDYDVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	KNFDEYSSAG	480
IPVKNGPAIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQEYAD	ADLSVVEKLK	EIIIQKVDI	YKVYGSSEKL	FDADVF		586

SEQ ID NO: 182                   moltype = AA   length = 787  
 FEATURE                        Location/Qualifiers  
 source                         1..787  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 182

LEKSLKKNDA	VVAIMKDLLD	SVKSPFENYIK	AFPGEGKETN	RDESFYGDV	LAYDILLKVD	60
HIYDAIRNYV	TQKPYSKDKF	KLYFQNPQPM	GGWDKDKETD	YRATILRYGS	KYYLAIMDKK	120
YAKCLQKIDK	DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYYNPSED	IQKIYKNGTF	180
KKGDMFNLND	CHKLIDFFKD	SISRYPKWSN	AYDFNFSETE	KYKDIAGFYR	EVEEQGYKVS	240
PESASKKEVD	KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	300
AELFMRRASL	KKEELVVHPA	NSPIANKNPD	NPKKTTLSY	DVYKDKRFE	DQYELHIPIA	360
INKCPKNIFK	INTEVRVLLK	HDDNPYVIGI	ARGERNLLYI	VVVDGKGNIV	EQYSLNEIIN	420
NFNGIRIKTD	YHSLLDKKEK	ERFEARQNW	SIENIKELKA	GYISQVVKHI	CELVEKYDAV	480
IATEDLNSGF	KNSRVKVEKQ	VYQKFEKMLI	DKLNYMVDK	SNPCATGGAL	KGQITNKFE	540
SFKSMSTQNG	FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSE	DRIMYVPEED	600
LFEPALDYKN	FSRTDADYIK	KWKLYSYGNR	IRIFRNPKNK	NVPDWEVCL	TSAYKELFNK	660
YGINYQQGDI	RALLCEQSDK	AFYSSPMALM	SMLMQMRNSI	TGRTDVDFLI	SPVKNSDGIF	720
YDSRNYEAQE	NAILPKNADA	NGAYNIARKV	LWAIQGFKKA	EDEKLDKVKI	AISNKEWLEY	780
AQTSVKH						787

SEQ ID NO: 183                   moltype = AA   length = 695  
 FEATURE                        Location/Qualifiers  
 source                         1..695  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 183

MGSKLEKFTN	CYLSKTLRF	KAIPVGKTQE	NIDNKRLLE	DEKRAEDYKG	VKKLLDRYYL	60
SFINDVLHSI	KLKLNLYNIS	LFRKTRTEK	ENKELELEI	NLRKEIAKAF	KGNEGYKSLF	120
KKDIETILP	EFLDDKDEIA	LVNSFNGFTI	AFTGFFDNRE	NMFSEAKST	SIAPRCINEN	180
LTRYISNMDI	FEKVDAIFDK	HEVQEIKEKI	LNSDYDVEDF	FEGBFFNFVL	TQEGIDVYNA	240
IIGGFVTESG	EKIKGLNEYI	NLYNQTKQK	LPKFKPLYKQ	VLSDRRESLSF	YGENQTTQKG	300
QKNSRERMKR	IEEGIKELGS	QILKEHPVEN	TQLQNEKLYL	YYLQNGRDMY	VDQELDINRL	360
SDYDVDHIVP	QSFLKDDSID	NKVLTRSDKN	RGKSDNVPSE	EVVKKMKNYW	RQLLNAKLIT	420
QRKFDNLTKA	ERGLSEGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	KNFDEYSSAG	480
IPVKNGPAIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	540
SLEQLQEYAD	ADLSVVEKLK	EIIIQKVDI	YKVYGSSEKL	FDADFVLEKS	LKKNDAVVAI	600
MKDLLDSVKS	FENYIKAFFG	EKETNRDES	FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	660
YSKDKPKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYG			695

SEQ ID NO: 184                   moltype = AA   length = 678  
 FEATURE                        Location/Qualifiers  
 source                         1..678  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 184

SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYLKLPGNK	KMLPKVFFSK	KWMAYYNPSE	60
DIQKIYKNGT	FKKGMFNLN	DCHKLIDFPK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	120
REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMFYKLLFDE	180
NMHGQIRLSG	GAEELFMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKTTLS	YDVYKDKRFS	240
EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGNI	300
VEQYSLNEII	NNFNGIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVKH	360
ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QYQKFEKML	IDKLNVMVDK	KSNPCATGGA	420
LKGYQITNKF	ESFKSMSTQN	GFIYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISSE	480
FDRIMYVPEE	DLFEPALDYK	NFSRTDADYI	KWKLYSYGN	RIRIFRNPKN	NNVFDWEVCL	540
LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	SMLMQMRNS	ITGRTDVDFL	600
ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFK	AEDKLDKVK	660
IAISNKEWLE	YAQTSVKH					678

SEQ ID NO: 185                   moltype = DNA   length = 2538  
 FEATURE                        Location/Qualifiers  
 source                         1..2538  
                               mol\_type = other DNA  
                               organism = synthetic construct

SEQUENCE: 185

atgaaacgga	cagccgacgg	aagcgagttc	gagtcaccaa	agaagaagcg	gaaagtcaca	60
cttaatattg	aggatgaaca	tagattgcac	gagacctcta	aggaacctga	tgtttctcct	120
ggatcaactt	ggttgtcaga	tttccacaa	gcatgggcag	agaccggagg	tatgggtcct	180
gctgttaggc	aggcaccact	tattattcct	ttgaaggcaa	cctctactcc	tgtgtcaatt	240

-continued

aagcaatatic	caatgtctca	ggaagctagg	cttgggaatta	agcctcacat	tcaaagactt	300
ttggatcagg	gtatTTTTGGT	gccatgtcaa	tcacettgga	acacaccact	tttgctgtt	360
aagaagcctg	gtactaatga	ttacagacca	gtgcaagatt	tgagggagggt	taacaagaga	420
gtggaagata	ttaccacaac	tgttccaaac	ccttataatc	ttttgtctgg	attgccacct	480
tcacatcaat	ggtagacctgt	gcttgatttg	aaggatgcat	ttttctgctt	taggttgcct	540
ccaacatctc	agcctctttt	tgctttcgag	tgagagatc	ctgaaatggg	aatTTctggt	600
caacttacat	ggaccagggt	gcctcagggt	ttcaagaact	caccaacctt	gtttaatgag	660
gcacttcaca	gggatttggc	tgattttagg	atccaacatc	ctgatcttat	ccttttgcag	720
tatgttgatg	atcttttgc	tgctgcaact	tctgaattgg	attgtcaaca	gggaactagg	780
gcattgcttc	aaacacttgg	aaatttgggt	tacagagctt	cagcaagaa	ggctcagatt	840
tgccaaaagc	aggttaagta	tcttgatcac	ttgcttaagg	aaggacaaag	gtggttgacc	900
gaggctagaa	aggaactgt	gatgggtcaa	ccaacaccta	agacccctag	gcagcttaga	960
gagttcttgg	gaaaggcagg	cttttctagg	cttttctattc	caggatttgc	tgaatggct	1020
gcaccacttt	atcctttgac	caagcctgga	actttgttta	actgggttcc	agatcaacag	1080
aaggcatacc	aagaaattaa	gcaggctttg	cttactgctc	cagcaactgg	tttgctgat	1140
cttcaaaagc	catttgagtt	gttcgttgat	gaaaagcaag	gatatgcaaa	gggtgtgctt	1200
accagaaagt	gggacccttg	gagaaggcct	gttgcttacc	tttctaagaa	acttgatcca	1260
gtggctgcag	ggtggccacc	tgtctttaga	atgggtctgt	caattgcagt	gcttacaag	1320
gatgctggaa	agttagctat	gggacaacct	cttgttattt	tggcaccaca	cgctgtttag	1380
gcacttctga	agcagccacc	tgataggtgg	ttgtcaaacg	caagaatgac	ccattatcaa	1440
gctctctctt	tgatactga	taggggtcag	ttcgctctgt	ttgtggcttt	gaatccagca	1500
acacttttgc	cacttcttga	ggaaggattg	caacacaact	gccttgatat	tttgctgag	1560
gcacatggtg	caagacctga	tcttaccgat	cagccattgc	ctgatgctga	tcacacttgg	1620
tacacagatg	gatcttcaat	tttgcaagaa	ggacagagga	aggctgtgtc	tgcaagtact	1680
acagagactg	aagttagttg	ggctaaggca	cttccagctg	gaaactctgc	tcaaaagca	1740
gagcttatgt	ctttgacctg	ggcacttaag	atggctgaag	gaaagaagt	gaaactttac	1800
actgattcta	ggtatgcttt	cgcaacagct	catattcacc	gagaactcta	tagaaggaga	1860
ggatggttga	catcagagg	aaagaaat	aagaacaagg	atgaaatctt	tgcacttttg	1920
aagctctctt	ttcttctcaa	gagattgtct	attattcatt	gccacaggca	ccaaaagggt	1980
cattcagcag	aagctagggg	aaatagaatg	gctgatcagg	ctgcaagaaa	ggctgcaatt	2040
actgagacac	ctgatacctc	tactcttttg	atcgaaaact	cttaccctaa	ttcaaggctt	2100
attaactctg	gtggttcaag	cggaggctca	tctggcagcg	aaactccggg	cacttccgag	2160
tcagcttgcc	tgtcctacga	gacagagatc	ctgacagtg	agtatggcct	gctgccaatc	2220
ggcaagatcg	tggaagaag	gatcgagtg	accgtgact	ctgtggaata	caatggcaac	2280
atctatacac	agcccgctgg	acagtggcac	gataggggag	agcaggagg	gttcgagtat	2340
tgccctggagg	acggcagcct	gatcagggca	accaaggacc	acaagttcat	gacagtggat	2400
ggccagatgc	tgccctcaga	cgagatttct	gagcgggagc	tggacctgat	gagagtggat	2460
aacctgccta	atagcgggag	cagtaaaaga	acagcagacg	ggagtgagtt	tgagcccaag	2520
aaaaagagaa	aggtgttaa					2538

SEQ ID NO: 186 moltype = DNA length = 4155  
 FEATURE Location/Qualifiers  
 source 1..4155  
 mol\_type = other DNA  
 organism = synthetic construct

SEQUENCE: 186

atgaaaacgga	cagccgacgg	aagcggagttc	gagtcacca	agaagaagcg	gaaagtcac	60
aagattgcta	cagggaaata	cctgggaaag	cagaacgtgt	acgacatcgg	cgtggggcag	120
ccacacaact	tcgccctgaa	gaatggcttt	atcgccagca	attgcgcaac	tctgtgctct	180
agcggcgggt	cgtcaggagg	gtcttccaag	ctggagaagt	ttacaaaactg	ttacagcctc	240
tccaaaaccc	tcaggtttaa	agcgatccc	gtggccaaga	cccaggagaa	catcgacaac	300
aagaggctcc	tggtggaaga	cgagaagcgc	gccgaagact	acaagggcgt	gaagaagctg	360
ctcgataggt	actacctcag	ctttattaac	gacgtgctgc	acagcatcaa	actcaagaat	420
ctcaacaact	acatctccct	cttccgcaaa	aagaccgcga	ccgagaagga	gaacaaggag	480
ctggagaacc	tggagatcaa	cctccgcaag	gaaatcgcca	aagcgttcaa	gggcaatgaa	540
gggtacaaga	gcctcttcaa	gaaagacatc	atcgaaaacta	tcctcccaga	gtttctcgat	600
gacaaggacg	agatcgcgct	ggtgaactcc	ttaaacgggt	tcacaaccgc	gtttaccggc	660
ttctttgata	acagggaaaa	tatggtctcc	gaggaggcca	agtcaccacg	catcgcttcc	720
aggtgtatca	acgagaacct	caccgcctac	atttccaata	tggacatttt	cgagaagggtg	780
gatcgcatct	tcgataagca	cgaggtgcag	gagatcaaa	agaagattct	caattccgat	840
tatgacgtcg	aggatttctt	cgaaagggag	ttctttaat	ttgtgctcac	acaagagggc	900
attgacgtgt	acaacgcgat	tatcgggggc	ttcgtcacag	agtcggggga	gaagattaa	960
gggtggaatg	agtacatcaa	tctgtacaat	cagaagacca	agcagaact	gccgaatttc	1020
aagccgctct	acaagcaagt	cctgtccgat	agggaaagcc	tctccttcta	cggcaggggc	1080
tataccagcg	acgaggaggt	gctggaaagtc	tcccgcaaca	cactgaataa	gaatagcgag	1140
atTTTctcct	ccatcaagaa	gctcgagaag	ctctttaaga	actttgacga	gtacagctcc	1200
gccgggattt	tcgtgaagaa	cgggcggcg	atcagcacca	tctccaagga	catctttggc	1260
gagtggaacg	tcacagggga	caagtggaac	gccaggtacg	acgacatcca	cctgaagaag	1320
aaggcgggtg	tgaccagagaa	gtatgaggac	gatcgcagga	agtccttcaa	aaaaatcggc	1380
tccttcagcc	tcgaacagct	ccaggagat	gccgatcggg	atctgtccgt	cgtcgagaag	1440
ctgaaagaaa	tcatcattca	gaaagtcgac	gagatctata	aagtgaacgg	gtcccgcgag	1500
aagctggtcg	acgccgaact	tgtgctcgag	aagtcctca	aaaagaatga	cgccgtgggtg	1560
gccattatga	aagacctgct	cgactccgtg	aagtcctcg	aaaattacat	taaagcgttc	1620
ttggggaggt	ggaaggaac	taacagggat	gagtccttct	atggcgactt	tgtcctcgcg	1680
tacgacatcc	tgctgaaggt	gcaccacatt	tacgacgcga	tccgcaacta	cgtgacacag	1740
aagccgctact	ccaagacaa	gttcaagctg	tacttccaga	accgcgaatt	tatggggggc	1800

-continued

tgggacaag	ataaagagac	agactaccgc	gcgacaattc	tccgctatgg	ctccaaatac	1860
tatctggcca	tcatggacaa	gaagtacgcg	aagtgcctgc	agaagatcga	caaagacgac	1920
gtcaatggca	actatgaaaa	gatcaactac	aagctgctgc	cgggcccga	caagatgctc	1980
ccgaaggtgt	tcttcagcaa	gaagtggatg	gcctactaca	atccaagcga	ggatattcag	2040
aaaatctata	aaaacgggac	cttcaagaag	ggggacatgt	ttaacctcaa	cgactgccac	2100
aagctcoatg	atcttctcaa	ggatagcatt	tcccgcctacc	cgaaatggct	caatgctgtc	2160
gattttaact	tctccgagac	agaaaagtc	aaagacatcg	cgggcttcta	cagggaggtg	2220
gaggagcaag	ggataaaagt	ttcttttgaa	tccgcgagca	agaaggaagt	cgacaagctc	2280
gtcaggagg	gcaagctcta	catgttccaa	atctataaca	aggacttttc	cgacaagagc	2340
catgggacc	caaactccca	caccatgtac	ttcaactgc	tcttgacga	gaacaaccac	2400
gggcaaatca	cggtgacgg	cggcgccgaa	ttattcatgc	gcagggcctc	cctcaagaag	2460
gaagagctgg	tcgtccatcc	agccaattcc	ccgatccgca	acaagaacc	ggacaatccg	2520
aaaaagacca	ccaccctgtc	ctacgaogtc	tacaaggaca	aacgcttcag	cgaagaccag	2580
tacgaattca	acatcccaat	tgcgattaat	aagtgcctcaa	agaatattct	caaaaattat	2640
acagaggtca	gggtgctgct	caaacacgac	gacaatccgt	atgtcatcgg	cattgacagg	2700
ggcagcgcga	atctgctcta	tatcgtggtc	gtggatggga	agggcaatat	tgtggagcag	2760
tactccctga	acgagattat	caacaacttc	aatgggatta	ggattaagac	cgactcac	2820
agcctgctcg	acaagaaaga	aaaagagagg	tttgaggccc	gccaaaaactg	gacctccatt	2880
gagaatata	aaaatataa	ggccggctat	atctcccaag	tcgtccacaa	gatctgagag	2940
ctgggtggaga	aatatgacgc	cgtgattgcg	ctcgaagact	taaattctgg	gttcaagaac	3000
tcccgctgga	aggtggaaaa	acaggtgcat	cagaaattcg	agaaaatgct	gatcgacaaa	3060
ctcaattata	tgggtggata	gaagtccaac	ccgtgtgcca	cagggggcgc	gctgaagggc	3120
tatcagatca	ccaacaagt	cgagagcttc	aagagcatga	gcacccagaa	cgggtttatt	3180
ttctacatcc	cggcgtggct	caactccaag	attgaccoga	gcaccggctt	cgtgaacctc	3240
ctgaagacaa	agtataactc	catctgocgac	agcaagaagt	ttatctcctc	cttgaccgc	3300
attatgtatg	tgcggagga	ggacctcttc	gagttcgccc	tcgactacaa	aaactcagc	3360
cgcacagatg	cggattacat	caagaagtg	aagctgact	cctacgggaa	caggatcccg	3420
atcttcagga	atccaaaaaa	aaataacgtc	ttgactggg	aggaagtgtg	cctgacatcc	3480
gcctacaagg	aactgttcaa	taataacggc	atcaattacc	agcagggcga	catctcgccc	3540
ctcctctgtg	agcagtcoga	caaagcgttt	tactccagct	tcattggcctc	catgtccctg	3600
atgctccaaa	tgaggaatag	catcacaggg	cgcaccgacg	tcgactcctc	catcagcccg	3660
gtgaagaact	ccgacgggat	cttttacgac	tcccgcaact	atgaggcga	agagaatgcg	3720
atcctcccga	agaacccoga	tgcgaacggg	gcctataata	tcgcccagaa	agtgtcctg	3780
gccatcgggc	agttcaaaaa	ggcggaggat	gagaagctcg	acaaggtgaa	aattgcccatt	3840
tccaacaagg	agtggtgga	gtacgcgag	acctccgtga	agcactctgg	tggttcaagc	3900
ggaggctcat	ctggcagcga	aaactccggc	acttccagct	cagctactcc	tgagtctagc	3960
ggcgggtcgt	caggagggct	tgctcttgat	ttcttttcta	ggcttccatt	gccacctcca	4020
gtttctccaa	tttgaacttt	tgtgtcaact	getgcacaaa	agggcattcca	gcctccaagg	4080
tcatgcggat	ctggcggctc	aaaaagaacc	gccgacggca	gcgaattcga	gccccagaag	4140
aagaggaag	tctaa					4155

SEQ ID NO: 187 moltype = AA length = 845  
 FEATURE Location/Qualifiers  
 source 1..845  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 187

MKRTADGSEF	ESPKKKRKYV	LNIEDEHRLH	ETSKEPDVSL	GSTWLSDFPQ	AWAETGGMGL	60
AVRQAPLIIP	LKATSTPVSI	KQYPMSEQEAR	LGIKPHIQRL	LDQGLVPCQ	SPWNTPLLPV	120
KKPGTNDYRP	VQDLREVNKR	VEDIHPTVFN	PYNLLSGLPP	SHQWYTVLTL	KDAFFCLRLH	180
PTSQPLFAFE	WRDPEMIGIS	QLTWTRLPQG	FNKSPTLFNE	ALHRDLADF	IQHPDLILLQ	240
YVDLLLLAAT	SELDCQQGTR	ALLQTLGNLQ	YRASAKKAQI	CQKQVKYLG	LLKEGQRWLT	300
EARKETVMGQ	PTPKTPRQLR	EFLGKAGFCR	LFIPIGFAEMA	APLYPLTKPG	TLFNWGPDPQ	360
KAYQEI KQAL	LTAPALGLPD	LTKPFELFVD	EKQGYAKGVL	TQKLGWRRR	VAYLSKKLDP	420
VAAGWPPCLR	MVAIAIVLTK	DAGKLTMGQP	LVLAPHAVE	ALVRQPPDRW	LSNARMTHYQ	480
ALLLDTRVQ	FGPVVALNPA	TLPLPEEGL	QHNCLDILAE	AHGTRPDLTD	QPLPDADHTW	540
YTDGSSLLQE	GQRKAGAAVT	TETEVWAKA	LPAGTSAQRA	ELIALTQALK	MAEGKKLNIV	600
TDSRYAFATA	HIHGEIYRRR	GWLTSEGKEI	KNKDELALL	KALFLPKRLS	IIHCPGHQKG	660
HSAEARGNRM	ADQAARKAAI	TETPDTSTLL	IENSSPNSRL	INSGSSSGGS	SGSETPGTSE	720
SACLSYETEI	LTVEYGLLPI	GKIVEKRIEC	TVYSVDNNGN	IYTPVAQWH	DRGEQEVFEY	780
CLEDGSLIRA	TKDHHKMTVD	QMLPIDEIF	ERELDLMRVD	NLPNSGGSKR	TADGSEFEPK	840
KKRKV						845

SEQ ID NO: 188 moltype = AA length = 1384  
 FEATURE Location/Qualifiers  
 source 1..1384  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 188

MKRTADGSEF	ESPKKKRKYV	KIATRKYLGK	QNVYDIGVGE	PHNFALKNGF	IASNCATPES	60
SGGSSGGSSK	LEKFTNCSYL	SKTLRFKAI	VGKTQENIDN	KRLLEVEDEKR	AEDYKGVKKL	120
LDRYYLSFIN	DVLHSLKLN	LNNYISLFRK	KTRTEKENKE	LENLEINLRK	EIAKAFKNGE	180
GKSLFKKDI	IETILPEFLD	DKDEIALVNS	FNGFTTAPTG	FFDNRENMF	EAAKSTSI	240
RCINENLTRY	INMDFIEKV	DAIFDKHEVQ	EIKEKILNSD	YDVEDFFEGE	FFNFVLTQEG	300
IDVYNALIGG	FVTESGFKK	GLNEYINLVN	QKTKQKLPKF	KPLYKQLVLS	RESLSYFEG	360
YTSDEVLEV	FRNTLNKNS	IFSSIKKLEK	LFPKNPDEYSS	AGIPVKNGPA	ISTISKDIFG	420

-continued

EWNVIRDKWN	AEYDDIHLKK	KAVVTEKYED	DRRKSFKKIG	SFSLEQLQEY	ADADLSVVEK	480
LKEI IQKVD	EIYKVGSSSE	KLFDADFLVLE	KSLKKNDAVV	AIMKDLLDSV	KSPENYIKAF	540
PGEGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	KPYSKDKFKL	YFQNPQFMGG	600
WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	VNGNYEKINY	KLLPGPNKML	660
PKVFFSKKWM	AYYNPSEDIQ	KIYKNGTFKK	GDMFNLNDCH	KLIDFFKDSI	SRYPKWSNAY	720
DFNFSETEKY	KDIAGFYREV	EEQGYKVSPE	SASKKEVDKL	VEEGKLYMFQ	IYNKDFSDKS	780
HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRRASLKK	EELVVHPANS	PIANKNPDNP	840
KKTTTLSYDV	YKDKRFSEDO	YELHIPIAIN	KCPKNIFKIN	TEVRVLLKHD	DNPYVIGIDR	900
GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	SLLDKKEKER	FEARQNWTSI	960
ENIKELKAGY	ISQVVKICE	LVEKYDAVIA	LEDLNSGFKN	SRVKVEKQVY	QKFEKMLIDK	1020
LNMYVDKKS	PCATGGALKG	YQITNKFESF	KSMSTQNGFI	FYIPAWLTSK	IDPSTGFVNL	1080
LKTKYTSIAD	SKKFISDFDR	IMYVPEEDLF	EFALDYKNFS	RTDADYIKKW	KLYSYGNRIR	1140
I FRNPKKNV	FDWEEVCLTS	AYKELPNKYG	INYQQGDIRA	LLCEQSDKAF	YSSFALMSL	1200
MLQMRNSITG	RTDVFLLISP	VKNSDGIFYD	SRNYEAQENA	ILPKNADANG	AYNIARKVLW	1260
AIGQPKAED	EKLDKVKIAI	SNKEWLEYAQ	TSVKHSGGSS	GGSSGSETPG	TSESATPSS	1320
GGSSGGSALD	FLSRLPLPPP	VSPICTFVSP	AAQKAFQPPR	SCGSGGSKRT	ADGSEFEPKK	1380
KRKV						1384

SEQ ID NO: 189 moltype = AA length = 20  
 FEATURE Location/Qualifiers  
 source 1..20  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 189  
 SGGSSGGSSG SETPGTSESA 20

SEQ ID NO: 190 moltype = AA length = 12  
 FEATURE Location/Qualifiers  
 source 1..12  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 190  
 TPESGGSSG GS 12

SEQ ID NO: 191 moltype = AA length = 61  
 FEATURE Location/Qualifiers  
 source 1..61  
 mol\_type = protein  
 organism = synthetic construct

VARIANT 4..60  
 note = Residues are present or absent

SEQUENCE: 191  
 GSSGSSGSSG SSGSSGSSG SSGSSGSSG SSGSSGSSG SSGSSGSSG 60  
 G 61

SEQ ID NO: 192 moltype = AA length = 1300  
 FEATURE Location/Qualifiers  
 source 1..1300  
 mol\_type = protein  
 organism = Francisella tularensis

SEQUENCE: 192  
 MSIQEFVVK YSLSKTLRFE LIPQGTKLEN IKARGLILD EKRADYKKA KQIIDKYHQF 60  
 FIEELSSVC ISEDLQNY S DVYFKLKKSD DDNLQKDFKS AKDTIKKQIS EYIKDSEKFK 120  
 NLFNQNLIDA KKGQESDLIL WLKQSKDNGI ELFKANSBIT DIDEALEI K SPKGWTYYPK 180  
 GFHENRKNVY SSNDIPTSII YRIVDDNLPK FLENKAKYES LKDKAPEAIN YEQIKKDLAE 240  
 ELTFDIDYKT SEVNQRFVSL DEVFEIANFN NYLNQSGITK FNTIIGGKQV NGENTKRRKI 300  
 NEYINLVSQQ INDKTLKKYK MSVLFKQILS DTESKSFVID KLEDDSDVVT TMQSFYEQIA 360  
 AFKTVEEKSI KETLSLLFDD LKAQKLDLSK IYFKNDKSLT DLSQQVFDY SVIGTAVLEY 420  
 ITQIAPKNL DNPSKKEQEL IAKKTEKAKY LSLETIKLAL EEFNKHRDID KQCRFEEILA 480  
 NFAAIPMIFD EIAQNKDNLA QISIKYQNGG KDLLQASAE DDVKAIKDLL DQTNLLHLKL 540  
 KIFHISQSED KANILDKDEH FYLVFECEYF ELANIVPLYN KIRNYITQKP YSDEKPKLNF 600  
 ENSTLANGWD KNKEPDNTAI LFIKDDKYLL GVMNKKNNKI PDDKAIKENK GEGYKIVYK 660  
 LLPGANKMLP KVFPKSAKIK FYNPSEDLR IRNHSTHTKN GSPQKGYEKF EFNIEDCRKF 720  
 IDFYKQSIK HPEWKDPGFR FSDTQRYSNI DEFYREVENQ GYKLTFFENIS ESVIDSVVQ 780  
 GKLYLFQIYN KDFSAYSKGR PNLHTLYWKA LFDERNLQDV VYKLNGEAEL FYRKQSIPIPK 840  
 ITHPAKEAIA NKNKDNPKKE SVFEYDLIKD KRFTEDKFFF HCPITINFKS SGANKFNDEI 900  
 NLLLKEKAND VHILSIDRGE RHLAYTYLVD GKGNI IKQDT FNIIGNDRMK TNYHDKLAAI 960  
 EKDRDSARKD WKKINNKEK KEGYLSQVHV EIAKLVI EYN AIVVFDLNF GPKRGRFKVE 1020  
 KQVYQKLEKM LIEKLNLYLVF KDNEFKDTGG VLRAYQLTAP FETPKKMGKQ TGI IYVVPAG 1080  
 PTSKICPVYTG FVNQLYPKYE SVSKSQEFPF KFDKICYNLD KGYFEFSDY KNPFGDKAAK 1140  
 KWTIASFGSR LINFRNSDKN HNWDTREVPY TKELEKLLKD YSIEYGHGEC IKAACGESD 1200  
 KKFFAKLTSV LNTILQMRNS KTGTELDYLI SPVADVNGNF FDSRQAPKNM PQDADANGAY 1260  
 HIGLKGLMLL GRIKNNQEGK KLNLVIKNEE YFEFVQNRNN 1300

SEQ ID NO: 193 moltype = DNA length = 3681  
 FEATURE Location/Qualifiers

-continued

```

source          1..3681
                mol_type = genomic DNA
                note = Lachnospiraceae bacterium
                organism = unidentified

SEQUENCE: 193
tccaagctgg agaagtttac aaactgttac agcctctcca aaacctcag gtttaagcg 60
atcccggtag gcaagccca ggagaacatc gacaacaaga ggctcctggt ggaagacgag 120
aagcgcgccc aagactacaa gggcgtgaag aagctgctcg ataggtaacta cctcagcttt 180
attaacgacg tgctgcacag catcaaactc aagaatctca acaactacat ctccctcttc 240
cgcaaaaaga cccgcaccga gaaggagAAC aaggagctgg agaacctgga gatcaacctc 300
cgcaagggaaa tcgccaagc gttcaagggc aatgaagggt acaagagcct cttcaagaaa 360
gacatcatcg aaactatcct cccagagttt ctccgatgaca aggacgagat cgcgctgggtg 420
aactccttta accgggttcc aaccgcgttt accggctctc ttgataacag ggaaaatag 480
ttctccgagg aggcacaagtc caccagcatc gccttcagggt gtatcaacga gaaacctacc 540
cgctacattt ccaatatgga cattttcagag aaggtggatg cgatcttcga taagcagcag 600
gtgcaggaga tcaagagaaa gatctcfaat tccgattatg acgtcagaga tttcttcgaa 660
ggggagttct ttaattttgt gctcacacaa gagggcattg acgtgtacaa cgcgattatc 720
gggggcttcg tcacagagtc cgggggagaag attaaagggc tgaatgagta catcaatctg 780
tacaatcaga agaccaagtc gaaactgccc aaattcaagc cgcctcaaaa gcaagtcccg 840
tccgataggg aaagcctctc ttctacggc gagggctata ccagcagca ggagggtcgtg 900
gaagtctctc gtaacaacat gaataagaat agcagagatt tctcctccat caagaagctc 960
gagaagctct ttaagaactt tgacagatc agctccgccc ggattttcgt gaagaacggg 1020
ccggcgatca gcaccatctc caaggacatc ttggcgagt ggaacctcat cagggacaaag 1080
tggaacgccc agtaccgaca catccacctg aagaagaagg cgggtggtgac cgagaagtat 1140
gaggacgata cgcggaagtc gttcctacggc gagggctata ccagcagca ggagggtcgtg 1200
gagtatgccc atgcccgatc gtccgctcgc gagaagctga aggaaatcat catcagaag 1260
gtccagcaga tctataaagt gtaccgggtcc agcagagaagc tggctcagacg cacttttgtg 1320
ctcagaaagt cctcaaaaaa gaatgacgccc gtgggtggcca ttatgaaaga cctgctcgac 1380
tccgtgaaagt ccttcgaaaa ttacattaaa gcggtctctg gggaggggaa ggaacctaac 1440
agggatgagt cctctctatg cgactttgtc ctccgctacg acatcctgct gaaggtcgac 1500
cacatttacg accgcatccg caactacgtg acacagaagc cgtactccaa agacaagttc 1560
aagctgtact tccagaaccc gcaatttatg gggggctggg acaaggataa agagacagac 1620
taccgcccga caattctccg ctatggctcc aaatactatc tggccatcat ggacaagaag 1680
tacgcgaagt gctgcagaaa gatcgacaaa gacgacgtca atggcaacta tgaagaagatc 1740
aactacaagc tgcctgcggg cccgaacaag atgctcccga aggtgttctt cagcaagaag 1800
tggatggcct actacaatcc aagcagagat attcagaaaa tctataaaaa cgggaccttc 1860
aagaaggggg actatgttaa cctcaacgac tgccacaagc tcattgattt cttcaaggat 1920
agcatttccc gctaccggaa atgggtccaat gcgtacgatt ttaactctc cgagacagaa 1980
aagtacaaag acatcgcggg cttttacagg gaggtggagg agcaagggta taaagtttct 2040
tttgaatccg agagcaagaa ggaagtccgac aagctcgtcg aggagggcaa gctctacatg 2100
ttccaaattt ataacaagga cttttccgac aagagccatg ggacccccaa cctccacacc 2160
atgtacttca aactgcctct tgacgagAAC aaccacgggc aaatcagggt gagcggcggc 2220
gccgaattat tcatgcccag ggcctccctc aagaaggaag agctgggtcgt ccatccagcc 2280
aattccccga tcgcaacaaa gaaccgggac aatccgaaaa agaccaccac cctgtcctac 2340
gacgtctaca aggcaaaagc cttcagcga gaccagtagc aattacacat cccaattgcy 2400
attaataagt gcccaagaaa tatctcaaaa attaatacag aggtcaggggt gctgctcaaa 2460
cacgacgaca atccgtatgt catcggcatt gacaggggcy agcgcactct gctctatctc 2520
gtggctcgtg atgggaaggg caatatgtg gagcagtagc ccctgaaacga gattatcaac 2580
aacttcaatg ggattaggat taagaccgac tatcacagcc tgcctgacaa gaaagaaaaa 2640
gagaggtttg agggccgcca aaactggacc tccattgaga atatcaaaaga attaaaggcc 2700
ggctatattt cccaagtcgt ccacaagatc tgcagagctg tggagaataa tgacgcccgt 2760
attgcgctcg aagacttaaa ttctgggttc aagaactccc gcgtgaaagt ggaaaaacag 2820
gtgtatcaga aatcgcagaa aatcgtgatc gacaaaactc attataggt ggataagaag 2880
tccaaccctg gtgcccacag gggcgcgctg aagggctatc agatcaccaa caagttcgag 2940
agcttcaaga gcatgagcac ccagaacggg tttatttctc acatcccggc gtggctcacc 3000
tccaagattg acccgagcac cggctctctg aacctcctga agacaaaagta taacctcatt 3060
gccgacagca agaagtttat ctccctcttc gaccgcatta tgtatgtgcc ggaggaggac 3120
ctcttcgagt tcgccctcga ctacaaaaac ttcagcccga cagatgcgga ttacatcaag 3180
aagtggaagc tgtactccta cgggaacagg atccgcatct tcagggaatc aaaaaaaaaa 3240
aacgtctttg actgggagga agtgtgcctg acatccgctc acaaggaact gttcaataaa 3300
tacggcatca attaccagca gggcgacatt cgcgccctcc tctgtgagca gtccgacaaa 3360
cgtttttact ccagcttcat ggcctcctatg tccctgatgc tccaatgag gaatagcatc 3420
acagggcgca ccgacgtcga cttcctcctc agcccggta agaactccga cgggatcttt 3480
tacgactccc gcaactatga ggcgcaagag aatgcgatcc tcccgaagaa cgcgatgccc 3540
aacggggcct ataatatgc cagggaaagt ctctgggcca tcgggcagtt caaaaagcgc 3600
gaggatgaga agctcgacaa ggtgaaaatt gccatttcca acaaggagtg gctggagatc 3660
gcgagacct ccgtaagca c 3681
    
```

```

SEQ ID NO: 194          moltype = AA length = 1228
FEATURE                Location/Qualifiers
source                 1..1228
                        mol_type = protein
                        organism = synthetic construct

SEQUENCE: 194
MSKLEKFTNC YLSKTLRFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKKTREKE NKELENLEIN LRKEIAKAFK GNEGYSKSLFK 120
    
```

-continued

KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDALFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESEGE	KIKGLNEYIN	LYNQKTKQKL	PKFKPLYKQV	LSDRESLSFY	GEGYTSDEEV	300
LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKV	GPAISTISKD	IFGEWNVIRD	360
KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	420
KVDEIYKVYG	SSEKLPDADF	VLEKSLKKNL	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	480
NRDESFYGDG	VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	540
DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	600
KWMAYYNPSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDPFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYFKLLFDE	NNHQGIRLSG	GAELFMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTITLS	780
YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	840
IVVVDGKGNL	VEQYSLNEII	NNFNGIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	900
AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	960
KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	1020
IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	1080
NNVPDWEEVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMRNS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAG	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	1200
AEDEKLDKVK	IAISNKEWLE	YAQTSVKH				1228

SEQ ID NO: 195           moltype = AA   length = 1228  
 FEATURE                Location/Qualifiers  
 source                  1..1228  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 195

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDALFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESEGE	KIKGLNEYIN	LYNQKTKQKL	PKFKPLYKQV	LSDRESLSFY	GEGYTSDEEV	300
LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	YSSAGIFVKV	GPAISTISKD	IFGEWNVIRD	360
KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	420
KVDEIYKVYG	SSEKLPDADF	VLEKSLKKNL	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	480
NRDESFYGDG	VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	540
DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	600
KWMAYYNPSE	DIQKIYKNGT	FKKGMFNLN	DCHKLIDPFK	DSISRYPKWS	NAYDFNFSET	660
EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	720
TMYFKLLFDE	NNHQGIRLSG	GAELFMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTITLS	780
YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IDRGERNLLY	840
IVVVDGKGNL	VEQYSLNEII	NNFNGIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	900
AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	960
KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	1020
IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	1080
NNVPDWEEVC	LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSPMAL	MSLMLQMANS	1140
ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAG	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	1200
AEDEKLDKVK	IAISNKEWLE	YAQTSVKH				1228

SEQ ID NO: 196           moltype = AA   length = 1315  
 FEATURE                Location/Qualifiers  
 source                  1..1315  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 196

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNNYISLF	RKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFPDNRENM	FSEBAKSTS	IAPRCINENL	180
RYISNMDIFE	KVDALFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFPNFVLTQ	EGIDVYNAI	240
GGFVTESEGE	IKGLNEYINL	YNQKTKQKLP	PKFKPLYKQV	SDRESLSFYG	EGSSGIDGVK	300
LSSTEKKKMD	EIAPPKGSVF	TCPICEKRSI	VGVTANLVHD	HNHDTGWGRE	WICDSNTGL	360
GRFKDNPKFL	EKVLIEYLKKG	YTSDEEVLEV	FRNTLNKNS	IFSSIKKLEK	LKFNDFEYSS	420
AGIFVKNKGA	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLKK	KAVVTEKYED	DRRKSFKKIG	480
SFSLEQLQEQ	ADADLSVVEK	LKEIIIQKVD	EIYKVGYSSE	KLPDADPHE	KSLKKNDAVV	540
AIMKDLDSV	KSFENYIKAF	FGGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	600
KPYSKDKFKL	YFQNPQFMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	660
VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYYNPSEDIQ	KIYKNGTFKK	GDMFNLMDCH	720
KLIDFFKDSI	SRYPKWSNAY	DFNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	780
VEEGKLYMFG	IYNKDFSDKS	HGTPNLHTMY	FKLLDFDENNH	GQIRLSGGAE	LFMRRASLKK	840
EELVVHPANS	PIANKPNPDP	KKTITLSYDV	YDKKRFSEDO	YELHIPIAIN	KCPKNIFKIN	900
TEVRVLLKHD	DNPYVIGAR	GERNLIIYVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	960
SLLDKKEKER	FEARQNTSI	ENIKELKAGY	ISQVVHKICE	LVEKYDAVIA	LEDLNSGFKN	1020
SRVVEKQVY	QKFEKMLIDK	LNYMVDKSN	PCATGGALKG	YQITNKFESF	KSMSTQNGFI	1080
FYIPAWLTSK	IDPSTGFVNL	LTKYTSIAD	SKKFISSPDR	IMYVPEEDLF	EFALDYKNFS	1140
RTDADYIKKW	KLYSYGNRIR	IFRNPKNNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1200
LLCEQSDKAF	YSSFMALMSL	MQMRNSITG	RTDVFLLISP	VKNSDGI FYD	SRNYEAGENA	1260
ILPKNADANG	AYNIARKVLW	AIGQFKKAE	EKLDKVKIAI	SNKEWLEYAQ	TSVKH	1315



-continued

SEQ ID NO: 197                   moltype = AA   length = 1501  
 FEATURE                        Location/Qualifiers  
 source                         1..1501  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 197

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNMYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTEGSEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGAAPNI	300
HGWGKEGHEI	ICKIAQTRL	ETAAKAVKEL	LPESAEGDLS	SLCLWADRVK	FRYHWSSPLH	360
YINTPDACS	QYNRDCCKDES	GEKGRCVAGA	IYNYTTQLLS	YKTAASSQSQ	YNLTEALLFV	420
SHFMGDHQP	LHVSYASDKG	GNTIEVHWYT	RKANLHHIWD	SNI IETAEAD	LYNSALEGMV	480
DALKKNITE	WADQVQRWET	CTKKTACPI	YASEGIQAAC	DWAYKGVTEG	DTLEDEYFYS	540
RLPIVYQRLA	QGGVRLAATL	NRIFGGYTS	BEVLEVFRNT	LNKNSEIFSS	IKKLEKLFKN	600
PDEYSSAGIF	VKNGPAISTI	SKDIFGEWNV	IRDKNWABYD	DIHLKKAQV	TEKYEDDRK	660
SFKKIGSFL	YKINAYTL	LSVVEKLKEI	IQKVDIYK	VYGSSEKLF	ADPVEKLSL	720
KNDVAVAIMK	DLDSVKSFE	NYIKAFFGEG	KETNRDESFP	GDFVLAYDIL	LKVDHIYDAI	780
RNYVTQPKYS	KDKFKLYFQN	PQFMGGWDK	KETDYRATIL	RYGSKYYLAI	MDKKYAKCLQ	840
KIDKDDVNGN	YKINAYTL	GNPKMLPKVF	ESKKWMAYYN	PSEDIQKIYK	NGTFKKGDMF	900
NLNDCHKLID	PFKDSISRY	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	YKVPFESASK	960
KEVDKLVVEE	KLYMFQIYNK	DFSDKSHGTP	NLHTMYFKLL	FDENNHGQIR	LSGGALFMR	1020
RASLKEELV	VHPANSPAN	KPNPNPKTT	TLSDYVYKDK	RFSEDEQELH	IPIAINKCPK	1080
NIFKINTEVR	VLLKHDDNPY	VIGIARGERN	LLYIVVVDGK	GNIVEQYSLN	EIINNPNFNGIR	1140
IKTDYHSLLD	KKEKERPEAR	QNWTSIENIK	ELKAGYISQV	VHKICELVEK	YDAVIALEDL	1200
NSGFKNSRVK	VEKQVYQKFE	KMLIDLKLYM	VDKKSNPCAT	GGALKGYQIT	NKFPFKSMS	1260
TQNGFIFYIP	AWLTSKIDPS	TGFVNLLKTK	YTSIADSKKF	ISSFDRIMYV	PEEDLPEFAL	1320
DYKNSRSTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNNVFDWE	EVCLTSAYKE	LFNKYGINYQ	1380
QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	DGIFYDSRNY	1440
EAQENAILPK	NADANGAYNI	ARKVLWAIGQ	PKKAEDEKLD	KVKIAISNKE	WLEYAQTSVK	1500
H						1501

SEQ ID NO: 198                   moltype = AA   length = 1454  
 FEATURE                        Location/Qualifiers  
 source                         1..1454  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 198

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNMYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTEGSEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGARVRT	300
YFNVSHANTH	YKNTVSSKLL	PFTANYQLQL	GELDNLNRAT	FSHIQLQDRH	ETKDVRTKIN	360
YDPVGHWHNY	FPYGDGSKSS	WVMNRGHLVG	YQFCGLNDEP	RNLVAMTAWL	NTGAYSGAND	420
SNPEGMYYE	NRLDSWLALH	PDFWLDYKVT	PIYSGNEVVP	RQIELQYVGI	DSSGELLTIR	480
LNSNKESIDE	NGVTTVILEN	SAPNINLDYL	NGTATPKNGY	TSDEEVLVVF	RNTLNKNSEI	540
FSSIKKLEKL	FKNFPEYSSA	GIPVKNGPAI	STISKDIFGE	WNVIRDKWNA	EYDDIHLKCK	600
AVVTEKYEDD	RRKSFKKIGS	FSLEQLQEYA	DADLSVVEKL	KEII IQKQVDE	IYKVYGSSEK	660
LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	SFENYIKAFF	GEGKETNRDE	SFYGDFVLAY	720
DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	FQNPQFMGGW	DKDKETDYRA	TILRYGSKYY	780
LAIMDKKYAK	CLQKIDKDDV	NGNYEKINYK	LLPGPNKMLP	KVFPKSKWMA	YVNPSEDIQK	840
IYKNGTFKKG	DMFNLDNDCHK	LIDFFKDSIS	RYPKWSNAYD	FNFSETEKYK	DIAGFYREVE	900
EQGYKVSFES	ASKKEVDKLV	EEGKLYMFQI	YNKDFSDKSH	GTPNLHTMYF	KLLDFDENNHG	960
QIRLSGGAEL	FMRRASLKKE	ELVVHPANSP	IANKPNPNK	KTTTSLSDYVY	KDKRFSEDEQY	1020
ELHPIAIANK	CPKNIFKINT	EVRLVKHDD	NPYVIGIARG	ERNLLYIVVV	DGKGNIVEQY	1080
SLNEIINNFN	GIRIKTDYHS	LLDKKEKERF	EARQNWTSIE	NIKELKAGYI	SQVVKICEL	1140
VEKYDAVIAL	EDLNSGPKNS	RVKVEKQVYQ	KFEKMLIDKL	NYMVDKSNP	CATGGALKGY	1200
QITNKFSFVK	SMSTQNGFIF	YIPAWLTSKI	DPSTGFVNLL	KTKYTSIADS	KKFISSFDRI	1260
MYVPEEDLFE	FALDYKNFSR	TDADYIKKWK	LYSYGNRIRI	FRNPKKNMVF	DWEEVCLTSA	1320
YKELFNKYGI	NYQQGDIRAL	LCEQSDKAPY	SSFALMSLM	LQMRNSTGR	TDVDFLISPV	1380
KNSDGI FYDS	RNYEAQENAI	LPKNADANGA	YNIARKVLWA	IGQPKKADE	KLDKVKIAIS	1440
NKEWLEYAQT	SVKH					1454

SEQ ID NO: 199                   moltype = AA   length = 1375  
 FEATURE                        Location/Qualifiers  
 source                         1..1375  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 199

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNMYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240

-continued

GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGENQTT	300
GKGKNNRPR	YKSLKAIKE	FGSQILKEHP	TDNQELRNNR	LYLYYLQNGK	DMYTGQDLDI	360
HNLSNYDIDH	IVPQSFITDN	SIDNLVLTSS	AGNREKGGDV	PPLIIVRKRK	VFWEKLYQGN	420
LMSKRKFDYL	TKAERGLGTG	YTSDEEVLEV	FRNTLNKNS	IFSSIKKLEK	LKFNDFEYSS	480
AGIFVKNGPA	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLKK	KAVVTEKYED	DRRKSFKKIG	540
SFSLBQLQEQY	ADADLSVVEK	LKEIIIQKVD	EIYKVYGSSE	KLPDADPVLE	KSLKKNDAVV	600
AIMKDLLDSV	KSFENYIKAF	FGEGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQPMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPSSEDIQ	KIYKNGTFPK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMFQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRASLKK	900
EELVVHPANS	PIANKNPDNP	KKTTLSYDV	YDKRFSEDQ	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIAR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKHICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVKVEKQVY	QKFEKMLDK	LNVMVDKKS	PCATGGALKG	YQITNKPESF	KSMSTQNGFI	1140
FYIPAWLTSK	IDPSTGPNV	LKTKYTSIAD	SKKFISSPDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSPMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGIIFYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQFKKAE	EKLKVKIAI	SNKEWLEYAQ	TSVKH	1375

SEQ ID NO: 200           moltype = AA   length = 1375  
 FEATURE                Location/Qualifiers  
 source                 1..1375  
                        mol\_type = protein  
                        organism = synthetic construct

SEQUENCE: 200

SKLEKFTNCY	SLSKTLRFKA	IPVGTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAP	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAII	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGENQTT	300
NQGRNSQOR	LKGLTDSIKE	FGSQILKEHP	VENSQIQNDR	LFLYLLQNGR	DMYTGEELDI	360
DYLSQYDIDH	IIPQAFIKDN	SIDNRVLTSS	KENRGSDDV	PSKDVVRKMK	SYWSKLLSAK	420
LITQRKFDNL	TKAERGLGTG	YTSDEEVLEV	FRNTLNKNS	IFSSIKKLEK	LKFNDFEYSS	480
AGIFVKNGPA	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLKK	KAVVTEKYED	DRRKSFKKIG	540
SFSLBQLQEQY	ADADLSVVEK	LKEIIIQKVD	EIYKVYGSSE	KLPDADPVLE	KSLKKNDAVV	600
AIMKDLLDSV	KSFENYIKAF	FGEGKETNRD	ESFYGDFVLA	YDILLKVDHI	YDAIRNYVTQ	660
KPYSKDKFKL	YFQNPQPMGG	WDKDKETDYR	ATILRYGSKY	YLAIMDKKYA	KCLQKIDKDD	720
VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPSSEDIQ	KIYKNGTFPK	GDMFNLDCH	780
KLIDFFKDSI	SRYPKWSNAY	DNFSETEKY	KDIAGFYREV	EEQGYKVSFE	SASKKEVDKL	840
VEEGKLYMFQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENNH	GQIRLSGGAE	LFMRASLKK	900
EELVVHPANS	PIANKNPDNP	KKTTLSYDV	YDKRFSEDQ	YELHIPIAIN	KCPKNIFKIN	960
TEVRVLLKHD	DNPYVIGIAR	GERNLLYIVV	VDGKGNIVEQ	YSLNEIINNF	NGIRIKTDYH	1020
SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKHICE	LVEKYDAVIA	LEDLNSGFKN	1080
SRVKVEKQVY	QKFEKMLDK	LNVMVDKKS	PCATGGALKG	YQITNKPESF	KSMSTQNGFI	1140
FYIPAWLTSK	IDPSTGPNV	LKTKYTSIAD	SKKFISSPDR	IMYVPEEDLF	EFALDYKNFS	1200
RTDADYIKKW	KLYSYGNRIR	IFRNPKNNV	FDWEEVCLTS	AYKELFNKYG	INYQQGDIRA	1260
LLCEQSDKAF	YSSPMALMSL	MLQMRNSITG	RTDVFLLISP	VKNSDGIIFYD	SRNYEAQENA	1320
ILPKNADANG	AYNIARKVLW	AIGQFKKAE	EKLKVKIAI	SNKEWLEYAQ	TSVKH	1375

SEQ ID NO: 201           moltype = AA   length = 1398  
 FEATURE                Location/Qualifiers  
 source                 1..1398  
                        mol\_type = protein  
                        organism = synthetic construct

SEQUENCE: 201

SKLEKFTNCY	SLSKTLRFKA	IPVGTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAP	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAII	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGVREGF	300
VTEKRAREMD	GDMRRAARN	AKLFQEMQEK	LNVOGKPSRA	DLWRYQSVQR	QNCQCAYCGS	360
PITFSNSEMD	HIVPRAQGS	TNTRENLVAV	CHRCNSQKGN	TPPAIWAQNT	SIEGVSVKEA	420
VERTRHWVTD	TGMRSTDFKK	FTKAVVERPQ	RATMDEEIDA	RSGYTSDEEV	LEVFRNTLNLK	480
NSEIFSSIKK	LKLEKFNKFE	YSSAGIFVKN	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	540
LKKKAVVTEK	YEDDRRSFK	KIGSFSLEQL	QYADADLSV	VEKLKEIIIQ	KVDEIYKVYV	600
SSEKLFADAF	VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAFPGEGKET	NRDESFYGDF	660
VLAYDILLKV	DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	DYRATILRYG	720
SKYYLAIMDK	KYAKCLOKID	KDDVNGNYEK	INYLKLPQPN	KMLPKVFFSK	KWMAYYNPSE	780
DIQKIYKNGT	FKKGDMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNPFSE	EKYKDIAGFY	840
REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMFYKLLFDE	900
NNHQQIRLSG	GAELEFMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKTTTTL	YDVYKDKRFS	960
EDQYELHIPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGN	1020
VEQYSLNEII	NNFNIRIKT	DYHSLDDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVKH	1080
ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	1140
LKGYQITNKF	ESPKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLKTKYTS	IADSKKFISS	1200

-continued

FDRIMYVPEE	DLFEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	NNVFDWEVC	1260
LTSAYKELFN	KYGINYQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	1320
ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	AEDEKLDKVK	1380
IAISNKEWLE	YAQTSVKH					1398

SEQ ID NO: 202                   moltype = AA   length = 1491  
 FEATURE                        Location/Qualifiers  
 source                         1..1491  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 202

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELLENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENEM	FSEBAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGGKAQL	300
DIKNPPELYR	TTERVYKKSQ	QSTKPVTVSN	IHYSLVDGYG	RSGEAYGIIT	KDMIDMSAGY	360
REKWESKPEP	SGWYSYFFKN	TNQRATESDY	KHSPKNVSKI	SNNIKASILL	SNGNVRNGYL	420
FDRSHLIADS	LGGRPFRNNL	ITGTRTQNVG	NDRKGGMQY	IENKVLDDHK	RNPKVHVYK	480
ATPVYQGSSEL	LPRAVLVSAE	SSDGFIDETV	RVFNNAVAGFN	IDYQNGGLLS	STADVDDINNV	540
EENEIETTDD	EIEEGGYTSD	EEVLEVFRNT	LNKNSIPISS	IKKLEKLFKN	FDEYSSAGIF	600
VKNGPAISTI	SKDIFGEWNV	IRDKWNAEYD	DIHLKKAQV	TEKYEDDRRK	SFKKIGSFSL	660
EQLQEYADAD	LSVVEKLEKI	IIQKVDEIYK	VYGSSEKLPD	ADPVLKESLK	KNDAVVAIMK	720
DLDSVKSFE	NYIKAPFGEK	KETNRDESPY	GDFVLAYDIL	LKVDHIYDAI	RNYVTQKPY	780
KDKPKLYFQN	PQFMGGWDKD	KETDYPATIL	RYGSKYYLAI	MDKKYAKCLQ	KIDKDDVNGN	840
YEKINYKLLP	GPKNMLPKVF	FSKWMAYYN	PSEDIQKIYK	NGTFKKGDMF	NLNDCHKLID	900
FPKDSISRYP	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	YKVSFESASK	KEVDKLEVEE	960
KLYMFQIYNK	DFSDKSHGTP	NLHTMYFKLL	FDENNHGQIR	LSGGAELEFMR	RASLKKKEELV	1020
VHPANSPIAN	KNPDNPCKTT	TLSYDVYKDK	RFSEDOYELH	IPIAINKCPK	NIFKINTEVR	1080
VLLKHDDNPN	VIGIARGERN	LLYIVVVDGK	GNIVEQYSLN	EIINNPNFNGIR	IKTDYHSLDD	1140
KKEKERPEAR	QNWTSIENIK	ELKAGYISQV	VHKICELVEK	YDAVIALEDL	NSGFKNRSVK	1200
VEKQVYQKFE	KMLIDKLNMY	VDKKSNPCAT	GGALKGYQIT	NKFESFKSMS	TQNGFIFYIP	1260
AWLTSKIDPS	TGFVNLKTK	YTSIADSKKF	ISSPDRIMYV	PEEDLPEFAL	DYKNFSRTDA	1320
DYIKKWKLYS	YGNRIRIFRN	PKKNVFDWE	EVCLTSAYKE	LFNKYGINYQ	QGDIRALLCE	1380
QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	DGIFYDSRNY	EAQENAILPK	1440
NADANGAYNI	ARKVLWAIQ	FKKADEKLD	KVKIAISNKE	WLEYAQTSVK	H	1491

SEQ ID NO: 203                   moltype = AA   length = 1351  
 FEATURE                        Location/Qualifiers  
 source                         1..1351  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 203

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELLENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENEM	FSEBAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGSNNSY	300
LRAKVPFTEH	GVCQLCNVNA	QELFLRLRDA	PKSQRLNLLY	ATWTSKLPLE	QLNEMIRNPG	360
EGHFWQVDHI	KPVYGGGGQC	SLDNLQTLCT	VCHKERTARQ	AKERSQVRRQ	SLASKGYTSD	420
EEVLEVFRNT	LNKNSIPISS	IKKLEKLFKN	FDEYSSAGIF	VKNGPAISTI	SKDIFGEWNV	480
IRDKWNAEYD	DIHLKKAQV	TEKYEDDRRK	SFKKIGSFSL	EQLQEYADAD	LSVVEKLEKI	540
IIQKVDEIYK	VYGSSEKLPD	ADPVLKESLK	KNDAVVAIMK	DLDSVKSFE	NYIKAPFGEK	600
KETNRDESPY	GDFVLAYDIL	LKVDHIYDAI	RNYVTQKPY	KDKPKLYFQN	PQFMGGWDKD	660
KETDYPATIL	RYGSKYYLAI	MDKKYAKCLQ	KIDKDDVNGN	YEKINYKLLP	GPKNMLPKVF	720
FSKWMAYYN	PSEDIQKIYK	NGTFKKGDMF	NLNDCHKLID	FPKDSISRYP	KWSNAYDFNF	780
SETEKYKDIA	GFYREVEEQG	YKVSFESASK	KEVDKLEVEE	KLYMFQIYNK	DFSDKSHGTP	840
NLHTMYFKLL	FDENNHGQIR	LSGGAELEFMR	RASLKKKEELV	VHPANSPIAN	KNPDNPCKTT	900
TLSYDVYKDK	RFSEDOYELH	IPIAINKCPK	NIFKINTEVR	VLLKHDDNPN	VIGIARGERN	960
LLYIVVVDGK	GNIVEQYSLN	EIINNPNFNGIR	IKTDYHSLDD	KKEKERPEAR	QNWTSIENIK	1020
ELKAGYISQV	VHKICELVEK	YDAVIALEDL	NSGFKNRSVK	VEKQVYQKFE	KMLIDKLNMY	1080
VDKKSNPCAT	GGALKGYQIT	NKFESFKSMS	TQNGFIFYIP	AWLTSKIDPS	TGFVNLKTK	1140
YTSIADSKKF	ISSPDRIMYV	PEEDLPEFAL	DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	1200
PKKNVFDWE	EVCLTSAYKE	LFNKYGINYQ	QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	1260
RNSITGRTDV	DFLISPVKNS	DGIFYDSRNY	EAQENAILPK	NADANGAYNI	ARKVLWAIQ	1320
FKKADEKLD	KVKIAISNKE	WLEYAQTSVK	H			1351

SEQ ID NO: 204                   moltype = AA   length = 1367  
 FEATURE                        Location/Qualifiers  
 source                         1..1367  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 204

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELLENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENEM	FSEBAKSTSI	AFRCINENLT	180

-continued

RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGDEPGV	300
ATGNQOPVTG	NWLAGASQGD	GVPIPSQIAD	QLRGKEFKSW	RDFREQFWMA	VSKDPSALEN	360
LSPSNRYFVVS	QGLAPYAVPE	EHLGSKKEFE	IHHVVPLESG	GALYNIDNLV	IVTPKRHSEI	420
HKELKLRKE	KGYTSDDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLFKNFDEY	SSAGIFVKNG	480
PAISTISKDI	FGEWNVIRDK	WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	IGSFSLEQLQ	540
EYADADLSVV	EKLKEII IQK	VDEIYKVYGS	SEKLPDADFV	LEKSLKKNDA	VVAIMKDLLD	600
SVKSFENYIK	AFPGEGKETN	RDESFGYDFV	LAYDILLKVD	HIYDAIRNYV	TQKPYSKDKF	660
KLYFQNPQFM	GGWDKDKETD	YRATILRYGS	KYLLAIMDKK	YAKQLQKIDK	DDVNGNYEKI	720
NYKLLPGPNK	MLPKVFFSKK	WMAYYNPSED	IQKIYKNGTF	KKGMDFNLND	CHKLIDFFKD	780
SISRYPKWSN	AYDFNFSETE	KYKDIAGFYR	EVEEQGYKVS	FESASKKEVD	KLVEEGKLYM	840
FQIYNKDFSD	KSHGTPNLHT	MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	KKEELVVHPA	900
NSPIANKNPD	NPKKTTLTSLY	DVYKDKRFSE	DQYELHIPIA	INKCPKNIFK	INTEVRVLLK	960
HDDNPYVIGI	ARGERNLLYI	VVVDGKGNIV	EQYSLNEIIN	NFNIGIRIKTD	YHSLDKKKEK	1020
ERFEARQNW	SIENIKELKA	GYISQVVHKI	CELVEKYDAV	IATEDLNSGF	KNSRVKVEKQ	1080
VYQKFEKMLI	DKLNMYMDKK	SNPCATGGAL	KGYQITNKFE	SFKSMSTQNG	FIFYIPAWLT	1140
SKIDPSTGFV	NLLKTKYTSI	ADSKKFISSF	DRIMYVPEED	LFEFALDYKN	FSRTDADYIK	1200
KWKLYSYGNR	IRIFRNPKNK	NVFDWEEVCL	TSAYKELPNK	YGINYQQGDI	RALLCQESDK	1260
AFYSSFMALM	SMLQMRNSI	TRTDDVDFLI	SPVKNSDGI	YDSRNYEAQE	NAILPKNADA	1320
NGAYNIARKV	LWAIGQPKKA	EDEKLDKVKI	AISNKEWLEY	AQTSVKH		1367

SEQ ID NO: 205                   moltype = AA   length = 1299  
 FEATURE                        Location/Qualifiers  
 source                         1..1299  
                               mol\_type = protein  
                               organism = synthetic   construct

SEQUENCE: 205

SKLEKFTNICY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENEM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGRLREQ	300
ALMRDKGLCL	HCKNNRKLKV	ADMVDHIIPI	KVDPSSLKLLK	ENLQSLCNPC	HNRKTAEDKK	360
KYGGYTSDEE	VLEVFRNTLN	KNSEIFSSIK	KLEKLFKNFD	EYSSAGIFVK	NGPAISTISK	420
DIFGEWNVIR	DKWNAEYDDI	HLKKKAVVTE	KYEDDRRKSF	KKIGSFSLEQ	LQYADADLS	480
VVEKLEKII	QKVDEIYKVY	GSSEKLFDDAD	FVLEKSLKKN	DAVVAIMKDL	LDSVKSFENY	540
IKAFPGEGEKE	YIVVVDGKGN	FVLAYDILLK	VDHIYDAIRN	YVTQKPYSKD	KFKLYFQNPQ	600
FMGGWDKDK	TDYRATILRY	GSKYYLAIMD	KKYAKCLOKI	DKDDVNGNVE	KINYKLLPGP	660
NKMLPKVFFS	KKWMAYYNPS	EDIQKIYKNG	TFKKGDMFNL	NDCHKLIDFF	KDSISRYPKW	720
SNAYDFNFSE	TEKYNDIAGF	YREVEEQGYK	VSFESASKKE	VDKLVVEEGKL	YMFQIYNKDF	780
SDKSHGTPNL	HTMYFKLLFD	ENNHGQIRLS	GGAEFMRRAS	SLKKEELVVH	PANSPIANKN	840
PDNPKKTTTL	SYDVYKDKRF	SEDQYELHIP	IAINKCPKNI	FKINTEVRVL	LKHDDNPYVI	900
GIARGERNLL	YIVVVDGKGN	IVEQYSLNEI	INNFNIGIRIK	TDYHSLLDKK	EKERFPEARQN	960
WTSIENIKEL	KAGYISQVVH	KICELVEKYD	AVIALEDLNS	GFKNSRVKVE	KQVYQKFEKM	1020
LIDKLNMYMD	KSNPCATGG	ALKGQITNK	FESFKSMSTQ	NGFIFYIPAW	LTSKIDPSTG	1080
FVNLKTKYKT	SIADSKKFI	SFDRIMYVPE	EDLFEFALDY	KNFSRTDADY	IKKWKLYSYG	1140
NRIRIFRNPK	KNNVFDWEEV	CLTSAYKELF	NKYGINYQQG	DIRALLCEQS	DKAFYSSFMA	1200
LMSLMLQMRN	SITGRTDVDF	LISPVKNSDG	IFYDSRNYEA	QENAILPKNA	DANGAYNIAR	1260
KVLWAIGQFK	KADEKLDKV	KIAISNKEWL	EYAQTSVKH			1299

SEQ ID NO: 206                   moltype = AA   length = 1328  
 FEATURE                        Location/Qualifiers  
 source                         1..1328  
                               mol\_type = protein  
                               organism = synthetic   construct

SEQUENCE: 206

SKLEKFTNICY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYLSF	60	
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120	
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENEM	FSEEAKSTSI	AFRCINENLT	180	
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240	
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGMNYFI	300	
VEVSEQEVKR	EKEKARELRR	SQWKNRIAR	GICHYCGEIF	PPEELTMDHL	VPVVRGGKST	360	
RGNVVPACK	ENNRKYYLLP	VEWEEYLDL	ESGYTSDDEE	LEVFRNTLNK	NSEIFSSIKK	420	
LEKLFKNFDE	YSSAGIFVK	GPAISTISKD	IFGEWNVIR	KWNAEYDDIH	LKKKAVVTEK	480	
YEDDRRKSFK	KIGSFSLEQL	QYADADLSV	VEKLEKII IQ	KVDEIYKVY	SSEKLPDADF	540	
VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAFPGEGKET	NRDESFGYDF	VLAYDILLKV	600	
DHIYDAIRNY	VTQKPYSKDK	KLYFQNPQF	MGGWDKDKET	DYRATILRYG	SKYYLAIMDK	660	
KYAKCLOKID	KDDVNGNVE	INYLKNGYK	INYLKNGYK	KMLPKVFFSK	KWMAYYNPSE	DIQKIYKNGT	720
FKKGMDFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSETE	EKYKDIAGFY	REVEEQGYKV	780	
SFESASKKEV	DKLVEEGKLY	MFQIYNKDF	DKSHGTPNLH	TMYFKLLFDE	NNHGQIRLSG	840	
GAELFMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTTLS	YDVYKDKRF	EDQYELHIPI	900	
AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGNIV	VEQYSLNEI I	960	
NNFNIGIRIK	DYHSLDKKKE	KERFEARQNW	TSIENIKELK	AGYISQVVHK	ICELVEKYDA	1020	
VIALEDLNSG	FKNRSRVKVEK	QVYQKFEKML	IDKLNMYMDK	KSNPCATGGA	LKGQITNKFE	1080	
ESFKSMSTQN	FIFYIPAWLT	TSKIDPSTGF	VNLKTKYTSI	IADSKKFISS	FDRIMYVPEE	1140	
DLFEFALDYK	NFSRTDADYI	KWKLYSYGN	RIRIFRNPKN	NNVFDWEEV	LTSAYKELFN	1200	

-continued

KYGINYQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVFDFL	ISPVKNSDGI	1260
FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQPFKK	AEDEKLDKVK	IAISNKEWLE	1320
YAQTSVKH						1328

SEQ ID NO: 207           moltype = AA   length = 1441  
 FEATURE                Location/Qualifiers  
 source                   1..1441  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 207

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTEGSEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGPPSSF	300
SKAKKEAVKI	YLDYPTSFYC	CDCITWKNKK	KGIPLESCEG	YQVRKQEKRA	SRIEWEHVVP	360
AWQFGHQRC	WQKGGGRNCT	RNDKQPKSME	ADLHNLVPAI	GEVNGDRSNF	RFSQWNGSKG	420
AFYQQCAFVK	DFKGRVAEPP	AQSRGAIART	YLYMNEYKFK	NLSKAQRQLM	EAWNKQYVPS	480
TWECTRDERI	AKIQGNHNQF	VYKACGYTSD	EEVLEVFRNT	LNKNSEIFSS	IKKLEKLFKN	540
FDEYSSAGIF	VKNGPAISTI	SKDIPGEWNV	IRDKWNAEYD	DIHLKKAQAV	TEKYEDDRRK	600
SFKKIGSFSL	EQLQEQYADAD	LSVVEKLEKI	I IQKVDEIYK	VYGSSEKLPD	ADPVLEKSLK	660
KNDAVVAIMK	DLLDSVKFSFE	NYIKAFPGEG	KETNRDESFY	GDFVLAYDIL	LKVDHIYDAI	720
RNYVTQKPYS	KDKFKLYFQN	PQFMGGWDKD	KETDYRATIL	RYGSKYYLAI	MDKKYAKCLQ	780
KIDKDDVNGN	YEKINYKLLP	GNPKMLPKVF	FSKKWMAYYN	PSEDIQKIYK	NGTFPKKDMF	840
NLNDCHKLID	FFKDSISRYP	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	YKVSFESASK	900
KEVDKLVVEG	KLYMFQIYNK	DFSDKSHGTP	NLHTMYFKLL	FDENNHGQIR	LSGGAELEFMR	960
RASLKEELV	VHPANSPIAN	KNPDNPKKTT	TLSDYVYKDK	RFSDEQYELH	IPIAINKCKPK	1020
NIFKINTEVR	VLLKHDNDPY	VIGIARGERN	LLYIVVVVDGK	GNIVEQYSLN	EIINNPNNGIR	1080
IKTDYHSLLD	KKEKERPEAR	QNWTSIENIK	ELKAGYISQV	VHKICELVEK	YDAVIALEDL	1140
NSGFKNRVRK	VEKQVYQKFE	KMLIDKLNLM	VDKKSNPCAT	GGALKGYQIT	NKFPSPKMS	1200
TQNGFIFYIP	AWLTSKIDPS	TGFVNLLKTK	YTSIADSKKF	ISSPDRIMYV	PEEDLPEFAL	1260
DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNNVFDWE	EVCLTSAYKE	LFNKYGINYQ	1320
QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	DGIFYDSRNY	1380
EAQENAILPK	NADANGAYNI	ARKVLWAIQ	FKKADEKLD	KVKIAISNKE	WLEYAQTSVK	1440
H						1441

SEQ ID NO: 208           moltype = AA   length = 1506  
 FEATURE                Location/Qualifiers  
 source                   1..1506  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 208

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTEGSEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGWRRRR	300
EDARAAPGLL	GRLPVLVPAV	AAELPPVPGG	PRGPGLAKY	GLPLGLAQLK	RESYVLCYDP	360
RTRGALWVVE	QLRPERLRGD	DRRRECFRE	DDSVHAYHRA	TNADYRSGSF	DRGHAAAAAN	420
HRWSQKAMDD	TFYLSNVAPO	VPHLNQNAWN	NLEKYSRSLT	RSYQNVYVCT	GPLFLPRTEA	480
DGKSYVKYQV	IGKNHVAVPT	HFFKVLILEA	AGGQIELRTY	VMPNAPVDEA	IPLERPLVPI	540
ESIERASGLL	FVFNILARAG	SLKAITAGSK	GYTSDDEEVL	VFRNTLNKNS	EIFSSIKKLE	600
KLFKNFDEYS	SAGIFVKNKP	AISTISKDIF	GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	660
DDRRKSPFKI	GSFSLEQLQE	YADADLSVVE	KLKEI IQKV	DEIYKVYSS	EKLFDADFVL	720
EKSLKKNDAV	VAIMKDLLDS	VKSFENYIKA	FPGEKGTNR	DESPYGDVFL	AYDILLKVDH	780
IYDAIRNYVT	QKPYSKDKFK	LYFQNPQFMG	GWDKDKETDY	RATILRYGSK	YYLAIMDKKY	840
AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYNPSEDI	QKIYKNGTFK	900
KGDMFNLND	HKLIDFFPKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGPYRE	VEEQYKVSF	960
ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHTM	YFKLLFDENN	HGQIRLSGGA	1020
ELFMRRASLK	KEELVHPAN	SPIANKNPDN	PKKTTTLSYD	VYKDKRPSED	QYELHPIPIA	1080
NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	1140
FNGIRIKTDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	YISQVVKHIC	ELVEKYDAVI	1200
ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	GYQITNKFES	1260
FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	LLKTKYTSIA	DSKKFISSFD	RIMYVPEEDL	1320
FEFALDYKNF	SRTADYIKK	WKLYSYGNRI	RIFRNPKNKN	VFDWEEVCLT	SAYKELFNKY	1380
GINYQQGDIR	ALLCEQSDKA	FYSSFMALMS	LMLQMRNSIT	GRTDVDFLIS	PVKNSDGIFY	1440
DSRNYEAQEN	AAILPKNADAN	GAYNIARKVL	WAIQQFKKAE	DEKLDKVKIA	ISNKEWLEYA	1500
QTSVKH						1506

SEQ ID NO: 209           moltype = AA   length = 1508  
 FEATURE                Location/Qualifiers  
 source                   1..1508  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 209

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
------------	------------	------------	-------------	------------	------------	----

-continued

INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENM	FSEBAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGWSKEG	300
HVMTCRIAQG	LLNDEAAHAV	KMLLPEYVNG	DLSALCVWPD	QVRHWYKYKW	TSPLHFIDTP	360
DKACNFDYER	DCHDQHGVDK	MCVAGAIQNF	TTQLSHYREG	TSDRRYNMT E	ALLFLSHFMG	420
DIHQPMHYGF	TS DAGGNSID	LRWFRHKS NL	HHVWDREIIL	TAAKDYAKD	INLLEEDIEG	480
NFTDGIWSD	LASWRECGNV	FSCVNFKATE	SINIACKWGY	KGVEAGETLS	DDYFNSRLPI	540
VMKRVAQGGI	RLAMLNINV	GASQQEDSVV	ATGYTSDEEV	LEVFRNTLNK	NSEIFSSIKK	600
LEKLFKNPDE	YSSAGIFVK	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	LKKKAVVTEK	660
YEDDRRKSFK	KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	KVDEIYKVG	SSEKLPDADF	720
VLEKSLKKN	AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	NRDESFGDF	VLAYDILLKV	780
DHIYDAIRNY	VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	DYRATILRYG	SKYYLAIMDK	840
KYAKCLQKID	KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYYNPSE	DIQKIYKNGT	900
FKKGDMPN LN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	REVEEQGYKV	960
SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYFKLLFDE	NNHGQIRLSG	1020
GAEFLMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKT T T T L S	YDVYKDKRFS	EDQYELHIPI	1080
AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNL LY	IVVVDGKGN I	VEQYSLNEI I	1140
NNFNIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVKH	ICELVEKYDA	1200
VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	LKGYQITNKF	1260
ESFKSMSTQN	GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	FDRIMYVPEE	1320
DLFEFALDYK	NFSRTDADYI	KWKLYSYGN	RIRIFRNPCK	NNVFDWEVC	LTSAYKELFN	1380
KYGINYQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	ISPVKNSDGI	1440
FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	AEDEKLDKVK	IAISNKEWLE	1500
YAQTSVKH						1508

SEQ ID NO: 210                   moltype = AA   length = 1318  
FEATURE                           Location/Qualifiers  
source                             1..1318  
                                  mol\_type = protein  
                                  organism = synthetic construct

SEQUENCE: 210

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENM	FSEBAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGMKSKI	300
SEYTEKEFLE	FVKDIYTNK	KKPTEESHI	QAVLEFKKLT	EHPSGSDLLY	YPNENREDS P	360
AGVVEKVEK	RASKGLPGFK	AGGYTSDEEV	LEVFRNTLNK	NSEIFSSIKK	LEKLFKNPDE	420
YSSAGIFVK	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	480
KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	KVDEIYKVG	SSEKLPDADF	VLEKSLKKN	540
AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	NRDESFGDF	VLAYDILLKV	DHIYDAIRNY	600
VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	660
KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYYNPSE	DIQKIYKNGT	FKKGDMPN LN	720
DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	780
DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYFKLLFDE	NNHGQIRLSG	GAEFLMRRAS	840
LKKEELVVHP	ANSPIANKNP	DNPKKT T T T L S	YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	900
KINTEVRVLL	KHDDNPYVIG	IARGERNL LY	IVVVDGKGN I	VEQYSLNEI I	NNFNIRIKT	960
DYHSLLDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVKH	ICELVEKYDA	VIALEDLNSG	1020
FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	1080
GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	FDRIMYVPEE	DLFEFALDYK	1140
NFSRTDADYI	KWKLYSYGN	RIRIFRNPCK	NNVFDWEVC	LTSAYKELFN	KYGINYQQGD	1200
IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	1260
ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	AEDEKLDKVK	IAISNKEWLE	YAQTSVKH	1318

SEQ ID NO: 211                   moltype = AA   length = 1318  
FEATURE                           Location/Qualifiers  
source                             1..1318  
                                  mol\_type = protein  
                                  organism = synthetic construct

SEQUENCE: 211

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNYYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIIETILPEF	LDDKDEIALV	NSFNGFTTAF	TGFFDNRENM	FSEBAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGMELKN	300
SISDYTEAEF	VQLKEIEKE	NVAATDDVLD	VLLEHFVKIT	EHPDGTDLIY	YPSDNRDDSP	360
EGIVKEIKEW	RANGKPGFK	QGGYTSDEEV	LEVFRNTLNK	NSEIFSSIKK	LEKLFKNPDE	420
YSSAGIFVK	GPAISTISKD	IFGEWNVIRD	KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	480
KIGSFSLEQL	QEYADADLSV	VEKLKEIIIQ	KVDEIYKVG	SSEKLPDADF	VLEKSLKKN	540
AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	NRDESFGDF	VLAYDILLKV	DHIYDAIRNY	600
VTQKPYSKDK	FKLYFQNPQF	MGGWDKDKET	DYRATILRYG	SKYYLAIMDK	KYAKCLQKID	660
KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYYNPSE	DIQKIYKNGT	FKKGDMPN LN	720
DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	780
DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYFKLLFDE	NNHGQIRLSG	GAEFLMRRAS	840
LKKEELVVHP	ANSPIANKNP	DNPKKT T T T L S	YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	900

-continued

KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKJNI	VEQYSLNEII	NNFNGIRIKT	960
DYHSLDDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVHK	ICELVEKYDA	VIALEDLNSG	1020
PKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	LKGYQITNKF	ESFKSMSTQN	1080
GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	FDRIMYVPEE	DLFEFALDYK	1140
NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	NNVFDWEVVC	LTSAYKELFN	KYGINYQQGD	1200
IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	1260
ENAILPKNIAD	ANGAYNIARK	VLWAIQGFKK	AEDEKLDKVK	IAISNKEWLE	YAQTSVKH	1318

SEQ ID NO: 212                   moltype = AA   length = 1341  
 FEATURE                        Location/Qualifiers  
 source                         1..1341  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 212

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLMNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAP	TGFFDNRENM	FSEEAkstSI	AFRCINENLT	180
RYISNMDIFE	KVDAIPDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGGRTP T	300
AEERRIANAL	GALPCACIACYM	HGVISNEVSL	HHIAGRTPAG	CHKKQLPLCR	WHHQHAAPAE	360
VREKYPWLVP	VHADGVVGGK	KEFTLLNKSE	MELLADAYEM	ANIMHGYTSD	EEVLEVFRNT	420
LKNKSEIFSS	IKKLEKLFKN	FDEYSSAGIF	VKNGPAISTI	SKDIFGEWNV	IRDKWNAEYD	480
DIHLKKKAVV	TEKYEDDRRK	SFKKIGSFSL	EQLQEYADAD	LSVVEKLKEI	IIQKVDEIYK	540
VYGSSEKFLD	ADFVLEKSLK	KNDAVVAIMK	DLLDSVSKFE	NYIKAPFPEG	KETNRDESFY	600
GDFVLAYDIL	LKVDHIYDAI	RNVVTQKPYS	KDKFKLYFQN	PQFMGGWDDK	KETDYRATIL	660
RYGSKYYLAI	MDKKYAKCLO	KIDKDDVNGN	YEKINYKLLP	GPKNMPLPKVF	FSKKNMAYYN	720
PSEDIQKIYK	NGTFKKGDMF	NLNDCHKLID	FPKDISIRYP	KWSNAYDFNF	SETEKYKDIA	780
GFYREVEEQG	YKVSFESASK	KEVDKLVVEG	KLYMPQIYNK	DFSDKSHGTP	NLHTMYFKLL	840
FDENNHGQIR	LSGGAEFLMR	RASLKKEELV	VHPANSPIAN	KNPDNPKKTT	TLSYDVYKDK	900
RFSEDDQYELH	IPIAINCKPK	NIFKINTEVR	VLLKHDDNPY	VIGIARGERN	LLYIVVVDGK	960
GNIVEQYSLN	EIINNPNFNGIR	IKTDYHSLLD	KKEKERFEAR	QNWTSIENIK	ELKAGYISQV	1020
VHKICELVEK	YDAVIALEDL	NSGFKNRSVK	VEKQVYQKFE	KMLIDKLNMY	VDKKSNPCAT	1080
GGALKGYQIT	NKFPESFKSMS	TQNGFIFYIP	AWLTSKIDPS	TGPNVLLKTK	YTSIADSKKF	1140
ISSFDRIMYV	PEEDLFEFAL	DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNNVFDWE	1200
EVCLTSAYKE	LFNKYGINYQ	QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	1260
DFLISPVKNS	DGIFYDSRNY	EAQENAILPK	NADANGAYNI	ARKVLWAIQ	FKKAEDKLD	1320
KVKIAISNKE	WLEYAQTsvk	H				1341

SEQ ID NO: 213                   moltype = AA   length = 1336  
 FEATURE                        Location/Qualifiers  
 source                         1..1336  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 213

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLMNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGFTTAP	TGFFDNRENM	FSEEAkstSI	AFRCINENLT	180
RYISNMDIFE	KVDAIPDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGMEWKD	300
IKGYEGHYQV	SNTGEVYSIK	SGKTLKHQIP	KDGYHRIGLF	KGGKGTFOV	HLVVAIHFC E	360
GYEGLVVDH	KDGNKDNINLS	TNLRWVTQKI	NVENQMSRGT	GYTSDEEVLE	VFRNTLNKNS	420
EIFSSIIKLE	KLFPNFDYD	SAGIFVKNGP	AISTI SKDIF	GEWNVIRDKW	NAEYDDIHLK	480
KKAVVTEKYE	DDRKSFPKFI	GSPSLEQLQE	YADADLSVVE	KLKEIIIQKV	DEIYKVYGSS	540
EKLFDADPVL	EKSLKKNDAV	VAIMKDLLDS	VKSPENYIKA	FPGEGKETNR	DESIFYGDFVL	600
AYDILLKVDH	IYDAIRNYVT	QKPYSKDKPK	LYFQNPQFPMG	GWDKDKETDY	RATILRYGSK	660
YYLAIMDKKY	AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	720
QKIYKNGTFK	KGMFNFNLDK	HKLIDFPFKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGFYRE	780
VEEQGYKVSF	ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHTM	YFKLLFDENN	840
HGQIRLSGGA	ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	PKKTTLTSLYD	VYKDKRFSED	900
QYELHIPIAI	NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	960
QYSLNEIINN	FNGIRIKTDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	YISQVVKIK	1020
ELVEKYDAVI	ALEDLNSGPK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	1080
GYQITNKPE	FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	LLKTKYTSIA	DSKFFISSPD	1140
RIMYVPEEDL	FEFALDYKFN	SRDADYIKK	WKLYSYGNRI	RIFRNPCKNN	VFDWEVCLT	1200
SAYKELFNKY	KYGINYQQDIR	ALLCEQSDKA	FYSSFMALMS	LMLQMRNSIT	GRTDVDFLIS	1260
PVKNSDGI FY	DSRNYEAQEN	AAILPKNADAN	GAYNIARKVL	WAIQGFKKA E	DEKLDKVKIA	1320
ISNKEWLE YA	QTSVKH					1336

SEQ ID NO: 214                   moltype = AA   length = 1501  
 FEATURE                        Location/Qualifiers  
 source                         1..1501  
                               mol\_type = protein  
                               organism = synthetic construct

SEQUENCE: 214

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLMNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120

-continued

DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAkstSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGWGALG	300
HATVAVVAQH	YVSEEAASWA	QGILGSSSSS	YLASTASWAD	EYRLTSAGKW	SASLHFIDAE	360
DNPPPTNCNVD	YERDCGSSGC	SISAIANYTQ	RVSDSSLSSE	NHAEALRFLV	HFIGDMTQPL	420
HDEAYAVGGN	KINVTDPGYH	DNLHSDWDTY	MPQKLIIGHA	LSDAESWAKT	LVQNIESGNY	480
TAQAIGWIKG	DNISEPITTA	TRWASDANAL	VCTVVMPHGA	AALQTGDLYP	TYYSVIDTI	540
ELQIAKGGYR	LANWINEIHG	SEIAKGYTSD	EEVLEVFRNT	LNKNSEIFSS	IKKLEKLFKN	600
PDEYSSAGIF	VKNQPAISTI	SKDIPGEWNV	IRDKWNAEYD	DIHLKKKAVV	TEKYEDDRRK	660
SFKIGSPSL	EQLQEQYADAD	LSVVEKLKEI	I IQKVDEIYK	VYGSSEKLF	ADPVLKESLK	720
KNDVAVAIMK	DLSDSVKSFE	NYIKAFFGEG	KETNRDESFY	GDFVLAYDIL	LKVDHIYDAI	780
RNYVTQKPY	KDKFKLYFQN	PQFMGGWDD	KETDYPATIL	RYGSKYLA	MDKKYAKCLQ	840
KIDKDDVNGN	VHPANSPIAN	GNPKMLPKVF	FSKKWMAYYN	PSEDIQKIYK	NGTFKKGDMF	900
NLNDCHKLID	FFKDSISRYP	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	YKVSFESASK	960
KEVDKLVVEG	KLYMFPQYNK	DFSDKSHGTP	NLHTMYFKLL	FDENNHGQIR	LSGGAEFLMR	1020
RASLKEELV	VHPANSPIAN	KNPDPKKT	TLSDYVYKDK	RFSQYELH	IPIAINKCPK	1080
NIFKINTEVR	VLLKHDDNPY	VIGIARGERN	LLYIVVVDGK	GNIVEQYSLN	EIINNPNFNGIR	1140
IKTDYHSLLD	KKEKERPEAR	QNWTSIENIK	ELKAGYISQV	VHKICELVEK	YDAVIALEDL	1200
NSGFKNRVRK	VEKQVYADAD	KMLIDKLNVM	VDKKSNPCAT	GGALKGYQIT	NKFSFKSMS	1260
TQNGFIFYIP	AWLTSKIDPS	TGFVNLLKTK	YTSIADSKKF	ISSFDRIMYV	PEEDLPEFAL	1320
DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNNVFDWE	EVCLTSAYKE	LFNKYGINYQ	1380
QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	DGIFYDSRNY	1440
EAQENAILPK	NADANGAYNI	ARKVLWAIQ	FKKAEDEKLD	KVKIAISNKE	WLEYAQTSVK	1500
H						1501

SEQ ID NO: 215           moltype = AA   length = 1498  
 FEATURE                Location/Qualifiers  
 source                 1..1498  
                        mol\_type = protein  
                        organism = synthetic   construct

SEQUENCE: 215

SKLEKFTNCY	SLSKTLRFA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYSKLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAkstSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGWGALG	300
HETVAVIAQS	FVASSTESFC	QNILGDDSTS	YLANVATWAD	TYKYTDAGEF	SKPYHFIQAQ	360
DNPPQSCGVD	YDRDCGSAGC	SISAIQNYTN	ILLESFNGSE	ALNALKFVVH	IIGDIHQPLH	420
DENLEAGNG	IDVTDGETT	NLHHIWDTNM	PEEAAGGYSL	SVAKTYADLL	TERIKTGTYS	480
SKKDSWTDGI	DIKDPVSTSM	IWAADANTYV	CSTVLDDGLA	YINSTDLGSE	YYDKSQVPE	540
ELIAKAGYRL	AAWLDIASQ	PSGYTSDEEV	LEVFRNTLNK	NSEIFSSIKK	LEKLFKNFDE	600
YSSAGIFVKN	GPAISTISKD	IPGEWNVIRD	KWNAEYDDIH	LKKKAVVTEK	YEDDRRKSFK	660
KIGSFSLEQL	QEQYADADLSV	VEKLKEIIIQ	KVDEIYKVVY	SSEKLFADDF	VLEKSLKKNDA	720
AVVAIMKDLL	DSVKSFENYI	KAFFGEGKET	NRDESFGYGF	VLAYDILLKV	DHIYDAIRNY	780
VTQKPYSKDK	FKLYFQNPQF	MGWDKDKET	DYRATILRYG	SKYLAIMDK	KYAKCLQKID	840
KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYYNPSE	DIQIKYKNGT	FKKGDMPNLN	900
DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	REVEEQGYKV	SFESASKKEV	960
DKLVEEGKLY	MFQIYNKDFP	DKSHGTPNLH	TMYPKLLPDE	NNHGQIRLSG	GAEFLPMRRAS	1020
LKKEELVVHP	ANSPIANKNP	DNPKKTTTLS	YDVYKDKRFS	EDQYELHIPI	AINKCPKNIF	1080
KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGN	VEQYSLNEII	NNFNGIRIKT	1140
DYHSLLDKKE	KERPEARQNW	TSIENIKELK	AGYISQVVKH	ICELVEKYDA	VIALEDLNSG	1200
FKNSRVKVEK	QYVYADADLSV	IDKLNVMVDK	KSNPCATGGA	LKGQYITNKF	ESFMSMTQNS	1260
GFIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	FDRIMYVPEE	DLPEFALDYK	1320
NFSRTDADYI	KKWKLYSYGN	RIRIFRNPCK	NNVFDWEVVC	LTSAYKELFN	KYGINYQGGD	1380
IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	ISPVKNSDGI	FYDSRNYEAQ	1440
ENAILPKNAD	ANGAYNIARK	VLWAIQGFKK	AEDEKLDKVK	IAISNKEWLE	YAQTSVKH	1498

SEQ ID NO: 216           moltype = AA   length = 1317  
 FEATURE                Location/Qualifiers  
 source                 1..1317  
                        mol\_type = protein  
                        organism = synthetic   construct

SEQUENCE: 216

SKLEKFTNCY	SLSKTLRFA	IPVGKTQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYLSF	60
INDVLHSIKL	KNLNNYISLF	RKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYSKLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAkstSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGMELKH	300
SISDYTEAEF	LQLVTTICNA	DTSSSEELVK	LVTHFEEMTE	HPSGSDLIY	PKEGDDDDSPS	360
GIVNTVQKWR	AANGKSGFKQ	GGYTSDEEVL	EVFRNTLNKN	SEIFSSIKKL	EKLKFNPFDEY	420
SSAGIFVKNG	PAISTISKDI	FGWNVIRDK	WNAEYDDIHL	KKKAVVTEK	EDDRRKSFKK	480
IGSFSLEQLQ	EYADADLSV	EKLKEIIIQ	VDEIYKVVY	SEKLFADDFV	LEKSLKKNDA	540
VVAIMKDLLD	SVKSFENYIK	AFPGEGKETN	RDESFGYGFV	LAYDILLKVD	HIYDAIRNYV	600
TQKPYSKDKF	KLYFQNPQFM	GGWDKDKETD	YRATILRYGS	KYYLAIMDKK	YAKCLQKIDK	660
DDVNGNYEKI	NYKLLPGPNK	MLPKVFFSKK	WMAYYNPSED	IQIKYKNGTF	KKGDMPNLND	720
CHKLIDFFPK	SISRYPKWSN	AYDFNFSETE	KYKDIAGFYR	EVEEQGYKVS	FESASKKEVD	780





-continued

## SEQUENCE: 219

```

SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYKSLFKK 120
DIIETILPEF LDDKDEIALV NSFNGPTTAF TGFDFNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDAIFDKHE VQEIKEKILN SDYDVEDFFE GEFNFVLTQ EGIDVYNAI I 240
GGFVTESEGEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGADLPA 300
LPGGPAGGTG ELAKYGLPGV AQLRSRESYV LSYDPRTRGA LWVLEQLRPE RLRGDGDRSA 360
CDFREDDSVH AYHRATNADY RSGSGFDRGHL AAAANHRWSQ RAMDDTFYLS NVAPQVPHLN 420
QNAWNNLERY SRSLTRTYQN VYVCTGPLFL PRTEADGKSY VKYQVIGKNH VAVPTHFFKV 480
LILEAAGGQI ELSYVMPNA PVDETIPLER FLVPIESIER ASGLLFPVNI LARAGNLKAI 540
TAGSGYTSDE EVLEVFRNTL NKNSEIFSSI KKLEKLFKNF DEYSSAGIFV KNGPAISTIS 600
KDIFGEWNV I RDKWNAEYDD IHLKKA VVT EKYEDDRKS FKKIGSFSL EQLQYADADL 660
SVVEKLKEII IQKVDEIYKV YGSSEKLFDA DVFLEKSLKK NDVAIVMKD LLDVSKFEN 720
YIKAFFGEGK ETNRDESFGY DFLVAYDILL KVDHIYDAIR NYVTQKPYSK DKFKLYFQNP 780
QPMGGWDKDK ETDYRATILR YGSKYYLAIM DKKYAKCLQK IDKDDVNGNY EKINYKLLPG 840
PNKMLPKVFF SKKMAYMAYN SEDIQKIYKN GTFKKGDMFN LNDCHKLIDF FKDISIRYPK 900
WSNAYDFNFS ETEKYKDIAG FYREVEEQGY KVSFESASKK EVDKLVEEGK LYMFQIYNKD 960
FSDKSHGTPN LHTMYFKLLF DENNHGQIRL SGGAEFLPMR ASLKKKEELV HPANSPIANK 1020
NPDNPKKTTT LSYDVIYDKR SLEDQYELHI PIAINKCPKN IFKINTEVRV LKRDNDPNVY 1080
IGIARGERNL LYIVVVDGKG NIVEQYSLNE IINNFGIRI KTDYHSLLDK KEKERFEARQ 1140
NWTSIENIKE LKAGYISQV HIKCELVEKY DAVIALEDLN SGFKNSRVKV EKQVYQKFEK 1200
MLIDKLNVM DKKNSPCATG GALKGYQITN KFESFKSMST QNGPIFYIPA WLTSKIDPST 1260
GPNLLKTKY TSIADSKKFI SSFDRIMYVP EEDLPEFALD YKNFSRTDAD YIKKWKLYSY 1320
GNRIRIFRNP KKNVFPWEE VCLTSAYKEL FNKYGINYQQ GDIRALLCEQ SDKAFYSSFM 1380
ALMSLMLQMR NSITGRDVID FLISPVKNSD GIFYDSRNYE AQENAILPKN ADANGAYNIA 1440
RKVLWAIQGF KKAEBEKLDK VKIAISNKEW LEYAQTSVKH 1480

```

```

SEQ ID NO: 220      moltype = AA length = 1382
FEATURE            Location/Qualifiers
source              1..1382
                    mol_type = protein
                    organism = synthetic construct

```

## SEQUENCE: 220

```

SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYKSLFKK 120
DIIETILPEF LDDKDEIALV NSFNGPTTAF TGFDFNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDAIFDKHE VQEIKEKILN SDYDVEDFFE GEFNFVLTQ EGIDVYNAI I 240
GGFVTESEGEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGKKNK 300
DAQMINEMQ KRNQRTNERI EBIIRTTGKE NAKYLIEKIK LHMDEGKCL YSLEAIPLED 360
LLNPFNYEV DHIIPRSVFS DNSFNKVLV KQEENSKGN RPPFYLSS DSKISYETPK 420
KHILNLAKGK GRISKTKKEY LLEERDGYTS DEEVLEVFRN TLNKNSEIFS SIKKLEKLPK 480
NFDEYSSAGI FVKNQPAIST ISKDIPEGWN VIRDKNWAEY DDIHLKKKAV VTEKYEDDRR 540
KSFKKIGSFS LEQLQYADA DLSVVEKLKE IIIIQVDEIY KVYGSSEKLF DADFVLEKSL 600
KKNDAVVAIM KDLLDSVKSF ENYIKAFFGE GKETNRDES F YGDFVLAYDI LKVDHIYDA 660
IRNYVTQKPY SKDKFKLYFQ NPQPMGGWDK DKETDYRATI LRYGSKYYLA IMDKYYAKCL 720
QKIDKDDVNG NYEKINYKLL PGNKMLPKV FFSKWMAYY NPSEDIQKIY KNGTFKKGDM 780
FNLNDCHKLI DFFKDISIRY PKWSNAYDFN FSETEKYKDI AGFYREVEEQ GYKVSFESAS 840
KKEVDKLV E GKL YMPQIYN KDFSDKSHGT PNLHTMYFKL LFDENNHGQI RLSGGAEFLPM 900
RRASLKEEL VVHPANSPIA NKNPDNPKKT TFLSYDVYK KRFSEDEYEL HIPAIINKCP 960
KNIFKINTEV RVLLKHDDNP YVIGIARGER NLLYIVVDG KGNIVEQYSL NEIINNFGI 1020
RIKTDYHSL DKKKKERFEA RQNWTSIENI KELKAGYISQ VVHKICELVE KYDAVIALED 1080
LNSGFKNSRV ESKKIDKLN MVDKKSNPCA TGGALKGYQI TNKFESFKSM 1140
STQNGFIFYI PAWLTSKIDP STGFVNLKKT KYTSIADSK FISSFDRIMY VPEDLFEFA 1200
LDYKNFSRTD ADYIKKWKLY SYGNRIRIFR NPKNVFPDW EEVCLTSAYK ELFNKYGINY 1260
QQGDIRALLC EQSDKAFYSS FMALMSLMLQ MRNSITGRD VDFLISPVKN SDGIFYDSRN 1320
YEAQENAILP KNADANGAYN IARKVLWAIQ QPKKAEBEKL DKVKIAISNK EWLEYAQTSV 1380
KH 1382

```

```

SEQ ID NO: 221      moltype = AA length = 1335
FEATURE            Location/Qualifiers
source              1..1335
                    mol_type = protein
                    organism = synthetic construct

```

## SEQUENCE: 221

```

SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYKSLFKK 120
DIIETILPEF LDDKDEIALV NSFNGPTTAF TGFDFNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDAIFDKHE VQEIKEKILN SDYDVEDFFE GEFNFVLTQ EGIDVYNAI I 240
GGFVTESEGEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGDGNH 300
TVNPSKLVSH RLDGLGTVQQ IDRACPTALW CALTREKDFD EKNGLPARED RAIRVHGHEI 360
KSSDYIQVFS KRKTDSDRD ETPFGAIAVR GGFVEIGPSG YTSDEEVLEV FRNTLNKNSE 420
IFSSIKKLEK LFKNFDEYSS AGIFVKNQGA ISTISKDIFG EWNVIRDKWN AEYDDIHLKK 480
KAVVTEKYED DRRKSFKKIG SFSLEQLQY ADADLSVVEK LKEII IQKVD EIYKVGSSSE 540
KLFDAFVLE KSLKKNDAVV AIMKDLLDSV KSFENYIKAF FGEKGTNRD ESFYGDFVLA 600
YDILLKVDHI YDAIRNYVTQ KPYSKDKFKL YFQNPQFMGG WDKDKETDYR ATILRYGSKY 660
YLAIMDKKYA KCLQKIDKDD VNGNYEKINY KLLPGPNKML PKVFPFKWM AYNPSEDIQ 720

```

-continued

KIYKNGTPKK	GDMFNLNDCH	KLIDFPKDSI	SRYPKWSNAY	DFNPFSETEKY	KDIAGFYREV	780
EEQGYKVSFE	SASKKEVDKL	VEEGKLYMPQ	IYNKDFSDKS	HGTPNLHMTY	FKLLFDENN	840
GQIRLSGGAE	LFMRRASLKK	EELVVHPANS	PIANKNPDP	KKTTTLYSDV	YKDKRPFSE	900
YELHIPIAIN	KCPKNIKFKN	TEVRVLLKHD	DNPHYVIGIAR	GERNLLYIVV	VDGKGNIVEQ	960
YSLNEIINNF	NGIRIKTDYH	SLLDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKHICE	1020
LVEKYDVAIA	LEDLNSGFKN	SRVKVEKQVY	QKFEKMLIDK	LNVMVDKSN	PCATGGALKG	1080
YQITNKFESF	KSMSTQNGFI	FYIPAWLTSK	IDPSTGFVNL	LKTKYTSIAD	SKKFISSFDR	1140
IMYVPEEDLF	EFALDYKNFS	RTDADYIKKW	KLYSYGNRIR	IFRNPCKNNV	FDWEEVCLTS	1200
AYKELFNKYG	INYQOGDIRA	LLCEQSDKAF	YSSFMALMSL	MLQMRNSITG	RTDVPDLISP	1260
VKNSDGFYD	SRNYEAQENA	ILPKNADANG	AYNIARKVLW	AIGQFKKAED	EKLKVKIAI	1320
SNKEWLEYAQ	TSVKH					1335

SEQ ID NO: 222 moltype = AA length = 1381  
 FEATURE Location/Qualifiers  
 source 1..1381  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 222

SKLEKFTNCY	SLSKTLRFKA	IPVGTKQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNMYISLF	RKKTRTEKEN	KELNLEINL	RKEIAKAFKG	NEGYKSLFPK	120
DIIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGENQYT	300
NQGKSNQQOR	LKRLEKSLKE	LGSKILKENI	PAKLSKIDMN	ALQNDRLYLY	YLQNGKDMYT	360
GDDLDIRLS	NYDIDHII PQ	APLKDNSIDN	KVLVSSASNR	GKSDDFPSLE	VVKRRTFWY	420
QLLKSCLISQ	RKPDNLTKAE	RGGLLGYTSD	BEVLEVFRNT	LNKNSIPISS	IKKLEKLFKN	480
FDEYSSAGIF	VKNQPAISTI	SKDIFGEWNV	IRDKNWABED	DIHLKKAQAV	TEKYEDDRR	540
SFKKIGSFSL	EQLQEYADAD	LSVVEKLKEI	IIQKVDEIYK	VYGSSEKLF	ADPFVLEKSLK	600
KNDVAVAIMK	DLDSVKSFE	NYIKAPFGE	KETNRDESFP	GDFVLAYDIL	LKVDHIYDAI	660
RNYVTQKPY	KDKFKLYFQN	PQPMGGWDK	KETDYRATIL	RYGSKYYLAI	MDKKYAKCLQ	720
KIDKDDVNGN	YEKINYKLLP	GNKMLPKVF	ESKKWMAYYN	PSEDIQKIYK	NGTFKKGDMF	780
NLNDCHKLID	PFKDSISRYP	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	YKVSFESASK	840
KEVDKLVVEE	KLYMFQIYNK	DFSDKSHGTP	NLHMTYFKLL	FDENNHGQIR	LSGGALFMR	900
RASLKEELV	VHPANSPIAN	KNPDPKKT	TLSDYVYKDK	RFSEDDQYELH	IPIAINKCPK	960
NIFKINTEVR	VLLKHDDNPY	VIGIARGERN	LLYIVVVDGK	GNIVEQYSLN	EIINNPNFIR	1020
IKTDYHSLLD	KKEKERPEAR	QNWTSIENIK	ELKAGYISQV	VHKICELVEK	YDAVIALEDL	1080
NSGFKNSRVK	VEKQVYQKFE	KMLIDKLNVM	VDKKSNPCAT	GGALKGYQIT	NKFESPKSMS	1140
TQNGFIFYIP	AWLTSKIDPS	TGPFVNLKTK	YTSIADSKKF	ISSFDRIMYV	PEEDLPEFAL	1200
DYKNFSRTPA	DYIKKWLKYS	YGNRIRIFRN	PKKNNVPDWE	EVCLTSAYKE	LFNKYGINYQ	1260
QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	DGIFYSRNY	1320
EAQENAILPK	NADANGAYNI	ARKVLWAIGQ	FKKAEDEKLD	KVKIAISNKE	WLEYAQTSVK	1380
H						1381

SEQ ID NO: 223 moltype = AA length = 1347  
 FEATURE Location/Qualifiers  
 source 1..1347  
 mol\_type = protein  
 organism = synthetic construct

SEQUENCE: 223

SKLEKFTNCY	SLSKTLRFKA	IPVGTKQENI	DNKRLLEVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNMYISLF	RKKTRTEKEN	KELNLEINL	RKEIAKAFKG	NEGYKSLFPK	120
DIIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDPFE	GEFFNFVLTQ	EGIDVYNAI I	240
GGFVTESEGEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGFPNFB	300
GEPKSKDILK	LRLYEQQHGF	CLYSGKEINL	GRLNEKGYVE	IDHALPFSRT	WDDSFNNKVL	360
VLGSENQKNG	NQTPYEYFNG	KDNSREWQEF	KARVETSRFP	RSKKQRILLQ	KGYTSDEEVL	420
EVFRNTLNKN	SEIFSSIKKL	EKLFPKNFDEY	SSAGIFVKNG	PAISTISKDI	FGEWNVIRDK	480
WNAEYDDIHL	KKKAVVTEKY	EDDRRKSFKK	IGSFSLEQLQ	EYADADLSV	EKLKEII IQK	540
VDEIYKVYGS	SEKLFADDFV	LEKSLKKKDA	VVAIMKDLLD	SVKSFENYIK	APFGEGKETN	600
RDESYGDFV	LAYDILLKVD	HIYDAIRNV	TQKPYSKDKF	KLYPQNPQFM	GGWDKDKETD	660
YRATILRYGS	KYLAIMDKK	YAKCLQKIDK	DDVNGNYEKI	NYKLLPGFNK	MLPKVFFSKK	720
WMAYNPNSED	IQKIYKNGTF	KKGDMFNLND	CHKLIDFPK	SISRYPKWSN	AYDFNPFSETE	780
KYKDIAGFYR	EVBEQGYKVS	FESASKEVD	KLVEEGKLYM	FQIYNKDFSD	KSHGTPNLHT	840
MYFKLLFDEN	NHGQIRLSGG	AELFMRRASL	KKEELVVHPA	NSPIANKNPD	NPKTTTLYS	900
DVYDKRPFSE	DQYELHPIA	INKCPKNI FK	INTEVRVLLK	HDDNPYVIGI	ARGERNLLYI	960
VVVDGKGNIV	EQYSLNBI IN	NFNGIRIKTD	YHSLLDKKEK	ERFEARQNW	SIENIKELKA	1020
GYISQVHVHI	CELVEKYDAV	IALEDLNSGF	KNSRVKVEKQ	VYQKFEKMLI	DKLNYMVDK	1080
SNPCATGGAL	KGYQITNKFE	SPKSMSTQNG	FIFYIPAWLT	SKIDPSTGFV	NLLKTKYTSI	1140
ADSKKFISF	DRIMYVPEED	LPEFALDYKN	FSRTDADYIK	KWKLYSYGNR	IRIFRNPCKN	1200
NVFDWEEVCL	TSAYKELFNK	YGINYQOGDI	RALLCEQSDK	AFYSSFMALM	SLMLQMRNSI	1260
TGRTDVDFLI	SPVKNSDGIF	YDSRNYEAQE	NAILPKNADA	NGAYNIARKV	LWAIGQFKKA	1320
EDEKLDKVKI	AISNKEWLEY	AQTSVKH				1347

SEQ ID NO: 224 moltype = AA length = 1390  
 FEATURE Location/Qualifiers  
 source 1..1390

-continued

```

mol_type = protein
organism = synthetic construct

SEQUENCE: 224
SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYSKLFKK 120
DIIETILPEF LDDKDEIALV NSFNGFTTAF TGFFDNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDIAFPKHE VQEIKEKILN SDYDVEDPFE GEPFNFVLTQ EGIDVYNAI I 240
GGFVTEGSEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGSPENI 300
PKDKNNRIKE FAKGISAYSQ ANLTDGDFDG AKEELDHIIP RSHKKYGTLN DEANLICVTR 360
GDNKNKGNRI FCLRDLADNY KLRQFETDD LEIEKKIADT IWDANKKDFK FGNYRSFINL 420
TPQEQKAPRH ALFLADENPI KQAVIRAINN RNRTGYTSDE EVLEVFRNTL NKNSEIFSSI 480
KKLEKLFKFN DEYSSAGIFV KNGPAISTIS KDIFGEWNI RDKWNAEYDD IHLKKKAVVT 540
EKYEDDRRKS FKKIGSFSLE QLQEQYADADL SVVEKLKEII IQKVDEIYKV YGSSEKLFDA 600
DFVLEKSLKK NDAVVAIMKD LLDVSVKSFEN YIKAFFGEGK ETNRDESFGY DFVLAYDILL 660
KVDHIYDAIR NYVTQKPYSK DKFKLYFQNP QFMGGWDDK ETDYRATILR YGSKYLAIM 720
DKKYAKLQK IDKDDVNGNY EKINYKLLPG PNKMLPKVFF SKKWMAYYNP SEDIQKIYKN 780
GTFKKGDMFN LNDCHKLIDF FKDSISRYPK WSNAYDFNFS ETEKYKDIAG FYREVEEQGY 840
KVSFESASKK EVDKLVBEKG LYMFQIYNKD FSDKSHGTPN LHTMYFKLLF DENNHGQIRL 900
SGGALFMNR ASLRDLADNY HPANSPIANK NPDNPKKTTT LSYDVKDFK FSEDQYELHI 960
PIAINKCPKN IFKINTEVRV LLKHDDNPYV IGIARGERNL LYIVVVDGKG NIVEQYSLNE 1020
IINNFGIRI KTDYHSLLDK KEKERFEARQ NWTSIENIKE LKAGYISQV HIKCELVEKY 1080
DAVIALEDLN SGFKNSRVKQ ELQVYQKFEK MLIDKLNVM DKKSNPCATG GALKGYITN 1140
KPFESFKSMST QNGFIFYIPA WLTSKIDPST GFVNLLKTKY TSIADSKKFI SSFDRIMYVP 1200
EDLFEFALD YKNFSRTDAD YIKKWKLYSY GNRIRIFRNP KKNVFDWEE VLCTSAYKEL 1260
FNKYGINYQQ GDIRALLCEQ SDKAFYSSFM ALMSLMLQMR NSITGRDQVD FLISPVKNSD 1320
GIFYDSRNYE AQENAILPKN ADANGAYNIA RKVLWAIQGF KKAEBDEKLDK VKIAISNKEW 1380
LEAQTQSVKH 1390

```

```

SEQ ID NO: 225      moltype = AA length = 1337
FEATURE           Location/Qualifiers
source           1..1337
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 225
SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYSKLFKK 120
DIIETILPEF LDDKDEIALV NSFNGFTTAF TGFFDNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDIAFPKHE VQEIKEKILN SDYDVEDPFE GEPFNFVLTQ EGIDVYNAI I 240
GGFVTEGSEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGHKHC 300
QVCGIVIEVD VGPYSQGAHI RPLGRKHGGP DVESNMLCLC PNDHVRFDNG ALYITDDLKV 360
VNALNGEVIG PLRVHPRHVI DLDHIRYHRS QLPNIPLEGS SGYTSDEEVL EVFRNTLNKN 420
SEIFSSIKKL EKLKFNDEY SSAGIFVKNG PAISTISKDI FGEWNVIRDK WNAEYDDIHL 480
KKKAVVTEKY EDDRKKSFKK IGSFSLQQLQ EYADADLSVV EKLEKIIQK VDEIYKVGYS 540
SEKLPDADFV LEKSLKKNDA VVAIMKDLLD SVKSPENYIK APFGGEGKETN RDESFGYDFV 600
LAYDILLKVD HIYDAIRNYV TQKPYSKDKF KLYFQNPQFM GGWDKDKETD YRATILRYGS 660
KYLLAIMDKK YAKCLQKIDK DDVNGNYEKI NYKLLPGPNK MLPKVFFSKK WMAYYNPSED 720
IQKIYKNGTF KKGDMFNLDN CHKLIDFFPKD SISRYPKWSN AYDFNFSETE KYKDIAGFYR 780
EVVEQGYKVS FESASKKEVD KLVVEEGKLYM FQIYNKDFSD KSHGTPNLHT MYFKLLFDEN 840
NHGQIRLSGG AELDLNSVNI KKEELVVHPA NSPIANKNPD NPKKTTLSY DVYKDRFSE 900
DQYELHIPIA INKCPKNIFK INTEVRVLLK HDDNPYVIGI ARGERNLLYI VVDGKGNIV 960
BQYSLNETHN INFNGIRIKTD YHSLLDKKEK ERFPEARQNT SIENIKELKA GYISQVWHKI 1020
CELVVEKYDAV IALDELNSVNI KNSRVKVEKQ VYQKFEKMLI DKLNYMVDKK SNPCTATGGAL 1080
KGYQITNKFE SFKSMSTQNG FIFYPAWLT SKIDPSTGFV NLLKTKYTSI ADSKKFISSF 1140
DRIMYVPEED LFEPALDYKN FSRTDADYIK KWKLYSYGNR ITRFRNPKKN NVDFWEEVCL 1200
TSAYKELFNK YGINYQQGDI RALLCEQSDK AFYSSFMALM SLMLQMRNSI TGRDQVDFLI 1260
SPVKNSDGIF YDSRNYEAQE NAILPKNADA NGAYNIARKV LWAIGQPKKA EDEKLDKVKI 1320
AISNKEWLEY AQTSVKH 1337

```

```

SEQ ID NO: 226      moltype = AA length = 1393
FEATURE           Location/Qualifiers
source           1..1393
                 mol_type = protein
                 organism = synthetic construct

```

```

SEQUENCE: 226
SKLEKFTNCY SLSKTLRFKA IPVGKTQENI DNKRLLEVEDE KRAEDYKGVK KLLDRYYLSF 60
INDVLHSIKL KNLNNYISLF RKKTRTEKEN KELENLEINL RKEIAKAFKG NEGYSKLFKK 120
DIIETILPEF LDDKDEIALV NSFNGFTTAF TGFFDNRENM FSEEAKSTSI AFRGINENLT 180
RYISNMDIFE KVDIAFPKHE VQEIKEKILN SDYDVEDPFE GEPFNFVLTQ EGIDVYNAI I 240
GGFVTEGSEK IKGLNEYINL YNQKTKQKLP KFKPLYKQVL SDRESLSFYG EGSSGSEAE 300
VIFGPDATTE ITTTADAIIEC QISNDASIDE TEKHQLVKSQ RGQGI FRSRRL EQVESRCRV 360
GVQLKNHLIA SHIKPWAVSI NQRERLDGHNG LLLAPHVDHL FDKGFI SFDG NGEMIVSEKL 420
NLDVLKAWSI SQGNYGYFSK QQQEYMYCYHR ENVFKKLGYT SDBEVLEVFR NTLNKNSEIF 480
SSIKKLEKLF KNFDEYSSAG IFVKNGPAIS TISKDFGEW NVIRDKNWAE YDDIHLKKKA 540
VVTEKYEDDR RKSFKKIGSF SLEQLQEQYAD ADLSVVEKLEK EIIIQKVDEI YKVGYSSEKL 600
PDADFVLEKS LKKNDAVVAI MKDLLDSVKS FENYIKAFPG EGKETNRDES FYGDFVLAYD 660
ILLKVDHIYD AIRNRYVQKP YSKDKFKLYF QNPQFMGGWD KDKETDYRAT ILRYGSKYYL 720

```

-continued

AIMDKKYAKC	LQKIDKDDVN	GNYEKINYKL	LPGPKNMLPK	VFFSKKWMAY	YNPSEDIQKI	780
YKNGTFKKGD	MFNLNDCHKL	IDPFKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVEE	840
QGYKVSFESA	SKKEVDKLV	EGKLYMFQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	900
IRLSGGAELE	MRRASLKKEE	LVVHPANSPI	ANKNPDNPKK	TTTLSYDVYK	DKRFSEDOYE	960
LHIPIAINKC	PKNIFKINTE	VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	1020
LNEIINNPNQ	IRIKTDYHSL	LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVHKICELV	1080
EKYDAVIALE	DLNSGDFNSR	KVVEKQVYQK	FEKMLIDKLN	YMVDKKSNPC	ATGGALKGYQ	1140
ITNKFESFKS	MSTQNGFIFY	IPAWLTSKID	PSTGFVNLLK	TKYTSIADSK	KFISSFDRIM	1200
YVPEEDLFEF	ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNVWFV	WEEVCLTSAY	1260
KELFNKYGIN	YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	DVDFLISPVK	1320
NSDGFIFYDSR	NYEAQENAIL	PKNADANGAY	NIARKVLWAI	GQFKKAEDK	LDKVKIAISN	1380
KEWLEYAQT	VKH					1393

SEQ ID NO: 227           moltype = AA   length = 1356  
 FEATURE                Location/Qualifiers  
 source                   1..1356  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 227

SKLEKFTNCY	SLSKTLRFKA	IPVGKTQENI	DNKRLLVEDE	KRAEDYKGVK	KLLDRYYLSF	60
INDVLHSIKL	KNLNNYISLF	RKKTRTEKEN	KELENLEINL	RKEIAKAFKG	NEGYKSLFKK	120
DIETILPEF	LDDKDEIALV	NSFNGPTTAF	TGFFDNRENM	FSEAKSTSI	AFRCINENLT	180
RYISNMDIFE	KVDAIFDKHE	VQEIKEKILN	SDYDVEDFFE	GEFFNFVLTQ	EGIDVYNAI	240
GGFVTESEK	IKGLNEYINL	YNQKTKQKLP	KFKPLYKQVL	SDRESLSFYG	EGSSGDEPGV	300
ATNGQPVTG	NWLAGASQGD	GVPIPSQIAD	QLRGKEFKSW	RDFREQFWVA	VANDPELVKY	360
FRKTNAGGMR	DGLSPPTPKA	EQAGGRDKYE	IHHVVQISQG	GAVYDIDNLR	VMTPKMHIQV	420
GYTSDVEEVL	VFRNTLNKNS	EIPSSIKKLE	KLFPNFDEYS	SAGIFVKNPG	AISTISKDIF	480
GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	DRRKSFKKI	GSFLEQLQE	YADADLSVVE	540
KLKEIIQKVD	DEIYKVGSS	EKLFDADFVL	EKSLKKNDAV	VAIMKDLDS	VKSFENYIKA	600
PFGEKGTNR	DESYGDFVL	AYDILLKVDH	IYDAIRNVVT	QKPYSKDKFK	LYFQNPQFMG	660
GWDDKEDTDY	RATILRYGSK	YLAIMDKKY	AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	720
LPKVFFSKKW	MAYNPSEDI	QKIYKNGTFK	KGDMFNLNDC	HKLIDFFKDS	ISRYPKWSNA	780
YDFNFSETEK	YKLAGYFRE	VEBQGYKVSF	ESASKEVVDK	LVEEGKLYMF	QIYNKDFSDK	840
SHGTPNLHTM	YFKLLFDENN	HGQIRLSGGA	ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	900
PKKTTTLYSD	VYKDKRSEDE	QYELHIPIAI	NKCPKNIPKI	NTEVRVLLKH	DDNPYVIGIA	960
RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	PNGIRIKTDY	HSLDDKKEKE	RPEARQNWTS	1020
IENIKELKAG	YISQVVKHIC	ELVEKYDAVI	ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	1080
KLNYMVDKKS	NPCATGGALK	GYQITNKFES	FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	1140
LLKTKYTSIA	DSKFISSFD	RIMYVPEEDL	FEFALDYKNF	SRTDADYIKK	WKLYSYGNRI	1200
RIFRNPKNKN	VDFWEEVCLT	SAYKELFNKY	GINYQQGDIR	ALLCEQSDKA	FYSFMALMS	1260
LMLQMRNSIT	GRTDVDFLIS	PVKNSDGFIFY	DSRNYEAQEN	AILPKNADAN	GAYNIARKVL	1320
WAIGQFKKAE	DEKLDKVKIA	ISNKWLEYA	QTSVKH			1356

SEQ ID NO: 228           moltype = AA   length = 1395  
 FEATURE                Location/Qualifiers  
 source                   1..1395  
                           mol\_type = protein  
                           organism = synthetic   construct

SEQUENCE: 228

MSKLEKFTNC	YLSKTLRFKA	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	KNLNNYISLF	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGTTAF	FTGFFDNREN	MFSSEAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEPPNFVLT	QEGIDVYNAI	240
IGGFVTESEK	SSGSPENIFK	DKNNRIKFA	KGISAYSGAN	LTDGDFDGAK	EELDHIIPRS	300
HKKYGTLDNE	ANLICVTRGD	NKKNKGNRIFC	LRDLADNYKL	KQFETTDLE	IEKKIADTIW	360
DANKKDFKFG	NYRSFINLTP	QEQKAPRHAL	FLADENPIKQ	AVIRAINNRN	RTGSSGEKIK	420
GLNEYINLYN	QKTKQKLPKF	KPLYKQVLS	RESLSFYGEG	YTSDEEVLEV	FRNTLNKNS	480
IFSSIKKLEK	LFKNFDEYSS	AGIFVKNNGA	ISTISKDIFG	EWNVIRDKWN	AEYDDIHLKK	540
KAVVTEKYED	DRRKSFKKIG	SFSLEQLQEY	ADADLSVVEK	LKEIIQKVD	EIYKVGSSSE	600
KLFDADFVLE	KSLKKNDAV	AIMKDLDSV	KSFENYIKAF	PFGEKGTNRD	ESFYGDFVLA	660
YDILLKVDHI	YDAIRNVVTQ	KPYSKDKFKL	YFQNPQFMGG	WDDKEDTDYR	ATILRYGSKY	720
YLAIMDKKYA	KCLQKIDKDD	VNGNYEKINY	KLLPGPNKML	PKVFFSKKWM	AYNPSEDIQ	780
KIYKNGTFPK	GDMFNLNDCH	KLIDPFKDSI	SRYPKWSNAY	DFNFSETEKY	KDIAGFYREV	840
EEQGYKVSFE	SASKEVVDK	VEBKLYMPQ	IYNKDFSDKS	HGTPNLHTMY	FKLLFDENN	900
GQIRLSGGAE	LFMRRASLKK	EELVVHPANS	PIANKNPDNP	KKTTTLYSDV	YKDKRSEDO	960
YELHIPIAIN	KCPKNIPKIN	TEVRVLLKHD	DNPYVIGIAR	GERNLLYIVV	VDGKGNIVEQ	1020
YSLNEIINN	NGIRIKTDYH	SLDDKKEKER	FEARQNWTSI	ENIKELKAGY	ISQVVKHICE	1080
LVEKYDAVIA	LEDLNSGFKN	SRVKVEKQVY	QKFEKMLIDK	LNVMVDKKS	PCATGGALKG	1140
YQITNKFESF	KSMSTQNGFI	FYIPAWLTSK	IDPSTGFVNL	LKTKYTSIAD	SKKFISSFDR	1200
IMYVPEEDLF	EFALDYKNFS	RTDADYIKKW	KLYSYGNRIR	IFRNPKNKNV	FDWEEVCLTS	1260
AYKELFNKYG	INYQQGDIRA	LLCEQSDKAF	YSSFMALMSL	MLQMRNSITG	RTDVDFLISP	1320
VKNSDGFIFYD	SRNYEAQENA	ILPKNADANG	AYNIARKVLW	AIGQFKKAED	EKLDKVKIAI	1380
SNKWELEYAQ	TSVKH					1395

SEQ ID NO: 229           moltype = AA   length = 1361  
 FEATURE                Location/Qualifiers

-continued

```

source          1..1361
                mol_type = protein
                organism = synthetic construct

SEQUENCE: 229
MSKLEKFTNC    YLSKTLRPFK AIPVGKTQEN IDNKRLLEDV EKRAEDYKGV KLLDRYYS 60
FINDVLHSIK    LKNLNNYISL FRKTRTEKE  NKELENLEIN LRKEIAKAFK GNEGYSKSLFK 120
KDIIETILPE    FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEAKSTS IAFRCINENL 180
TRYISNMDIF    EKVDAlFDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESGG    SSGDEPGVAT GNGQPVTGNW LAGASQGDGV PIPSQIADQL RGKEFKSWRD 300
FREQFWVAVA    NDPELVKYFR KTNAGMRDGG LSPFTPKAEQ AGGRDKYEH HVVQISQGGA 360
VYDIDNLRVM    TPKMHQVGS  SGEKIKGLNE YINLYNQKTK QKLPKFKPLY KQVLSDRSL 420
SFYGEYTS    EEVLEVRPNT LNKNSEIFSS IKKLEKLPKN FDEYSSAGIF VKNGPAISTI 480
SKDIFGEWNV    IRDKWNAEYD DIHLKKKAVV TEKYEDDRRK SFKKIGSFSL EQLQEYADAD 540
LSVVEKLEKEI  IIQKVDEIYK VYGSSEKLPD ADFVLEKSLK KNDAVVAIMK DLLDSVKSFE 600
NYIKAFPEGEG  KETNRDESFY GDFVLAIDIL LKVDHIYDAI RNYVTQKPY S KDFKLYFQN 660
PQFMGGWGD    KETDYPATIL RYGSKYLLAI MDKKYAKCLQ KIDKDDVNGN YEKINYKLLP 720
GPNKMLPKVF   FSKKWMAYYN PSEDIQKIYK NGTFKKGDMF NLNDCHKLID FFKDSISRYP 780
KWSNAYDFNF   SETEKYKIDIA GFYREVVEEQ YKVSFESASK KEVDKLVVEG KLYMFQIYNK 840
DFSDKSHGTP   NLHTMYFKLL FDENNHGQIR LSGGAELFMR RASLKKELV VHPANSPIAN 900
KNPDNPKKT    TLSYDVYKDK RFSEDQYELH IPIAINKCPK NIFKINTEVR VLLKHDDNPY 960
VIGIARGERN   LLYIVVVDGK GNIVEQYSLN EIINNFNGIR IKTDYHSLLD KKEKERFEAR 1020
QNWTSIENIK   ELKAGYISQV VHKICELVEK YDAVIALDEL NSGPKNSRVK VEKQVYQKFE 1080
KMLIDKLNVM   VDKKSNPCAT GGALKGYQIT NKFESFKSMS TQNGFIFYIP AWLTSKIDPS 1140
TGFVNLKTK    YTSIADSKKF ISSFDRIMYV PEEDLPEFAL DYKNFSRTDA DYIKKWKLYS 1200
YGNRIRIFRN   PKKNNVDFWE EVCLTSAYKE LFNKYGINYQ QGDIRALLCE QSDKAFYSSF 1260
MALMSLMLQM   RNSITGRTDV DFLISPVKNS DGIFYDSRNY EAQENAILPK NADANGAYNI 1320
ARKVLWAIGQ   FKKADEKELD KVKIAISNKE WLEYAQTSVK H 1361

```

```

SEQ ID NO: 230      moltype = AA length = 1342
FEATURE            Location/Qualifiers
source             1..1342
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 230
MSKLEKFTNC    YLSKTLRPFK AIPVGKTQEN IDNKRLLEDV EKRAEDYKGV KLLDRYYS 60
FINDVLHSIK    LKNLNNYISL FRKTRTEKE  NKELENLEIN LRKEIAKAFK GNEGYSKSLFK 120
KDIIETILPE    FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEAKSTS IAFRCINENL 180
TRYISNMDIF    EKVDAlFDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESGG    SSGHKHRCQV CGIVIEVDVG PYSQGAHIRP LGRKHGGPDV ESNMLCLCPN 300
DHVRFDNGAL   YITDDLKVVN ALNGEVIGPL RVHPRHVIDL DHIRYHRSQ L PNIPLGSSG 360
SSGEKIKGLN   EYINLYNQKT KQKLPKFKPL YKQVLSDRSL SFYGEYTS DEEVLEVFRN 420
TLNKNSEIFS   SIKKLEKLPK NPDEYSSAGI FVKNGPAIST ISKDIPEWNV VIRDKWNAEY 480
DDIHLKKKAV   VTEKYEDDRR KSFKKIGSFS LEQLQEYADA DLSVVEKLEK I I I QKVEIY 540
KVYGSSEKLF   DADFVLEKSL KKNDAVVAIM KDLLDSVKSF ENYIKAFGE GKETNRDES 600
YGDFVLAIDI   LLKVDHIYDA IRNYVTQKPY SKDKFKLYFQ NPQFMGGWGD DKETDYPATI 660
LRYGSKYYLA   IMDKKYAKCL QKIDKDDVNG NYEKINYKLL PGPNKMLPKV FFSKWMAYY 720
NPSEDIQKIY   KNGTFKKGDM FNLNDCHKLI DFFKDSISRY PKWSNAYDFN FSETEKYKDI 780
AGFYREVVEEQ  GYKVSFESAS KKEVDKLVVEE GKLYMFQIYN KDFSDKSHGT PNLHTMYFKL 840
LFDENNHGQI   RASLKKELV  VHPANSPIA  NKNPDNPKKT TTSYDVYKD 900
KRFSQYEL     HIPIAINKCP KNIFKINTEV RVLLKHDDNP YVIGIARGER NLLYIVVVDG 960
KGNIVEQYSL   NEIINNNGFI RIKTDYHSLD DKEKERFEA RQNWTSIENI KELKAGYISQ 1020
VVKICELVE   YKDAVIALDE LNSGFKNRSV KVEKQVYQKF EKMLIDKLN Y MVDKSNPCA 1080
TGGALKGYQI   TNKFESFKSM STQNGFIFYI PAWLTSKIDP STGFVNLKKT KYTSIADSKK 1140
FISSFDRIMY   VPEEDLPEFA LDYKNFSRTD ADYIKKWKLY SYGNRIRIFR NPKNNVDFW 1200
EEVCLTSAYK   ELFNKYGINY QGDIRALLC EQSDKAFYSS FMALMSLMLQ MRNSITGRTD 1260
VDFLISPVKN   SDGIFYDSRN YEAQENAILP KNADANGAYN IARKVLWAIG QFKKADEKEL 1320
DKVKIAISNK   EWLEYAQTSV KH 1342

```

```

SEQ ID NO: 231      moltype = AA length = 1398
FEATURE            Location/Qualifiers
source             1..1398
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 231
MSKLEKFTNC    YLSKTLRPFK AIPVGKTQEN IDNKRLLEDV EKRAEDYKGV KLLDRYYS 60
FINDVLHSIK    LKNLNNYISL FRKTRTEKE  NKELENLEIN LRKEIAKAFK GNEGYSKSLFK 120
KDIIETILPE    FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEAKSTS IAFRCINENL 180
TRYISNMDIF    EKVDAlFDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESGG    SSGSEAEVI  FGFADTTEIT TTADAIECQI SNDASIDETE KHQLVKSRRG 300
QGIFRSRLEQ   VESRCRVTVG QLNHLIAASH IKPVAWSNNQ ERLDGHNGLL LAPHVDHLFD 360
KGFISFEDNG   EMIVSEKLN  DVLKAWISIQ  GNYGYFSKQQ QEYMCYHREN VFKLGSSE 420
KIKGLNEYIN   LYNQKTKQKL PKFKPLYKQV LSDRESLSFY GEGYTSDEEV LEVFRNTLNK 480
NSEIFSSIKK   LEKLFKNFDE YSSAGIFVK  GPAISTISK  IFGEWNVIRD KWNAEYDDIH 540
LKKKAVVTEK   YEDDRKSPK  KIGSFSLEQL QEYADADLSV VEKLEKIIQ KVDEIYKVVY 600
SSEKLFADADF  VLEKSLKND  AVVAIMKDLL DSVKSFENYI KAPFGEKET NRDESFYGDF 660
VLAYDILKLV   DHIYDAIRNY VTQKPYSKDK FPLYFQNPQF MGGWDKDKET DYRATILRYG 720

```

-continued

SKYYLAIMDK	KYAKCLOKID	KDDVNGNYEK	INYKLLPGPN	KMLPKVFFSK	KWMAYYNPSE	780
DIQKIYKNGT	FKKGDMFNLN	DCHKLIDFFK	DSISRYPKWS	NAYDFNFSET	EKYKDIAGFY	840
REVEEQGYKV	SFESASKKEV	DKLVEEGKLY	MFQIYNKDFS	DKSHGTPNLH	TMYPKLLFDE	900
NNHGQIRLSG	GAEFLMRRAS	LKKEELVVHP	ANSPIANKNP	DNPKKTTLTS	YDVYKDKRFS	960
EDQYELHPI	AINKCPKNIF	KINTEVRVLL	KHDDNPYVIG	IARGERNLLY	IVVVDGKGNL	1020
VEQYSLNEII	NNFNIGIRIKT	DYHSLLDKKE	KERFEARQNW	TSIENIKELK	AGYISQVVHK	1080
ICELVEKYDA	VIALEDLNSG	FKNSRVKVEK	QVYQKFEKML	IDKLNVMVDK	KSNPCATGGA	1140
LKGYQITNKF	ESFKSMSTQN	GPIFYIPAWL	TSKIDPSTGF	VNLLKTKYTS	IADSKKFISS	1200
PDRIMYVPEE	DLFEFALDYK	NFSRTDADYI	KKWKLYSYGN	RIRIFRNPKK	NNVFDWEEVC	1260
LTSAYKELFN	KYGINVQQGD	IRALLCEQSD	KAFYSSFMAL	MSLMLQMRNS	ITGRTDVDFL	1320
ISPVKNSDGI	FYDSRNYEAQ	ENAILPKNAD	ANGAYNIARK	VLWAIGQFPK	AEDEKLDKVK	1380
IAISNKEWLE	YAQTSVKH					1398

SEQ ID NO: 232                   moltype = AA   length = 1352  
 FEATURE                        Location/Qualifiers  
 source                         1..1352  
                                mol\_type = protein  
                                organism = synthetic   construct

SEQUENCE: 232

MSKLEKFTNC	YLSKTLRPF	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYVLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSEEAQSTS	IAFRCINENL	180
TRYISNMDIF	EKVDAlFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEPPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGFNFVGE	PKSKDILKLR	LYEQQHKGKCL	YSGKEINLGR	LNEKGYVEID	300
HALPFSRFTW	DSFNKFLVLI	GSENGKGNQ	TPYEYFNGKD	NSREWFQEFKA	RVETSRRFPRS	360
KKQRILLQKG	SSGEKIKGLN	EYINLYNQKT	KQKLPKFKPL	YKQVLSDRS	LSFYGEGYTS	420
DEEVLEVPFN	TLNKNSEIFS	SIKKLEKLPK	NFDEYSSAGI	FKVNGPAIST	ISKDIPGEWN	480
VIRDKWNAEY	DDIHLKKAIV	VTEKYEDDRR	KSFKKIGSFS	LEQLQEQYADA	DLSSVVEKLE	540
IIIQKVDEIY	KVYGSSEKLF	DADFVLEKSL	KNDAVVAIM	KDLLDSVKSF	ENYIKAPFGE	600
GKETNRDESF	YGFVFLAYDI	LLKVDHIYDA	IRNYVTQKPY	SKDKFKLYFO	NPQFMGGWDK	660
DKETDYRATI	LRYSKYLLA	IMDKKYAKCL	QKIDKDDVNG	NYEKINYLKL	PGPNKMLPKV	720
FFSKKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	DFFKDSISRY	PKWSNAYDPN	780
FSETEKYKDI	AGFYREVEEQ	GYKVSFESAS	KKEVDKLVVE	GKLYMFOIYN	KDFSDKSHGT	840
NLHFTMYPKL	LFDENNHGDI	RLSGGAELFM	RRASLKKEEL	VVHPANSPIA	NKNPDNPKKT	900
TTLSDYVYKD	KRFSEDOYEL	HIPIAINKCP	KNIFKINTEV	RVLLKHDDNP	YVIGIARGER	960
NLLYIVVVDG	KGNIVEQYSL	NEIINNFNFI	RIKTDYHSL	DKKEKERFEA	RQNWTSIENI	1020
KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNSRV	KVEKQVYQKF	EKMLIDKLN	1080
MVDKKSNPCA	TGGALKGYQI	TNKFESFKSM	STQNGFIFYI	PAWLTSKIDP	STGFVNLLKT	1140
KYTSIADSKK	FISFSDRIMY	VPEDLFEFPA	LDYKNFSRTD	ADYIKWKWLY	SYGNRIRIFR	1200
NPKKNVDFDW	EIVCLTSAYM	ELFNKYGINY	QQGDIRALLC	EQSDKAFYSS	FMALMSLMQ	1260
MRNSITGRTD	VDFLISPVKN	SDGIFYDSRN	YEAQENAILP	KNADANGAYN	IARKVLWAIG	1320
QFKKAEDEKL	DKVKIAISNK	EWLEYAQTSTV	KH			1352

SEQ ID NO: 233                   moltype = AA   length = 1386  
 FEATURE                        Location/Qualifiers  
 source                         1..1386  
                                mol\_type = protein  
                                organism = synthetic   construct

SEQUENCE: 233

MSKLEKFTNC	YLSKTLRPF	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYVLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSEEAQSTS	IAFRCINENL	180
TRYISNMDIF	EKVDAlFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEPPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGENQYTNQ	GKSNSQORLK	RLEKSLKELG	SKILKENIPA	KLSKIDNNAL	300
QNDRLYLTYL	QNGKDMYTG	DLDIDRLSNY	DIDHIIPQAF	LKDNSIDNKV	LVSASNRGK	360
SDDFPSLEV	KKRKTFWYQL	LKSKLISQRK	FDNLTKAERG	GLLGSSGEKI	KGLNEYINLY	420
NQKTKQKLPK	FKPLYKQVLS	DRESLSFYGE	GYTSDEEVLE	VPRNTLNKNS	EIPFSSIKKLE	480
KLFKNFDEYS	SAGIFVKNP	ALSTISKDIF	GEWNVIRDKW	NAEYDIIHLK	KKAVVTEKYE	540
DDRRKSFKKI	GFSFLEQLQE	YADADLSVVE	KLKEIIIQKV	DEIYKVGSS	EKLFDADFVL	600
EKSLKKNDAV	VAIMKDLLDS	VKSPENYIKA	PFGEGETNR	DESPYGFVFL	AYDILLKVDH	660
IYDAIRNYVT	KQPYSKDKFK	LYFQNPQFMG	GWDKDKETDY	RATILRYGSK	YLAIMDKKY	720
AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	QKIYKNGTFK	780
KGDMFNLNDC	HKLIDFPKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGFYRE	VEEQGYKVSF	840
ESASKKEVDK	LVEEGKLYPM	QIYNKDFSDK	SHGTPNLHMT	YFKLLFDENN	HGQIRLSGGA	900
ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	PKKTTLSYD	VYKDKRFS	QYELHPIPIAI	960
NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	1020
FNGIRIKTDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	YISQVVKHIC	ELVEKYDAVI	1080
ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	GYQITNKFES	1140
FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	LLKTKYTSIA	DSKKFISSFD	RIMYVPEEDL	1200
FEFALDYKNF	SRTDADYIKK	WKLYSYGNRI	RIFRNPKKNN	VFDWEEVCLT	SAYKELFNKY	1260
GINYQQGDIR	ALLCEQSDIR	FYSFMMALMS	LMLQMRNSIT	GRTDVDFLIS	PVKNSDIFYI	1320
DSRNYEAQEN	AAILPKNADAN	GAYNIARKVL	WAIGQFKKAE	DEKLDKVKIA	ISNKEWLEYA	1380
QTSVKH						1386

SEQ ID NO: 234                   moltype = AA   length = 1340  
 FEATURE                        Location/Qualifiers

-continued

```

source                1..1340
                      mol_type = protein
                      organism = synthetic construct

SEQUENCE: 234
MSKLEKFTNC  YLSKTLRPFK  AIPVGKTQEN  IDNKRLLED  EKRAEDYKGV  KLLDRYYLS  60
FINDVLHSIK  LKNLNNYISL  FRKTRTEKE  NKELENLEIN  LRKEIAKAFK  GNEGYSKLPK  120
KDIIETILPE  FLDDKDEIAL  VNSFNGFTTA  FTGFFDNREN  MFSEAKSTS  IAFRCINENL  180
TRYISNMDIF  EKVDAIFDKH  EVQEIKEKIL  NSDYDVEDFF  EGEFFNFVLT  QEGIDVYNAI  240
IGGFVTESGG  SSGDGNHTV  NPSKLVSHRL  GDGLTVQQID  RACTPALWCA  LTREKDFDEK  300
NGLPAREDRA  IRVHGHEIKS  SDYIQVFSKR  KKTDSDRDET  PFGAIAVRGG  FVEIGPSGSS  360
GEKIKGLNEY  INLYNQTKQ  KLPKFKPLYK  QVLSDRSLS  FYGEGYTSDE  EVLEVPFRNTL  420
NKNSEIFSSI  KKLEKLFKNF  DEYSSAGIFV  KNGPAISTIS  KDIFGEWNI  RDKWNAEYDD  480
IHLKKKAVVT  EKYEDDRRKS  FKKIGSFSLE  QLQYADADL  SVVEKLEKII  IQKVDEIYKV  540
YGSSEKLFDA  DFVLEKSLKK  NDAVVAIMKD  LLDSVKSPEN  YIKAFFGEGK  ETNRDESFGY  600
DFVLAYDILL  KVDHIYDAIR  NYVTQKPYSK  DKFKLYFQNP  QFMGGWDKDK  ETDYRATILR  660
YGSKYLAIM  DKKYAKLQK  IDKDDVNGNY  EKINYKLLPG  PNKMLPKVFF  SKKMMAYYNP  720
SEDIQKIYKN  GTFPKGDMFN  LNDCHKLIDF  FKDSISRYPK  WSNAYDFNFS  ETEKYKDIAG  780
FYREVEEQGY  KVSFESASKK  EVDKLVVEEG  LYMFQIYNKD  FSDKSHGTPN  LHTMYFKLLF  840
DENNHGQIRL  SGAELFMRR  ASLKEELVV  HPANSPIANK  NPDNPKTTT  LSYDVKDKR  900
FSEDQYELHI  PIANKCPKN  IPKINTEVRV  LLKHDDNPYV  IGIARGERNL  LYIVVVDGKG  960
NIVEQYSLNE  IINNFNGIR  KTDYHSLDDK  KEKERFEARQ  NWTSENIKE  LKAGYSQVV  1020
HKICELVKEV  DAVIALDELN  SGFKNSRVK  EKQVYQKPEK  MLIDKLNVMV  DKSNSPCATG  1080
GALKGYQITN  KPFESFKSM  QNGFIFYIPA  WLTSKIDPST  GFVNLKTKY  TSIADSKKFI  1140
SSFDRIMYVP  EEDLFEFALD  YKNFSRTDAD  YIKKWKLYSY  GNRIRIFRNP  KKNVFPDWE  1200
VCLTSAYKEL  FNKYGINYQQ  GDIRALLCEQ  SDKAFYSSFM  ALMSLMLQMR  NSITGRDVED  1260
FLISPVKNSD  GIFYDSRNYE  AQENAILPKN  ADANGAYNIA  RKVLWAIQGF  KKAEDKLDK  1320
VKIAISNKEW  LEYAQTSVKH

```

```

SEQ ID NO: 235      moltype = AA length = 1387
FEATURE            Location/Qualifiers
source             1..1387
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 235
MSKLEKFTNC  YLSKTLRPFK  AIPVGKTQEN  IDNKRLLED  EKRAEDYKGV  KLLDRYYLS  60
FINDVLHSIK  LKNLNNYISL  FRKTRTEKE  NKELENLEIN  LRKEIAKAFK  GNEGYSKLPK  120
KDIIETILPE  FLDDKDEIAL  VNSFNGFTTA  FTGFFDNREN  MFSEAKSTS  IAFRCINENL  180
TRYISNMDIF  EKVDAIFDKH  EVQEIKEKIL  NSDYDVEDFF  EGEFFNFVLT  QEGIDVYNAI  240
IGGFVTESGG  SSGEKNKSDA  KMINEMQKR  NRQTNRIEIE  IIRTTGKENA  KYLIEKIKLH  300
DMQEGKCLYS  LEAIPLEDLL  NNPNFYEVHD  IIPRSVSPDN  SFNNKVLVKQ  EENSKKGNRT  360
PFQYLSSSDS  KISYETPKKH  ILLAKGKGR  ISKTKKEYLL  EERDSSGEEK  IKGLNEYINL  420
YNQTKQKQLP  KFKPLYQVLF  SDRSLSFYG  EGYTSDEEVL  EVFRNTLNKN  SEIFSSIKKL  480
EKLFPNFDEY  SSGAIFVKNG  PAISTISKDI  FGEWNVIRDK  WNAEYDDIHL  KKKAVVTEKY  540
EDDRKSPFK  IGSFSLQQL  EYADADLSV  EKLKEIIQK  VDEIYKVYGS  SEKLPDADFV  600
LEKSLKKNDA  VVAIMKDLLD  SVKSPENYIK  AFFGEGKETN  RDESFGYDFV  LAYDILLKVD  660
HIYDAIRNYV  TQKPYSDKF  KLYFQNPQFM  GGWDKDKETD  YRATILRYGS  KYLAIMDKK  720
YAKCLQKIDK  DDVNGNYEKI  NYKLLPGPNK  MLPKVFFSKK  WMAYYNPSED  IQKIYKNGTF  780
KKGDMFNLND  CHKLIDFPKD  SISRYPKWSN  AYDFNFSETE  KYKDIAGFYR  EVEEQGYKVS  840
FESASKKEVD  KLVEEGKLYM  FQIYNKDFSD  KSHGTPNLHT  MYFKLLFDEN  NHGQIRLSGG  900
AELFMRRASL  KKEELVHVA  NSPIANKNPD  NPKTTTSLY  DVYKDKRFSE  DQYELHIPIA  960
INKCPKNIFK  INTFVRVLLK  HDDNPVYIGI  ARGERNLLYI  VVVDGKGNIV  EQYSLNEIIN  1020
NFGIRIKTD  YHSLLDYKKE  ERPEARQNW  SIENIKELKA  GYISQVHVKI  CELVEKYDAV  1080
IALEDLNSGF  KNSRVKVEKQ  VYQKFEKMLI  DKLNYMVDK  SNPCATGGAL  KGYQITNKFE  1140
SFKSMSTQNG  FIFYIPAWLT  SKIDPSTGFP  NLLKTKYTSI  ADSKKFISSF  DRIMYVPEED  1200
LFEFALDYKN  FSRTDADYIK  KWKLYSYGNR  IRIFRNPKKN  NVFDWEEVCL  TSAYKELFNK  1260
YGINYQQGDI  RALLCEQSDK  AFYSSPMALM  SMLLQMRNSI  TGRDVEDFLI  SPVKNSDGIF  1320
YDSRNYEAQE  NAILPKNADA  NGAYNIARKV  LWAIGQFKKA  EDEKLDKVKI  AISNKEWLEY  1380
AQTSVKH

```

```

SEQ ID NO: 236      moltype = AA length = 1485
FEATURE            Location/Qualifiers
source             1..1485
                  mol_type = protein
                  organism = synthetic construct

```

```

SEQUENCE: 236
MSKLEKFTNC  YLSKTLRPFK  AIPVGKTQEN  IDNKRLLED  EKRAEDYKGV  KLLDRYYLS  60
FINDVLHSIK  LKNLNNYISL  FRKTRTEKE  NKELENLEIN  LRKEIAKAFK  GNEGYSKLPK  120
KDIIETILPE  FLDDKDEIAL  VNSFNGFTTA  FTGFFDNREN  MFSEAKSTS  IAFRCINENL  180
TRYISNMDIF  EKVDAIFDKH  EVQEIKEKIL  NSDYDVEDFF  EGEFFNFVLT  QEGIDVYNAI  240
IGGFVTESGG  SSGADLPALP  GGPAGGTGEL  AKYGLPGVAQ  LRSRESYVLS  YDPRTRGALW  300
VLEQLRPERL  RGDGDRSACD  FREDDSVHAY  HRATNADYRG  SGFDRGHLLA  AANHRWSQRA  360
MDDTFYLSNV  APQVPHLNQN  AWNNLERYSR  SLTRTYQNVY  VCTGPLFLPR  TEADGKSYVK  420
YQVIGKNHVA  VPTHFFKVL  LEAAGGQIEL  RSYVMPNAPV  DETIPLERFL  VPIESIERAS  480
GLLFPVNI  LARAGLKAITA  GSGSSGEEKIK  GLNEYINLYN  QKTKQKLPKF  KPLYKQVLS  540
RESLSFYEGE  YTSDEEVLEV  FRNTLNKNS  E  IFSSIKLEK  LFKNFDEYSS  AGIFVKN  600
ISTISKDIFG  EWNVIRDKWN  AEYDDIHLKK  KAVVTEKYED  DRRKSPK  SFSLEQLQ  660

```



-continued

```
ADADLSVVEK LKEIIQKVD EYKVGYSSE KLFDAFVLE KSLKKNDAV AIMKDLLDSV 720
KSPFENYKAF FGEKGKTRND ESFYGDFVLA YDILLKVDHI YDAIRNYVTQ KPYSKDKFKL 780
YFQNPQPMGG WDKDKETDYR ATILRYGSKY YLAIMDKKYA KCLQKIDKDD VNGNYEKINY 840
KLLPGPNKML PKVFFSKWM AYYNPSEDIQ KIYKNGTFKK GDMFNLNDCH KLIDFFKDSI 900
SRYPKWSNAY DFNPFSETEKY KDIAGFYREV EEQGYKVSFE SASKKEVDKL VEEGKLYMPQ 960
IYNKDFSDKS HGTPNLHTMY FKLKPFENNH GQIRLSGGAE LFMRRASLKK EELVVPHPANS 1020
PIANKNPDPN KKTITLSYDV YKDKRFSQED YELHIPIAIN KCPKNIFKIN TEVRVLKHD 1080
DNPYVIGIAR GERNLLYIVV VDGKGNIVEQ YSLNEIINNF NGIRIKTDYH SLLDKKEKER 1140
FEARQNWTSI ENIKELKAGY ISQVHVHICE LVEKYDAVIA LEDLNSGFKN SRVKVEKQVY 1200
QKFEKMLIDK LNYMVDKKS PCATGGALKG YQITNKFESF KSMSTQNGFI FYIPAWLTSK 1260
IDPSTGFVNL LKTKYTSIAD SKKFISSFDR IMYVPEEDLF EFALDYKNFS RTDADYIKKW 1320
KLYSYGNRIR IFRNPKNNV FDWEEVCLTS AYKELFNKYG INYQQGDIRA LLCEQSDKAF 1380
YSSFMALMSL MLQMRNSITG RTDVFLLISP VKNSDGIFYD SRNYEAQENA ILPKNADANG 1440
AYNIARKVLW AIGQFKKAED EKLDKVKIAI SNKEWLEYAQ TSVKH 1485
```

```
SEQ ID NO: 237 moltype = AA length = 1443
FEATURE Location/Qualifiers
source 1..1443
mol_type = protein
organism = synthetic construct
```

```
SEQUENCE: 237
MSKLEKFTNC YLSKTLRFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKKTRETEKE NKELENLEIN LRKEIAKAFK GNEGYKSLFK 120
KDIIETILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEBAKSTS IAFRCINENL 180
TRYISNMDF EKVDALPDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESSG SSGSFSHAKN EAVKIYRDHP VSFYCGCEIR WQGGKGIPLD ESCGYQVRKN 300
ENRASRIEWE HVDPAWQFGH QLQCWQQGGR KNCTRTSPEF NQMEADLHNL TPAIGEVNGD 360
RSNFSFSQWN GVDGVTYQOC EMQVNFKERT AMPPERARGA IARTYLYMSE QYGLRLSKAQ 420
SQLMQAWNNQ YPVSEWECVR DQRIEKVQGN SNRFVREQCP GSSGEKIKGL NEYINLYNQK 480
TKQKLPKFKP LYKQVLSRE SLSFYGEGYT SDEEVLEVFR NTLNKNSEIF SSIKLEKLF 540
KNFDEYSSAG IFVKNKPAIS TISKDIFGEW NVIRDKNWAE YDDIHLKKA VVTEKYEDDR 600
RKSFKKIGSF SLEQLQEYAD ADLSVVEKLE EIIIQKVDI YKVGYSSEKL FDADFVLEKS 660
LKNDAVVAI MKDLLDSVKS FENYIKAPFG EGKETNRDES FYGDFVLAYD ILLKVDHIYD 720
AIRNYVTQPK YSKDKPKLYF QNPQFMGGWD KDKETDYRAT ILRYGSKYYL AIMDKKYAKC 780
LQKIDKDDVN GNYEKINYKL LPPGNKMLPK VFFSKKWMAY YNPSEDIQKI YKNGTFKKGD 840
MFNLNDCHKL IDFPKDSISR YPKWSNAYDF NPFSETEKYD IAGFYREVEE QGYKVSFESA 900
SKKEVDKLVE EGKLYMPQIY NKDFSDKSHG TPNLHTMYFK LFPDENNHGQ IRLSGGAELE 960
MRRASLKKEE LVVHPANSPI ANKNPDNPKK TTTLSYDVYK DKRFSQEDYE LHIPIAINKC 1020
PKNIFKINTE VRVLLKHDDN PYVIGIARGE RNLLYIVVVD GKGNIVEQYS LNEIINNPNF 1080
IRIKTDYHSL LDKKEKERFE ARQNWTSIEN IKELKAGYIS QVVHICELV EKYDAVIALE 1140
DLNSGFKNRSR VKVEKQVYQK FEKMLIDKLN YMVDKKS NPC ATGGALKGYQ ITNKFESPKS 1200
MSTQNGFIFY IPAWLTSKID PSTGFVNLLK TKYTSIADSK KFISSFDRIM YVPEEDLFEF 1260
ALDYKNFSRT DADYIKKWL YSYGNRIRIF RNPKNNVDF WEEVCLTSAY KELFNKYGIN 1320
YQQGDIRALL CEQSDKAFYS SFMALMSLML QMRNSITGRT DVDFLISPVK NSDGFYDSR 1380
NYEAQENAIL PKNADANGAY NIARKVLWAI GQFKKAEDK LDKVKIAISN KEWLEYAQT 1440
VKH 1443
```

```
SEQ ID NO: 238 moltype = AA length = 1333
FEATURE Location/Qualifiers
source 1..1333
mol_type = protein
organism = synthetic construct
```

```
SEQUENCE: 238
MSKLEKFTNC YLSKTLRFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKKTRETEKE NKELENLEIN LRKEIAKAFK GNEGYKSLFK 120
KDIIETILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEBAKSTS IAFRCINENL 180
TRYISNMDF EKVDALPDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESSG SSGMLLTGKL YKKEKQKQFYD AQNGKCLICQ RELNPDVQAN HLDHDLHLNG 300
PKAGKVRGLL CNLCNAABEQ MKHKFNRSGL KGQGVLDYLEW LENLLTYLKS GSSGEKIKGL 360
NEYINLYNQK TKQKLPKFKP LYKQVLSRE SLSFYGEGYT SDEEVLEVFR NTLNKNSEIF 420
SSIKLEKLF KNFDEYSSAG IFVKNKPAIS TISKDIFGEW NVIRDKNWAE YDDIHLKKA 480
VVTEKYEDDR RKSFKKIGSF SLEQLQEYAD ADLSVVEKLE EIIIQKVDI YKVGYSSEKL 540
FDADFVLEKS LKNDAVVAI MKDLLDSVKS FENYIKAPFG EGKETNRDES FYGDFVLAYD 600
ILLKVDHIYD AIRNYVTQPK YSKDKPKLYF QNPQFMGGWD KDKETDYRAT ILRYGSKYYL 660
AIMDKKYAKC LQKIDKDDVN GNYEKINYKL LPPGNKMLPK VFFSKKWMAY YNPSEDIQKI 720
YKNGTFKKGD MFNLNDCHKL IDFPKDSISR YPKWSNAYDF NPFSETEKYD IAGFYREVEE 780
QGYKVSFESA SKKEVDKLVE EGKLYMPQIY NKDFSDKSHG TPNLHTMYFK LFPDENNHGQ 840
IRLSGGAELE MRRASLKKEE LVVHPANSPI ANKNPDNPKK TTTLSYDVYK DKRFSQEDYE 900
LHIPIAINKC PKNIFKINTE VRVLLKHDDN PYVIGIARGE RNLLYIVVVD GKGNIVEQYS 960
LNEIINNPNF IRIKTDYHSL LDKKEKERFE ARQNWTSIEN IKELKAGYIS QVVHICELV 1020
EKYDAVIALE DLNSGFKNRSR VKVEKQVYQK FEKMLIDKLN YMVDKKS NPC ATGGALKGYQ 1080
ITNKFESPKS MSTQNGFIFY IPAWLTSKID PSTGFVNLLK TKYTSIADSK KFISSFDRIM 1140
YVPEEDLFEF ALDYKNFSRT DADYIKKWL YSYGNRIRIF RNPKNNVDF WEEVCLTSAY 1200
KELFNKYGIN YQQGDIRALL CEQSDKAFYS SFMALMSLML QMRNSITGRT DVDFLISPVK 1260
NSDGFYDSR NYEAQENAIL PKNADANGAY NIARKVLWAI GQFKKAEDK LDKVKIAISN 1320
KEWLEYAQT VKH 1333
```

-continued

SEQ ID NO: 239                   moltype = AA   length = 1322  
 FEATURE                        Location/Qualifiers  
 source                         1..1322  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 239

MSKLEKFTNC	YLSKTLRFP	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKLNLYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGMELKHSI	SDYTEAEFLQ	LVTTCNADT	SSEELVKLV	THPEEMTEHP	300
SGSLLIYYPK	EGDDSPSGI	VNTVKQWRAA	NGKSGFKQGG	SSGEKIKGLN	EYINLYNQKT	360
KQKLPKFKPL	YKQVLSDRS	LSFYGEGYTS	DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLPK	420
NFDEYSSAGI	FVKNPAST	ISKDIFGEWN	VIRDKWNAEY	DDIHLKKKAV	VTEKYEDDRR	480
KSPFKIGSFS	LEQLQEQYADA	DLSSVVEKLE	IIIQKVDIY	KVYGSSEKLF	DADFVLEKSL	540
KKNDAVVAIM	KDLLDSVKSF	ENYIKAFFGE	GKETNRDES	YGFVFLAYDI	LLKVDHIYDA	600
IRNYVTQKPY	SKDKFKLYFP	NPQFMGGWDK	DKETDYRATI	LRYSKYKYL	IMDKKYAKCL	660
QKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	FFSKWMAY	NPSEDIQKIY	KNGTFKKGDM	720
FNLNDCHKLI	DFPKDSISR	PKWSNAYDFN	FSETEKYKDI	AGFYREVEEQ	GYKVSFESAS	780
KKEVDKLEE	GKLYMPQIYN	KDFSDKSHGT	PNLHTMYPKL	LFDENNHGQI	RLSGGAELEFM	840
RRASLKKEEL	VVHPANSP	ANKNPDNPKK	TTLSYDVYK	KRFSEDOYE	HPIPIANKCP	900
KNIFKINTEV	RVLLKHDDNP	YVIGIARGER	NLLYIVVVDG	KGNIVEQYSL	NEIINNPNFI	960
RIKTDYHSL	LKKKKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	1020
LNSGFKNSRV	KVEKQVYQK	EKMLIDKLN	MVDKKSNPCA	TGGALKGYQI	TNKFESFKSM	1080
STQNGFIFY	PAWLTSKIDP	STGFVNLLKT	KYTSIADSK	FISSFDRIMY	VPEEDLFEP	1140
LDYKNFSRTD	ADYIKKWKLY	YSYGNRIRIP	RNPKNVDF	EEVCLTSAYK	ELFNKYGIN	1200
QQGDIRALLC	EQSDKAFYSS	FMALMSLMLQ	MRNSITGRD	VDPLISPVK	SDGIFYDSRN	1260
YEAQENAILP	KNADANGAYN	IARKVLWAI	QFKKADEKL	DKVKIAISNK	EWLEYAQTSTV	1320
KH						1322

SEQ ID NO: 240                   moltype = AA   length = 1503  
 FEATURE                        Location/Qualifiers  
 source                         1..1503  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 240

MSKLEKFTNC	YLSKTLRFP	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKLNLYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGWNLGHE	TVAYIAQSPV	ASSTESFCQN	ILGDDSTSYL	ANVATWADTY	300
KYTDAGEFSK	PYHFIDAQDN	PPQSCGVYD	RDCGSAGCSI	SAIQNYTNI	LESPNGSEAL	360
NALKFVVHII	GDIHQPLHDE	NLEAGNGID	VTYDGETTNL	HIIWDTNMP	EAAGGYSLSV	420
AKTYADLLTE	RIKTGTYSK	KDSWTDGIDI	KDPVSTSMI	AADANTYVCS	TVLDDGLAYI	480
NSTDLSGEYY	DKSQPVFEEL	IAKAGYRLAA	WDLIASQPS	GSSGEKIKGL	NEYINLYNQK	540
TKQKLPKFKP	LYKQVLSDR	SLSFYGEGYT	SDEEVLEVFR	NTLNKNSEIF	SIKKLEKLP	600
KNFDEYSSAG	IFVKNPAST	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKKA	VVTEKYEDDR	660
RKSPFKIGSF	SLEQLQEQYAD	ADLSVVEKLE	EIIIQKVDI	YKVGSSSEKLF	FDADFVLEKS	720
LKKNDAVVAI	MKDLLDSVKS	FENYIKAFFG	EKGKTRNDES	FYGFVFLAYD	ILLKVDHIYD	780
AIRNYVTQKPY	SKDKFKLYFP	NPQFMGGWDK	DKETDYRATI	LRYSKYKYL	AIMDKKYAKC	840
LQKIDKDDVNG	NYEKINYKLL	PGPNKMLPKV	FFSKWMAY	NPSEDIQKIY	KNGTFKKGDM	900
MFNLNDCHKL	IDFPKDSISR	PKWSNAYDFN	NFSETEKYKDI	IAGFYREVEEQ	QYKVSFESAS	960
SKKEVDKLEE	EGKLYMPQIYN	KDFSDKSHGT	PNLHTMYPKL	LFDENNHGQI	RLSGGAELEFM	1020
MRRASLKKEE	LVVHPANSP	ANKNPDNPKK	TTLSYDVYK	KRFSEDOYE	LHPIPIANKC	1080
PKNIFKINTE	RVLLKHDDNP	YVIGIARGER	RNLLYIVVVDG	KGNIVEQYSL	NEIINNPNFI	1140
IRIKTDYHSL	LKKKKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	1200
DLNSGFKNSRV	KVEKQVYQK	EKMLIDKLN	YMDKKSNPCA	TGGALKGYQI	TNKFESFKSM	1260
MSTQNGFIFY	IPAWLTSKID	PSTGFVNLLK	KYTSIADSK	FISSFDRIMY	VPEEDLFEP	1320
ALDYKNFSRTD	DADYIKKWKLY	YSYGNRIRIP	RNPKNVDF	EEVCLTSAYK	KELFNKYGIN	1380
YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	QMRNSITGRD	DVDPLISPVK	NSDIFYDSRN	1440
NYEAQENAIL	PKNADANGAY	NIARKVLWAI	QFKKADEKL	DKVKIAISNK	KWLEYAQTSTV	1500
VKH						1503

SEQ ID NO: 241                   moltype = AA   length = 1506  
 FEATURE                        Location/Qualifiers  
 source                         1..1506  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 241

MSKLEKFTNC	YLSKTLRFP	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKLNLYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGWNLGHE	TVAYVAQHYV	SPEAASWAQG	ILGSSSSSYL	ASTASWADEY	300
RLTSAGKWSA	SLHFIDAEDN	PPTNPNVDYE	RDCGSSGCSI	SAIANYTQRV	SDSSLSENH	360

-continued

AEALRFLVHF	IGDMTQPLHD	EAYAVGGNKI	NVTFDGYHDN	LHSDWDTYMP	QKLIGGHALS	420
DAESWAKTLV	QNIESGNYTA	QAIGWIKGDN	ISEPITTATR	WASDANALVC	TVVMPHGAAA	480
LQTGDLYPTY	YDSVIDTIEL	QIAKGGYRLA	NWINEIHGSE	IAKGSSGEKI	KGLNEYINLY	540
NQKTKQKLPK	FKPLYKQVLS	DRESLSFYGE	GYTSDEEVLE	VFRNTLNKNS	EIPSSIKKLE	600
KLFKNFDEYS	SAGIFVKNP	AISTISKDIF	GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	660
DDRRKSFKKI	GSFSLQLQE	YADADLSVVE	KLKEI IQKV	DEIYKVGSS	EKLFDADFVL	720
EKSLKKNDAV	VAIMKDLDS	VKSFENYIKA	FPGEGKETNR	DESPYGFVFL	AYDILLKVDH	780
IYDAIRNYVT	QKPYSKDKFK	LYFQNPQFMG	GWDKDKETDY	RATILRYGSK	YYLAIMDKKY	840
AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	QKIYKNGTFK	900
KGDMFNLNDC	HKLIDFFPKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGFYRE	VEEQGYKVSF	960
ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHMT	YFKLLFDENN	HGQIRLSGGA	1020
ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	PKKTTLSYD	VYKDKRFSED	QYELHIPAI	1080
NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	1140
FNGIRIKTDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	YISQVVKIK	ELVEKYDAVI	1200
ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	GYQITNKFES	1260
FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	LLKTKYTSIA	DSKKFISFSD	RIMYVPEEDL	1320
FEPALDYKNF	SRTDADYIKK	WKLYSYGNRI	RIFRNPKNMN	VFDWEEVCLT	SAYKELFNKY	1380
GINYQQGDIR	ALLCEQSDKA	FYSFPMALMS	LMLQMRNSIT	GRTDVDFLIS	PVKNSDGIFY	1440
DSRNYEAQEN	AILPKNADAN	GAYNIARKVL	WAIGQFKKAE	DEKLDKVKIA	ISNKEWLEYA	1500
QTSVKH						1506

SEQ ID NO: 242            moltype = AA   length = 1341  
FEATURE                    Location/Qualifiers  
source                      1..1341  
                             mol\_type = protein  
                             organism = synthetic   construct

SEQUENCE: 242

MSKLEKFTNC	YSLSKTLRPF	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLKLDRIYLS	60
FINDVLHSIK	LKLNLYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGPFNDREN	MFSBEAKSTS	IAFRGINENL	180
TRYISNMDF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTEGSG	SSGMEWKDII	GYEGHYQVSN	TGEVYSIKSG	KTLKHQIPKD	GYHRIGLFGK	300
GKGTQFVHR	LVAIHFCBGY	EEGLVVDHKD	GNKDNLNSTN	LRWVTQKINV	ENQMSRGTGS	360
SGEKIKGLNE	YINLYNQKTK	QKLPKPKPLY	KQVLSDRRESL	SFYGEGYTS	EEVLEVRFRNT	420
LNKNSIPISS	IKKLEKLFKN	FDEYSSAGIF	VKNPASTI	SKDIFGEWNV	IRDKWNAEYD	480
DIHLKKKAVV	TEKYEDRRK	SPFKIGSFSL	EQLOEYADAD	LSVVEKLEKI	IIQKVDEIYK	540
YVGSSEKLF	ADFLVLEKSLK	KNDAVVAIMK	DLLDSVKSFE	NYIKAFFGEG	KETNRDESFY	600
GDFVLAYDIL	LKVDHIYDAI	RNYVTQKPY	KDKFKLYFQ	PQFMGGWDKD	KETDYPATIL	660
RYGSKYLA	MKKYAKCLQ	KIDKDDVNGN	YEKINYKLLP	GNKMLPKVF	FSKKNMAYYN	720
PSEDIQKIYK	NGTFKKGDMF	NLNDCHKLID	FPKDSISRY	KWSNAYDFNF	SETEKIDIA	780
GPYREVVEQG	YKVSFESASK	KEVDKLVVEG	KLYMFIYIN	DFSDKSHGTP	NLHTMYFKLL	840
FDENNHGQIR	LSGAELEFMR	RASLKEELV	VHPANSPIAN	KNPDNPKTT	TLSYDVYKDK	900
RFEDEQYELH	IPIAINCKPK	NIFKINTEVR	VLLKHDDNPF	VIGIARGERN	LLYIVVVDGK	960
GNIVEQYSLN	EIINNFNGIR	IKTDYHSLLD	KKEKERFEAR	QNWTSIENIK	ELKAGYISQV	1020
VHKICELVEK	YDAVIALEDL	NSGFKNRSRV	VEKQVYKQFE	KMLIDKLNMY	VDKKSNPCAT	1080
GGALRGYQIT	NKPFESFKSMS	TQNGFIFYIP	AWLTSKIDPS	TGFVNLKTK	YTSIADSKKF	1140
ISSFDRIMYV	PEEDLFEFAL	DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNVFDWE	1200
EVCLTSAYKE	LFNKYGINYQ	QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	1260
DFLISPVKNS	DGIFYDSRNY	EAQENAILPK	NADANGAYNI	ARKVLWAIGQ	PKAEDEKLD	1320
KVKIAISNKE	WLEYAQTSVK	H				1341

SEQ ID NO: 243            moltype = AA   length = 1346  
FEATURE                    Location/Qualifiers  
source                      1..1346  
                             mol\_type = protein  
                             organism = synthetic   construct

SEQUENCE: 243

MSKLEKFTNC	YSLSKTLRPF	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLKLDRIYLS	60
FINDVLHSIK	LKLNLYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGPFNDREN	MFSBEAKSTS	IAFRGINENL	180
TRYISNMDF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTEGSG	SSGGRTPAE	ERRIANALGA	LPCIACYMHG	VISNEVSLHH	IAGRTPAGCH	300
KQPLPLCRWH	HQHAAPAEVR	EKYPWLVPVH	ADGVVGGKKE	FTLLNKSEME	LLADAYEMAN	360
IMHGSSGEKI	KGLNEYINLY	NQKTKQKLPK	FKPLYKQVLS	DRESLSFYGE	GYTSDEEVLE	420
VFRNTLNKNS	EIPSSIKKLE	KLFKNFDEYS	SAGIFVKNP	AISTISKDIF	GEWNVIRDKW	480
NAEYDDIHLK	KKAVVTEKYE	DDRRKSFKKI	GSFSLQLQE	YADADLSVVE	KLKEI IQKV	540
DEIYKVGSS	EKLFDADFVL	EKSLKKNDAV	VAIMKDLDS	VKSFENYIKA	FPGEGKETNR	600
DESPYGFVFL	AYDILLKVDH	IYDAIRNYVT	QKPYSKDKFK	LYFQNPQFMG	GWDKDKETDY	660
RATILRYGSK	YYLAIMDKKY	AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	720
MAYYNPSEDI	QKIYKNGTFK	KGDMFNLNDC	HKLIDFFPKDS	ISRYPKWSNA	YDFNFSETEK	780
YKDIAGFYRE	VEEQGYKVSF	ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHMT	840
YFKLLFDENN	HGQIRLSGGA	ELFMRRASLK	KEELVVHPAN	SPIANKNPDN	PKKTTLSYD	900
VYKDKRFSED	QYELHIPAI	NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	960
VVDGKGNIVE	QYSLNEIINN	FNGIRIKTDY	HSLLDKKEKE	RFEARQNWTS	IENIKELKAG	1020
YISQVVKIK	ELVEKYDAVI	ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	1080
NPCATGGALK	GYQITNKFES	FKSMSTQNGF	IFYIPAWLTS	KIDPSTGFVN	LLKTKYTSIA	1140

-continued

DSKKFISSFD	RIMYVPEEDL	FEFALDYKNF	SRTDADYIKK	WKLYSYGNRI	RIFRNPCKNN	1200
VFDWEEVCLT	SAYKELFNKY	GINYQQGDIR	ALLCEQSDKA	FYSSFMALMS	LMLQMRNSIT	1260
GRTDVFLLIS	PVKNSDGIFY	DSRNIEAQEN	AILPKNADAN	GAYNIARKVL	WAIGQPKKAE	1320
DEKLDKVKIA	ISNKEWLEYA	QTSVKH				1346

SEQ ID NO: 244                   moltype = AA   length = 1513  
 FEATURE                        Location/Qualifiers  
 source                         1..1513  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 244

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDALFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPFNFLT	QEGIDVYNAI	240
IGGFVTEGG	SSGWSKEGHV	MTCRIAQGLL	NDEAAHAVKM	LLPEYVNGDL	SALCVWPDQV	300
RHWYKYKWT	PLHFIDTPDK	ACNFDYERDC	HDQHGKDMC	VAGAIQNFTT	QLSHYREGTS	360
DRRYNMTEAL	LFLSHFMGDI	HQPMHVGFST	DAGGNSIDLR	WFRHKSNLHH	VWDREIILTA	420
AKDYAKDIN	LLEEDIEGNF	TDGIWSDDLA	SWRECGNVFS	CVNKFATESI	NIACKWGYKG	480
VEAGETLSDD	YFNRSRLPVM	KRVAQGGIRL	AMLNNVPGA	SQQEDSVVAT	GSSGEKIKGL	540
NEYINLNYQK	TKQKLPKFKP	LYKQVLSRE	SLSFYGEGYT	SDEEVLEVFR	NTLNKNSEIF	600
SSIKLEKLF	KNFDEYSSAG	IFVKNGPAIS	TISKDIFGEW	NVIRDKWNAE	YDDIHLKKA	660
VVTEKYEDDR	RKSPFKIGSF	SLEQLQEQYAD	ADLSVVEKLI	EIIIQKVDI	YKVYGSSEKL	720
PDADFVLEKS	LKKNDAVVAI	MDLDSVSKS	FENYIKAPFG	EGKETNRDES	FYGDVFLAYD	780
ILLKVDHIYD	AIRNYVQKPK	YSKDKPKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	840
AIMDKKYAKC	LQKIDKDDVN	GNYEKINYKL	LPGPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	900
YKNGTFKKG	MFNLNDCHKL	IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVVEE	960
QGYKVSFESA	SKKEVDLVE	EGKLYMFQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	1020
IRLSGGAELF	MRRASLKEE	LUVHPANSPI	ANKNPDNPKK	TTTTLSYDVYK	DKRFSEDOYE	1080
LHIPAIINCK	PKNIFKINTE	VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	1140
LNEIINNPN	IRIKTDYHSL	LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVHKICELV	1200
EKYDAVIALE	DLNSGFKNSR	VKVEKQVYQK	FEKMLIDKLN	YMVDKKSNPC	ATGGALKGYQ	1260
ITNKFESFKS	MSTQNGPIFY	IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	KFISSPDRIM	1320
YVPEEDLPEF	ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNVDFD	WEEVCLTSAY	1380
KELFNKYGIN	YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	DVDFLISPVK	1440
NSDGIFYDSR	NYEAQENAIL	PKNADANGAY	NIARKVLWAI	GQPKKAEDK	LKVKIAISN	1500
KEWLEYAQT	SVKH					1513

SEQ ID NO: 245                   moltype = AA   length = 1446  
 FEATURE                        Location/Qualifiers  
 source                         1..1446  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 245

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDALFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPFNFLT	QEGIDVYNAI	240
IGGFVTEGG	SSGPPSSFSK	AKKEAVKIYL	DYPTSFCYCG	DITWKNKKKI	IPELESQGYQ	300
VRKQEKRASR	IEWEHVVPWA	QFHQRQCWQ	KGGRKNCTRN	DKQPKSMEAD	LHNLVPAIGE	360
VNGDRSNFRF	SQWNGSKGAF	YQGCAPKVD	KGRVAEPPAQ	SRGAIARTYL	YMNNEYKPNL	420
SKAQRQLMEA	WNKQYPVSTW	ECTRDERIAK	IQGNHNQFVY	KACGSSGEKI	KGLNEYINLY	480
NQKTQKLPK	FKPLYKQVLS	DRESLSFYGE	GYTSDEEVLE	VFRNTLNKNS	EIIFSSIKKLE	540
KLFPKDFEYS	SAGIFVKNP	AISTISKDIF	GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	600
DDRRKSFKKI	GSFSLQEQE	YADADLSVVE	KLKEIIQKV	DEIYKVGSS	EKLFDADFVL	660
EKSLKKNDAV	VAIMKDLLDS	VKSFENYIKA	FFGEGKETNR	DESFGDFVL	AYDILLKVDH	720
IYDAIRNVVT	QKPYSKDKFK	LYFQNPQFMG	GWDDKEDTDY	RATILRYGSK	YLAIMDKKY	780
AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	QKIYKNGTFK	840
KGDMFNLDNC	HKLIDFFKDS	ISRYPKWSNA	YDFNFSETEK	YKDIAGFYRE	VEEQGYKVSF	900
ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHMT	YPKLLFDENN	HGQIRLSGGA	960
ELFMRRASLK	KEELVVHPAN	SPIANKPNPD	PKKTTLSYD	VYKDKRFSAD	QYELHIPAI	1020
NKCPKNIFKI	NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	1080
FNGIRIKTDY	HSLLDKKEKE	RPEARQNWTS	IENIKELKAG	YISQVGHKIC	ELVEKYDAVI	1140
ALEDLNSGFK	SRVKEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	GYQITNKFES	1200
FKSMSTQNGF	IFYIPAALTS	KIDPSTGFVN	LLKTKYTSIA	DSKKFISSFD	RIMYVPEEDL	1260
FEFALDYKNF	SRTDADYIKK	WKLYSYGNRI	RIFRNPCKNN	VFDWEEVCLT	SAYKELFNKY	1320
GINYQQGDIR	ALLCEQSDKA	FYSSFMALMS	LMLQMRNSIT	GRTDVFLLIS	PVKNSDGIFY	1380
DSRNIEAQEN	AILPKNADAN	GAYNIARKVL	WAIGQPKKAE	DEKLDKVKIA	ISNKEWLEYA	1440
QTSVKH						1446

SEQ ID NO: 246                   moltype = AA   length = 1304  
 FEATURE                        Location/Qualifiers  
 source                         1..1304  
                                mol\_type = protein  
                                organism = synthetic construct

SEQUENCE: 246

-continued

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEEAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDAIPDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGRLREQAL	MRDKGLCLHC	KNNRRIKQAD	MVDHIPIKV	DPSLKLKLEN	300
LQSLCNPCHN	RKTAEDYKKY	GGSSGEKIKG	LNEYINLYNQ	KTKQKLPKFK	PLYQVLSDR	360
ESLSFYGGGY	TSDEEVLEVF	RTLNKNSEI	FSSIKKLEKL	FKNPDEYSSA	GIPVKNGPAP	420
STISKDIFGE	WNVIRDKWNA	EYDDIHLKKK	AVVTEKYEDD	RRKSFKKIGS	FSLEQLQEYA	480
DADLSVVEKL	KEIIIQKVDE	IYKVYGSSEK	LFDADFVLEK	SLKKNDAVVA	IMKDLLDSVK	540
SFENYIKAFF	GEGKETNRDE	SFYGDFVLAY	DILLKVDHIY	DAIRNYVTQK	PYSKDKFKLY	600
FQNPQFMGGW	DKDKETDYRA	TILRYGSKYY	LAIMDKKYAK	CLQKIDKDDV	NGNYEKINYK	660
LLPGPNKMLP	KVFPKSKWMA	YINPSEDIQK	IYKNGTFKKG	DMFNLNDCHK	LIDFPKDSIS	720
RYPKWSNAYD	VNFSETEKYK	DIAGFYREVE	EQGYKVSFES	ASKKEVDKLV	EEGKLYMFQI	780
YNKDFSDKSH	GTPNLHMYF	KLLFDENNHG	QIRLSGGGAE	FMRRASLKEE	ELVVHPANSP	840
IANKNPDPNK	KTTLSYDYVD	KDKRFSEDOY	ELHIPIAINK	CPKNI FKINT	EVRVLLKHDD	900
NPYVIGIARG	ERNLLYIVVV	DGKGNIVEQY	SLNEIINNEN	GIRIKTDYHS	LDDKKEKERF	960
EARQNWTSIE	NIKELKAGYI	SQVVKICIEL	VEKYDAVIAL	EDLNSGFKNS	RVKVEKQVYQ	1020
KFEKMLIDLK	NYMVDKSNP	CATGGALKGY	QITNKFESFK	SMSQTQNGFIF	YIPAWLTSKI	1080
DPSTGFVNL	KTKYTSYDRI	KYVPEEDLFE	FALDYKNFSR	TDADYIKKWK		1140
LYSYGNRIRI	FRNPKNKNNV	DWEEVCLTSA	YKELFNKYGI	NYQQGDIRAL	LCEQSDKAPY	1200
SSFALMMLM	LQMRNSITGR	TDVDFLISPV	KNSDGIIFYDS	RNYEAQENAI	LPKNADANGA	1260
YNIARKVLWA	IGQPKKAED	KLDKVKIAIS	NKEWLEYAQT	SVKH		1304

SEQ ID NO: 247                   moltype = AA   length = 1356  
FEATURE                            Location/Qualifiers  
source                              1..1356  
                                    mol\_type = protein  
                                    organism = synthetic   construct

SEQUENCE: 247

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEEAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDAIPDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGNNYSYLR	AKVFEHGV	CQLCNVNAQE	LFLRLRDAPK	SQRKNLLYAT	300
WTSKLPLEQL	NEMIRNPEGG	HFVQVDHIK	VYGGGQCSSL	DNLQTLCTVC	HKERTARQAK	360
ERSQVRRQSL	ASKSSSEKIK	KGLNEYNLY	NQKTKQKLPK	FKPLYKQVLS	DRESLSFYGE	420
GYSDEEVLE	VFRNTLNKNS	EIPSSIKKLE	KLFKNFDEYS	SAGIFVKNP	AISTISKDIF	480
GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	DDRRKSPFKI	GSFSLEQLQE	YADADLSVVE	540
KLKEIIQKV	DEIYKVYGS	EKLFDADFVL	EKSLKKNDAV	VAIMKDLLDS	VKSFENYIKA	600
PFGEKETNR	DESFGDFVL	AYDILLKVDH	IYDAIRNVVT	QKPYKDKFK	LYFQNPQFMG	660
GWDKKETDY	RATILRYGSK	YLAIMDKKY	AKCLQKIDKD	DVNGNYEKIN	YKLLPGPNKM	720
LPKVFPKSK	MAYINPSEDI	QKIYKNGTFK	KGDMFNLND	HKLIDFPKDS	ISRYPKWSNA	780
YDFNFSYTEK	YKDIAGFYRE	VERQGYKVSF	ESASKKEVDK	LVEEGKLYMF	QIYNKDFSDK	840
SHGTPNLHTM	YFKLLFDENN	HGQIRLSGGA	ELFMRRASLK	KEELVVHPAN	SPIANKPNPDN	900
PKTTTSLSYD	VYDKRFSEDO	QYELHIPIAI	NKCPKNI PKI	NTEVRVLLKH	DDNPYVIGIA	960
RGERNLLYIV	VVDGKGNIVE	QYSLNEIINN	FNGIRIKTDY	HSLDLKKEKE	RPEARQNWTS	1020
IENIKELKAG	YISQVVKIC	ELVEKYDAVI	ALEDLNSGFK	NSRVKVEKQV	YQKFEKMLID	1080
KLNYMVDKKS	NPCATGGALK	GYQITNKFES	FKSMTQNGF	IFYPAPWLT	KIDPSTGFVN	1140
LLKTKYTSIA	DKKFISSDF	RIMYVPEEDL	FEFALDYKNF	SRTDADYIKK	WKLYSYGNRI	1200
RIFRNPKKNN	VFDWEEVCLT	SAYKELFNKY	GINYQQGDIR	ALLCEQSDKA	FYSSPMALMS	1260
LMLQMRNSIT	GRTDVDFLIS	PVKNSDGIIFY	DSRNYEAQEN	AILPKNADAN	GAYNIARKVL	1320
WAIGQPKKAE	DEKLDKVKIA	ISNKEWLEYA	QTSVKH			1356

SEQ ID NO: 248                   moltype = AA   length = 1403  
FEATURE                            Location/Qualifiers  
source                              1..1403  
                                    mol\_type = protein  
                                    organism = synthetic   construct

SEQUENCE: 248

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEEAKSTS	IAPRCINENL	180
TRYISNMDIF	EKVDAIPDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGAYCGSPI	TFSNSEMDHI	VPRAGQGSTN	TRENLVAVCH	RCNQSKGNT	300
WRYQSVQRQN	EGVSVKBAVE	RTRHWVTDTG	MRSTDFKKFT	KAVVERFORA	TMDEEIDARS	420
FAIWAKNTSI	SEYINLYNQK	TQKQKLPKFK	LYKQVLSDR	SLSFYGEGYT	SDEEVLEVPF	480
GSSGEKIKGL	NEYNLYNQK	TKQKLPKFK	LYKQVLSDR	SLSFYGEGYT	SDEEVLEVPF	480
NLNLKNSIIF	SSIKKLEKLF	KNFDEYSSAG	IFVKNGPAPIS	TISKDIFGEW	NVIRDKWNAE	540
YDDIHLKKA	VVTEKYEDDR	RKSFKKIGSF	SLEQLQEYAD	ADLSVVEKLV	EIIIQKVDEI	600
YKVYGSSEKL	LFDADFVLEK	LKKNDAVVAI	MKDLLDSVKS	FENYIKAFFG	EGKETNRDES	660
FYGDVFLAYD	ILLKVDHIYD	AIRNYVTQKP	YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	720
ILRYGSKYYL	AIMDKKYAK	LQKIDKDDVN	GNYEKINYKL	LPGPNKMLPK	VFPKSKWMA	780
YINPSEDIQK	YKNGTFKKGD	MFNLNDCHKL	IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	840
IAGFYREVEE	QGYKVSFESA	SKKEVDKLV	EGKLYMFQIY	NKDFSDKSHG	TPNLHMYFK	900
LLFDENNHGQ	IRLSGGAELE	MRRASLKKEE	LVVHPANSP	ANKNPDPNPK	TTTTLSYDVYK	960
KDRFSEDOYE	LHIPIAINKC	PKNIFKINTE	VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	1020

-continued

GKGNIVEQYS	LNEIINNFG	IRIKTDYHSL	LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	1080
QVVHKICELV	EKYDAVIALE	DLNSGPKNSR	VKVEKQVYQK	FEKMLIDKLN	YMVDKKSNPC	1140
ATGGALKGYQ	ITNKFESFKS	MSTQNGFIPY	IPAWLTSKID	PSTGFVNLK	TKYTSIADSK	1200
KFISSFDRIM	YVPEEDLFEF	ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNVDFD	1260
WEEVCLTSAY	KELFNKYGIN	YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	1320
DVDFLISPVK	NSDGIFYDSR	NYEAQENAIL	PKNADANGAY	NIARKVLWAI	GQFKKAEDK	1380
LDKVKIAISN	KEWLEAQT	VKH				1403

SEQ ID NO: 249           moltype = AA   length = 1380  
 FEATURE                Location/Qualifiers  
 source                  1..1380  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 249

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKKTREKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTEGG	SSGENQNTNQ	GRNSQQRLK	GLTDSIKEFG	SQILKEHPVE	NSQLQNDRLF	300
LYYLQNGRDM	YTGEELDIDY	LSQYDIDHII	PQAFIKDNSI	DNRVLTSSKE	NRGKSDDVPS	360
KDVVRKMSY	WSKLLSAKLI	TQRKFDNLTK	AERGGTGS	GEKIKGLNEY	INLYNQKTKQ	420
KLPKFKPLYK	QVLSDRSLS	FYGEYTSDE	EVLEVFRNTL	NKNSEIFSSI	KKLEKLFKNF	480
DEYSSAGIFV	KNGPAISTIS	KDIFGEWVNI	RDKNWAEYDD	IHLKKKAVVT	EKYEDDRRKS	540
PKKIGSFSLE	QLQYADADL	SVVEKLKEII	IQKVDEIYKV	YGSSEKLFDA	DFVLEKSLKK	600
NDAVVAIMKD	LLDSVKSFEN	YKAPFGEKG	ETNRDESFG	DFVLAYDILL	KVDHIYDAIR	660
NYVTQKPYSK	DKFKLYFQNP	QFMGGWDKDK	ETDYRATILR	YGSKYLAIM	DKKYAKCLQK	720
IDKDDVNGNY	EKINYKLLPG	PNKMLPKVFF	SKKWMAYNP	SEDQIKYKN	GFPKKGMDFN	780
LNDCHKLIDF	EKDSISRYPK	WSNAYDFNFS	ETEKYKDIAG	FYREVEEQGY	KVSFESASKK	840
EVDKLVBEKG	LYMFOIYNKD	FSDKSHGTPN	LHTMYFKLLF	DENNHGQIRL	SGGAELFMRR	900
ASLKEELV	HPANSPIANK	NPDPNPKTTT	LSYDVYKDKR	FSEDQYELHI	PIAINKCPKN	960
IFKINTEVRV	LLKHDDNPYV	IGIARGERNL	LYIVVVDGKG	NIVEQYSLNE	IINNPNFIRI	1020
KTDYHSLDDK	KEKERFEARQ	NWTSIENIKE	LKAGYISQV	HKICELVEKY	DAVIALEDLN	1080
SGFKNSRVK	EKQVYQKFEK	MLIDKLNMYM	DKKSNPCATG	GALKGYQITN	KFESFKSMST	1140
QNGFIFYIPA	WLSKIDPST	GFVNLLKTKY	TSIADSKKFI	SSFDRIMYVP	EEDLFEFALD	1200
YKNFSRTDAD	YIKKWKLYSY	GNRIRIFRNP	KKNNVDFWEE	VCLTSAYKEL	FNKYGINYQQ	1260
GDIRALLCEQ	SDKAFYSFPM	ALMSLMLQMR	NSITGRTDVD	FLISPVKNSD	GIFYDSRNYE	1320
AQENAILPKN	ADANGAYNIA	RKVLWAIQGF	KKAEDKLDK	VKIAISNKEW	LEYAQT	1380

SEQ ID NO: 250           moltype = AA   length = 1459  
 FEATURE                Location/Qualifiers  
 source                  1..1459  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 250

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNLNNYISL	FRKKTREKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTEGG	SSGARVRTYP	NVSHANTHYK	NTVSSKLLPF	TANYQLQVGE	LDNLRATFS	300
HIQLQDRHET	KDVRTKINYD	PVGWHNYQFP	YDGSKSSWV	MNRGHLVGYQ	FCGLNDEPRN	360
LVAMTAWLNT	GAYSANDSN	PEGMLYYENR	LDSWLALHPD	FWDYKVTPI	YSGNEVVPRQ	420
IELQVGLDS	SGELLTIRLN	SNKESIDENG	VTTVILENSA	PNINLDYLVG	TATPKNGSSG	480
EKIKGLNEYI	NLYNQKTKQK	LPKFKPLYKQ	VLSDRSLSF	YGEYTSDEE	VLEVFRNTLN	540
KNSEIFSSIK	KLEKLFKINF	EYSSAGIFVK	NGPAISTISK	DIFGEWVNI	DKWNAEYDDI	600
HLKKKAVVTE	KYEDDRRKSF	KKIGSFSLEQ	LQYADADLS	VVEKLKEIII	QKVDEIYKVY	660
GSSEKLFADAD	FVLEKSLKKN	DAVVAIMKDL	LDSVKSFENY	IKAPFGEKGE	TNRDESFGYD	720
FVLAYDILLK	VDHIYDAIRN	YVTQKPYSKD	KFKLYFQNPQ	FMGWDKDKKE	TDYRATILRY	780
GSKYLAIMD	KKYAKCLQKI	DKDDVNGNYE	KINYKLLPGP	NKMLPKVFFS	KKWMAYNPS	840
EDIQKIYKNG	TFKKGDMFNL	NDCHKLIDFF	KDSISRYPKW	SNAYDFNFSE	TEKYKDIAGF	900
YREVEEQGYK	VSFESASKKE	VDKLVBEKGL	YMFQIYNKDF	SDKSHGTPNL	HTMYFKLLFD	960
ENNHGQIRLS	GGAEELFMRR	SLKKEELVHV	PANSPIANKN	PDNPKTTTTL	SYDVYKDKRF	1020
SEDQYELHIP	IAINKCPKNI	FKINTEVRVL	LKHDDNPYVI	GIARGERNLL	YIVVVDGKGN	1080
IVEQYSLNEI	IINNPNFIRIK	TDYHSLDDK	EKERFEARQN	WTSIENIKEL	KAGYISQVH	1140
KICELVEKYD	AVIALEDLNS	GFKNSRVKVE	KQVYQKFEKM	LIDKLNMYVD	KKSNPCATGG	1200
ALKGYQITNK	FESFKSMSTQ	NGFIFYIPAW	LTSKIDPSTG	FVNLLKTKYT	SIADSKKFIS	1260
SFDRIMYVPE	EDLFEFALDY	KNFSRTDADY	IKKWKLYSYG	NRIRIFRNP	KNNVDFWEEV	1320
CLTSAYKELF	NKYGINYQQG	DIRALLCEQS	DKAFYSFMPA	LMSLMLQMRN	SITGRTDVDV	1380
LISPVKNSDG	IFYDSRNYEA	QENAILPKNA	DANGAYNIAR	KVLWAIQGFK	KAEDKLDK	1440
KIAISNKEWL	EYAQT	SVKH				1459

SEQ ID NO: 251           moltype = AA   length = 1506  
 FEATURE                Location/Qualifiers  
 source                  1..1506  
                           mol\_type = protein  
                           organism = synthetic construct

SEQUENCE: 251

-continued

```
MSKLEKFTNC YLSKTLRPFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKTRTEKE NKELENLEIN LRKEIAKAFK GNEGYSKLPK 120
KDIIETILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEEAkstS IAFRCINENL 180
TRYISNMDIF EKVDAIPDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESSG SSGAAPNIHG WGKEGHEIIC KIAQTRLDDET AAKAVKELLP ESAEGDLSSL 300
CLWADRVRKFR YHWSPLHYI NTPDACSQYQ NRDCDESSE KGRCVAGAIY NYTTQLLSYK 360
TAASSQSQYN LTEALLFVSH FMGDIHQPLH VSYASDKGGN TIEVHWYTRK ANLHHIWDNS 420
IIETAADLY NSALEGMVDA LKKNITTEWA DQVKRWETCT KKTACPDIIYA SEGIQAACDW 480
AYKGVTEGDT LEDEYFYSRL PIVYQRLAQQ GVLRAATLNR IFGGSSGEKI KGLNEYINLY 540
NQKTKQKLPK FKPLYQVLS DRESLSFYGE GYTSDEEVLE VFRNTLNKNS EIFSSIKKLE 600
KLFKNFDEYS SAGIFVKNP AISTISKDIF GEWNVIRDKW NAEYDDIHLK KKAUVTEKYE 660
DDRRKSPKKI GSFLEQLQE YADADLSVVE KLKEIIQKV DEIYKVYGS EKLPDADFVL 720
EKSLKKNDAV VAIMKDLDS VKSFENYIKA FPGEGKETNR DESPYGDFVL AYDILLKVDH 780
IYDAIRNYVT QKPYSKDKFK LYFQNPQFMG GWDKDKETDY RATILRYGSK YYLAIMDKKY 840
AKCLQKIDKD DVNGNYEKIN YKLLPGPNKM LPKVFFSKKW MAYYNPSEDI QKIYKNGTFK 900
KGD MFNLDNC HKLIDFPKDS ISRYPKWSNA YDFNFSETEK YKDIAGFYRE VEEQYKVSF 960
ESASKEVDK LVEEGKLYMF QIYNKDFSDK SHGTPNLHTM YFKLLFDENN HGQIRLSGGA 1020
ELFMRRASLK KEELVHPAN SPIANKNPDN PKKTTTLSYD VYKDKRPFSD QYELHIPIAI 1080
NKCPKNIFPKI NTEVRVLLKH DNPYVIGIA RGERNLLYIV VVDGKGNIVE QYSLNEIINN 1140
FNGIRIKTDY HSLDDKKEKE RFEARQNWTS IENIKELKAG YISQVVKIC ELVEKYDAVI 1200
ALEDLNSGFK NSRVKVEKQV YQKFEKMLID KLNVMVDKKS NPCATGGALK GYQITNKFES 1260
FKSMSTQNGF IFYIPALDS KIDPSTGFVN LLTKYTSIA DSKKFISSFD RIMYVPEEDL 1320
FEFALDYKNF SRTDADYIKK WKLYSYGNRI RIFRNPKNKN VFDWEEVCLT SAYKELFNKY 1380
GINYQQGDIR ALLCEQSDKA FYSSFMALMS LMLQMRNSIT GRTDVDFLIS PVKNSDGIFY 1440
DSRNYEAQEN AILPKNADAN GAYNIARKVL WAIGQFKKAE DEKLDKVKIA ISNKEWLEYA 1500
QTSVKH
```

SEQ ID NO: 252 moltype = AA length = 1320  
FEATURE Location/Qualifiers  
source 1..1320  
mol\_type = protein  
organism = synthetic construct

```
SEQUENCE: 252
MSKLEKFTNC YLSKTLRPFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKTRTEKE NKELENLEIN LRKEIAKAFK GNEGYSKLPK 120
KDIIETILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEEAkstS IAFRCINENL 180
TRYISNMDIF EKVDAIPDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESSG SSGIDGVKLS STEKKKMDI APPKGSVFTC PICEKRSIVG VTANLVHDHN 300
HDTGWGREWI CDSNTEGLGR FKDNPKFLEK VIEYLKGGSS GEKIKGLNEY INLYNQKTKQ 360
KLPKFKPLYK QVLSDRSLS FYGEGYTSDE EVLEVFRNTL NKNSEIFSSI KKLEKFKNF 420
DEYSSAGIFV KNGPAISTIS KDIFGEWVNI RDKWNAEYDD IHLKKKAVVT EKYEDDRRS 480
PKKIGSFLE QLQYADADL SVVEKLKEII IQKVDEIYKV YGSSEKLFDA DFVLEKSLKK 540
NDAVVAIMKD LLDVSVKSFEN YIKAFPGEGK ETNRDESFPY DFLVAYDILL KVDHIYDAIR 600
NYVTQKPYSK DKFKLYFQNP QFMGGWDKDK ETDYRATILR YGSKYYLAIM DKKYAKLQK 660
IDKDVNGNY EKINYKLLPG PNKMLPKVFF SKKWMAYNP SEDIQKIYKN GTFPKGDMFN 720
LNDCHKLIDF FKYSISRYPK WSNAYDFNFS ETEKYKDIAG FYREVEEQGY KVSFESASKK 780
EVDKLVBEKG LYMFQIYNKD FSKDSSHGTPN LHTMYFKLLF DENNHGQIRL SGGAEFMRR 840
ASLKKKEELV HPANSPANK NPDNPKKTTT LSYDVYKDKR FSEDQYELHI PIAINCPKN 900
IFKINTEVRV LLDKDDNPYV IGIARGERNL LYIVVVDGKG NIVEQYSLNE IINNFGIRI 960
KTDYHSLDDK KEKERFEARQ NWTISIENIKE LKAGYISQV HIKICELVEKY DAVIALEDLN 1020
SGFKNSRVKV EKQYVQKFEK MLIDKLNMYV DKSNPCATG GALKGYQITN KPFESKSMST 1080
QNGFIFYIPA WLTSKIDPST GFVNLLKTKY TSIADSKKFI SSPDRIMYVP EEDLFEFALD 1140
YKNFSRTDAD YIKKWKLYSY GNRIRIFRNP KKNNVFDWEE VCLTSAYKEL FNKYGINYQQ 1200
GDIRALLCEQ SDKAFYSSFM ALMSLMLQMR NSITGRTDVD FLISPVKNSD GIFYDSRNYE 1260
AQENAILPKN ADANGAYNIA RKVLWAIGQF KKAEDKLDK VKIAISNKEW LEYAQTSVKH 1320
```

SEQ ID NO: 253 moltype = AA length = 1333  
FEATURE Location/Qualifiers  
source 1..1333  
mol\_type = protein  
organism = synthetic construct

```
SEQUENCE: 253
MSKLEKFTNC YLSKTLRPFK AIPVGKTQEN IDNKRLLED EKRAEDYKGV KLLDRYYLS 60
FINDVLHSIK LKNLNNYISL FRKTRTEKE NKELENLEIN LRKEIAKAFK GNEGYSKLPK 120
KDIIETILPE FLDDKDEIAL VNSFNGFTTA FTGFFDNREN MFSEEAkstS IAFRCINENL 180
TRYISNMDIF EKVDAIPDKH EVQEIKEKIL NSDYDVEDFF EGEFFNFVLT QEGIDVYNAI 240
IGGFVTESSG SSGMNYFIVE VSEQEVKREK EKARELRRSQ WKNRIARGI CHYCGEIFPP 300
EELTMDHLVP VVRGGKSTRG NVPVACKECN NRKKYLLPVE WEEYLDLSLE GSSGKIKGL 360
NEYINLYNQK TKQKLPKFKP LYQVLSDRE SLSFYGEGYT SDEEVLEVFR NTLNKNSEIF 420
SSIKKLEKLF KNDFEYSSAG IFVKNGPATIS TISKDIFGEV NVIRDKNWAE YDDIHLKKA 480
VUTEKYEDDR RKSFKKIGSF SLBQLQEYAD ADLSVVEKLE EIIIQKVDEI YKVYGSSEK 540
FDADFVLEKS LKKNDAVVAI MKDLLDSVKS FENYIKAPFG EGKETNRDES FYGDFVLAYD 600
ILLKVDHIYD AIRNYVQKQ YSKDKFKLYF QNPQFMGGWD KDKETDYRAT ILRYGSKYYL 660
AIMDKKYAKC LQKIDKDDVN GNYEKINYKL LPPGNKMLPK VFFSKKWMAY YNPSEDIQKI 720
YKNGTFKKGD MFNLDNCHKL IDFFKDISIR YPKWSNAYDF NPFSETEKYKDI IAGFYREVEE 780
QGYKVSFESA SKKEVDKLV EGGLEYMFQIY NKDFSDKSHG TPNLHTMYFK LLPDENNHGQ 840
```

-continued

IRLSGGAELF	MRRASLKKEE	LVVHPANSPI	ANKNPDNPKK	TTTLSYDVYK	DKRFSEDOYE	900
LHIPAIANKC	PKNIFKINTE	VRVLLKHDDN	PYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	960
LNEIINNPNQ	IRIKTDYHSL	LDKKEKERFE	ARQNWTSIEN	IKELKAGYIS	QVVHKICELV	1020
EKYDAVIALE	DLNSGFKNRSR	VKVEKQVYQK	FEKMLIDKLN	YMVDKKSNPC	ATGGALKGYQ	1080
ITNKFESFKS	MSTQNGFIFY	IPAWLTSKID	PSTGFVNLLK	TKYTSIADSK	KFISSPDRIM	1140
YVPEEDLPEF	ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNVDFD	WEEVCLTSAY	1200
KELFNKYGIN	YQQGDIRALL	CEQSDKAFYS	SFMALMSLML	QMRNSITGRT	DVDFLISPVK	1260
NSDGFIFYDSR	NYEAOENAIL	PKNADANGAY	NIARKVLWAI	GQFKKAEDK	LDKVKIAISN	1320
KEWLEYAQT	VKH					1333

SEQ ID NO: 254                   moltype = AA   length = 1496  
FEATURE                        Location/Qualifiers  
source                         1..1496  
                                 mol\_type = protein  
                                 organism = synthetic   construct

SEQUENCE: 254

MSKLEKFTNC	YLSKTLRPFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYS	60
FINDVLHSIK	LKNLNNYISL	FRKKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSBEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTEGG	SSGGAQLDI	KNFPELYRTT	ERVYKKSQGS	TKPVTVSNIH	YSVLDGYGRS	300
GEAYGIITKD	MIDMSAGYRE	KWESKPEPSG	WYSYFFKNTN	QRATESDYKH	SPKNVSKISN	360
NIKASILLSN	GNVRNGYLF	RSHLIADSLG	GRPFRNNLIT	GTRTQNVGNN	DRKGGMQYIE	420
NKVLDHIKRN	PKHVHYKAT	PVYQGSSELLP	RAVLVSALSS	DGFIDETVRV	FNNVAGFNID	480
YQNGGLLSST	ADVDDINNVEE	NEIETDDDEI	EEGSSSSEKI	KGLNEYINLY	NQTKKQLPK	540
FKPLYKQVLS	DRESLSFYGE	GYTSDEEVLE	VPRNTLNKNS	EIPSSIKKLE	KLPKNFDEYS	600
SAGIFVKNQP	AISTISKDIF	GEWNVIRDKW	NAEYDDIHLK	KKAVVTEKYE	DDRRKSFKKI	660
GSFLEQLQE	YADADLSVVE	KLKEI IQKV	DEIYKVYGS	EKLPDADFVL	EKSLKKNDAV	720
VAIMKDLDS	VKSFENYIKA	FFGEGKETNR	DESIFYGDFVL	AYDILLKVDH	IYDAIRNYVT	780
QKPYSKDKFK	LYFQNPQFMG	GWDKDKETDY	RATILRYGSK	YYLAIMDKKY	AKCLQKIDKD	840
DVNGNYEKIN	YKLLPGPNKM	LPKVFFSKKW	MAYYNPSEDI	QKIYKNGTFK	KGDMFNLDNC	900
HKLIDFFKDS	ISRYPKWSNA	YDFNPFSETEK	YKDIAGFYRE	VEEQYKVSF	ESASKKEVDK	960
LVEEGKLYMF	QIYNKDFSDK	SHGTPNLHTM	YFKLLFDENN	HGQIRLSGGA	ELFMRRASLK	1020
KEELVVHPAN	SPIANKNPDN	PKKTTLSYD	VYKDKRFS	QYELHIPIAI	NKCPKNI FKI	1080
NTEVRVLLKH	DDNPYVIGIA	RGERNLLYIV	VVDGKGNIVE	QYSLNEI INN	FNGIRIKTDY	1140
HSLLDKKEKE	RFEARQWNTS	IENIKELKAG	YISQVHVKIC	ELVEKYDAVI	ALEDLNSGPK	1200
NSRVKVEKQV	YQKFEKMLID	KLNYMVDKKS	NPCATGGALK	GYQITNKFES	FKSMSQNGF	1260
IFYIPAWLTS	KIDPSTGFVN	LLTKTYTSIA	DSKKFISSFD	RIMYVPEEDL	FEFALDYKNF	1320
SRTDADYTKK	WFLYSYGNRI	RIFRNPKNKN	VFDWEVECLT	SAYKELFNKY	GINYQQGDIR	1380
ALLCEQSDKA	FYSFMALMS	LMLQMRNSIT	GRTDVDFLIS	PVKNSDGFIFY	DSRNYEAQEN	1440
AILPKNADAN	GAYNIARKVL	WAIGQPKKAE	DEKLDKVKIA	ISNKEWLEYA	QTSVKH	1496

SEQ ID NO: 255                   moltype = AA   length = 1380  
FEATURE                        Location/Qualifiers  
source                         1..1380  
                                 mol\_type = protein  
                                 organism = synthetic   construct

SEQUENCE: 255

MSKLEKFTNC	YLSKTLRPFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYS	60
FINDVLHSIK	LKNLNNYISL	FRKKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFPDNREN	MFSBEAKSTS	IAFRGINENL	180
TRYISNMDIF	EKVDAIFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFFNFVLT	QEGIDVYNAI	240
IGGFVTEGG	SSGENQTTGK	GKNNSRPRYK	SLEKAIKEFG	SQILKEHPTD	NQELRNNRLY	300
LYYLQNGKDM	YTGQDLIDHN	LSNYDIDHIV	PQSFTIDNSI	DNLVLTSSAG	NREKGGDVPP	360
LEIVRKRKVF	WEKLYQGNLM	SKRKFDYLT	AERGGTGS	GEKIKGLNEY	INLYNQTKKQ	420
KLPKFKPLYK	QVLSDRESLS	FYGEGYTSDE	EVLEVFRNTL	NKNSEIFSSI	KKLEKLFKNF	480
DEYSAGIFV	KNGPAISTIS	KDIFGEWNV	RDKNWAEYDD	IHLKKKAVVT	EKYEDDRRS	540
FKKIGSFLE	QLQYADADL	SVVEKLKEII	IQKVDEIYKV	YGSSEKLFDA	DFVLEKSLKK	600
NDAVVAIMKD	LLDSVKSFEN	YIKAFPGGEG	ETNRDESFG	DFVLAYDILL	KVDHIYDAIR	660
NYVTQKPYSK	DKPKLYPQNP	QPMGGWDKDK	ETDYRATILR	YGSKYLAIM	DKKYAKCLQK	720
IDKDDVNGNY	EKINYKLLPG	PNKMLPKVVF	SKKWMAYYNP	SEDIQKIYKN	GTFKGMDFN	780
LNDCHKLIDF	FKDSISRYPK	WSNAYDFNFS	ETEKYKDIAG	FYREVVEQGY	KVSFESASKK	840
EVDKLVBEKG	LYMQIYNKD	FSDKSHGTPN	LHTMYFKLLF	DENNHGQIRL	SGGAELFMRR	900
ASLKKEELV	HPANSPIANK	NPDNPKKTTT	LSYDVYKDKR	FSEDQYELHI	PIAINKCPKN	960
IFKINTEVRV	LLKHDDNPYV	IGIARGERNL	LYIVVVDGKG	NIVEQYSLNE	IINNPNGIRI	1020
KTDYHSLLDK	KEKERFEARQ	NWTSIENIKE	LKAGYISQVV	HKICELVEKY	DAVIALEDLN	1080
SGFKNSRVKV	EKQVYQKFEK	MLIDKLNMYV	DKKSNPCATG	GALKGYQITN	KFESPKSMST	1140
QNGFIFYIPA	WLTSKIDPST	FVNLLKTKY	TSIADSKKFI	SSPDRIMYVP	EEDLPEFALD	1200
YKNFSRTDAD	YIKKWKLYSY	GNRIRIFRNP	KKNVDFDWE	VCLTSAYKEL	FNKYGINYQQ	1260
GDIRALLCEQ	SDKAFYSFPM	ALMSLMLQMR	NSITGRTD	FLISPVKNSD	GIFYDSRNYE	1320
AQENAILPKN	ADANGAYNIA	RKVLWAIGQF	KKAEDKELDK	VKIAISNKEW	LEYAQTSVKH	1380

SEQ ID NO: 256                   moltype = AA   length = 1323  
FEATURE                        Location/Qualifiers  
source                         1..1323  
                                 mol\_type = protein



-continued

organism = synthetic construct

SEQUENCE: 256

MSKLEKPTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNNLNNYISL	FRKKTRETEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDIAFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGMELKNSI	SDYTEAEFVQ	LLKEIEKENV	AATDDVLDVL	LEHFVKITEH	300
PDGTDLIYYP	SDNRDSDPEG	IVKEIKEWRA	ANGKPGFKQG	GSSGEEKIKGL	NEYINLYNQK	360
TKQKLPKFKP	LYKQVLSDRS	SLSFYGEGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	420
KNFDEYSSAG	IFVKNGPAIS	TISKDFGFEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	480
RKSPFKKIGSF	SLEQLQEYAD	ADLSVVEKLEK	EIIIQKVEI	YKVYGSSEKL	FDADVFLEKS	540
LKKNDAVAI	MKDLLDSVKS	FENYIKAPFG	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	600
AIRNVYVTKP	YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	660
LQKIDKDDVN	GNYEKINYKL	LPGPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	YKNGTFPKKGD	720
MFNLNDCHKL	IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVEE	QGYKVSFESA	780
SKKEVDKLVE	BGKLYMPQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELEF	840
MRRASLKKEE	LVVHPANSPI	ANKNPDNPKK	TTTTLSYDVYK	DKRFSSEDQYE	LHIPIAINKC	900
PKNIFKINTE	VRVLLKHDDN	PVYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNPNFNG	960
IRIKTDYHSL	LDKKEKRFPE	ARQNWTSIEN	IKELKAGYIS	QVVKHICELV	EKYDAVIALE	1020
DLNSGFKNRS	VKVEKQVYQK	FEKMLIDKLN	YVMDKKSNPC	ATGGALKGYQ	ITNKPESFKS	1080
MSTQNGFIYF	IPAWLTSKID	PSTGFVNLLK	TKYTSIADSK	KFISSEFDRIM	YVPEEDLFEF	1140
ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNNVFED	WEEVCLTSAY	KELFNKYGIN	1200
YQQGDIRALL	CEQSDKAFYS	SFIMALMSLML	QMRNSITGRT	DVDFLISPVK	NSDGIIFYDSR	1260
NYEAQENAIL	PKNADANGAY	NIARKVLWAI	GQFKKADEK	LDKVKIAISN	KEWLEYAQTS	1320
VKH						1323

SEQ ID NO: 257                   moltype = AA   length = 1323

FEATURE

source                            Location/Qualifiers

                                  1..1323

                                  mol\_type = protein

                                  organism = synthetic construct

SEQUENCE: 257

MSKLEKPTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNNLNNYISL	FRKKTRETEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDIAFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGMKSKI SE	YTEKEPLEFV	KDIYTNKKK	FPTTEESHQA	VLEFKKLTEH	300
PSGSDLLYYP	NENREDSPAG	VVKEVKEWRA	SKGLPGFKAG	GSSGEEKIKGL	NEYINLYNQK	360
TKQKLPKFKP	LYKQVLSDRS	SLSFYGEGYT	SDEEVLEVFR	NTLNKNSEIF	SSIKKLEKLF	420
KNFDEYSSAG	IFVKNGPAIS	TISKDFGFEW	NVIRDKWNAE	YDDIHLKKA	VVTEKYEDDR	480
RKSPFKKIGSF	SLEQLQEYAD	ADLSVVEKLEK	EIIIQKVEI	YKVYGSSEKL	FDADVFLEKS	540
LKKNDAVAI	MKDLLDSVKS	FENYIKAPFG	EGKETNRDES	FYGDVFLAYD	ILLKVDHIYD	600
AIRNVYVTKP	YSKDKFKLYF	QNPQFMGGWD	KDKETDYRAT	ILRYGSKYYL	AIMDKKYAKC	660
LQKIDKDDVN	GNYEKINYKL	LPGPNKMLPK	VFFSKKWMAY	YNPSEDIQKI	YKNGTFPKKGD	720
MFNLNDCHKL	IDFPKDSISR	YPKWSNAYDF	NFSETEKYKD	IAGFYREVEE	QGYKVSFESA	780
SKKEVDKLVE	BGKLYMPQIY	NKDFSDKSHG	TPNLHTMYFK	LLFDENNHGQ	IRLSGGAELEF	840
MRRASLKKEE	LVVHPANSPI	ANKNPDNPKK	TTTTLSYDVYK	DKRFSSEDQYE	LHIPIAINKC	900
PKNIFKINTE	VRVLLKHDDN	PVYVIGIARGE	RNLLYIVVVD	GKGNIVEQYS	LNEIINNPNFNG	960
IRIKTDYHSL	LDKKEKRFPE	ARQNWTSIEN	IKELKAGYIS	QVVKHICELV	EKYDAVIALE	1020
DLNSGFKNRS	VKVEKQVYQK	FEKMLIDKLN	YVMDKKSNPC	ATGGALKGYQ	ITNKPESFKS	1080
MSTQNGFIYF	IPAWLTSKID	PSTGFVNLLK	TKYTSIADSK	KFISSEFDRIM	YVPEEDLFEF	1140
ALDYKNFSRT	DADYIKKWKL	YSYGNRIRIF	RNPKNNVFED	WEEVCLTSAY	KELFNKYGIN	1200
YQQGDIRALL	CEQSDKAFYS	SFIMALMSLML	QMRNSITGRT	DVDFLISPVK	NSDGIIFYDSR	1260
NYEAQENAIL	PKNADANGAY	NIARKVLWAI	GQFKKADEK	LDKVKIAISN	KEWLEYAQTS	1320
VKH						1323

SEQ ID NO: 258                   moltype = AA   length = 1511

FEATURE

source                            Location/Qualifiers

                                  1..1511

                                  mol\_type = protein

                                  organism = synthetic construct

SEQUENCE: 258

MSKLEKPTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KLLDRYYLS	60
FINDVLHSIK	LKNNLNNYISL	FRKKTRETEKE	NKELENLEIN	LRKEIAKAFK	GNEGYKSLFK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGFTTA	FTGFFDNREN	MFSEBAKSTS	IAPRCINENL	180
TRYISNMDF	EKVDIAFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEFPNFVLT	QEGIDVYNAI	240
IGGFVTESGG	SSGWRRRRD	ARAAPGLLGR	LPVLPVAAA	ELPPVPGGPR	GPGLAKAYGL	300
PGLAQLKSR	SYVLCYDPR	RGALWVVEQL	RPERLRGDGD	RRECDFREDD	SVHAYHRATN	360
ADYRSGGPDF	GHLAAAANHR	WSQKAMDDTF	YLSNVAPQVP	HLNQNAWNNL	EKYSRSLTRS	420
YQNVYVCTGP	LFLPRTEADG	KSYVYQVIG	KNHVAVPTHF	FKVLI LEAAG	GQIELRTRYVM	480
PNAPVDEAIP	LERFLVPIES	IERASGLLFP	PNILARAGSL	KAITAGSKGS	SGEKIKGLNE	540
YINLYNQKTK	QKLPKFKPLY	KQVLSDRESL	SFYGEGYTS	EEVLEVFRNT	LNKNSEIFSS	600
IKKLEKLFKN	FDEYSSAGIF	VKNGPAISTI	SKDFGEMNV	IRDKWNAEYD	DIHLKKAUV	660
TEKYEDDRK	SFKKIGSFL	EQLQEYADAD	LSVVEKLEI	IIQKVEIYK	YVGSSEKLPD	720
ADFVLEKSLK	KNDVAIVAIMK	DLLDSVKSPF	NYIKAFFGEG	KETNRDESFY	GDFVFLAYDIL	780
LKVDHIYDAI	RNVYVTKPYS	KDKFKLYFQN	PQFMGGWDK	KETDYRATIL	RYGSKYYLAI	840

-continued

MDKKYAKCLQ	KIDKDDVNGN	YEKINYKLLP	GPNKMLPKVF	FSKKWMAYYN	PSEDIQKIYK	900
NGTFPKGDMF	NLNDCHKLID	FPKDSISRYP	KWSNAYDFNF	SETEKYKDIA	GFYREVEEQG	960
YKVSFESASK	KEVDKLVVEEG	KLYMPQIYNK	DFSDKSHGTP	NLHTMYFKLL	FDENNHGQIR	1020
LSGGAELEFMR	RASLKKEELV	VHPANSPIAN	KNPDNPKKTT	TLSDYDVYKDK	RFSEDQYELH	1080
IPIAINKCPK	NIPKINTEVR	VLLKHDDNPY	VIGIARGERN	LLYIVVVVDGK	GNIVEQYSLN	1140
EIINNFNGIR	IKTDYHSLLD	KKEKERFEAR	QNWTISIENIK	ELKAGYISQV	VHKICELVEK	1200
YDAVIALLEDL	NSGPKNSRVK	VEKQVYQKFE	KMLIDKLNVM	VDKKSNPCAT	GGALKGYQIT	1260
NKPFESFKSMS	TQNGFIFYIP	AWLTSKIDPS	TGFVNLLKTK	YTSIADSKKF	ISSFDRIMYV	1320
PEEDLFEFAL	DYKNFSRTDA	DYIKKWKLYS	YGNRIRIFRN	PKKNNVFDWE	EVCLTSAYKE	1380
LFNKYGINYQ	QGDIRALLCE	QSDKAFYSSF	MALMSLMLQM	RNSITGRTDV	DFLISPVKNS	1440
DGIFYDSRNY	EQAENAILPK	NADANGAYNI	ARKVLWAIGQ	FKKAEDEKLD	KVKIAISNKE	1500
WLEYAQTSVK	H					1511

SEQ ID NO: 259                   moltype = AA   length = 1372  
 FEATURE                        Location/Qualifiers  
 source                           1..1372  
                                   mol\_type = protein  
                                   organism = synthetic construct

SEQUENCE: 259

MSKLEKFTNC	YLSKTLRFK	AIPVGKTQEN	IDNKRLLED	EKRAEDYKGV	KKLLDRYVLS	60
FINDVLHSIK	LKNLNYYISL	FRKTRTEKE	NKELENLEIN	LRKEIAKAFK	GNEGYSKLPK	120
KDIIETILPE	FLDDKDEIAL	VNSFNGTTA	FTGFNDREN	MFSEAKSTS	IAFRINENL	180
TRYISNMDIF	EKVDIAFDKH	EVQEIKEKIL	NSDYDVEDFF	EGEPPNFVLT	QEGIDVYNAI	240
IGGFVTEGG	SSGDEPGVAT	GNGQPVTGNW	LAGASQGDGV	PIPSQIADQL	RGKEFKSWRD	300
FREQFMMAVS	KDPSALENLS	PSNRYFVSQG	LAPYAVPEEH	LGSKEKFEIH	HVPLESGGA	360
LYNIDNLVIV	TPKRHSEIHK	ELKLRKKEKG	SSGEKIKGLN	EYINLYNQKT	KQKLPKFKPL	420
YKQVLSDES	LSFYGEGYTS	DEEVLEVFRN	TLNKNSEIFS	SIKKLEKLPK	NPDEYSSAGI	480
FVKNGPAIST	ISKDIFGEWN	VIRDKWNAEY	DDIHLKKAIV	VTEKYEDDR	KSPFKIGSFS	540
LEQLQEYADA	DLSVVEKLKE	IIIQVDEIY	KVYGSSEKLF	DADFVLEKSL	KKNDVAVAIM	600
KDLLDSVKSF	ENYIKAFPEE	GKETNRDESF	YGFVFLAYDI	LLKVVDHYDA	IRNYVTQKPY	660
SKDKFKLYFQ	NPQFMGGWCK	DEKTDYRATI	LRYGSKYVLA	IMDKKYAKCL	QKIDKDDVNG	720
NYEKINYKLL	PGPNKMLPKV	FSKKWMAYY	NPSEDIQKIY	KNGTFKKGDM	FNLNDCHKLI	780
DFPKDSISRY	PKWSNAYDFN	FSETEKYKDI	AGFYREVEEQ	GYKVSFESAS	KKEVDKLVVE	840
GKLYMPQIYN	KDFSDKSHGT	PNLHTMYFKL	LFDENNHGQI	RLSGGAELFM	RRASLKKEEL	900
VVHPANSPIA	NKNPDNPKKT	TTLSDYVYKD	KRFSEDQYEL	HIPIAINKCP	KNIFKINTEV	960
RVLLKHDDNP	YVIGIARGER	NLLYIVVVVDG	KGNIVEQYSL	NEIINNPNGI	RIKTDYHSLD	1020
DKKEKERFEA	RQNWTSIENI	KELKAGYISQ	VVHKICELVE	KYDAVIALED	LNSGFKNSRV	1080
KVEKQVYQKF	EKMLIDKLNVM	MVDKSNPCAT	TGGALKGYQI	TNKFESFKSM	STQNGFIFYI	1140
PAWLTSKIDP	STGFVNLLKT	KYTSIADSKK	FISSFDRIMY	VPEEDLFEFA	LDYKNFSRTD	1200
ADYIKKWKLY	YGNRIRIFRN	PKKNNVFDWE	EEVCLTSAYK	ELFNKYGINY	QGDIRALLC	1260
EQSDKAFYSS	FMALMSLMLQ	MRNSITGRTD	VDFLISPVKN	SDGIFYDSRN	YEAQENAILP	1320
KNADANGAYN	IARKVLWAIG	QPKKAEDEKL	DKVKIAISNK	EWLEYAQTSV	KH	1372

**1-10.** (canceled)

**11.** The composition of claim **23**, wherein the first fusion protein and/or the second fusion protein further comprises a reverse transcriptase.

**12.** The composition of claim **23**, wherein the first Cas12a polypeptide and/or the second Cas12a polypeptide comprises about 175, 310, 406, 441, or 550 consecutive amino acids of a Cas12a protein.

**13.** The composition of claim **23**, wherein the first Cas12a polypeptide and/or the second Cas12a polypeptide has at least 70% sequence identity to one or more of SEQ ID NOs:150-159 and 175-184.

**14.** The composition of claim **23**, wherein the first fusion protein and/or the second fusion protein has at least 70% sequence identity to one or more of SEQ ID NOs:100-109 or 188.

**15.-22.** (canceled)

**23.** A composition comprising:

a first fusion protein that comprises a first Cas12a polypeptide fused to a first intein polypeptide; and  
 a second fusion protein that comprises a second Cas12a polypeptide fused to a second intein polypeptide.

**24.** The composition of claim **23**, wherein the first fusion protein and the second fusion protein are different.

**25.-28.** (canceled)

**29.** A method of modifying a target nucleic acid, the method comprising:

introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell comprising the target nucleic acid, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a first Cas12a polypeptide fused to a first intein polypeptide and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a second Cas12a polypeptide fused to a second intein polypeptide;

contacting the target nucleic acid in the cell with a guide nucleic acid and a protein comprising at least a portion of the first Cas12a polypeptide and at least a portion of the second Cas12a polypeptide,

optionally wherein the protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**30.-32.** (canceled)

**33.** The method of claim **29**, wherein the first intein polypeptide and the second polypeptide associate to form an intein that is a *Nostoc punctiforme* (Npu) intein and/or a portion of a mutant Npu intein.

**34.** The method of claim **29**, wherein the first intein polypeptide and/or the second intein polypeptide has at least 70% sequence identity to one or more of SEQ ID NOs:110-112.

**35.** (canceled)

**36.** The method of claim **29**, wherein the protein has at least 70% sequence identity to one or more of SEQ ID NOs:38-60, 113-149, 192-195, and 196-259.

**37.** The method of claim **29**, wherein the first fusion protein has at least 70% sequence identity to one of SEQ ID NOs:100, 102, 104, 106, and 108 and the second fusion protein has at least 70% sequence identity to one of SEQ ID NOs:101, 103, 105, 107, and 109, respectively, wherein the first fusion protein and the second fusion protein are different.

**38.-41.** (canceled)

**42.** An engineered protein comprising an amino acid sequence that has at least 70% sequence identity to one or more of SEQ ID NOs:100-109 and 187-188.

**43.** A nucleic acid molecule encoding the engineered protein of claim **42**.

**44.-69.** (canceled)

**70.** A method of modifying a target nucleic acid, the method comprising:

introducing a first nucleic acid molecule and a second nucleic acid molecule into a cell comprising the target nucleic acid, wherein the first nucleic acid molecule encodes a first fusion protein, the first fusion protein comprising a polypeptide of interest fused to a first intein polypeptide and the second nucleic acid molecule encodes a second fusion protein, the second fusion protein comprising a Cas12a polypeptide fused to a second intein polypeptide;

contacting the target nucleic acid in the cell with a guide nucleic acid (e.g., a guide RNA) and a protein comprising at least a portion of the polypeptide of interest and at least a portion of the Cas12a polypeptide,

optionally wherein the protein and the guide nucleic acid form a complex or are comprised in a complex, thereby modifying the target nucleic acid.

**71.-73.** (canceled)

**74.** The method of claim **70**, wherein the first intein polypeptide and the second polypeptide associate to form an intein that is a *Nostoc punctiforme* (Npu) intein and/or a portion of a mutant Npu intein.

**75.** The method of claim **70**, wherein the first intein polypeptide and/or the second polypeptide has at least 70% sequence identity to one or more of SEQ ID NOs:110-112.

**76.** The method of claim **70**, further comprising cleaving the polypeptide of interest from the first fusion protein and cleaving the Cas12a polypeptide from the second fusion protein.

**77.** The method of claim **76**, wherein the fusion protein has at least 70% sequence identity to one or more of SEQ ID NOs:38-60, 113-149, 192-195, and 196-259.

**78.** The method of claim **70**, wherein the first fusion protein has at least 70% sequence identity to SEQ ID NO:187 and the second fusion protein has at least 70% sequence identity to SEQ ID NO:188.

**79.-81.** (canceled)

**82.** The method of claim **70**, wherein the method has increased efficiency in modifying the target nucleic acid compared to the efficiency of a control method.

\* \* \* \* \*